---
document_datetime: 2023-09-21 20:20:37
document_pages: 154
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/bavencio-h-c-004338-ii-0018-epar-assessment-report-variation_en.pdf
document_name: bavencio-h-c-004338-ii-0018-epar-assessment-report-variation_en.pdf
version: success
processing_time: 282.7621345
conversion_datetime: 2025-12-23 06:47:06.412457
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

10 December 2020 EMA/CHMP/3166/2021 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Bavencio

International non-proprietary name: avelumab

Procedure No. EMEA/H/C/004338/II/0018

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                              | ..............................................7                                                          |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ................................................................................................ | 7                                                                                                        |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 8                                                |
| 2. Scientific discussion                                                                                                | ................................................................................9                        |
| 2.1. Introduction                                                                                                       | ...................................................................................................... 9 |
| 2.1.1. Problem statement                                                                                                | .......................................................................................... 9             |
| 2.1.2. About the product                                                                                                | ........................................................................................... 9            |
| 2.1.3. The development programme/compliance with CHMP guidance/scientific advice                                        | ..... 10                                                                                                 |
| 2.1.4. General comments on compliance with GCP                                                                          | ...................................................... 10                                                |
| 2.2. Non-clinical aspects..........................................................................................     | 10                                                                                                       |
| 2.2.1. Ecotoxicity/environmental risk assessment........................................................                | 10                                                                                                       |
| 2.3. Clinical aspects                                                                                                   | ................................................................................................ 11      |
| 2.3.1. Introduction                                                                                                     | ................................................................................................. 11     |
| 2.3.2. Pharmacokinetics                                                                                                 | .......................................................................................... 12            |
| 2.3.3. Pharmacodynamics........................................................................................         | 30                                                                                                       |
| 2.3.4. PK/PD modelling............................................................................................      | 30                                                                                                       |
| 2.3.5. Discussion on clinical pharmacology .................................................................            | 36                                                                                                       |
| 2.3.6. Conclusions on clinical pharmacology                                                                             | ............................................................... 37                                       |
| 2.4. Clinical efficacy                                                                                                  | ................................................................................................ 38      |
| 2.4.1. Main study                                                                                                       | ................................................................................................... 38   |
| 2.4.2. Discussion on clinical efficacy ..........................................................................       | 94                                                                                                       |
| 2.4.3. Conclusions on the clinical efficacy...................................................................          | 97                                                                                                       |
| 2.5. Clinical safety                                                                                                    | .................................................................................................. 97    |
| 2.5.1. Discussion on clinical safety                                                                                    | ...........................................................................134                           |
| 2.5.2. Conclusions on clinical safety                                                                                   | .........................................................................136                             |
| 2.5.3. PSUR cycle                                                                                                       | ..................................................................................................136    |
| 2.6. Risk management plan.....................................................................................136       |                                                                                                          |
| 2.7. Update of the Product information                                                                                  | .....................................................................149                                 |
| 2.7.1. User consultation..........................................................................................149   |                                                                                                          |
| 2.7.2. Additional monitoring....................................................................................149     |                                                                                                          |
| 3. Benefit-Risk Balance............................................................................149                  |                                                                                                          |
| 3.1. Therapeutic Context                                                                                                | ........................................................................................149              |
| 3.1.1. Disease or condition......................................................................................149    |                                                                                                          |
| 3.1.2. Available therapies and unmet medical need                                                                       | ....................................................150                                                  |
| 3.1.3. Main clinical studies                                                                                            | ......................................................................................150                |
| 3.2. Favourable effects...........................................................................................150   |                                                                                                          |
| 3.3. Uncertainties and limitations about favourable effects                                                             | ..........................................151                                                            |
| 3.4. Unfavourable effects........................................................................................151    |                                                                                                          |
| 3.5. Uncertainties and limitations about unfavourable effects                                                           | .......................................152                                                               |
| 3.6. Effects Table                                                                                                      | ..................................................................................................152    |
| 3.7. Benefit-risk assessment and discussion                                                                             | ..............................................................153                                        |
| 3.7.1. Importance of favourable and unfavourable effects                                                                | ...........................................153                                                           |
| 3.7.2. Balance of benefits and risks..........................................................................153       |                                                                                                          |

<div style=\"page-break-after: always\"></div>

3.7.3. Additional considerations on the benefit-risk balance .........................................  153

3.8. Conclusions  ....................................................................................................  153

4. Recommendations ...............................................................................  154

5. EPAR changes  ......................................................................................  154

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Term                                                |
|----------------|-----------------------------------------------------|
| ADA            | anti-drug antibody                                  |
| ADCC           | antibody-dependent cell-mediated cytotoxicity       |
| ADR            | adverse drug reaction                               |
| AE             | adverse event                                       |
| aRCC           | advanced renal cell carcinoma                       |
| aUC            | locally advanced or metastatic urothelial carcinoma |
| BICR           | blinded independent central review                  |
| BLA            | Biologics License Application                       |
| BOR            | best overall response                               |
| BSC            | best supportive care                                |
| BTD            | Breakthrough Designation                            |
| CHMP           | Committee for Medicinal Products for Human Use      |
| CI             | confidence interval                                 |
| CL             | total systemic clearance                            |
| CPK            | creatinine phosphokinase                            |
| CO             | Clinical Overview                                   |
| CR             | complete response                                   |
| CSR            | Clinical Study Report                               |
| C trough       | predose concentration                               |
| CV             | coefficient of variation                            |
| eCRF           | electronic case report form                         |
| DR             | duration of response                                |
| DRS-P          | Disease Related Symptoms - Physical                 |
| ECG            | electrocardiogram                                   |
| ECOG           | Eastern Cooperative Oncology Group                  |
| EMA            | European Medicines Agency                           |
| EQ-5D-5L       | EuroQol 5 dimensions 5 levels                       |
| ESMO           | European Society for Medical Oncology               |
| EU             | European Union                                      |
| FACT           | Functional Assessment of Cancer Therapy             |

<div style=\"page-break-after: always\"></div>

| FBlSI-18   | FACT Bladder Symptom Index                                               |
|------------|--------------------------------------------------------------------------|
| FDA        | Food and Drug Administration                                             |
| GCP        | Good Clinical Practice                                                   |
| GGT        | gamma-glutamyl transferase                                               |
| GMP        | Good Manufacturing Practice                                              |
| HR         | hazard ratio                                                             |
| ICH        | International Conference for Harmonisation                               |
| IHC        | immunohistochemistry                                                     |
| Ig         | Immunoglobulin                                                           |
| IND        | Investigational New Drug                                                 |
| IR         | Incident Rate per 100 patient months                                     |
| irAE       | immune-related adverse event                                             |
| IRR        | infusion related reaction                                                |
| ISS        | Integrated Summary of Safety                                             |
| IV         | intravenous                                                              |
| LLQ        | lower limit of quantification                                            |
| mAb        | monoclonal antibody                                                      |
| MAH        | Marketing Authorisation Holder                                           |
| MCC        | Merkel cell carcinoma                                                    |
| nAb        | neutralizing antibody                                                    |
| NCCN       | National Comprehensive Cancer Network                                    |
| NCI CTCAE  | National Cancer Institute Common Terminology Criteria for Adverse Events |
| NE         | not evaluable                                                            |
| OR(R)      | objective response (rate)                                                |
| OS         | overall survival                                                         |
| PBRER      | Periodic Benefit-Risk Evaluation Report                                  |
| PD         | progressive disease                                                      |
| PD-1       | programmed cell death protein 1                                          |
| PD-L1      | programmed cell death protein-ligand 1                                   |
| PFS        | progression-free survival                                                |
| PIPD       | potentially important protocol deviation                                 |
| PK         | pharmacokinetics                                                         |

<div style=\"page-break-after: always\"></div>

| PM          | Patient Months of Exposure                                    |
|-------------|---------------------------------------------------------------|
| PMAR        | Population Modelling Analysis Report                          |
| popPK       | population pharmacokinetics                                   |
| PR          | partial response                                              |
| PRO         | patient-reported outcomes                                     |
| PT          | preferred term                                                |
| Q2W         | every 2 weeks                                                 |
| RCC         | renal cell carcinoma                                          |
| RCI         | repeated confidence interval                                  |
| RECIST v1.1 | Response Evaluation Criteria in Solid Tumours Version 1.1     |
| RTOR        | Real Time Oncology Review                                     |
| SAP         | statistical analysis plan                                     |
| SAE         | serious adverse event                                         |
| SBS         | Summary of Biopharmaceutics and Associated Analytical Methods |
| sBLA        | Supplemental Biologics License Application                    |
| SCE         | Summary of Clinical Efficacy                                  |
| SCP         | Summary of Clinical Pharmacology Studies                      |
| SCS         | Summary of Clinical Safety                                    |
| SD          | stable disease                                                |
| SmPC        | Summary of Product Characteristics                            |
| TKI         | tyrosine kinase inhibitor                                     |
| TEAE        | treatment-emergent adverse event                              |
| TTD         | time to deterioration                                         |
| UC          | urothelial carcinoma                                          |
| US          | United States                                                 |
| VEGFR       | vascular endothelial growth factor receptor                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Europe B.V. submitted to the European Medicines Agency on 26 May 2020 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include a new indication for Bavencio as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy; as a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.3 of the RMP has also been submitted.

The variation requested amendments to the Summary of Product Characteristics, Annex II and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0242/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0242/2018 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

## Scientific advice

The applicant received Scientific Advice on 22 October 2015 (EMEA/H/SA/2771/5/2015/II) for the development programme supporting the indication granted by the CHMP.

<div style=\"page-break-after: always\"></div>

| Date       | Reference                | SAWP Co-ordinators                    |
|------------|--------------------------|---------------------------------------|
| 22/10/2015 | EMEA/H/SA/2771/5/2015/II | Dr Pierre Démolis and Dr Jens Ersbøll |

The Scientific Advice pertained to the following clinical aspects of the dossier:

- Discussion on the design of the pivotal study B9991001 (including study population, selection of comparator, safety monitoring, study design, endpoints, statistical plan, inclusion of patients reported outcome results in the SmPC).

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Filip Josephson,

Co-Rapporteur: N/A

| Timetable                                                                                                                                  | Actual dates      |
|--------------------------------------------------------------------------------------------------------------------------------------------|-------------------|
| Submission date                                                                                                                            | 26 May 2020       |
| Start of procedure:                                                                                                                        | 20 June 2020      |
| CHMP Rapporteur's preliminary assessment report circulated on:                                                                             | 21 August 2020    |
| PRAC Rapporteur's preliminary assessment report circulated on:                                                                             | 24 August 2020    |
| PRAC RMP advice and assessment overview adopted by PRAC on:                                                                                | 3 September 2020  |
| CHMP Rapporteur's updated assessment report circulated on:                                                                                 | 10 September 2020 |
| Request for supplementary information adopted by the CHMP on:                                                                              | 17 September 2020 |
| MAH's responses submitted to the CHMP on:                                                                                                  | 9 October 2020    |
| CHMP Rapporteur's preliminary assessment report on the MAH's responses circulated on:                                                      | 10 November 2020  |
| PRAC Rapporteur's preliminary assessment report on the MAH's responses circulated on:                                                      | 13 November 2020  |
| PRAC RMP advice and assessment overview adopted by PRAC on:                                                                                | 26 November 2020  |
| CHMP Rapporteur's updated assessment report on the MAH's responses circulated on:                                                          | 3 December 2020   |
| CHMP opinion:                                                                                                                              | 10 December 2020  |
| The CHMP adopted a report on the novelty of the indication/significant clinical benefit for Bavencio in comparison with existing therapies | 10 December 2020  |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Urothelial Carcinoma (UC) includes tumours originating from the urothelial cells lining the bladder, renal pelvis, ureter, and urethra. Bladder cancer alone accounts for 90% of UC, with approximately 550,000 new cases and 200,000 deaths attributed to bladder cancer worldwide each year. In Europe, an estimated 151, 297 new cases of bladder cancer were diagnosed in 2012. In 2012, there were 52 395 deaths from bladder cancer with an annual crude mortality rate of 7.1/100 000. Approximately 70% of patients with bladder cancer are &gt;65 years of age. (Bellmunt et al, 2014). The incidence of bladder cancer has remained unchanged over the last 25 years.

## State the claimed therapeutic indication

Bavencio is indicated as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with firstline platinum-based induction chemotherapy.

## Management

Platinum-based regimens are the standard-of-care first-line treatment for patients with locally advanced or metastatic urothelial carcinoma (aUC) and result in median OS ranging from 9-14 months (De Santis et al, 2012; Calabro et al, 2009). Despite initial high response rates, durations of PFS and OS are limited because of emergent chemotherapy resistance. Further, severe side effects limit longterm use of current chemotherapy agents. Following successful first-line treatment, patients are typically managed with BSC until disease progression. Most patients will experience disease progression within 9 months after the initiation of treatment (von der Maase et al, 2005).

Recently approved PD-L1 inhibitors are new systemic therapies for aUC, both for 1L treatment in cisplatinineligible patients for patients with tumours expressing ≥ 5% PD -L1 and for patients experiencing disease progression after platinum-based chemotherapy regardless of PD-L1-status.

Galsky et al evaluated PD-1 inhibitor pembrolizumab as a maintenance treatment versus placebo in a Phase 2 study in patients with metastatic UC (mUC) following first-line treatment. PFS according to irRECIST was significantly longer in patients randomized to pembrolizumab versus placebo (log-rank p=0.038; Galsky et al, 2019).

## 2.1.2. About the product

Avelumab is a human Ig G1 mAb directed against PD-L1, which is expressed by tumour cells, as well as by a number of immune cell types. Avelumab binds to PD-L1 and blocks the interaction between PD-L1 and its receptors PD-1 and B7.1. This removes the suppressive effects of PD-L1 on anti-tumour CD8+ T-cells, resulting in the restoration of a cytotoxic T-cell response. In vitro, avelumab is capable of stimulating an antibody-dependent cell-mediated cytotoxicity (ADCC) against PD-L1-positive tumour

<div style=\"page-break-after: always\"></div>

cells.

Approved indications:

- Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).
- Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).

## 2.1.3. The development programme/compliance with CHMP guidance/scientific advice

## EMA Scientific advice (SA) was received by the Applicant on  22 October 2015 (EMEA/H/SA/2771/5/2015/II)

The scope of the SA was to discuss the overall study design of Study B9991001.

It was brought to the attention of the Applicant the importance of PFS2 in the interpretation of a PFS benefit. In addition, the PD-L1-negative subgroup of patients was pointed out as important to support a MA claim in the entire population regardless of PD-L1-status. The applicant was advised to at least formulate hypotheses in the PD-L1-negative subgroup.

Pre-submission meeting with the Rapporteur on 30 March 2020

The pre-submission meeting concerned a discussion on the acceptability of study B9991001 results for approval of Bavencio as monotherapy in the first-line maintenance setting of locally advanced or metastatic urothelial carcinoma (aUC).

## 2.1.4. General comments on compliance with GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted with this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Avelumab is a protein, which is expected to be metabolised in the body and biodegrade in the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), avelumab is exempt from the submission of an Environmental Risk Assessment as the product and excipients do not expect to pose a significant risk to the environment.

<div style=\"page-break-after: always\"></div>

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

Table 1. Overview of clinical studies.

| Study ID                                                   | Phase, Study design, control type                                                                                                                             | Population                                                                                                                                                      | Study Posology                                     | Study Objective                                                                                                                                                         | Subjs by arm entered/ compl.                                                                                        |
|------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| B9991001 [JAVELIN Bladder 100] EudraCT No. 2015- 003262-86 | Phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) plus BSC versus BSC alone as maintenance treatment. | Patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum- containing chemotherapy. | Avelumab 10 mg/kg IV Q2W plus BSC                  | Primary objective: Demonstrate the benefit of avelumab plus BSC versus BSC alone in prolonging OS for patients with PD-L1 positive tumours and all randomized patients. | Total: Avelumab +BSC: ITT: n=350 BSC: ITT: n=350 PD-L1- positive tumours: Avelumab +BSC: ITT: n=189 BSC: ITT: n=169 |
| EMR100070 -001 EudraCT No. 2013- 002834-19                 | Phase 1, open- label, multiple- ascending dose trial.                                                                                                         | Patients with metastatic or locally advanced solid tumours.                                                                                                     | Dose escalation, 1.0 mg/kg, 3.0 mg/kg, 10.0 mg/kg. | Investigate the safety, tolerability, pharmaco- kinetics, biological and clinical activity                                                                              | Total: N=1758 Dose Escalation Phase: n=61                                                                           |

<div style=\"page-break-after: always\"></div>

## 2.3.2. Pharmacokinetics

To support the proposed dosing regimen in the current aUC submission, the following clinical pharmacology analyses and evaluations were provided based on data from avelumab PK and ADA data from study B9991001:

- An assessment of the popPK of avelumab in patients with aUC to estimate avelumab exposures.  This analysis employed the monotherapy avelumab steady-state popPK model from the previous submissions.
- The justification of the 800 mg IV Q2W flat-dosing regimen in the aUC analysis population.
- Evaluation of exposure-response relationships of avelumab with key safety and efficacy endpoints.
- The immunogenicity of avelumab where the incidence of ADA was evaluated (see section 4.5.1).  Moreover, the influence of ADA on PK and safety was assessed.

A full characterisation of the avelumab PK properties was provided in the original marketing authorisation application. A summary of the avelumab PK characteristics is provided below.

## Absorption

Bavencio is for intravenous infusion only.

UC expansion cohort:

Patients with Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, or urethra) with relapsed, refractory, or progressive disease following last line of treatment of avelumab and expansion to selected indications.

Dose Expansion Phase: n=1697

· aUC secondar y expansio n cohort - n= 44 aUC efficacy expansion cohort n=205

<div style=\"page-break-after: always\"></div>

## Distribution

The volumes of the central and peripheral compartments, according to a population PK analysis, were 2.84 L and 1.21 L in the typical subject, respectively. The geometric mean Vss (calculated from individual V1 and V2 parameter values) for a subject receiving 10 mg/kg was 4.72 L.

## Elimination

Following IV administration of a 10 mg/kg dose the mean clearance determined by non-compartmental analysis was 0.36 mL/h/kg. The corresponding mean half-life was 95 h (~4 days). From a population PK analysis, the estimated t½ was approximately 6 days in subjects receiving 10 mg/kg every 2 weeks. According to population PK analysis, estimated mean maximal reduction from baseline CL was 32% in the mMCC population and 28% in the head and neck population.

## Dose proportionality and time dependencies

The dose-normalized Cmax and AUC0-336hr after first dose were approximately similar across 3 to 20 mg/kg. Ctrough increased proportionally with doses between 10 to 20 mg/kg, but more than proportionally for doses between 1 to 10 mg/kg.

Table 2 lists the single study contributing PK and ADA data in the aUC patient population.

Table 2 . Clinical Study Providing Clinical Pharmacology Data

| Protocol/Location/C utoff date                                                                                                                                         | Study population (2)                                                                                                                                           | PK/ADA sampling                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Treatments                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| B9991001 (Phase 3) Locations: North America, Central/South America, Asia- Pacific including Japan, and Europe Cutoff date: 21 Oct 2019 PK/ADA Cutoff date: 30 Jun 2019 | Adult patients with aUC without progressive disease previously treated with platinum-based induction chemotherapy. N=700 randomized. · 350inArm A 350 in Arm B | PK samples collected (Arm A only) Avelumab PK blood sample (3.5 mL) collected from all patients pre-dose and end of infusion (immediatelybefore end of avelumab infusion) on Days 1 & 15 of Cycles 1-3, then pre-dose and at end of infusion (immediately before end of avelumab infusion) on Day 1 of Cycles 5, 7, 9, 11, & 13. Avelumab PK (n=344) ADA samples collected (Arm A only) Blood sample(3.5 mL) for ADAs collected pre-dose on Day 1 & Day 15 of Cycles 1-3, and then on Day 1 of Cycles 5,7,9,11,& 13. All samples drawn within 2 hrs before start of avelumab infusion. Samples that arepositivefor ADA may undergo characterization for neutralizing antibodies. | Avelumab10mg/kgon Day1&Day15ofeach 4-wk treatment cycle. |

Avelumab ADA (n=344)

<div style=\"page-break-after: always\"></div>

## Analytical methods

Validated avelumab serum concentration analytical method and anti-drug antibody assay have been used.

## Pharmacokinetic Analysis

Summary statistics of avelumab Ctrough and Cmax were provided for study B9991001. A population pharmacokinetic (popPK) analysis across studies was conducted to characterise the PK of avelumab in the aUC population. The popPK analysis is further described below.

## Population Pharmacokinetic Analysis

The present popPK analysis included PK data from patients with aUC in study B9991001 and used the based structural component of the pre-established steady-state popPK model (Modeling &amp; Simulation PopPK Report, ver 1.0, March 2017, previously submitted).

To derive summary measures of avelumab exposure, first the PK from study B9991001 was fit using the base structural component (including body weight by allometric scaling) of the pre-established steady-state popPK model. The population PK analysis dataset included avelumab PK data from the pooled studies (studies EMR100070-001, EMR100070-002, and EMR100070-003), with the addition of avelumab PK data in the first-line maintenance aUC analysis population (study B9991001, Arm A). Individual empirical Bayes estimates of avelumab PK parameters were generated for the aUC analysis population from this popPK model, and subsequently used for deriving both single-dose and steadystate exposure metrics of Ctrough, Cmax, and AUC.

As a pre-established steady-state popPK structural model was used, traditional covariate screening was not conducted because covariate effects have been characterized in the general solid tumour population.  However, study B9991001 specific covariate effects such as ADA and PD L1 ≥ 25% status (dichotomous, yes/no) were graphically explored and final model individual estimates of clearance were compared to evaluate their potential influence on avelumab PK.

Outliers were identified in an initial NONMEM run as observations having an absolute conditional weighted residuals (CWRES) value exceeding 4. These were permanently excluded from subsequent analysis.

Model adequacy and goodness of fit plots were assessed including scatterplots of observed concentrations versus population and individual predicted concentration, and scatterplots of conditional weighted residuals versus population predictions and versus time after dose.

The popPK analysis was performed using NONMEM version 7.4.3 (ICON Development Solutions, Dublin, Ireland), and post-processing was conducted using R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria).

## Results

A total of 2,171 patients receiving avelumab were included in the population PK analysis; 1,827 patients were from the avelumab monotherapy solid tumour popPK dataset previously reported and 344 patients were from the current study B9991001 in which avelumab was administered as first-line maintenance therapy to patients with aUC. In total there were 15,392 PK records with measurable avelumab concentration, 4,566 of which were from the UC first-line maintenance population. In the

<div style=\"page-break-after: always\"></div>

344 patients with UC who received first-line maintenance treatment, 66 were ADA ever-positive and 278 were ADA never-positive. A 15% higher baseline clearance in ADA ever-positive patients versus ADA never-positive patients is consistent with the trend seen in patients with renal cell carcinoma. A total of 187 patients had PD-L1-positive tumours, 137 had PD-L1-negative tumours, and 20 patients were missing PD-L1 status. The baseline demographics and continuous variables are presented in Table 3.

Table 3 . Baseline Continuous Variables in UC First-line Maintenance Population

| Exposure                               |   N |   Missing | Mean (SD)   | Median (Range)   |
|----------------------------------------|-----|-----------|-------------|------------------|
| Age (yr)                               | 344 |         0 | 67.2 (9.59) | 68.5 (37-90)     |
| Baseline Weight (kg)                   | 344 |         0 | 75.2 (16.6) | 72.4 (40-136)    |
| Baseline Tumor Burden (mm)             | 344 |       115 | 29 (33.3)   | 19.9 (0-224)     |
| Baseline Creatinine Clearance (mL/min) | 344 |         0 | 66 (23.7)   | 62.1 (19.1-154)  |
| Baseline eGFR (mL/min/1.73m2           | 344 |         0 | 66.5 (21.4) | 63.6 (29.7-171)  |
| Baseline Albumin (g/L)                 | 344 |         1 | 40.5 (4.43) | 41 (19-51)       |
| Baseline Bilirubin (μumol/L)           | 344 |         0 | 7.3 (3.59)  | 6.8 (0.2-23.9)   |
| Baseline ALT (U/L)                     | 344 |         0 | 19.1 (10.2) | 16.8 (3-61.2)    |
| Baseline AST (U/L)                     | 344 |         0 | 22.1 (10)   | 19.8 (10.2-126)  |
| Baseline Hemoglobin (g/dL)             | 344 |         0 | 11.9 (1.42) | 11.8 (8.5-15.9)  |

Repository artifact ID FI-3199828. Line 1 substituted.

Baseline values were recorded after completing chemotherapy and prior to the first dose of avelumab. UC=urothelial carcinoma; AST=aspartate aminotransferase; ALT=alanine aminotransferase; eGFR=estimated glomerular filtration rate; yr=year; kg=kilogram; U=unit; μumol=micromol; g=gram; mL=milliliter; min=minute; N=total number of patients; Missing=number of patients without a measurement; SD=standard deviation; L=liter.

The observed concentration data from the monotherapy studies in solid tumour patients (EMR100070001, EMR100070-002 and EMR100070-003) were compared graphically to the observed data from the first-line maintenance aUC analysis population. The Ctrough values were overlapping in both populations (Figure 1).

<div style=\"page-break-after: always\"></div>

Figure 1 Plot of Observed Avelumab Ctrough Over Time by Population

<!-- image -->

Repository artifact ID FI-12264413.

Concentrations are plotted out to 1 year after first dose. Solid Tumour Monotherapy represents the population included in previous popPK analysis and is presented in red; aUC Maintenance represents aUC first-line maintenance population treated with avelumab and is presented in blue. LOESS line is shown by population in same color. Shaded areas represent the 95% confidence intervals for the LOESS lines.

aUC=locally advanced or metastatic urothelial carcinoma; Ctrough=trough concentration; mg=microgram; mL=milliliter; popPK=population pharmacokinetic

For the first-line maintenance aUC analysis population, the observed median avelumab Ctrough and Cmax values overlapped when grouped by PD-L1 status (Figure 2), indicating similar PK profiles between patients with PD-L1-positive tumours and those with PD-L1-negative tumours.

<div style=\"page-break-after: always\"></div>

Figure 2. Plot of Median Observed Avelumab Ctrough and Cmax Over Time by PD-L1 Status for UC First-line Maintenance Population

<!-- image -->

Repository artifact ID FI-1880446.

Ctrough and Cmax are grouped by PD-L1 status and plotted out to Cycle 13 Day 1. Negative PD-L1 status represents patients with &lt;25% PD-L1 immune cell expression by Ventana SP263 and is presented in red; Positive PD-L1 status represents patients with &gt;25% PD-L1 immune cell expression by Ventana SP263 and is presented in blue. Cmax observations are represented by dashed lines and Ctrough are represented by solid lines. UC=urothelial carcinoma; Ctrough=trough concentration; Cmax =maximum observed concentration; μg=microgram; mL=milliliter; popPK=population pharmacokinetic.

The final popPK model was a 2-compartment structural model with time-dependent clearance and fixed effects of baseline body weight on CL (baseline clearance), V1, V2, and Q, with exponents estimated on CL, V1, and V2. Final parameter estimates are presented in Table 4, model goodness-of-fit plots and visual predictive checks are presented in Figure 3 and Figure 4 , respectively.

<div style=\"page-break-after: always\"></div>

Table 4 . Final Parameter Estimates Using Pooled PK Dataset Including Solid Tumour Monotherapy and UC First-Line Maintenance Populations

| Parameter           |    Estimate | RSE (%)   | 95% CI            | Shrinkage (%)a   |
|---------------------|-------------|-----------|-------------------|------------------|
| OcL (L/h)           |     0.02731 | 1.02      | 0.02677;0.02786   |                  |
| 0v, (L)             |     3.305   | 0.7822    | 3.254 ; 3.355     |                  |
| 0v2 (L)             |     0.8147  | 6.305     | 0.714 ; 0.9153    |                  |
| Q (L/h)             |     0.0288  | 13.83     | 0.02099 ; 0.03661 |                  |
| 0Imax               |    -0.01856 | 54.62     | -0.03844 ;0.00131 |                  |
| 0Tso (days)         |    71.91    | 10.03     | 57.77 ; 86.06     |                  |
|                     |     2.319   | 16.27     | 1.579 ;3.059      |                  |
| Oweight on CL       |     0.5358  | 6.659     | 0.4659 ; 0.6058   |                  |
| Oweight on V1       |     0.5112  | 5.889     | 0.4522 ; 0.5702   |                  |
| Oweight on V2       |     0.6775  | 23.38     | 0.3671 ; 0.9879   |                  |
| Oproportional error |     0.1976  | 2.868     | 0.1865 ; 0.2087   | 11.28            |
| Oadditive error     |     1.747   | 9.462     | 1.423 ; 2.071     |                  |
| W2L                 |     0.088   | 29.66     | 0.08;0.09599      | 7.929            |
|                     |     0.04769 | 21.84     | 0.03626 ; 0.05912 | 30.01            |
| COVCL -V1           |     0.02956 | 17.19     | 0.02251 ; 0.03662 |                  |
| 0                   |     0       |           | NA ; NA           |                  |
|                     |     0.0672  | 25.92     | 0.0391 ; 0.09531  | 33.25            |
| OFVFOCE-I           | 99460.8     |           | NA ; NA           |                  |

Repository artifact ID FI-1284907. Line 1 substituted.

Final model results are from model including all 2171 patients in popPK analysis dataset (solid tumor monotherapy and UC first-line maintenance treatment populations); CL represents baseline CL (at time of O); fixed effect of body weight through allometric scaling of CL, V1, and V2 included estimated exponents (shown here as Os on the parameters); Imax is the maximal effect of time on CL; T5o is the time at which 50% of Imax is achieved; is the shape parameter; cov is the covariance between the IIV of the 2 parameters; IIV was incorporated as exponential random effect; RSE(%)=SE/estimate * 100%; 95% CI=estimate +/- 1.96 * SE. The 95%CIis calculated using the estimate and SE from the NONMEM output.

UC=urothelial carcinoma; CI=confidence interval; FOCE-I=first order conditional estimation method with interaction; h=hour; IIV=inter-individual variance; L=liter; popPK=population pharmacokinetic; RSE=relative standard error; SE=standard error.

aShrinkage reported in table row for proportional error is the shrinkage corresponding to both os (proportional and additive)

<div style=\"page-break-after: always\"></div>

Figure 3. Plot of Observed Avelumab Concentrations Versus Predicted Concentrations by Population

<!-- image -->

Repository artifact IDFI-1284344.

Solid tumor represents monotherapy population included in previous popPK analysis and is presented in red circles; C represents UC first-line maintenance population and is presented in blue circles.

UC=urothelial carcinoma; popPK=population pharmacokinetic.

<div style=\"page-break-after: always\"></div>

Figure 4. Visual Predictive Check for the Final PopPK Model for 3,200 Hour Time-course for Avelumab Overlaid with UC First-line Maintenance Population Observations

<!-- image -->

Repository artifact ID FI-1999710.

Figure shows time after first dose out to 3200 hours. The left panel displays Cmax and the right panel displays Ctrough. Shaded areas are the 90% confidence intervals around the simulated 5th, 50th, and 95th percentiles (from 100 simulated trials) and lines are the 5th, 50\"h, and 95th percentiles of the observed data, both from the entire model analysis population (avelumab solid tumor monotherapy and UC first-line maintenance population). Points display individual observations from the avelumab UC first-line maintenance population in blue.

UC=urothelial carcinoma; μug=microgram; Ctrough=trough concentration; Cmax=maximum concentration; h=hours; popPK=population pharmacokinetic.

Overall, the PK in the first-line maintenance aUC analysis population was consistent with the PK of the solid tumour population treated with monotherapy avelumab (Table 5 ). Furthermore, the η distribution in Imax across tumour type is visualised in Figure 5 .

<div style=\"page-break-after: always\"></div>

Table 5 . Comparison of Parameter Estimates by Population From Current PopPK Model to Previous PopPK Model in Monotherapy

| Parameter             | Population              | Geometric Mean   | Lower 95% CI   | Upper 95% CI   | Mean (SD)        | Median (Range)          |
|-----------------------|-------------------------|------------------|----------------|----------------|------------------|-------------------------|
| CLbaseline (L/h)      | UC Maintenance          | 0.0264           | 0.0256         | 0.0272         | 0.0276 (0.00869) | 0.0263 (0.00889-0.0819) |
|                       | MonotherapySolid Tumor  | 0.0275           | 0.0272         | 0.0279         | 0.0287 (0.0087)  | 0.0274 (0.00994-0.0754) |
|                       | Combined Population     | 0.0274           | 0.027          | 0.0277         | 0.0285 (0.0087)  | 0.0272 (0.00889-0.0819) |
|                       | Previous Model          | 0.0278           | 0.0274         | 0.0281         | 0.0289 (0.00863) | 0.0278 (0.00953-0.0718) |
| V (L)                 | UC Maintenance          | 3.55             | 3.45           | 3.64           | 3.67 (1.25)      | 3.49 (1.9-20.7)         |
|                       | Monotherapy Solid Tumor | 3.25             | 3.23           | 3.28           | 3.3 (0.575)      | 3.26 (1.55-6.44)        |
|                       | Combined Population     | 3.3              | 3.27           | 3.33           | 3.36 (0.736)     | 3.29 (1.55-20.7)        |
|                       | Previous Model          | 3.1              | 3.07           | 3.13           | 3.15 (0.599)     | 3.11 (1.48-6.21)        |
| V2 (L)                | UC Maintenance          | 0.833            | 0.82           | 0.846          | 0.842 (0.125)    | 0.825 (0.552-1.26)      |
|                       | Monotherapy Solid Tumor | 0.817            | 0.811          | 0.823          | 0.828 (0.14)     | 0.815 (0.458-1.66)      |
|                       | Combined Population     | 0.819            | 0.814          | 0.825          | 0.831 (0.138)    | 0.816 (0.458-1.66)      |
|                       | Previous Model          | 0.925            | 0.909          | 0.942          | 1.02 (0.759)     | 0.917 (0.214-16.3)      |
| Q (L/h)               | UC Maintenance          | 0.0297           | 0.0291         | 0.0304         | 0.0305 (0.00672) | 0.0293 (0.0162-0.0551)  |
|                       | Monotherapy Solid Tumor | 0.0289           | 0.0286         | 0.0293         | 0.0298 (0.00755) | 0.0288 (0.0123-0.0827)  |
|                       | Combined Population     | 0.0291           | 0.0288         | 0.0293         | 0.0299 (0.00743) | 0.0289 (0.0123-0.0827)  |
|                       | Previous Model          | 0.0313           | 0.0313         | 0.0313         | 0.0313 (0)       | 0.0313 (0.0313-0.0313)  |
| Imax                  | UC Maintenance          | NA               | NA             | NA             | 0.00735 (0.18)   | -0.00741 (-0.659-0.931) |
|                       | MonotherapySolidTumor   | NA               | NA             | NA             | -0.0239 (0.158)  | -0.0186 (-0.926-0.806)  |
|                       | Combined Population     | NA               | NA             | NA             | -0.019 (0.162)   | -0.0186 (-0.926-0.931)  |
|                       | Previous Model          | NA               | NA             | NA             | -0.0417 (0.178)  | 0 (-0.984-0.661)        |
| Max change in CL (%)a | UC Maintenance          | NA               | NA             | NA             | 2.42 (19.8)      | -0.739 (-48.3-154)      |
|                       | MonotherapySolid Tumor  | NA               | NA             | NA             | -1.14 (16.1)     | -1.84 (-60.4-124)       |
|                       | Combined Population     | NA               | NA             | NA             | -0.572 (16.8)    | -1.84 (-60.4-154)       |
|                       | Previous Model          | NA               | NA             | NA             | -2.6 (16.9)      | 0 (-62.6-93.6)          |
| T50 (days)            | UC Maintenance          | 71.9             | 71.9           | 71.9           | 71.9 (0)         | 71.9 (71.9-71.9)        |
|                       | MonotherapySolidTumor   | 71.9             | 71.9           | 71.9           | 71.9 (0)         | 71.9 (71.9-71.9)        |
|                       | Combined Population     | 71.9             | 71.9           | 71.9           | 71.9 (0)         | 71.9 (71.9-71.9)        |
|                       | Previous Model          | 70.6             | 70.1           | 71             | 71.4 (13.4)      | 68.4 (68.4-131)         |
| Gamma                 | UC Maintenance          | 2.32             | 2.32           | 2.32           | 2.32 (0)         | 2.32 (2.32-2.32)        |
|                       | Monotherapy Solid Tumor | 2.32             | 2.32           | 2.32           | 2.32 (0)         | 2.32 (2.32-2.32)        |
|                       | Combined Population     | 2.32             | 2.32           | 2.32           | 2.32 (0)         | 2.32 (2.32-2.32)        |
|                       | Previous Model          | 2.53             | 2.48           | 2.57           | 2.67 (0.643)     | 2.91 (0.73-2.91)        |
| Vss (L)               | UC Maintenance          | 4.39             | 4.29           | 4.5            | 4.51 (1.3)       | 4.32 (2.64-21.7)        |
|                       | Monotherapy Solid Tumor | 4.08             | 4.05           | 4.11           | 4.13 (0.682)     | 4.08 (2.23-7.49)        |
|                       | Combined Population     | 4.13             | 4.1            | 4.16           | 4.19 (0.823)     | 4.11 (2.23-21.7)        |
|                       | Previous Model          | 4.1              | 4.06           | 4.13           | 4.18 (0.973)     | 4.08 (2.22-21.5)        |

Repository artifact ID FI-1284854. Line 1 substituted.

UC Maintenance=344patientsfromStudyB9991001 treatedwith avelumabfor UCfirst-line maintenance,post-hocindividual estimates summarized descriptively here are from the current popPK model described within this report;

Combined Population=2,171 patients in the current popPK analysis population (pooled dataset including aforementioned 344 patients from Study B9991001 and1,827patients with solid tumors treated with monotherapy),post-hoc individual estimates summarized descriptively here are from the current popPK model described within this report;

Monotherapy Solid Tumor=1,827 patients with solid tumors treated with monotherapy who were included in the report for the initial marketing applications (M&amp;S PopPK Report [steady state data],version1.0 MAR2017),post-hoc individualestimates summarized descriptivelyhere arefrom the current popPK model described within this report;

Previous Model=1,827 patients with solid tumors treated with monotherapy, post-hoc individual estimates summarized descriptively here are from the Max change in CL from baseline (%) calculated as (elmax -1)*100%.

UC=urothelial carcinoma; CI=confidence interval of the geometric mean; h=hour; L=liter; NA=not applicable; popPK=population pharmacokinetic; SD=standard deviation; CL represents clearance; CLbaseline represents baseline CL (at time of O); V represents central volume; V2 represents peripheral volume; Q represents intercompartmental clearance; Imax is the maximal effect of time on CL; T5o is the time at which 50% of Imax is achieved; Gamma is the shape parameter; Vss represents the steady state volume of distribution

a Geometric mean and corresponding 95% CI not applicable as values can be negative for Imax and max change in CL (%).

<div style=\"page-break-after: always\"></div>

Figure 5. Boxplot of ETA Distributions of Imax by Tumour Type From Final popPK Model

<!-- image -->

Repository artifactIDFI-2077266.

Solid Tumor population includes all patients who received avelumab monotherapy with tumor types that were not H&amp;N, MCC, Melanoma, or UC (N=1286); UC population includes both solid tumor monotherapy and first-line maintenance patients (N=593)

H&amp;N=Head and Neck; MCC=Merkel Cell Carcinoma; UC=urothelial carcinoma; popPK=population pharmacokinetic; Imax represents the maximal effect of time on CL.

## Pharmacokinetics in target population

In study B9991001, mean and median trough and maximum concentrations for avelumab were plotted using a box whisker plot by cycle and day. Avelumab Ctrough (0H or prior to infusion) concentrations appeared to reach steady state at Cycle 2, the 3 rd  infusion of avelumab, and did not appear to increase over time (Figure 6). Study B9991001 employed the weight-based avelumab regimen of 10 mg/kg IV Q2W.

Geometric mean avelumab Ctrough concentrations ranged from 22.2 µg/mL to 32.4 µg/mL between Cycle 1, Day 15 and the last planned collection on Cycle 13, Day 1. The variability in geometric mean Ctrough (as geometric coefficient of variation, %) ranged from 48.6% to 85.2%, with overlapping distribution of concentration over time. Geometric mean avelumab Cmax concentrations ranged from 168.9 µg/mL to 222.8 µg/mL between Cycle 1 Day 1 and Cycle 13 Day 1. The variability in geometric mean Cmax (as geometric coefficient of variation, %) ranged from 30.3% to 86.2%, with overlapping distribution of concentration over time.

<div style=\"page-break-after: always\"></div>

## Figure 6. Box-Plots of Serum Avelumab 0H Concentration by Visit--Avelumab PK Concentration Analysis Set (Protocol B9991001)

Treatment Group=Avelumab+BSC

<!-- image -->

0H=prior to infusion or Ctrough.

Summary statistics have been calculated by setting concentration values below the lower limit of quantification to zero. The lower limit of quantification is 0.20 ug/mL.

Values included are from samples collected on day of infusion on or prior to infusion start time and following a prior dose that was within ±10% of 10 mg/kg and was administered within 14±3 days of the sample in case of cycles 1 to 3.

Values from anomalous sample which are 3 SD above or below the mean concentration for the same visit and nominal time have been excluded from the presentation.

Symbol in the box interior=Mean.  The horizontal line in the box interior=Median.  Upper and lower box lines=1 st  quantiles and 3 rd quantiles, respectively.

End of vertical lines=1 SD above and below the mean.

Symbol outside the box=measurements outside 1 SD from the mean.

Table 6 summarizes the exposure metrics, based on the current population PK model, derived for patients in study B9991001 who received at least 1 dose of avelumab (N=344 out of 350 in the avelumab+BSC arm).

<div style=\"page-break-after: always\"></div>

Table 6 . Summary of Avelumab Exposure Metrics

| Variable                                    |   N |   Nm | Mean (Stdev)         | Median (Max-Min)               |
|---------------------------------------------|-----|------|----------------------|--------------------------------|
| First-dose CL (L/h)                         | 344 |    0 | 0.028 (0.009)        | 0.026 (0.009-0.082)            |
| First-dose AUC (μg.h/mL)                    | 344 |    0 | 28655.142 (8123.010) | 28348.339 (5499.360-92407.316) |
| Trough concentration Cycle 1 Day 15 (μg/mL) | 344 |    0 | 23.215 (10.062 )     | 22.690 (2.232-96.307)          |
| First-dose Cmax (μg/mL)                     | 344 |    0 | 209.469 (49.535)     | 204.675 (37.541-434.980)       |
| First-dose amount (mg)                      | 344 |    0 | 746.743 (170.872)    | 720.000 (126.000-1350.000)     |

Repository artifact ID FI-2148268.

Only patients who received at least one dose of avelumab are summarized in the table.

AUC=area under the avelumab concentration-time curve; BSC=best supportive care; CL=clearance;

Cmax=maximum concentration; Max=maximum; Min=minimum value; N=number of patients; Nm=number of patients with missing observations; Stdev=standard deviation.

According to the population PK analysis, the geometric mean (95% CI) baseline CL of avelumab in the aUC population from study B9991001 was 0.0264 L/h (0.0256-0.0272), which was consistent with the baseline CL estimated with the previous pooled dataset of 0.0278 L/h (0.0274-0.0281). A comparison of avelumab baseline CL is represented in Figure 7. The change in CL over time of &lt;5% in the aUC population indicates no change in avelumab clearance over time in patients with aUC.

<div style=\"page-break-after: always\"></div>

Figure 7. Boxplot Comparing Estimated Avelumab Baseline Clearance between aUC First-line Maintenance and Solid Tumour Monotherapy Populations

<!-- image -->

Repository artifactIDFI-2014170.

Blue boxplot is baseline clearance in aUC population of 344 patients receiving first-line maintenance treatment following 10 mg/kg Q2W using the popPK model as described within this report; pink boxplot is baseline clearance in Solid Tumor Monotherapy population of 1,827 patients from the previous submission (M &amp; S PopPK Report [steady-state data], version 1.0 MAR2017).

In the 344 patients with aUC who received first-line maintenance treatment, 66 were ADA everpositive and 278 were ADA never-positive. Baseline CL and maximum change in CL from baseline were summarized by ADA status using the post-hoc estimates from the popPK model. Baseline CL was similar between the ADA status groups, with geometric mean (95% CI) of 0.0295 L/h (0.0271-0.0322) in ADA ever-positive patients, and 0.0257 (0.0249-0.0265) in ADA never-positive patients. Graphical comparison of avelumab baseline CL by ADA status is presented in Figure 8 and shows overlap of CL distributions by ADA status.

<div style=\"page-break-after: always\"></div>

Figure 8. Boxplot Comparing Estimated Avelumab Baseline Clearance for aUC First-line Maintenance Population from Study B9991001 by ADA Status

<!-- image -->

A total of 187 patients had PD-L1-positive tumours, 137 had PD-L1-negative tumours, and 20 patients were missing PD-L1 status. Avelumab baseline CL was similar between patients with PD L1 positive tumours and patients with PD-L1-negative tumours with geometric mean (95% CI) baseline CL of 0.0267 L/h (0.0256, 0.0279) in patients with PD-L1-positive tumours and 0.0259 L/h (0.0248, 0.0271) in patients with PD L1 negative tumours. Graphical comparison of avelumab baseline CL by PD-L1 status presented in Figure 9 and shows overlap of CL distributions by PD-L1 status.

<div style=\"page-break-after: always\"></div>

Figure 9. Boxplot Comparing Estimated Avelumab Baseline Clearance for UC First-line Maintenance Population from Study B9991001 by PD-L1 Status

<!-- image -->

Repository artifact ID FI-2000087.

Red boxplot represents baseline clearance in the PD-L1-Negative population (N=137); blue boxplot represents baseline clearance in the PD-L1-Positive population (N=187); patients with missing PD-L1 status (N=20) are notrepresentedhere.

UC=urothelial carcinoma; CL=clearance; L=liter; h=hour; PD-L1=Programmed Death Ligand-1.

Table 7 summarizes population PK predicted avelumab baseline CL by ADA status and PD-L1 status.

Table 7. Comparison of Baseline Clearance Estimates From Current PopPK Model by ADA Status and PD-L1 Status for UC First-line Maintenance Population

| Parameter        | Population        |   N |   Geometric Mean |   Lower 95% CI |   Upper 95%CI | Mean (SD)     | Median (Range)      |
|------------------|-------------------|-----|------------------|----------------|---------------|---------------|---------------------|
| CLbaseline (L/h) | ADAEver-Positive  |  66 |           0.0295 |         0.0271 |        0.0322 | 0.032 (0.013) | 0.030 (0.012-0.082) |
|                  | ADANever-Positive | 278 |           0.0257 |         0.0249 |        0.0265 | 0.027 (0.007) | 0.026 (0.009-0.053) |
|                  | PD-L1-Negative    | 137 |           0.0259 |         0.0248 |        0.0271 | 0.027 (0.008) | 0.026(0.015-0.053)  |
|                  | PD-L1-Positive    | 187 |           0.0267 |         0.0256 |        0.0279 | 0.028 (0.010) | 0.026 (0.009-0.082) |
|                  | PD-L1 Missing     |  20 |           0.0267 |         0.0245 |        0.0291 | 0.027 (0.006) | 0.026 (0.019-0.040) |

Repository artifact IDFI-2097927.Line1substituted.

UCfirst-linemaintenancepopulationincludes344patientsfromStudyB9991001treatedwith avelumab,andpost-hocindividualestimatessummarized ADANever-positivepopulationincludespatientswhonever tested positiveforADA;PD-L1-Negativestatusrepresents patientswith&lt;25%PD-L1immune cell expressionbyVentanaSP263;PD-L1-Positivestatusrepresents patients with&gt;25%PD-L1immunecellexpressionbyVentanaSP263

UC=urothelialcarcinoma;N=number ofpatients;ADA=anti-drug antibody;PD-L1=Programmed Death Ligand1;CI=confidenceintervalof thegeometric mean; h=hour; L=liter; NA=not applicable; popPK=population pharmacokinetic; SD=standard deviation.

a Geometric mean and geometric CI not applicable as values can be negative for Imax.

<div style=\"page-break-after: always\"></div>

## Flat-dose justification

The previous popPK model from avelumab monotherapy treatment of patients with solid tumours was used to derive single-dose and steady-state avelumab exposure metrics of AUC, Cmax, and Ctrough (Modeling and Simulation PopPK Report, version 1.0 March 2017, previously submitted). This previous popPK model utilized data from the pooled PK database of 1827 patients with solid tumours where the median baseline body weight was 70.6 kg (range: 30.4 to 204 kg). The simulated exposures for the 800 mg Q2W flat-dosing regimen from the previous popPK model served as the reference dataset and was imported into this current analysis.

For the first-line maintenance aUC analysis population, the same exposure metrics were derived from the final popPK model individual parameter estimates, and the predicted avelumab exposures were plotted alongside the exposure references of the previously simulated 800 mg Q2W exposure distributions.

Graphical comparison of avelumab exposures in patients with aUC from study B9991001 to those reference exposures simulated from the popPK model in patients with solid tumours with flat-dosing regimen are shown below in the form of boxplots for AUC at steady state (AUCtau, ss) (Figure 10) and Ctrough at steady state (Ctrough, ss) (Figure 11). The exposures estimated in the first-line maintenance aUC analysis population were overlapping with those reference simulations presented previously for the 10 mg/kg Q2W regimen and the 800 mg Q2W flat dosing regimen from patients with various solid tumours.

<div style=\"page-break-after: always\"></div>

Figure 10. Boxplot for Derived Avelumab AUCtau,ss in aUC and Simulated Reference AUCtau,ss Following Weight-Based and Flat Dosing Regimens

<!-- image -->

Repository artifactIDFI-1578623.

Green boxplot is AUCtauss (derived from individual parameter estimates) in aUC population of 344 patients receiving first-line maintenance treatment with 10 mg/kg Q2W using the popPK model as described within this report; red boxplot and blue boxplot are previously-simulated AUCtau.ss following 10 mg/kg Q2W and 800 mg Q2W, respectively, using popPK model results in solid tumor monotherapy population, as performed in the flat dosing report (M &amp; S Population Analysis Report for Flat Dosing. DEC2017,from previous submission).

<div style=\"page-break-after: always\"></div>

Figure 11. Boxplot for Derived Avelumab Ctrough,ss in aUC and Simulated Reference Ctrough,ss Following Weight-Based and Flat Dosing Regimens

<!-- image -->

Repository artifact ID FI-1578627.

receiving first-line maintenance treatment with 10 mg/kg Q2W using the popPK model as described within this report; red boxplot and blue boxplot are previously-simulated Ctough.ss following 10 mg/kg Q2W and 800 mg Q2W, respectively, using RopPK model results in solid tumor monotherapy population, as performed in the flat dosing report (M &amp; S Population Analysis Report for Flat Dosing, DEC2017, from previous submission).

## 2.3.3. Pharmacodynamics

There are no new conclusions regarding pharmacodynamics since the original mMCC submission.

## 2.3.4. PK/PD modelling

## Exposure-Efficacy Analysis

The population PK/PD exposure- efficacy analysis, included data from patients with aUC in study B9991001 randomized to Arm A and used the derived avelumab exposure metrics from the popPK analysis.

The efficacy endpoint analyzed in the exposure-response analyses was overall survival (OS) in patients randomized to Arm A of study B9991001, irrespective of PD-L1 expression on their tumours (N=350) and in patients with PD-L1-positive tumours (N=189). The definition for OS is the same as that for the

<div style=\"page-break-after: always\"></div>

analysis of clinical efficacy per study statistical analysis plan as reported in the CSR for B9991001. Figure 12 shows the OS for patients in Study B9991001. The left panel shows the OS for all randomized patients by treatment Arm (avelumab+BSC Arm (red) versus BSC Arm (blue)), and the right panel shows the OS for patients in the avelumab+BSC Arm of study B999100 stratified by avelumab exposure quartiles (Cycle 1 Day 15 trough concentration): quartile 1 red, quartile 2 blue, quartile 3 green, and quartile 4 purple).

Figure 12. OS for Patients in Study B9991001 Irrespective of PD-L1 Expression.

<!-- image -->

Repository artifact IDs are shown in subfigure labels.

The left panel shows the OS for patients in Study B9991001 by treatment arm (Arm A versus Arm B) and the right panel shows the OS for patients in Study B9991001 Arm A only (avelumab+BSC), stratified by avelumab exposure (Cycle 1 Day 15 trough concentration) quartiles. Arm A=avelumab+BSC arm; AUC=area under the concentration-time curve; Arm B=BSC arm; BSC=best supportive care; OS=overall survival; PD-L1=Programmed Death Ligand-1; Q1=avelumab Cycle 1 Day 15 trough concentration, first quartile ; Q2=avelumab Cycle 1 Day 15 trough concentration, second quartile; Q3=avelumab Cycle 1 Day 15 trough concentration, third quartile; Q4=avelumab Cycle 1 Day 15 trough concentration, fourth quartile.

The exposure-efficacy data were evaluated using time-to-event analyses where the available data were fit to a survival function.

In order to minimize the potential impact of post-treatment effects on avelumab PK, avelumab singledose exposure metrics (CL, AUC, Ctrough, and Cmax, and dose amount) were first evaluated in univariate analyses to assess the potential influence on the survival function.

A log-normal distribution best described the OS data based on likelihood ratio test and visual inspection of diagnostic plots. Avelumab single-dose Cycle 1 Day 15 Ctrough, using a power model, was identified as the most significant exposure metric in patients with aUC randomized to Arm A, irrespective of PD-L1 expression. The final model parameter estimates are presented in Table 8.

<div style=\"page-break-after: always\"></div>

Table 8. Final Model Parameter Estimates For OS Patients in the Avelumab+BSC Arm, Irrespective of PD-L1 Expression by PD-L1-Status

| Parameter                                                  |     Value | RSE (%)   | 95% CI            |
|------------------------------------------------------------|-----------|-----------|-------------------|
| 0o                                                         |    0.9525 | 6.02      | (0.840 - 1.065)   |
| Oμ                                                         |    6.5552 | 1.85      | (6.318 - 6.793)   |
| OAvelumab Cycle 1 Day 15 trough concentration on μ (μg/mL) |    0.0043 | 23.80     | (0.002 -0.006)    |
| OLog of baseline LDH on μ                                  |   -0.0839 | -32.16    | (-0.137 - -0.031) |
| OBaseline metastasis on μ (non - visceral)                 |    0.0552 | 38.56     | (0.013 -0.097)    |
| OPDL1 on μ (negative)                                      |   -0.0649 | -28.63    | (-0.101 - -0.028) |
| OPDL1 on μ (missing)                                       |   -0.0396 | -97.29    | (-0.115 -0.036)   |
| OBaseline hemoglobin on μ (g/L)                            |    0.2298 | 36.71     | (0.064 -0.395)    |
| OFV                                                        | 2221.62   |           |                   |

Repository artifact ID FI-2989650. Line 1 substituted.

CI=confidence interval; μos=location distribution parameter; Oos=scale distribution parameter; OFV=objective function value; OS=overall survival; PD-L1=Programmed Death Ligand-1; RSE=relative standard error.

## Exposure-Safety Analysis

The population PK/PD exposure-safety analysis included data from patients with aUC in Study B9991001 and used the derived avelumab exposure metrics from the popPK analysis described above.

The safety analysis included all patients with aUC from study B9991001 who received at least one dose of avelumab. The analysis captured all types of adverse events (AEs) that occurred at least once in each patient. The safety event endpoints that were assessed were TEAEs Grade ≥ 3, irAEs Any Grade, and IRRs Any Grade. All AE grades were derived using the NCI CTCAE version 4.03 definitions. For each type of safety event, patients were classified as experiencing the AE in the applicable severity/Grade category at least once during the duration of the study, or never experiencing the AE. The incidence of all selected AEs endpoints is presented in Table 9.

Table 9. Incidence of Reported Safety Endpoints

| Category                 | N (%)       |
|--------------------------|-------------|
| Total Number of Patients | 344 (100%)  |
| irAE Any Grade           | 101 (29.4%) |
| irAE Grade ≥3            | 24 (7%)     |
| TEAEAnyGrade             | 337 (98%)   |
| TEAE Grade≥3             | 163 (47.4%) |
| IRR Any Grade            | 74 (21.5%)  |

Repository artifact ID FI-3199826.

Grades reported were based on CTCAE version 4.03 definitions. irAE Grade ≥3 and TEAE Any Grade were not modeled.

N=number of subjects; irAE=immune-related adverse event; TEAE=treatment-emergent adverse event; IRR=infusion-related reaction; CTCAE=Common Terminology Criteria for Adverse Events.

A base model was developed for each of the safety endpoints using a logistic regression model. Univariate screen of avelumab exposures of AUCtau,sd, Ctrough,sd, Cmax,sd, and Ctrough,ss was performed to determine the exposure parameter with the largest change in deviance. The chosen exposure

<div style=\"page-break-after: always\"></div>

parameter was then selected for incorporation into the base model. The full model was comprised of the base model and all covariates of interest in scope. Covariates of interest included patient demographics, laboratory parameters, and disease-related values. Covariates were assessed for skewedness and collinearity and if two covariates were highly correlated (defined as |r| ≥ 0.6), only one was selected for multivariate analysis based on clinical relevance. The final model included the avelumab exposure metric along with any covariate effects on regression parameters that were retained during the backward elimination step using a threshold of α&lt; 0.01. Model adequacy and goodness of fit was assessed by the Hosmer-Lemeshow test.  Model predictive performance was based on the c-index (or area under the ROC curve).

The safety analysis was performed in R by binomial logistic regression using the glm function. R version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria) was also used for data processing, all modeling analyses, post-processing, and generation of figures and tables.

## Treatmentemergent Adverse Events of Grade ≥ 3

The final model for TEAEs Grade ≥ 3 included avelumab C max,sd (based on the largest change in deviance, p=0.07) and baseline hemoglobin. A relatively flat exposure-response relationship was observed, where the predicted probabilities of TEAEs Grade ≥ 3 appear greater in patients with aUC with high Cmax,sd. Predicted probabilities of TEAE Grade ≥ 3 as a function of Cmax,sd and separated by median HGB (11.78 g/dL) are shown in Figure 13. For the 5th to 95th percentiles of Cmax,sd (140.9291.5 µg/mL), the probabilities of TEAEs Grade ≥ 3 ranged from 0.560 -0.675 for patients with baseline hemoglobin ≤ 11.78, and 0.314 -0.404 for patients with baseline hemoglobin &gt;11.78. The correlation between baseline hemoglobin and predicted probabili ties of TEAEs Grade ≥ 3 is expected.

<div style=\"page-break-after: always\"></div>

Figure 13 . Predicted Probability of TEAE Grade ≥3 by Hemoglobin in Patients with UC

<!-- image -->

Repository artifact ID FI-3756699.

Red line and shaded region represent predicted probability of TEAE Grade ≥3 and 95% CI in patients with baseline hemoglobin ≤ 11.78 g/dL. Blue line and shaded region represent predicted probability of TEAE Grade ≥3 and 95% CI in patients with baseline hemoglobin &gt; 11.78 g/dL. Dashed vertical lines represent the 25th and 75th percentiles of Cmax,sd. Blue dotted vertical lines represent the 5th and 95th percentiles of Cmax,sd. Derived Cmax,sd for patients with no TEAE Grade ≥3 event are marked on the bottom of the plot, while derived Cmax,sd for patients with at least one TEAE Grade &gt;3 event are marked on the top of the plot.

TEAE=treatment-emergent adverse event; UC=urothelial carcinoma; Cmax,sd=maximum observed concentration after single dose; μg=microgram; mL=milliliter; g=gram; dL=deciliter; CI=confidence interval.

## Infusion-related Adverse Events of Any Grade

The final model for IRRs Any Grade included AUCtau,sd (based on the largest change in deviance, p =0.003). No other covariates were included based on backwards elimination threshold of α&lt;0.01. An inverse exposure-response relationship was found, where the predicted probabilities of IRRs Any Grade are higher in patients with aUC with lower avelumab AUCtau,sd (Figure 14). This is likely confounded by dose interruptions as all of the patients who experienced a dose interruption when receiving the first infusion also had AUCtau,sd values below the population median (the range of exposures in these 8 patients is represented by the pink shaded region in Figure 14). Therefore, based on the shallow relationship and the direction of the effect, it is not considered meaningful.

<div style=\"page-break-after: always\"></div>

Figure 14. Predicted Probability of IRR Any Grade in Patients with UC

<!-- image -->

## Repository artifact IDFI-3756698.

Blue line and shaded region represent predicted probability of IRR Any Grade and 95% CL Dashed vertical lines represent the 25th and 75th percentiles of AUCtausd. Blue dotted vertical lines represent the 5th and 95th who experienced a dose interruption when receiving their first infusion of avelumab. Derived AUCtau,sd for patients with no IRR Any Grade event are marked on the bottom of the plot, while derived AUCtau,sd for patients with at least one IRR Any Grade event are marked on the top of the plot.

IRR=infusion-related reaction; UC=urothelial carcinoma; AUCtau,sd=area under the concentration-time profile of dosing interval after single dose; mg=milligram; h=hour; L=liter; g=gram; Cl=confidence interval.

## Immune-related Adverse Events of Any Grade

The final model for irAEs Any Grade included Cmax,sd (based on the largest change in deviance, p=0.14). No other covariates were included based on backwards elimination threshold of α&lt;0.01. A relatively flat exposure-response relationship was observed, where the predicted probabilities of irAEs Any Grade appear higher in patients with aUC with higher Cmax,sd, visualized in Figure 15. For the 5 th  to 95 th  percentiles of Cmax,sd (140.9-291.5 µg/mL), the predicted probabilities for irAEs Any Grade ranged from 0.244-0.355, which is considered low.

<div style=\"page-break-after: always\"></div>

Figure 15. Predicted Probability of irAE Any Grade in Patients with UC

<!-- image -->

Repository artifact ID FI-3756619.

Blue line and shadedregion represent predicted probability of irAE Any Grade and 95%Cl Dashed vertical lines represent the 25th and 75ih percentiles of Cmax,sd. Blue dotted vertical lines represent the 5th and 95th percentiles of Cmax,sd. Derived Cmax,sg for patients with no irAE Any Grade event are marked on the bottom of the plot, while derived Cmax,sd for patients with at least one irAE Any Grade event are marked on the top of the plot.

irAE=immune-related adverse event; UC=urothelial carcinoma; Cmax,sd=maximum observed concentration after single dose; μ g=microgram; mL=milliliter; CI=confidence interval.

## 2.3.5. Discussion on clinical pharmacology

## Pharmacokinetics

The avelumab PK in the aUC population was mainly evaluated through population PK. A previously submitted avelumab PK model (in the mMCC submission), based on several solid tumour indications, served as the basis of the popPK analysis in the aUC population. This approach is accepted and of note, the approach was also applied in the aRCC submission. The model development and the population PK model results are endorsed.

Overall, the PK of avelumab in the aUC population is similar to the avelumab PK in solid tumours. Exploratory graphical assessment of observed concentration as well as the population PK analysis, indicate that there is no change in avelumab clearance over time in the aUC patient population. The population PK parameters in the aUC population were consistent to the previous avelumab PK model. Furthermore, patient population specific covariates, ADA and PD-L1 status, do not seem to have a relevant effect on avelumab PK in the aUC population.

## Flat-dose justification

The flat-dose justification is mainly based on the comparison between the expected (simulated) exposure range given the 10 mg/kg dose and the 800 mg flat-dose. In general, this approach is endorsed, and the objective is to ensure that the proposed flat-dose regimen results in a similar exposure range as the 10 mg/kg dosing regimen with the underlying assumption that the avelumab safety and efficacy profile remains the same. The comparison between simulated exposure range given 10 mg/kg Q2W or 800 mg Q2W, respectively, indicate that the 800 mg flat dose regimen in general

<div style=\"page-break-after: always\"></div>

results in slightly higher exposure than for the per kg dosing (for all exposure metrics). As expected, the body weight relationship is reversed, with the lowest exposures for the patients with the highest body weights and a higher exposure for low body weight. Nevertheless, the expected exposure levels are within the reference exposure range and the new dosing regimen is expected to result in similar or slightly higher exposure compared to the 10 mg/kg dosing regimen. Hence, the 800 mg flat dose can be accepted for all patients regardless of body weight.

## Exposure-response

It is important to note that several factors may limit the interpretation of the E-R modeling results. First, the range of data used in the analysis was limited to a single dose level (10 mg/kg IV Q2W), resulting in a narrow range of exposure evaluated (single-dose Cycle 1 Day 15 Ctrough ranged from 0 to 96 mg/L). In general, exposure-response analyses based on one dose level should be interpreted with caution since it is difficult to distinguish between effects of exposure and other variables that can confound the E-R relationship. Second, there was an imbalance of baseline health status across exposure quartiles, including more patients with ECOG=0 and higher body weight at baseline in higher exposure quartiles. As such, the E-R analyses should be considered exploratory only.

A univariate screen of avelumab exposures of AUCtau,sd, Ctrough,sd, Cmax,sd, and Ctrough,ss was performed to determine the most informative exposure parameter. As such, no mechanistic consideration has been made in the choice of exposure metric. For the exposure-efficacy analysis, only exposure metrics based on concentration samples from the first cycle were used in the analysis.

The exposure-OS results suggested that a higher exposure (Ctrough,sd) was associated with a higher probability of longer OS in the parametric survival models in patients irrespective of PD-L1 expression on their tumours and in patients with PDL1-positive tumours. The results are in line with the previously reported positive exposure-efficacy relationships for other indications of avelumab.

Models for safety endpoints TEAEs Grade ≥ 3 and irAEs Any Grade showed relatively shallow relationships between avelumab exposure (Cmax, sd) and safety events. The inverse relationship of avelumab AUCtau, sd and IRRs Any Grade is likely confounded by other factors, such as dose interruptions, hence the exposure cannot be considered an independent variable for infusion related response. Thus, the exposure-IRR relationship is not considered meaningful. In all models, ADA status and PD-L1 status were tested as covariates, but they were not significant for any safety endpoint and thus no associations were detected

Overall, the exposure-response relationships for safety endpoints were similar to those estimated previously for avelumab administered as monotherapy in patients with solid tumours and in combination with axitinib in patients with aRCC.

## 2.3.6. Conclusions on clinical pharmacology

In general, the clinical pharmacology documentation regarding the aUC indication is supported. Overall, the avelumab pharmacokinetics, PKPD and immunogenicity in the UC patient population is similar to what has been previously reported for solid state tumours and the aUC indication. The flat dose posology can be accepted.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical efficacy

## 2.4.1. Main study

## Title of Study

## Study B9991001

A Phase 3, multicentre, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) plus BSC versus BSC alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy (JAVELIN Bladder 100).

## Methods

Figure 16.  Study B9991001 design

<!-- image -->

- a.Allowedfirst-line chemotherapyregimens aregemcitabine+cisplatinorgemcitabine+carboplatin.
- b.Randomizationmust occurat least4andnotmore than10weeksafterthelast doseoffirst-linechemotherapy andwill be stratified by:bestresponse on1st-line therapy(CRorPRvs. SD)and metastatic disease site(visceral vs.non-visceral).

CR=completeresponse;IV=intravenous;PD=progressive disease;PR=partial response;Q2W=every 2weeks;SD= stabledisease

## Study participants

## Main inclusion criteria

- Diagnosis:
- a. Histologically confirmed, unresectable locally advanced or metastatic transitional cell carcinoma of the urothelium.
- b. Documented Stage IV disease (per American Joint Committee on Cancer/International Union for Cancer Control Tumour Node Metastasis (TNM) system, 7th edition) at the start of first-line chemotherapy.

<div style=\"page-break-after: always\"></div>

- c. Measurable disease prior to the start of first-line chemotherapy by RECIST v1.1.
- Prior first-line chemotherapy must have consisted of at least 4 cycles and no more than 6 cycles of gemcitabine + cisplatin and/or gemcitabine + carboplatin. No other chemotherapy regimens were allowed in this study.
- a. The last dose of first-line chemotherapy must have been received no less than 4 weeks, and no more than 10 weeks, prior to randomization in the present study.
- Patients without progressive disease as per RECIST v1.1 guideline (i.e., with an ongoing CR, PR, or SD) following completion of 4 to 6 cycles of first-line chemotherapy.
- a. Eligibility based on this criterion will be determined by investigator review of prechemotherapy and post-chemotherapy radiological assessments (CT/MRI scans).
- Provision of a recent formalin-fixed, paraffin-embedded (FFPE) tumour tissue block (or subsection thereof) from the most recent primary or metastatic tumour biopsy or resection obtained prior to treatment with first-line chemotherapy but within 24 months prior to randomization, with no intervening systemic anti-cancer therapy. If a FFPE tissue block cannot be provided, 15 freshly cut unstained slides (10 minimum) will be acceptable. If a suitable tissue sample is not otherwise available, then a de novo biopsy (core needle or excisional) must have been obtained for research purposes prior to randomization in this study. Note: tumour tissue from cytologic sampling (e.g., fine needle aspiration, including FFPE cell pellet material) or bone metastases are not acceptable and should not be submitted.
- Evidence of a signed and dated informed consent document indicating that the patient (or a legally acceptable representative, as allowed by local guideline/practice) has been informed of all pertinent aspects of the study.
- Age ≥18 years (≥20 years in Japan).
- Estimated life expectancy of at least 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1.
- Adequate bone marrow function, including:
- a. Absolute neutrophil count (ANC) ≥1,500/mm 3 or ≥1.5 x 10 9 /L;
- b. Platelets ≥100,000/mm 3 or ≥100 x 10 9 /L;
- c. Haemoglobin ≥9 g/dL (may have been transfused).
- Adequate renal function, defined as estimated creatinine clearance ≥30 mL/min as calculated using the Cockcroft-Gault equation or by 24-hour urine collection for creatinine clearance or according to the local institutional standard method.
- Adequate liver function, including:
- a. Total serum bilirubin ≤1.5 x upper limit of normal (ULN);
- b. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN, or, for patients with documented metastatic disease to the liver, AST and ALT levels ≤5 × ULN.

## Main exclusion criteria

- Patients whose disease progressed by RECIST v1.1 on or after first-line chemotherapy for urothelial cancer.

<div style=\"page-break-after: always\"></div>

- Prior adjuvant or neoadjuvant systemic therapy within 12 months of randomization.
- Prior immunotherapy with IL-2, IFNα, or an anti -PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or CTLA-4 antibody (including ipilimumab), or any other antibody or drug specifically targeting Tcell co-stimulation or immune checkpoint pathways.
- Major surgery ≤4 weeks or major radiation therapy ≤2 weeks prior to randomization. Prior palliative radiotherapy is permitted, provided it has been completed at least 48 hours prior to patient randomization.
- Patients with known symptomatic central nervous system (CNS) metastases requiring steroids. Patients with previously diagnosed CNS metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to randomization, have discontinued corticosteroid treatment for these metastases for at least 4 weeks, and are neurologically stable.
- Persisting toxicity related to prior therapy NCI CTCAE v4.0 Grade &gt;1; however, alopecia, sensory neuropathy Grade ≤2 is acceptable, or other Grade ≤2 adverse events not constituting a safety risk based on the investigator's judgment are acceptable.
- Diagnosis of any other malignancy within 5 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix, lowgrade (Gleason ≤6) prostate cancer on surveillance without any plans for treatment intervention (e.g., surgery, radiation, or castration), or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms.
- Participation in other studies involving investigational drug(s) within 4 weeks prior to randomization. Observational studies are permitted.
- Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.
- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (&lt;6 months prior to enrolment), myocardial infarction (&lt;6 months prior to enrolment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
- Active infection requiring systemic therapy.
- Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥3), any history of anaphylaxis, or uncontrolled asthma (i.e., 3 or more features of asthma symptom control per the Global Initiative for Asthma 2015).
- Current or prior use of immunosuppressive medication within 7 days prior to randomization, EXCEPT the following:
- c. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection);
- d. Systemic corticost eroids at physiologic doses ≤10 mg/day of prednisone or equivalent;
- e. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Positive test for human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).

<div style=\"page-break-after: always\"></div>

- Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).

In addition, the inclusion and exclusion criteria included restrictions regarding pregnancy, breastfeeding transplanted patients requiring immunosuppressive drugs, prior immunodeficiency, vaccinations within 4 weeks of study drug with non-inactive vaccines and other severe acute or chronic medical conditions.

## Determination of PD-L1-status

The IUO-labelled VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems, Inc., a member of the Roche Group) has been analytically validated in UC at a defined cut-off. For the purpose of this study, PD-L1 status is considered high if any of the follo wing are met:  ≥25% of tumour cells exhibit membrane staining; or, ICP &gt;1% and tumourassociated immune cells with staining (IC+) ≥25%; or, ICP = 1% and IC+ = 100%. PD-L1 status is considered low/negative if none of the above criteria for PD-L1 high status are met. If PD-L1 status is interpreted as high the tumour will be defined as PD-L1positive; PD-L1 low/negative status will be defined as PD-L1-negative.

## Treatments

- Avelumab plus BSC; avelumab 10 mg/kg administered as 1-hour IV infusion Q2W
- BSC alone

BSC was prescribed and/or administered per current treatment practices at each investigational site and per individual patient needs and could include treatment with antibiotics, antiemetics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC did not include any active anti-tumour therapy.

In order to mitigate infusion-related reactions, premedication with an antihistamine and with paracetamol (acetaminophen) approximately 30 to 60 minutes prior to the first 4 infusions of avelumab was mandatory (for example, 25-50 mg diphenhydramine and 500-650 mg paracetamol [acetaminophen] IV or oral equivalent). Premedication should be administered for subsequent avelumab doses based upon clinical judgment and presence/severity of prior infusion reactions. The premedication regimen may be modified based on local treatment standards and guidelines, as appropriate, provided it does not include systemic corticosteroids

For avelumab, no dose modifications were permitted in this study, but next infusion may be omitted based on persisting toxicity.

Treatment was to be continued until confirmed disease progression as assessed by BICR or unacceptable toxicity. Before amendment 4, in the absence of clinical deterioration, it was stipulated that the patient should remain on treatment until progression was confirmed by BICR at least 4 weeks after the first diagnosis of progression. However, avelumab could be continued at the investigator's discretion after discussion with the sponsor if the following criteria were met:

- Absence of clinical signs and symptoms (including worsening of laboratory values) of disease progression;
- No decline in ECOG PS;
- Absence of rapid disease progression evident in radiographic imaging;
- Absence of progressive tumour at critical anatomical sites (e.g., cord compression) requiring urgent alternative medical intervention.

<div style=\"page-break-after: always\"></div>

Patients could be eligible for re-treatment at the discretion of the investigator and after discussion with the sponsor's medical monitor if the following criteria were met:

- 1) no cancer treatment was administered other than BSC since the last dose of avelumab,
- 2) the patient did not meet the safety withdrawal criteria,
- 3) the trial was still open.

Drug-related adverse reactions (excluding infusion-related reaction/hypersensitivity and immunerelated AE) of Grade 3 severity required avelumab to be withheld until recovery to Grade ≤1 or baseline. Infusion -related reactions and irAEs were handled in agreement with 4.4 in SmPC.

Duration of on-treatment period was for safety endpoints defined as:

- Avelumab plus BSC:  time  from  the  first  dose  of  study treatment through  minimum  (30 days  +  last  dose  of study treatment, start day of new anti-cancer drug therapy -   1 day)
- BSC: time from Cycle 1 Day 1 through minimum  (30 days + end date of BSC, start day of new anti-cancer drug therapy - 1 day)

The MAH have proposed a different dosing regimen compared to what was used in the trial. The weight-based dosing regimen for avelumab (10 mg/kg IV Q2W) used in pivotal Phase 3 Study B9991001 was based on the dose identified in the Phase 1 Study EMR100070-001.

The recommended dosing regimen for the treatment of mMCC and aRCC is 800 mg of avelumab, given by IV infusion over 60 minutes Q2W, as summarized in the current SmPC. The proposed dosing regimen for avelumab for first-line maintenance treatment in patients with aUC is 800 mg IV Q2W.

## Objectives

Primary Objectives

- To demonstrate the benefit of maintenance treatment with avelumab plus BSC vs. BSC alone in prolonging OS in patients with unresectable locally advanced or metastatic UC whose disease did not progress on or following completion of first-line platinum-containing chemotherapy in each co-primary aUC patient population:
1. patients determined to have PD-L1-positive tumours (including infiltrating immune cells) by a verified Good Manufacturing Practice (GMP) PD-L1 immunohistochemistry (IHC) test,
2. all randomized patients.

Secondary Objectives

- To compare the PFS of avelumab plus BSC vs. BSC alone in patients determined to have PD-L1-positive tumours (including infiltrating immune cells) by a verified GMP PD-L1 IHC test, and in all randomized patients.
- To evaluate the anti-tumour activity of avelumab plus BSC and BSC alone according to Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 in patients determined to have PD-L1-positive tumours (including infiltrating immune cells) by a verified GMP PD-L1 immunohistochemistry (IHC) test, and in all randomized patients.
- To evaluate the overall safety profile of avelumab plus BSC and BSC alone.

and

<div style=\"page-break-after: always\"></div>

- To evaluate the PK of avelumab in each of the co-primary UC patient populations treated with avelumab.
- To assess the immunogenicity of avelumab in each of the co-primary UC patient populations treated with avelumab.
- To evaluate candidate predictive biomarkers of sensitivity or resistance to avelumab in pre-treatment tumour tissue in each of the co-primary UC patient populations treated with avelumab.
- To evaluate the effect of avelumab plus BSC and BSC alone on patient-reported outcomes (PROs) in each of the co-primary UC patient populations.

## Exploratory Objectives

- To explore the predictive and/or pharmacodynamic (PD) characteristics of peripheral blood and additional tumour tissue biomarkers relevant to the mechanism of action of or resistance to avelumab.

## Outcomes/endpoints

Table 10. Summary of key Efficacy endpoints: Definitions and Censoring Rules

| Efficacy endpoint                                                                                                | Definition                                                                                                                                                                                                                                                                                               | Censoring/Handling of data                                                                                                                                                        |
|------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary endpoint                                                                                                 |                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                   |
| Overall survival; PD-L1-positive tumours and All randomized patients Stratified by study stratification factors. | Time from the date of randomization to the date of death due to any cause.                                                                                                                                                                                                                               | Patients known to be alive will be censored at date of last contact. Other reasons for censoring include withdrawal of consent and lost to follow-up.                             |
| Secondary endpoint                                                                                               |                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                   |
| PFS based on BICR assessment per RECIST v1.1. 1                                                                  | Time from the date of randomization to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first. For all patients, radiological tumour assessments will be performed every 8 weeks for up to a year and every 12 weeks thereafter until disease | Censoring: • On the date of the last adequate tumour assessment for patients who do not have an event (PD or death), or; • start a new anti-cancer therapy prior to an event, or; |

1  The FDA rules for censoring of PFS was applied. A sensitivity analysis according to the EMA guidelines (EMA/CHMP/27994/2008/Rev.1 ( Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man Methodological consideration for using progression-free survival (PFS) or disease-free survival (DFS) in confirmatory trials ) was therefore requested.

<div style=\"page-break-after: always\"></div>

|                                                                                     | progression regardless of initiation of subsequent anti- cancer therapy. Upon investigator-assessed disease progression, all radiographic images collected for a patient from baseline onwards was to be submitted to the BICR for expedited review.                                              | • for patients with an event after 2 or more missing tumour assessments. Patients who do not have an adequate baseline tumour assessment or who do not have an adequate post-baseline tumour assessment will be censored on the date of randomization unless death occurred on or before the time of the second planned tumour assessment (i.e. ≤ 16 weeks after the date of randomization) in which case the death will be   |
|-------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective Response (OR), as assessed per RECIST v1.1 by BICR and investigator.      | Complete response (CR), or partial response (PR), according to RECIST v1.1, from the date of randomization, until the date of the first documentation of PD. Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first met. | Patients who do not have a adequate radiographic tumour assessment (eg, no baseline assessment or no follow-up assessments) will be counted as non-responders in the assessment of OR.                                                                                                                                                                                                                                        |
| Time to Tumour Response (TTR) as assessed per RECIST v1.1 by BICR and investigator. | For patients with an OR, as the time from the date of randomization to the first documentation of objective response (CR or PR) which is subsequently confirmed                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Duration of Response (DR) as assessed per RECIST v1.1 by BICR and investigator.     | For patients with OR, as the time from the first documentation of objective response (CR or PR) to the date of first documentation of PD or death due to any cause                                                                                                                                | If a patient has not had an event (PD or death), DR is censored in the same way as the PFS endpoint, with the exception of no adequate baseline assessment.                                                                                                                                                                                                                                                                   |
| Disease Control (DC) as assessed per RECIST v1.1 by BICR and investigator.          | CR, PR, non-CR/non-PD or stable disease (SD). Both CR and PR must be confirmed by repeat assessments performed no less than 4 weeks after the criteria for response are first                                                                                                                     | •                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| met. Criteria for SD and non- CR/non-PD must have been met at least 6 weeks after the date of randomization.   |
|----------------------------------------------------------------------------------------------------------------|

## Patient Reported Outcomes endpoints

Patient reported bladder cancer symptom, functioning, global quality of life (QOL), and Time to Deterioration (TTD) using the NCCN-FACT FBlSI-18; and health status using the EQ-5D-5L.

The patients were to complete the questionnaires at the clinic at Day1 of each cycle (Q4W), at EOT/withdrawal and day 30, 60 and 90 after last dose of study drug. For the NCCN-FACT FBlSI-18 multi-item scales, the score may be imputed as the mean of the non- missing questions if at least half the questions in that scale are answered. For EQ-5D-5L, the entire score for that cycle is deemed missing if the answer to any one of the 5 dimensions is missing.

## Exploratory Endpoints

Biomarkers: Peripheral blood and additional tumour tissue biomarkers consisting of the levels of cells, deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or proteins that may be related to anti-tumour immune response and/or response to or disease progression on avelumab, such as genes related to IFNγ or transforming growth factor (TGF)β .

## Sample size

The study was designed to test the two primary populations in parallel.

Overall type I error rate was maintained at or below 1-sided 0.025 by allocating 0.015 alpha to the OS comparison for all randomized patients and 0.01 to the OS comparison for patients with PD-L1-positive tumours. The significance levels for each test also took into account the group-sequential nature of the design.

Approximately 668 patients were to be randomized to the treatment arms using a 1:1 randomization stratified by best response to first-line chemotherapy (CR or PR vs SD) and site of metastasis (visceral vs non -visceral) at time of initiating first-line chemotherapy. It was estimated that at least 50% of the randomized patients would be determined to have PD -L1 -positive tumours.

The sample size for this study was determined based on the following assumptions:

- The median OS is 12 months for all patients and for patients with PD-L1-positive tumours, who receive BSC alone after first-line chemotherapy.
- The median OS was assumed to be 17.1 months for all patients receiving avelumab plus BSC after first-line chemotherapy.
- The median OS was assumed to be 18.5 months for patients with PD-L1-positive tumours, receiving avelumab plus BSC after first-line chemotherapy.
- 5% drop-out rate for OS within each treatment arm.

This corresponds to a hazard ratio (HR) of 0.7 for all patients and 0.65 for patients with PD -L1-positive tumours under the exponential model assumption.

For all patients, a total of 425 OS events were required to have 93% power to detect a HR of 0.7 using a one-sided log rank test at a significance level of 0.015 and a 2-look group sequential design.

<div style=\"page-break-after: always\"></div>

For patients with PD-L1-positive tumours, a total of 219 OS events were required to have 80% power to detect a HR of 0.65 using a one-sided log rank test at a significance level of 0.01 and a 2-look group sequential design.

The study was considered positive if the stratified log rank test for OS is significant at the respective adjusted levels at the interim or at the final analyses, for either of the two co-primary populations.

## Randomisation

Patients were randomized in a 1:1 ratio to receive avelumab plus BSC or BSC alone.

Randomization using web based IRT was stratified according to:

- Best response to first-line chemotherapy (CR/PR vs SD), and
- Metastatic disease site (visceral vs non-visceral) at the time of initiating first-line chemotherapy.
- Site of metastasis was defined at the time of initiation of the first-line chemotherapy.  The 'non-visceral' stratum includes patients with locally advanced disease as well as patients with only non-visceral disease. Patients with both visceral metastases and non-visceral sites of disease were categorized as 'visceral'.

<div style=\"page-break-after: always\"></div>

Table 11. Disease Sites and Designation of Visceral vs Non-Visceral Site of Metastasis

<!-- image -->

| Disease Site              | Site of Metastasis = Visceral Disease                                                                  |
|---------------------------|--------------------------------------------------------------------------------------------------------|
| Bladder                   | Yes if the primary tumor did not arise in the bladder                                                  |
| Lung                      | Yes                                                                                                    |
| Bone                      | No                                                                                                     |
| Lymph node (any location) | No                                                                                                     |
| Liver                     | Yes                                                                                                    |
| Vagina                    | Yes                                                                                                    |
| Urinary Tract             | Yes if the lesion is distinct from the primary tumor                                                   |
| Prostate Gland            | Yes                                                                                                    |
| Uterus                    | Yes                                                                                                    |
| Peritoneum                |                                                                                                        |
| Kidney                    | Yes if it is not locally advanced disease (ie, an extension of a tumor that arose in the renal pelvis) |
| Renal Pelvis              | Yes if the primary tumor did not arise in that renal pelvis                                            |
| Adrenal                   | Yes if it is distinct from the primary tumor                                                           |
| Pleura                    | Yes                                                                                                    |
| Pericardium               |                                                                                                        |
| Brain                     | Yes                                                                                                    |
| Heart                     |                                                                                                        |

Study treatment (Cycle 1 Day 1) must start within 3 days after patient randomization.

## Blinding (masking)

Study B9991001 was not blinded.

In the evaluation of imaging, all independent reviewers were blinded to subject name, date of birth, subject initials, treatment arm and investigator site identifiers.

## Statistical methods

## Analysis Sets

The analysis populations are defined as follows.

Full Analysis Set : All randomized patients. This set was used for Efficacy, PRO, patient characteristics endpoints.

Per Protocol Analysis Subset of FAS : Excludes from the FAS patients who did not receive the assigned treatment, patients with a baseline ECOG status 2 or higher, patients who did not meet inclusion criteria 1, 2, or 3, and patients who met exclusion criterion 1. This set was used for sensitivity analysis on the OS endpoint.

## Primary Analysis Overall Survival

A 1-sided stratified log-rank test was used within each comparison at the interim and/or final analyses with the overall significance level preserved at its respective levels (1-sided 0.015 for all patients and

<div style=\"page-break-after: always\"></div>

1-sided 0.01 for patients with PD-L1-positive tumours). OS time was summarized by treatment arm based on the FAS using the Kaplan-Meier method. The Cox proportional hazards model was fitted to compute the hazard ratios and the corresponding CIs. In order to account for the group-sequential design in this study, the RCI method was used to construct the 2 -sided RCI for the hazard ratios.

## Sensitivity Analyses Overall Survival

Sensitivity analyses were performed to explore robustness of primary analyses; the primary analyses (p-value, HR and 95% CIs) were repeated with Per protocol population and unstratified analysis.

Additionally, validity of proportional hazards assumptions was checked visually by plotting log(log(OS)) versus log(time) within each randomization stratum and also by plotting Schoenfeld residuals for the stratified Cox proportional regression model. If the plots showed large departures from proportional hazards, OS assessment was to be analysed based on RMST differences.

Also, multivariable Cox regression analyses were performed to assess and adjust the treatment effect for relevant baseline factors of potential prognostic impact.

## Progression-Free Survival

A stratified log-rank test (1-sided) was used to compare the PFS time between the experimental arm and the control arm. PFS time was summarized by treatment arm based on the FAS using the KaplanMeier method. The Cox proportional hazards model was fitted to compute the hazard ratios and the corresponding CIs.

A summary of PFS by the BICR assessment versus investigator assessment was provided. Measures of discordance were used to evaluate potential bias.

## Objective Response

OR was defined as BOR of confirmed CR or PR according to RECIST v1.1 taking into account assessments performed from randomization until the first documentation of PD; only assessments performed on or before the start date of any further anti-cancer therapies were considered. ORR, the proportion of patients with OR, was calculated along with the 2-sided 95% CI using the ClopperPearson method for each treatment arm.

Patients with a CR after chemotherapy could only have a BOR of NE or PD after randomization.

A summary of BOR and OR by BICR assessment versus investigator assessment is provided along with concordance rates. Difference in concordance rates between treatment arms was used to evaluate potential evaluation bias.

## Interim Analysis

Two analyses were planned for OS:

- 1) the IA, after all patients have been randomized, at least 315 of all randomized patients have died (74% of the target number of OS events for the 'all patients' population), and at least 146 patients with PD-L1-positive tumours have died (approximately 66.7% of the total OS events expected in the 'patients with PD-L1-positive tumours' population);
- 2) the final analysis after at least 425 of all randomized patients and at least 219 patients with PD-L1-positive tumours have died, and the last patient randomized in the study has been followed for at least 12 months after randomization.

To protect the integrity of the study and to preserve the type I error rate, a fraction of α for efficacy was planned to be spent at the IA and accounted for in the overall type I error rate (if the IA was

<div style=\"page-break-after: always\"></div>

performed exactly at the planned number of OS events, α spent at IA is 0.005 for all patients and 0.002 for patients with PD-L1-positive tumours). The significance levels for the interim and final efficacy analyses of OS are determined by using the Lan-DeMets procedure with an O'Brien-Fleming stopping boundary. The overall significance level for the efficacy analysis of OS were preserved at (1sided) 0.015 for all patients and 0.01 for patients with PD-L1-positive tumours.

The goals of the IA were to allow early stopping of treatment arm(s) for futility or efficacy and to potentially adjust the sample size. The study would have met its primary objective if the experimental arm was statistically significantly superior to the control arm for either one of the coprimary populations, either at the time of the IA or at the time of the final analysis.

Since the observed number of events at the IA was not exactly equal to the planned number of events, the efficacy and futility boundaries were determined based on the actual number of observed events using the prespecified α -and β -spending functions.

Table 12. Efficacy and Futility Boundaries at Interim Analysis- Randomized Patients

|                                 | Population Patients with PD-L1-positive   | Population Patients with PD-L1-positive   |
|---------------------------------|-------------------------------------------|-------------------------------------------|
|                                 | All patients                              | tumors                                    |
| Observednumberofevents          | 324 (76.2%)                               | 143 (65.3%)                               |
| p-value (z-value) for efficacy  | <0.0053                                   | <0.0014                                   |
|                                 | (<-2.553)                                 | (<-2.981)                                 |
| p-value (z-value) for futilitya | >0.1849                                   | >0.3718                                   |
|                                 | (>-0.897)                                 | (>-0.327)                                 |

Source: Output from EAST?

a Non-binding.

No multiple testing procedure was used for secondary endpoints.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

Figure 17. Participant flow Study B9991001.

<!-- image -->

## Recruitment

The first patient was recruited in May 2016 (first subject visit 28 April 2016) and the last patient was recruited in June 2019. Data cut-off date for pre-specified interim analysis was 21 October 2019.

Patients were enrolled among 231 sites in 29 countries. The number of patients enrolled and randomized per country are summarized in descending order:

Spain 110, France 85, Japan 73, Italy 62, Australia 59, Republic of Korea 45, Greece 25, Belgium 24, Denmark 23, Taiwan 21, United Kingdom 19, United States 19, Russian Federation 17, Canada 15, Netherlands 15, Brazil 13, New Zealand 12, Serbia 10, Israel 7, Mexico 7, Norway 7, Sweden 7, India 6, Portugal 6, Poland 5, Argentina 4, Hong Kong 2, Czech Republic 1, Hungary 1.

The median duration of follow-up at the interim analysis for OS for all randomized patients was 19.6 months and 19.2 months for patients in the avelumab plus BSC arm and BSC alone arm, respectively. For patients with PD-L1-positive tumours, the median duration of follow-up for OS was 18.3 months and 20.0 months for avelumab plus BSC arm and the BSC alone arm, respectively.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

## Tumour assessments

For all patients, anti-tumour activity will be assessed through radiological tumour assessments conducted at baseline (including chest, abdomen, and pelvic CT or MRI scans), at 8 weeks after randomization, then every 8 weeks for up to 1 year from randomization, and every 12 weeks thereafter until documented disease progression as assessed by BICR regardless of initiation of subsequent anti-cancer therapy. Additional radiological tumour assessments should also be conducted whenever disease progression is suspected (e.g., symptomatic deterioration).

## Protocol amendments

The Original Study B9991001 protocol was dated 29 October 2015. During the study, there were 4 protocol amendments (17 December 2015, 24 March 2016, 19 December 2016, 28 March 2019).

Key changes are summarized below:

## Amendment 1, (17 December 2015)

Clarifications to the protocol were made, inclusion criteria were modified and a rule for discontinuation of treatment was added.

## Amendment 2, 24 March 2016

Clarifications to the protocol were made and exclusion criteria were modified.

## Amendment 3, 19 December 2016

Clarifications to the protocol were made, inclusion criteria regarding requirements for tumour tissue were modified, alternate methods for estimating creatinine clearance was added to the inclusion criteria 11, exceptions for exclusion criteria for persisting toxicity related to prior treatment and resected prostate cancer was added, AE collection period were extended, a higher eligibility limit for AST and ALT elevations in patients with liver metastases was added and the analysis of disease control was modified.

## Amendment 4, 28 March 2019

Clarifications to the protocol were made, the exploratory endpoint of irRECIST was removed and associated elements were revised or removed accordingly and management of avelumab toxicity was updated to reflect current standards.

Amendment 1 and 2 were made before the first patient was recruited.

## Protocol deviations

At least 1 potentially important protocol deviation (PIPD) was reported in 38.9% of all randomized patients (Table 13). The protocol deviation category with the highest frequency pertained to deviations from inclusion/exclusion criteria (12.0% in the avelumab plus BSC arm and 20.0% in the BSC alone arm). There were 9.6% patients with a PIPD associated with randomization in the IRT system under the wrong stratification value (Table 13).

## Table 13. Potentially important protocol deviations, FAS

| Avelumab+BSC (N=350) n (%)   | BSC (N=350) n (%)   | Total (N=700) n (%)   |
|------------------------------|---------------------|-----------------------|

<div style=\"page-break-after: always\"></div>

| Subjects with any potentially important deviations   | 145 (41.4)   | 127 (36.3)   | 272 (38.9)   |
|------------------------------------------------------|--------------|--------------|--------------|
| CCMEDS                                               | 39 (11.1)    | 2 (0.6)      | 41 (5.9)     |
| Inclusion/exclusion                                  | 42 (12.0)    | 70 (20.0)    | 112 (16.0)   |
| Informed consent                                     | 52 (14.9)    | 38 (10.9)    | 90 (12.9)    |
| Investigational product                              | 14 (4.0)     | 0            | 14 (2.0)     |
| Procedures/tests                                     | 9 (2.6)      | 9 (2.6)      | 18 (2.6)     |
| Protocol specific discontinuation criteria           | 0            | 3 (0.9)      | 3 (0.4)      |
| Randomization                                        | 32 (9.1)     | 35 (10.0)    | 67 (9.6)     |

10 patients treated with avelumab+BSC and 17 patients BSC arm did not meet inclusion criterion 03 2 according to PA3 and later. In the PA2 and earlier there was 1 patient treated with avelumab plus BSC that did not meet inclusion criterion 3 3 .

Table 14. Subject disposition of actual treatment versus treatment assigned at randomization.

<!-- image -->

|                   | AsRandomized   | AsRandomized   | AsRandomized   | AsRandomized   |
|-------------------|----------------|----------------|----------------|----------------|
|                   | Avelumab+BSC   | BSC            | Not Randomized | Total          |
| AsTreated         |                |                |                |                |
| Avelumab+BSC      | 344            | 0              | 0              | 344            |
| %of As Randomized | 98.3           | 0.0            | 0.0            |                |
| %of As Treated    | 100.0          | 0.0            | 0.0            |                |
| BSC               | 0              | 345            | 0              | 345            |
| %ofAs Randomized  | 0.0            | 98.6           | 0.0            |                |
| %ofAs Treated     | 0.0            | 100.0          | 0.0            |                |
| Not Treated       | 6              | 5              | 0              | 11             |
| %ofAsRandomized   | 1.7            | 1.4            | 0.0            |                |
| %ofAs Treated     | 54.5           | 45.5           | 0.0            |                |
| Total             | 350            | 350            | 0              | 700            |

2  Inclusion criterion 3 according to PA3 and later: Patients without progressive disease as per RECIST v1.1 guideline following completion of first-line chemotherapy as determined by investigator review.

3  Inclusion criterion 3 according to PA2 and earlier: Patients without progressive disease as per RECIST v1.1 guideline following completion of first-line chemotherapy as determined by independent central review.

<div style=\"page-break-after: always\"></div>

Table 15. Specification of randomization deviations.

|                                                                                      | Avelumab+BSC (N=350) n (%6)   | BSC Total (N=350) (N=700) n (96) n (%6)   |
|--------------------------------------------------------------------------------------|-------------------------------|-------------------------------------------|
| RANDOMIIZATION                                                                       | 32 (9.1)                      | 35 (10.0) 67 (9.6)                        |
| Randomized under wrong stratification of CR PR. vs SD AND visceral vs non- Tisceral. | 1(0.3)                        | 2 (0.6) 3(0.4)                            |
| Randomized under Wrong stratification of CR PR. vs SD.                               | 23 (6.6)                      | 22 (6.3)45 (6.4)                          |
| Randomized under wrong stratification of visceral vs. non-visceral.                  | 8(2.3)                        | 11(3.1)19 (2.7)                           |

The denominator to calculate percentages is N, the number of subjects in the full analysis set withim each treatment group. PFIZER CONFIDENTIAL. SDTMI Creatiom: 22NOV2019 (07:14) Source Data: DV Output File:

B9991001 B9991001\\_CSR/addt\\_s001 Date of Generation: 14JAN2020 (08:13) Cutoff date: 21OCT2019 Snapshot Date:21N0V2019

Table 16. Summary of overall survival considering actual strata - FAS

|                                                                         | All Subjects         | All Subjects         | SubjectswithPD-Ll-PositiveTumors   | SubjectswithPD-Ll-PositiveTumors   |
|-------------------------------------------------------------------------|----------------------|----------------------|------------------------------------|------------------------------------|
|                                                                         | Avelumab+BSC (N=350) | BSC (N=350)          | Avelumab+BSC (N=189)               | BSC (N=169)                        |
| Subjects with event, n (%)                                              | 145 ( 41.4)          | 179 ( 51.1)          | 61 ( 32.3)                         | 82 ( 48.5)                         |
| Subjects censored, n (%)                                                | 205 ( 58.6)          | 171 ( 48.9)          | 128 ( 67.7)                        | 87 ( 51.5)                         |
| Reason for censoring, n (%)                                             |                      |                      |                                    |                                    |
| Withdrawal of consent                                                   | 16 ( 4.6)            | 22 (6.3)             | 8 (4.2)                            | 8 (4.7)                            |
| Lost to follow-up [1]                                                   | 5 ( 1.4)             | 6 ( 1.7)             | 3 ( 1.6)                           | 2 ( 1.2)                           |
| Alive                                                                   | 184 ( 52.6)          | 143 ( 40.9)          | 117 ( 61.9)                        | 77 ( 45.6)                         |
| Probability of being event-free (95% CI) [2]                            |                      |                      |                                    |                                    |
| at6months                                                               | 0.888 (0.849, 0.917) | 0.822 (0.777, 0.859) | 0.924 (0.875, 0.954)               | 0.824 (0.756, 0.874)               |
| at 12 months                                                            | 0.713 (0.660, 0.760) | 0.584 (0.527, 0.637) | 0.791 (0.721, 0.845)               | 0.604 (0.520, 0.677)               |
| at 18 months                                                            | 0.613 (0.554, 0.667) | 0.438 (0.378, 0.497) | 0.700 (0.619,0.768)                | 0.478 (0.390, 0.561)               |
| at 24 months                                                            | 0.481 (0.413, 0.547) | 0.372 (0.309, 0.434) | 0.577 (0.481, 0.662)               | 0.405 (0.314, 0.494)               |
| at30 months                                                             | 0.398 (0.318, 0.477) | 0.330 (0.252, 0.411) | 0.504 (0.386, 0.610)               | 0.405 (0.314, 0.494)               |
| Kaplan-Meier estimates of Time to Event (months) Quartiles (95% CI) [3] |                      |                      |                                    |                                    |
| Q1                                                                      | 10.5 (8.7, 12.5)     | 7.9 (6.5, 8.8)       | 13.8 (10.3, 18.2)                  | 8.0 (6.0, 9.3)                     |
| Median                                                                  | 21.4 (18.9, 26.1)    | 14.3 (12.9, 17.9)    | NE (20.3, NE)                      | 17.1 (13.5, 23.7)                  |
| Q3                                                                      | NE (NE, NE)          | 33.0 (33.0, NE)      | NE (NE, NE)                        | NE (33.0, NE)                      |
| Stratified analysis [4] Comparison vs BSC                               |                      |                      |                                    |                                    |
| Hazard Ratio []                                                         | 0.70                 |                      | 0.56                               |                                    |
| [5] 10 %56                                                              | 0.560, 0.870         |                      | 0.403, 0.786                       |                                    |
| 1-sided p-value [6]                                                     | 0.0006               |                      | 0.0003                             |                                    |
| 2-sided p-value [6]                                                     | 0.0013               |                      | 0.0006                             |                                    |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

CIs are derived using the log-log transformation with back transformation to untransformed scale.

[1] Includes subjects deemed to be lost to follow-up by the Investigator and subjects with last follow-up &gt; 16 weeks prior to data cutoff (21OCT2019).

CIs are calculated using Brookmeyer and Crowley method.

Cox proportional hazard model used.

Stratified by best response to first-line chemotherapy (CR or PR vs. SD), metastatic disease site (visceral vs. non-visceral) based on CRF-derived stratification factors.

[6] Log-rank test is used.

<div style=\"page-break-after: always\"></div>

## Baseline data

Table 17. Demographic, baseline and disease characteristics - FAS

|                                           |                                           |              |              |               | Subjects Subjects with PD-L1-Positive   | Subjects Subjects with PD-L1-Positive   | Subjects Subjects with PD-L1-Positive   |
|-------------------------------------------|-------------------------------------------|--------------|--------------|---------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|
|                                           | Avelumab+BSC (N=350)                      | All          | BSC (N=350)  | Total (N=700) | Avelumab+BSC (N=189)                    | BSC (N=169)                             | Tumours Total (N=358)                   |
| Age (years), n (%)                        |                                           |              |              |               |                                         |                                         |                                         |
| <65 years                                 | 129 (36.9)                                | 107 (30.6)   | 236 (33.7)   | 62 (32.8)     | 49                                      | (29.0)                                  | 111 (31.0)                              |
| ≥65 years                                 | 221 (63.1)                                | 243 (69.4)   | 464 (66.3)   | 127 (67.2)    | 120                                     | (71.0)                                  | 247 (69.0)                              |
| 65-<75 years                              | 136 (38.9)                                | 163 (46.6)   | 299 (42.7)   | 72 (38.1)     | 73                                      | (43.2)                                  | 145 (40.5)                              |
| 75-<85 years                              | 80 (22.9)                                 | 78 (22.3)    | 158 (22.6)   | 51 (27.0)     | 47                                      | (27.8)                                  | 98 (27.4)                               |
| ≥85 years                                 | 5 (1.4)                                   | 2 (0.6)      | 7 (1.0)      | 4 (2.1)       |                                         | 0                                       | 4 (1.1)                                 |
| n [1]                                     | 350                                       | 350          | 700          | 189           |                                         | 169                                     | 358                                     |
| Mean (SD)                                 | 67.2 (9.52)                               | 67.7 (9.20)  | 67.5 (9.36)  | 68.2 (9.87)   | 68.0                                    | (9.71)                                  | 68.1 (9.78)                             |
| Q1                                        | 61.00                                     | 62.00        | 62.00        | 62.00         |                                         | 62.00                                   | 62.00                                   |
| Median                                    | 68.00                                     | 69.00        | 69.00        | 70.00         |                                         | 70.00                                   | 70.00                                   |
| Q3                                        | 74.00                                     | 74.00        | 74.00        | 75.00         |                                         | 75.00                                   | 75.00                                   |
| Range (min, max)                          | (37.0, 90.0)                              | (32.0, 89.0) | (32.0, 90.0) | (37.0, 90.0)  | (32.0,                                  | 84.0)                                   | (32.0, 90.0)                            |
| Race, n (%) Black or                      | 2                                         |              | 0            | 2 (0.3)       |                                         |                                         |                                         |
| African                                   | African                                   | (0.6)        |              |               | 1 (0.5)                                 | 0                                       | 1 (0.3)                                 |
| American American Indian or               | American American Indian or               | 0            | 0            | 0             | 0                                       | 0                                       | 0                                       |
| Alaska Native Asian                       | Alaska Native Asian                       | 75 (21.4)    | 81 (23.1)    | 156 (22.3)    | 42 (22.2)                               | 33 (19.5)                               | 75 (20.9)                               |
| Native Hawaiian or Other Pacific Islander | Native Hawaiian or Other Pacific Islander | 0            | 0            | 0             | 0                                       | 0                                       | 0                                       |
| White                                     | White                                     | 232 (66.3)   | 238 (68.0)   | 470 (67.1)    | 121 (64.0)                              | 119 (70.4)                              | 240 (67.0)                              |
| Other                                     | Other                                     | 21 (6.0)     | 15 (4.3)     | 36 (5.1)      | 12 (6.3)                                | 7 (4.1)                                 | 19 (5.3)                                |
| Unknown                                   | Unknown                                   | 20 (5.7)     | 16 (4.6)     | 36 (5.1)      | 13 (6.9)                                | 10 (5.9)                                | 23 (6.4)                                |
| Gender, n (%)                             |                                           |              |              |               |                                         |                                         |                                         |
| Male                                      | Male                                      | 266 (76.0)   | 275 (78.6)   | 541 (77.3)    | 145 (76.7)                              | 129 (76.3)                              | 274 (76.5)                              |
| Female                                    | Female                                    | 84 (24.0)    | 75 (21.4)    | 159 (22.7)    | 44 (23.3)                               | 40 (23.7)                               | 84 (23.5)                               |
| Ethnicity, n (%)                          |                                           |              |              |               |                                         |                                         |                                         |
| Hispanic or Latino                        | Hispanic or Latino                        | 18 (5.1)     | 12 (3.4)     | 30 (4.3)      | 9 (4.8)                                 | 3 (1.8)                                 | 12 (3.4)                                |
| Not Hispanic or Latino                    | Not Hispanic or Latino                    | 286 (81.7)   | 298 (85.1)   | 584 (83.4)    | 152 (80.4)                              | 146 (86.4)                              | 298 (83.2)                              |
| Not reported                              | Not reported                              | 42 (12.0)    | 36 (10.3)    | 78 (11.1)     | 24 (12.7)                               | 18 (10.7)                               | 42 (11.7)                               |
| Unknown                                   | Unknown                                   | 4 (1.1)      | 4 (1.1)      | 8 (1.1)       | 4 (2.1)                                 | 2 (1.2)                                 | 6 (1.7)                                 |

<div style=\"page-break-after: always\"></div>

|                                                | All Subjects   | All Subjects   | All Subjects   |                                                   |             |                       |
|------------------------------------------------|----------------|----------------|----------------|---------------------------------------------------|-------------|-----------------------|
| Avelumab+BSC (N=350)                           |                | BSC (N=350)    | Total (N=700)  | Subjects with PD-L1-Positive Avelumab+BSC (N=189) | BSC (N=169) | Tumours Total (N=358) |
| Pooled Geographic Region, n (%)                |                |                |                |                                                   |             |                       |
| North America                                  | 12 (3.4)       | 22 (6.3)       | 34 (4.9)       | 8 (4.2)                                           | 8 (4.7)     | 16 (4.5)              |
| Europe                                         | 214 (61.1)     | 203 (58.0)     | 417 (59.6)     | 110 (58.2)                                        | 102 (60.4)  | 212 (59.2)            |
| Asia                                           | 73 (20.9)      | 74 (21.1)      | 147 (21.0)     | 40 (21.2)                                         | 31 (18.3)   | 71 (19.8)             |
| Australasia                                    | 34 (9.7)       | 37 (10.6)      | 71 (10.1)      | 20 (10.6)                                         | 24 (14.2)   | 44 (12.3)             |
| Rest of the World                              | 17 (4.9)       | 14 (4.0)       | 31 (4.4)       | 11 (5.8)                                          | 4 (2.4)     | 15 (4.2)              |
| Best response to first-line chemotherapy (IRT) |                |                |                |                                                   |             |                       |
| CR or PR                                       | 253 (72.3)     | 252 (72.0)     | 505 (72.1)     | 139 (73.5)                                        | 128 (75.7)  | 267 (74.6)            |
| SD                                             | 97 (27.7)      | 98 (28.0)      | 195 (27.9)     | 50 (26.5)                                         | 41 (24.3)   | 91 (25.4)             |
| Site of metastasis (IRT)                       |                |                |                |                                                   |             |                       |
| Visceral                                       | 191 (54.6)     | 191 (54.6)     | 382 (54.6)     | 88 (46.6)                                         | 79 (46.7)   | 167 (46.6)            |
| Non-Visceral                                   | 159 (45.4)     | 159 (45.4)     | 318 (45.4)     | 101 (53.4)                                        | 90 (53.3)   | 191 (53.4)            |
| Histopathological classification               |                |                |                |                                                   |             |                       |
| Carcinoma                                      | 306 (87.4)     | 292 (83.4)     | 598 (85.4)     | 163 (86.2)                                        | 137 (81.1)  | 300 (83.8)            |
| Carcinoma with Squamous                        | 16 (4.6)       | 26 (7.4)       | 42 (6.0)       | 8 (4.2)                                           | 13 (7.7)    | 21 (5.9)              |
| Carcinoma with Glandular                       | 6 (1.7)        | 9 (2.6)        | 15 (2.1)       | 3 (1.6)                                           | 6 (3.6)     | 9 (2.5)               |
| Carcinoma with Variant                         | 22 (6.3)       | 22 (6.3)       | 44 (6.3)       | 15 (7.9)                                          | 13 (7.7)    | 28 (7.8)              |
| Other                                          | 0              | 1 (0.3)        | 1 (0.1)        | 0                                                 | 0           | 0                     |
| ECOG performance                               | status         |                |                |                                                   |             |                       |
| 0                                              | 213 (60.9)     | 211 (60.3)     | 424 (60.6)     | 114 (60.3)                                        | 107 (63.3)  | 221 (61.7)            |
| 1                                              | 136 (38.9)     | 136 (38.9)     | 272 (38.9)     | 74 (39.2)                                         | 61 (36.1)   | 135 (37.7)            |
| 2                                              | 1 (0.3)        | 0              | 1 (0.1)        | 1 (0.5)                                           | 0           | 1 (0.3)               |
| 3                                              | 0              | 3 (0.9)        | 3 (0.4)        | 0                                                 | 1 (0.6)     | 1 (0.3)               |
| 4                                              | 0              | 0              | 0              | 0                                                 | 0           | 0                     |
| Not reported                                   | 0              | 0              | 0              | 0                                                 | 0           | 0                     |
| PD-L1 Status                                   |                |                |                |                                                   |             |                       |
| Positive                                       | 189 (54.0)     | 169 (48.3)     | 358 (51.1)     | 189 (100.0)                                       | 169 (100.0) | 358 (100.0)           |
| Negative                                       | 139 (39.7)     | 132 (37.7)     | 271 (38.7)     | 0                                                 | 0           | 0                     |
| Unknown                                        | 22 (6.3)       | 49 (14.0)      | 71 (10.1)      | 0                                                 | 0           | 0                     |

<div style=\"page-break-after: always\"></div>

| All Subjects         | All Subjects   | All Subjects   | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   |
|----------------------|----------------|----------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Avelumab+BSC (N=350) | BSC            | Total          | Avelumab+BSC (N=189)                   | BSC                                    | Total (N=358)                          |
|                      | (N=350)        | (N=700)        |                                        | (N=169)                                |                                        |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group. Baseline is defined as the last assessment on or prior to randomization for subjects randomized but not dosed, and the last assessment on or prior to first dose of study treatment for subjects randomized and dosed.

[1] n is the number of subjects with non-missing age. Age at Screening (years) = (date of given informed consent - date of birth + 1)/365.25.

Cut-off date: 21OCT2019 Snapshot Date: 21NOV2019

Table 18 Demographic, Baseline and Disease Characteristics - Subjects with PD-L1Negative Tumours and Subjects with PD-L1-Unknown Tumours in the Full Analysis Set (Protocol B9991001)

|                                  | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Unknown Tumours   | Subjects with PD-L1-Unknown Tumours   | Subjects with PD-L1-Unknown Tumours   |
|----------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                  | Avelumab +BSC (N=139)                  | BSC (N=131 )                           | Total (N=270)                          | Aveluma b+BSC (N=22)                  | BSC (N=50)                            | Total (N=72)                          |
| Age (years), n (%)               |                                        |                                        |                                        |                                       |                                       |                                       |
| <65 years                        | 55 (39.6)                              | 40 (30.5)                              | 95 (35.2)                              | 12 (54.5)                             | 18 (36.0)                             | 30 (41.7)                             |
| ≥65 years                        | 84 (60.4)                              | 91 (69.5)                              | 175 (64.8)                             | 10 (45.5)                             | 32 (64.0)                             | 42 (58.3)                             |
| 65-<75 years                     | 57 (41.0)                              | 63 (48.1)                              | 120 (44.4)                             | 7 (31.8)                              | 27 (54.0)                             | 34 (47.2)                             |
| 75-<85 years                     | 26 (18.7)                              | 26 (19.8)                              | 52 (19.3)                              | 3 (13.6)                              | 5 (10.0)                              | 8 (11.1)                              |
| ≥85 years                        | 1 (0.7)                                | 2 (1.5)                                | 3 (1.1)                                | 0                                     | 0                                     | 0                                     |
| n [1]                            | 139                                    | 131                                    | 270                                    | 22                                    | 50                                    | 72                                    |
| Mean (SD)                        | 66.6 (8.80)                            | 68.2 (8.64)                            | 67.4 (8.75)                            | 62.7 (9.57)                           | 65.6 (8.71)                           | 64.7 (9.01)                           |
| Q1                               | 61.00                                  | 63.00                                  | 62.00                                  | 56.00                                 | 59.00                                 | 58.50                                 |
| Median                           | 68.00                                  | 69.00                                  | 68.00                                  | 62.50                                 | 67.50                                 | 66.50                                 |
| Q3                               | 73.00                                  | 74.00                                  | 73.00                                  | 69.00                                 | 72.00                                 | 72.00                                 |
| Range (min, max)                 | (38.0, 86.0)                           | (43.0, 89.0)                           | (38.0, 89.0)                           | (39.0, 78.0)                          | (43.0, 82.0)                          | (39.0, 82.0)                          |
| Race, n (%) Black or             |                                        |                                        |                                        |                                       |                                       |                                       |
| African                          | 1 (0.7)                                | 0                                      | 1 (0.4)                                | 0                                     | 0                                     | 0                                     |
| American Indian or Alaska Native | 0                                      | 0                                      | 0                                      | 0                                     | 0                                     | 0                                     |
| Asian                            | 27 (19.4)                              | 30 (22.9)                              | 57 (21.1)                              | 6 (27.3)                              | 18 (36.0)                             | 24 (33.3)                             |

<div style=\"page-break-after: always\"></div>

|                                                | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Unknown   | Subjects with PD-L1-Unknown   | Subjects with PD-L1-Unknown   |
|------------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                                                | Avelumab +BSC (N=139)                  | BSC (N=131 )                           | Total (N=270)                          | Aveluma b+BSC (N=22)          | BSC (N=50)                    | Total (N=72)                  |
| Native Hawaiian or Other Pacific Islander      | 0                                      | 0                                      | 0                                      | 0                             | 0                             | 0                             |
| White                                          | 96 (69.1)                              | 90 (68.7)                              | 186 (68.9)                             | 15 (68.2)                     | 29 (58.0)                     | 44 (61.1)                     |
| Other                                          | 8 (5.8)                                | 6 (4.6)                                | 14 (5.2)                               | 1 (4.5)                       | 2 (4.0)                       | 3 (4.2)                       |
| Unknown                                        | 7 (5.0)                                | 5 (3.8)                                | 12 (4.4)                               | 0                             | 1 (2.0)                       | 1 (1.4)                       |
| Gender, n (%)                                  |                                        |                                        |                                        |                               |                               |                               |
| Male                                           | 103 (74.1)                             | 108 (82.4)                             | 211 (78.1)                             | 18 (81.8)                     | 38 (76.0)                     | 56 (77.8)                     |
| Female                                         | 36 (25.9)                              | 23 (17.6)                              | 59 (21.9)                              | 4 (18.2)                      | 12 (24.0)                     | 16 (22.2)                     |
| Ethnicity, n (%)                               |                                        |                                        |                                        |                               |                               |                               |
| Hispanic or Latino                             | 7 (5.0)                                | 4 (3.1)                                | 11 (4.1)                               | 2 (9.1)                       | 5 (10.0)                      | 7 (9.7)                       |
| Not Hispanic or Latino                         | 115 (82.7)                             | 110 (84.0)                             | 225 (83.3)                             | 19 (86.4)                     | 42 (84.0)                     | 61 (84.7)                     |
| Not reported                                   | 17 (12.2)                              | 15 (11.5)                              | 32 (11.9)                              | 1 (4.5)                       | 3 (6.0)                       | 4 (5.6)                       |
| Unknown                                        | 0                                      | 2 (1.5)                                | 2 (0.7)                                | 0                             | 0                             | 0                             |
| Pooled Geographic Region, n (%)                |                                        |                                        |                                        |                               |                               |                               |
| North America                                  | 4 (2.9)                                | 11 (8.4)                               | 15 (5.6)                               | 0                             | 3 (6.0)                       | 3 (4.2)                       |
| Europe                                         | 92 (66.2)                              | 79 (60.3)                              | 171 (63.3)                             | 12 (54.5)                     | 22 (44.0)                     | 34 (47.2)                     |
| Asia                                           | 27 (19.4)                              | 26 (19.8)                              | 53 (19.6)                              | 6 (27.3)                      | 17 (34.0)                     | 23 (31.9)                     |
| Australasia                                    | 12 (8.6)                               | 10 (7.6)                               | 22 (8.1)                               | 2 (9.1)                       | 3 (6.0)                       | 5 (6.9)                       |
| Rest of the World                              | 4 (2.9)                                | 5 (3.8)                                | 9 (3.3)                                | 2 (9.1)                       | 5 (10.0)                      | 7 (9.7)                       |
| Best response to first-line chemotherapy (IRT) |                                        |                                        |                                        |                               |                               |                               |
| CR or PR                                       | 101 (72.7)                             | 91 (69.5)                              | 192 (71.1)                             | 13 (59.1)                     | 33 (66.0)                     | 46 (63.9)                     |
| SD                                             | 38 (27.3)                              | 40 (30.5)                              | 78 (28.9)                              | 9 (40.9)                      | 17 (34.0)                     | 26 (36.1)                     |
| Site of metastasis (IRT)                       |                                        |                                        |                                        |                               |                               |                               |
| Visceral                                       | 90 (64.7)                              | 82 (62.6)                              | 172 (63.7)                             | 13 (59.1)                     | 30 (60.0)                     | 43 (59.7)                     |

<div style=\"page-break-after: always\"></div>

|                                     | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Unknown   | Subjects with PD-L1-Unknown   | Subjects with PD-L1-Unknown   |
|-------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                                     | Avelumab +BSC (N=139)                  | BSC (N=131 )                           | Total (N=270)                          | Aveluma b+BSC (N=22)          | BSC (N=50)                    | Total (N=72)                  |
| Non-Visceral                        | 49 (35.3)                              | 49 (37.4)                              | 98 (36.3)                              | 9 (40.9)                      | 20 (40.0)                     | 29 (40.3)                     |
| Histopathologica l classification   |                                        |                                        |                                        |                               |                               |                               |
| Carcinoma                           | 124 (89.2)                             | 115 (87.8)                             | 239 (88.5)                             | 19 (86.4)                     | 40 (80.0)                     | 59 (81.9)                     |
| Carcinoma with Squamous             | 6 (4.3)                                | 10 (7.6)                               | 16 (5.9)                               | 2 (9.1)                       | 3 (6.0)                       | 5 (6.9)                       |
| Carcinoma with Glandular            | 3 (2.2)                                | 2 (1.5)                                | 5 (1.9)                                | 0                             | 1 (2.0)                       | 1 (1.4)                       |
| Carcinoma with Variant              | 6 (4.3)                                | 4 (3.1)                                | 10 (3.7)                               | 1 (4.5)                       | 5 (10.0)                      | 6 (8.3)                       |
| Other                               | 0                                      | 0                                      | 0                                      | 0                             | 1 (2.0)                       | 1 (1.4)                       |
| ECOG performance status             |                                        |                                        |                                        |                               |                               |                               |
| 0                                   | 84 (60.4)                              | 71 (54.2)                              | 155 (57.4)                             | 15 (68.2)                     | 33 (66.0)                     | 48 (66.7)                     |
| 1                                   | 55 (39.6)                              | 58 (44.3)                              | 113 (41.9)                             | 7 (31.8)                      | 17 (34.0)                     | 24 (33.3)                     |
| 2                                   | 0                                      | 0                                      | 0                                      | 0                             | 0                             | 0                             |
| 3                                   | 0                                      | 2 (1.5)                                | 2 (0.7)                                | 0                             | 0                             | 0                             |
| 4                                   | 0                                      | 0                                      | 0                                      | 0                             | 0                             | 0                             |
| Not reported                        | 0                                      | 0                                      | 0                                      | 0                             | 0                             | 0                             |
| First-line chemotherapy regimen     |                                        |                                        |                                        |                               |                               |                               |
| Cisplatin                           | 0                                      | 0                                      | 0                                      | 0                             | 0                             | 0                             |
| Gemcitabin                          | 0                                      | 0                                      | 0                                      | 0                             | 0                             | 0                             |
| Cisplatin+G emcitabine              | 69 (49.6)                              | 74 (56.5)                              | 143 (53.0)                             | 13 (59.1)                     | 34 (68.0)                     | 47 (65.3)                     |
| Carboplatin +Gemcitabine            | 65 (46.8)                              | 53 (40.5)                              | 118 (43.7)                             | 8 (36.4)                      | 15 (30.0)                     | 23 (31.9)                     |
| Carboplatin +Cisplatin+Gem citabine | 5 (3.6)                                | 4 (3.1)                                | 9 (3.3)                                | 1 (4.5)                       | 1 (2.0)                       | 2 (2.8)                       |
| Not reported                        | 0                                      | 0                                      | 0                                      | 0                             | 0                             | 0                             |
| Creatinine clearance at baseline    |                                        |                                        |                                        |                               |                               |                               |
| ≥60 mL/min                          | 60 (43.2)                              | 70 (53.4)                              | 130 (48.1)                             | 17 (77.3)                     | 29 (58.0)                     | 46 (63.9)                     |
| <60 mL/min                          | 79 (56.8)                              | 57 (43.5)                              | 136 (50.4)                             | 5 (22.7)                      | 21 (42.0)                     | 26 (36.1)                     |

<div style=\"page-break-after: always\"></div>

|         | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Unknown Tumours   | Subjects with PD-L1-Unknown Tumours   | Subjects with PD-L1-Unknown Tumours   |
|---------|----------------------------------------|----------------------------------------|----------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|         | Avelumab +BSC (N=139)                  | BSC (N=131 )                           | Total (N=270)                          | Aveluma b+BSC (N=22)                  | BSC (N=50)                            | Total (N=72)                          |
| Unknown | 0                                      | 4 (3.1)                                | 4 (1.5)                                | 0                                     | 0                                     | 0                                     |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group. Baseline is defined as the last assessment on or prior to randomization for subjects randomized but not dosed, and the last assessment on or prior to first dose of study treatment for subjects randomized and dosed.

[1] n is the number of subjects with non-missing age. Age at Screening (years) = (date of given informed consent - date of birth + 1)/365.25.

Cutoff date: 21OCT2019 Snapshot Date: 21NOV2019

Table 19. Disease characteristics: Primary diagnosis duration - FAS

|                                           | All Subjects         | All Subjects   | All Subjects   | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   |
|-------------------------------------------|----------------------|----------------|----------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                           | Avelumab+BSC (N=350) | BSC (N=350)    | Total (N=700)  | Avelumab+BSC (N=189)                  | BSC (N=169)                           | Total (N=358)                         |
| Time since initial diagnosis (months) [1] |                      |                |                |                                       |                                       |                                       |
|                                           | 350                  | 350            | 700            | 189                                   | 169                                   | 358                                   |
| Mean (SD)                                 | 23.9 (29.03)         | 27.4 (45.00)   | 25.7 (37.88)   | 25.1 (30.25)                          | 22.4 (26.55)                          | 23.9 (28.56)                          |
| Q1                                        | 7.0                  | 7.1            | 7.1            | 7.1                                   | 6.7                                   | 7.0                                   |
| Median                                    | 11.5                 | 12.8           | 12.1           | 13.3                                  | 10.2                                  | 11.6                                  |
| Q3                                        | 26.8                 | 28.4           | 28.0           | 29.2                                  | 25.9                                  | 27.4                                  |
| Range (min, max)                          | (2.4, 178.2)         | (3.3, 448.0)   | (2.4, 448.0)   | (2.8, 178.2)                          | (3.3,135.7)                           | (2.8, 178.2)                          |

|                                           | Subjects with PD-Ll-Negative Tunors   | Subjects with PD-Ll-Negative Tunors   | Subjects with PD-Ll-Negative Tunors   | Subjects with PD-Ll-Unknown Tumors   | Subjects with PD-Ll-Unknown Tumors   | Subjects with PD-Ll-Unknown Tumors   |
|-------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|
|                                           | Avelumab+BSC (N=139)                  | BSC (N=131)                           | Total (N=270)                         | Avelumab+BSC (N=22)                  | BSC (N=50)                           | Total (N=72)                         |
| Time since initial diagnosis (months) [1] |                                       |                                       |                                       |                                      |                                      |                                      |
| n                                         | 139                                   | 131                                   | 270                                   | 22                                   | 50                                   | 72                                   |
| Mean (SD)                                 | 22.2 (28.05)                          | 35.0 (63.56)                          | 28.4 (48.96)                          | 24.0 (24.75)                         | 24.2 (32.23)                         | 24.1 (29.97)                         |
| Q1                                        | 6.7                                   | 7.2                                   | 7.0                                   | 8.5                                  | 7.5                                  | 7.5                                  |
| Median                                    | 10.1                                  | 15.6                                  | 12.3                                  | 12.2                                 | 20.3                                 | 17.1                                 |
| Q3                                        | 23.6                                  | 38.5                                  | 28.5                                  | 28.8                                 | 27.0                                 | 27.3                                 |
| Range (min, max)                          | (2.4, 151.3)                          | (3.5, 448.0)                          | (2.4, 448.0)                          | (5.2, 84.2)                          | (5.3, 220.7)                         | (5.2, 220.7)                         |

<div style=\"page-break-after: always\"></div>

Table 20. Disease characteristics: Measurable disease at baseline by BICR - FAS

|                                                      | All Subjects                | All Subjects      | All Subjects        | Subjects with PD-Ll-Positive Tumors   | Subjects with PD-Ll-Positive Tumors   | Subjects with PD-Ll-Positive Tumors   |
|------------------------------------------------------|-----------------------------|-------------------|---------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                                                      | Avelumab+BS C (N=350) n (%) | BSC (N=350) (%) u | Total (N=700) (%) u | Avelumab+BS C (N=189) (%) u           | BSC (N=169) n (%)                     | Total (N=358) (%) u                   |
| Measurable disease at baseline by BICR assessment[4] |                             |                   |                     |                                       |                                       |                                       |
| Yes                                                  | 164 ( 46.9)                 | 167 ( 47.7)       | 331 ( 47.3)         | 78 ( 41.3)                            | 78 ( 46.2)                            | 156 ( 43.6)                           |
| No                                                   | 116 ( 33.1)                 | 110 ( 31.4)       | 226 ( 32.3)         | 70 ( 37.0)                            | 50 ( 29.6)                            | 120 ( 33.5)                           |
| No disease                                           | 70 ( 20.0)                  | 73 ( 20.9)        | 143 ( 20.4)         | 41 ( 21.7)                            | 41 ( 24.3)                            | 82 ( 22.9)                            |

|                                                  | Subjects with PD-L1-Negative Tumors   | Subjects with PD-L1-Negative Tumors   | Subjects with PD-L1-Negative Tumors   | Subjectswith PD-L1-UnknownTumors   | Subjectswith PD-L1-UnknownTumors   | Subjectswith PD-L1-UnknownTumors   |
|--------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                                  | Avelumab+BSC (N=139)                  | BSC (N=131)                           | Total (N=270)                         | Avelumab+BSC (N=22)                | BSC (N=50)                         | Total (N=72)                       |
|                                                  | n (%)                                 | n (%)                                 | n (%)                                 | n (%)                              | n (%)                              | n (%)                              |
| MeasurablediseaseatbaselinebyBICR assessment [4] |                                       |                                       |                                       |                                    |                                    |                                    |
| Yes                                              | 77 ( 55.4)                            | 62 ( 47.3)                            | 139 ( 51.5)                           | 9 ( 40.9)                          | 27 ( 54.0)                         | 36 (50.0)                          |
| No                                               | 39 ( 28.1)                            | 44 ( 33.6)                            | 83 (30.7)                             | 7 ( 31.8)                          | 16 ( 32.0)                         | 23 ( 31.9)                         |
| No disease                                       | 23 (16.5)                             | 25 ( 19.1)                            | 48 ( 17.8)                            | 6 ( 27.3)                          | 7 (14.0)                           | 13 ( 18.1)                         |

Table 21. Frequency of CR/PR/SD treated with avelumab + BSC or BSC by PD-L1-status

|    | AllSubjects                       | AllSubjects                       | AllSubjects                       | SubjectswithPD-L1-PositiveTumor's   | SubjectswithPD-L1-PositiveTumor's   | SubjectswithPD-L1-PositiveTumor's   |
|----|-----------------------------------|-----------------------------------|-----------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|
| CR | Avelumab+BSC (N=90)               | BSC (N=89)                        | Total (N=179)                     | Avelumab+BsC (N=60)                 | BSC (N=53)                          | Total (N=113)                       |
| PR | Avelumab+BSC (N=163)              | BSC (N=163)                       | Total (N=326)                     | Avelumab+BSC (N=79)                 | BSC (N=75)                          | Total (N=154)                       |
| SD | Avelumab+BSC (N=97)               | BSC (N=98)                        | Total (N=195)                     | Avelumab+BSC (N=50)                 | BSC (N=41)                          | Total (N=91)                        |
|    | SubjectswithPD-L1-NegativeTumor's | SubjectswithPD-L1-NegativeTumor's | SubjectswithPD-L1-NegativeTumor's | SubjectswithPD-L1-UnknownTumor's    | SubjectswithPD-L1-UnknownTumor's    | SubjectswithPD-L1-UnknownTumor's    |
| CR | Avelumab+BSC (N=25)               | BSC (N=25)                        | Total (N=50)                      | Avelumab+BSC (N=5)                  | BSC (N=11)                          | Total (N=16)                        |
| PR | Avelumab+BSC (N=76)               | BSC (N=66)                        | Total (N=142)                     | Avelumab+BSC (N=8)                  | BSC (N=22)                          | Total (N=30)                        |
| SD | Avelumab+BSC (N=38)               | BSC (N=40)                        | Total (N=78)                      | Avelumab+BSC (N=9)                  | BSC (N=17)                          | Total (N=26)                        |

<div style=\"page-break-after: always\"></div>

## Numbers analysed

Table 22. Summary of analysis data sets - Number of participants

|                                   | Arelumab+BSC n (%)   | BSC n (%)   | Total n (%)   |
|-----------------------------------|----------------------|-------------|---------------|
| Screened                          |                      |             | 1005          |
| Full analysis set [1]             | 350                  | 350         | 700           |
| Safety analysis set [2]           | 344 ( 98.3)          | 345 (98.6)  | 689 (98.4)    |
| Per protocol analysis set [3]     | 316 (90.3)           | 310 (88.6)  | 626 ( 89.4)   |
| PK concentration analysis set [4] | 344 ( 98.3)          | 0           | 344 ( 49.1)   |
| PK parameter analysis set [5]     | 344 ( 98.3)          | 0           | 344 ( 49.1)   |
| Immumogenicity analysis set [6]   | 344 ( 98.3)          | 0           | 344 ( 49.1)   |
| Biomarker analysis set [7]        | 324 ( 92.6)          | 299 (85.4)  | 623 (89.0)    |

The denominator to calculate percentages is the number of subjects in the full analysis set within each treatment group. [1] Full analysis set: randomized subjects.

[3]Per protocol analysis set: subjects in the full analysis set who do not meet any of the criteria that could impact the primary objectives of the study.

[2] Safety analysis set: subjects who received at least one dose of study drug on Avelumab+BSC or completed C1D1 visit on BSC.

The criteria for excluding patients fromPer Protocol AnalysisSet are specified in SAP.

[4]PK concentration analysis set: subjects in the safety analysis set who have at least one post-dose concentration measurement above

the lower limit of quantitation (LLQ) for avelumab.

[6] Immunogenicity analysis set: subjects in the safety analysis set who have at least one ADA/nAb sample collected for avelumab

[5] PK parameter analysis set: subjects in the PK concentration analysis set who have at least one of the PK parameters of interest for avelumab.

[7] Biomarker Analysis Set: subjects in the safety analysis set who have at least one baseline biomarker assessment perfomed.

PFIZERCONFIDENTIAL SDTM Creation:21DEC2019(12:42) SourceData:ADSLOutput File:

30JUN2019 (PK and Immunogenicity) Snapshot Date: 21NOV2019; 24DEC2019 (Immunogenicity)

B9991001\\_restricted/B9991001/adsl\\_s002Date ofGeneration:14JAN2020(07:46) CutoffDate:210CT2019;

Table 14.1.1.1 is for Pfizer intemal use.

## Outcomes and estimation

Data from two data cut-offs are presented for the primary endpoint, overall survival; the pre-specified interim analysis (data cut-off date 21 October 2019), and an updated analysis performed at the request of the Agency (data cut-off date 19 January 2020). For all other endpoints only the interim analysis data cut-off date is used.

## Primary endpoint of OS in co-primary analysis populations - all subjects and subjects with PD-L1-positive tumours

The primary endpoint OS (21 Oct 2019) was statistically significant improved for all patients (n=700) assigned to avelumab plus BSC compared with patients assigned to BSC (stratified HR 0.69; 95% CI 0.556, 0.863; 1-sided p-value 0.0005).  The median OS was 21.4 months (95% CI: 18.9, 26.1) in the avelumab plus BSC arm, and 14.3 months (95% CI: 12.9, 17.9) in the BSC arm. In patients with PDL1-positive tumours (n=358) a statistically significant improvement in OS was also demonstrated for patients assigned to avelumab plus BSC compared with patients assigned to BSC (stratified HR 0.56; 95% CI: 0.404, 0.787; 1-sided p value 0.0003). The median OS was not reached (95% CI: 20.3 months, not reached) in the avelumab plus BSC arm, and was 17.1 months (95% CI: 13.5, 23.7) in the BSC arm.

For all randomized patients, the median duration of follow-up for OS was more than 19 months and similar for both treatment arms.

<div style=\"page-break-after: always\"></div>

Table 23. Overview of primary endpoint

Summary of Overall Survival (Primary Analysis) - All Subjects and Subjects with PD-L1Positive Tumours in the Full Analysis Set (Protocol B9991001, data cut-off date 21 Oct. 2019)

|                                                                         | All Subjects         | All Subjects         | Subjects with PD-L1-Positive   | Subjects with PD-L1-Positive   |
|-------------------------------------------------------------------------|----------------------|----------------------|--------------------------------|--------------------------------|
|                                                                         | Avelumab+BSC (N=350) | BSC (N=350)          | Tumours Avelumab+BSC (N=189)   | BSC (N=169)                    |
| Subjects with event, n (%)                                              | 145 (41.4)           | 179 (51.1)           | 61 (32.3)                      | 82 (48.5)                      |
| Subjects censored, n (%)                                                | 205 (58.6)           | 171 (48.9)           | 128 (67.7)                     | 87 (51.5)                      |
| Reason for censoring, n (%)                                             |                      |                      |                                |                                |
| Withdrawal of consent                                                   | 16 (4.6)             | 22 (6.3)             | 8 (4.2)                        | 8 (4.7)                        |
| Lost to follow-up [1]                                                   | 5 (1.4)              | 6 (1.7)              | 3 (1.6)                        | 2 (1.2)                        |
| Alive                                                                   | 184 (52.6)           | 143 (40.9)           | 117 (61.9)                     | 77 (45.6)                      |
| Probability of being event- free (95% CI) [2]                           |                      |                      |                                |                                |
| at 6 months                                                             | 0.888 (0.849, 0.917) | 0.822 (0.777, 0.859) | 0.924 (0.875, 0.954)           | 0.824 (0.756, 0.874)           |
| at 12 months                                                            | 0.713 (0.660, 0.760) | 0.584 (0.527, 0.637) | 0.791 (0.721, 0.845)           | 0.604 (0.520, 0.677)           |
| at 18 months                                                            | 0.613 (0.554, 0.667) | 0.438 (0.378, 0.497) | 0.700 (0.619, 0.768)           | 0.478 (0.390, 0.561)           |
| at 24 months                                                            | 0.481 (0.413, 0.547) | 0.372 (0.309, 0.434) | 0.577 (0.481, 0.662)           | 0.405 (0.314, 0.494)           |
| at 30 months                                                            | 0.398 (0.318, 0.477) | 0.330 (0.252, 0.411) | 0.504 (0.386, 0.610)           | 0.405 (0.314, 0.494)           |
| Kaplan-Meier estimates of Time to Event (months) Quartiles (95% CI) [3] |                      |                      |                                |                                |
| Q1                                                                      | 10.5 (8.7, 12.5)     | 7.9 (6.5, 8.8)       | 13.8 (10.3, 18.2)              | 8.0 (6.0, 9.3)                 |
| Median                                                                  | 21.4 (18.9, 26.1)    | 14.3 (12.9, 17.9)    | NE (20.3, NE)                  | 17.1 (13.5, 23.7)              |
| Q3                                                                      | NE (NE, NE)          | 33.0 (33.0, NE)      | NE (NE, NE)                    | NE (33.0, NE)                  |
| Stratified analysis [4] Comparison vs BSC                               |                      |                      |                                |                                |
| Hazard Ratio [5]                                                        | 0.69                 |                      | 0.56                           |                                |
| 95% CI [5]                                                              | 0.556, 0.863         |                      | 0.404, 0.787                   |                                |
| RCI [6]                                                                 | 0.536, 0.923         |                      | 0.388, 0.937                   |                                |
| 1-sided p-value [7]                                                     | 0.0005               |                      | 0.0003                         |                                |
| 2-sided p-value [7]                                                     | 0.0010               |                      | 0.0007                         |                                |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

[1] Includes subjects deemed to be lost to follow-up by the Investigator and subjects with last follow-up &gt; 16 weeks prior to data cut-off (21OCT2019).

[2] CIs are derived using the log-log transformation with back transformation to untransformed scale.

[3] CIs are calculated using Brookmeyer and Crowley method.

[4] Stratified by best response to first-line chemotherapy (CR or PR vs. SD), metastatic disease site (visceral vs. non-visceral). IRT stratification values used.

[5] Cox proportional hazard model used.

[6] Repeated confidence interval method used to take into account the group-sequential nature of the design.

[7] Log-rank test is used.

Cut-off date: 21OCT2019

<div style=\"page-break-after: always\"></div>

Figure 18 Kaplan-Meier Plot of Overall Survival - FAS (Study B9991001, 21 Oct. 2019)

<!-- image -->

Figure 19 Kaplan-Meier Plot of Overall Survival - Subjects with PD-L1-Positive Tumours (Study B9991001, 21 Oct. 2019)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Updated OS data

A non pre-specified OS update was requested based on data from the safety database lock 19 January 2020, 90 days following the cut-off date of 21 October 2019.

For all randomized patients, the median duration of follow-up for OS was 21.9 months and 21 months for patients in the avelumab plus BSC arm and BSC alone arm, respectively. For patients with PD-L1positive tumours, the median duration of follow-up for OS was 19.9 months and 21.9 months for patients in the avelumab plus BSC arm and BSC alone arm, respectively.

The updated OS data is similar to the OS from the interim analysis and confirms the conclusions drawn from the interim analysis.

The updated OS-data with an additional 90 days of follow-up with cut-off date 19 January 2020 rendered a median OS for all patients treated with avelumab and BSC of 22.1 months (95% CI 19.0, 26.1) and for patient treated with BSC 14.6 months (95% CI 12.8, 17.8) and HR 0.70 (95% CI 0.564, 0.862; 2 sided p value 0.0008). For patients with PD-L1-positive tumours the updated median OS was NE (95% CI 20.6, NE) for patients treated with avelumab and BSC and 17.5 months (95% CI 13.5, 31.6) for  patients treated with BSC alone, HR 0.60 (95% CI 0.439, 0.833; 2 sided p value 0.0019).

OS for patients with PD-L1-negative patients was an exploratory analysis and part of the subgroup analysis. OS for patients with PD-L1-unknown tumours was not a prespecified endpoint. Using the updated OS-data with an additional 90 days of follow-up with cut-off date 19 January 2020, the median OS for patients with PD-L1-negative tumours was 18.9 months (95% CI 13.3, 22.1) for patients treated with avelumab and BSC and 13.4 months (95% CI 10.4, 17.3) for patients treated with BSC alone, HR 0.83 (95% CI 0.603, 1.131). For patients with PD-L1-unknown tumours the updated median OS was 20.1 months (95% CI 10.6, NE) for patients treated with avelumab and BSC and 13.0 months (95% CI 9.6, NE) for patients treated with BSC alone, HR 0.69 (95% CI 0.306, 1.550). The subgroup of patients with PD-L1-unknown tumours was small and hence no firm conclusions have been drawn from the data. However, data is presented for completeness.

## OS in all patients and patients with PD-L1-positive tumours (not prespecified analysis, data cut-off date 19 Jan 2020)

Table 24. Summary of Overall Survival (Primary Analysis) - All Subjects and Subjects with PD-L1-Positive Tumours in the Full Analysis Set (Protocol B9991001, 19 Jan. 2020)

|                                                          | All Subjects         | All Subjects         | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   |
|----------------------------------------------------------|----------------------|----------------------|----------------------------------------|----------------------------------------|
|                                                          | Avelumab+BSC (N=350) | BSC (N=350)          | Avelumab+BSC (N=189)                   | BSC (N=169)                            |
| Subjects with event, n (%)                               | 156 (44.6)           | 190 (54.3)           | 68 (36.0)                              | 85 (50.3)                              |
| Subjects censored, n (%)                                 | 194 (55.4)           | 160 (45.7)           | 121 (64.0)                             | 84 (49.7)                              |
| Reason for censoring, n (%) Withdrawal of consent        | 17 (4.9)             | 21 (6.0)             | 9 (4.8)                                | 8 (4.7)                                |
| Lost to follow-up [1]                                    | 6 (1.7)              | 7 (2.0)              | 4 (2.1)                                | 3 (1.8)                                |
| Alive                                                    | 171 (48.9)           | 132 (37.7)           | 108 (57.1)                             | 73 (43.2)                              |
| Probability of being event-free (95% CI) [2] at 6 months | 0.888 (0.850, 0.917) | 0.822 (0.777, 0.859) | 0.924 (0.875, 0.954)                   | 0.824 (0.756, 0.874)                   |

<div style=\"page-break-after: always\"></div>

|                                                                         | All Subjects         | All Subjects         | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   |
|-------------------------------------------------------------------------|----------------------|----------------------|----------------------------------------|----------------------------------------|
|                                                                         | Avelumab+BSC (N=350) | BSC (N=350)          | Avelumab+BSC (N=189)                   | BSC (N=169)                            |
| at 12 months                                                            | 0.719 (0.667, 0.764) | 0.577 (0.521, 0.630) | 0.793 (0.725, 0.845)                   | 0.607 (0.525, 0.679)                   |
| at 18 months                                                            | 0.614 (0.556, 0.666) | 0.439 (0.381, 0.495) | 0.685 (0.607, 0.752)                   | 0.483 (0.398, 0.563)                   |
| at 24 months                                                            | 0.478 (0.414, 0.539) | 0.380 (0.321, 0.439) | 0.560 (0.469, 0.641)                   | 0.418 (0.331, 0.504)                   |
| at 30 months                                                            | 0.410 (0.340, 0.479) | 0.337 (0.271, 0.405) | 0.507 (0.407, 0.599)                   | 0.418 (0.331, 0.504)                   |
| Kaplan-Meier estimates of Time to Event (months) Quartiles (95% CI) [3] |                      |                      |                                        |                                        |
| Q1                                                                      | 10.5 (9.2, 12.7)     | 7.9 (6.5, 8.7)       | 13.6 (10.3, 18.2)                      | 8.0 (6.0, 9.3)                         |
| Median                                                                  | 22.1 (19.0, 26.1)    | 14.6 (12.8, 17.8)    | NE (20.6, NE)                          | 17.5 (13.5, 31.6)                      |
| Q3                                                                      | NE (NE, NE)          | NE (31.6, NE)        | NE (NE, NE)                            | NE (33.0, NE)                          |
| Stratified analysis [4] Comparison vs BSC                               |                      |                      |                                        |                                        |
| Hazard Ratio [5]                                                        | 0.70                 |                      | 0.60                                   |                                        |
| 95% CI [5]                                                              | 0.564, 0.862         |                      | 0.439, 0.833                           |                                        |
| 1-sided p-value [6]                                                     | 0.0004               |                      | 0.0010                                 |                                        |
| 2-sided p-value [6]                                                     | 0.0008               |                      | 0.0019                                 |                                        |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

[1] Includes subjects deemed to be lost to follow-up by the Investigator and subjects with last follow-up &gt; 16 weeks prior to data cutoff (19JAN2020).

[2] CIs are derived using the log-log transformation with back transformation to untransformed scale.

[3] CIs are calculated using Brookmeyer and Crowley method.

[4] Stratified by best response to first-line chemotherapy (CR or PR vs. SD), metastatic disease site (visceral vs. non-visceral). IRT stratification values used.

[5] Cox proportional hazard model used.

[6] Log-rank test is used.

Cutoff date: 19JAN2020.

<div style=\"page-break-after: always\"></div>

Figure 20. Kaplan-Meier Plot of Overall Survival--FAS (Protocol B9991001) - Updated analysis (19 Jan. 2020)

<!-- image -->

Figure 21. Kaplan-Meier Plot of Overall Survival--Subjects with PD-L1-Positive Tumours in the FAS (Protocol B9991001)--Updated analysis (19 Jan. 2020)

<!-- image -->

<div style=\"page-break-after: always\"></div>

OS in patients with PD-L1-negative (exploratory analysis) and PD-L1-unknown tumours (not prespecified analysis, data cut-off date 19 Jan. 2020)

Table 25 Summary of Overall Survival -  patients with PD-L1-Negative (exploratory analysis) and PD-L1-Unknown tumours in the Full Analysis Set (Protocol B9991001, not prespecified analysis, 19 Jan. 2020)

|                                                                          | Subjects with PD-L1-Negative Tumors Subjects with PD-L1-Unknown Tumors   | Subjects with PD-L1-Negative Tumors Subjects with PD-L1-Unknown Tumors   | Subjects with PD-L1-Negative Tumors Subjects with PD-L1-Unknown Tumors   | Subjects with PD-L1-Negative Tumors Subjects with PD-L1-Unknown Tumors   |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
|                                                                          | Avelumab+BSC (N-139)                                                     | BSC (N-131)                                                              | Avelumab+BSC (N-22)                                                      | BSC (N-50)                                                               |
| Subjects with event, n (96)                                              | 80 (57.6)                                                                | 80 (61.1)                                                                | 8(36.4)                                                                  | 25 (50.0)                                                                |
| Subjects censored, n (%6)                                                | 59 (42.4)                                                                | 51(38.9)                                                                 | 14 (63.6)                                                                | 25 (50.0)                                                                |
| Reason for censoring, n (%%)                                             |                                                                          |                                                                          |                                                                          |                                                                          |
| Withdrawal of consent                                                    | 5(3.6)                                                                   | 5(3.8)                                                                   | 3 (13.6)                                                                 | 8 (16.0)                                                                 |
| Lost to follow-up []                                                     | 1 (0.7)                                                                  | 2(1.5)                                                                   | 1 (4.5)                                                                  | 2(4.0)                                                                   |
| Alive                                                                    | 53 (38.1)                                                                | 44 (33.6)                                                                | 10 (45.5)                                                                | 15 (30.0)                                                                |
| Probability of being event-free (95% CD) [2]                             |                                                                          |                                                                          |                                                                          |                                                                          |
| at 6 months                                                              | 0.832 (0.758, 0.885)                                                     | 0.821 (0.743. 0.877)                                                     | 0.944 (0.666, 0.992)                                                     | 0.818 (0.669, 0.905)                                                     |
| at 12 months                                                             | 0.621 (0.533,0.697)                                                      | 0.547 (0.454, 0.630)                                                     | 0.705 (0.428, 0.866)                                                     | 0.557 (0.397. 0.691)                                                     |
| at 18 months                                                             | 0.525 (0.434, 0.607)                                                     | 0.388 (0.297. 0.478)                                                     | 0.555 (0.279, 0.763)                                                     | 0.421 (0.267. 0.5671                                                     |
| at 24months                                                              | 0.378 (0.285, 0.470)                                                     | 0.315 (0.224, 0.410)                                                     | 0.463 (0.195, 0.695)                                                     | 0.421 (0.267. 0.567)                                                     |
| at 30 months                                                             | 0.284 (0.189,0.386)                                                      | 0.234 (0.137, 0.346)                                                     | 0.463 (0.195, 0.695)                                                     | 0.281 (0.079, 0.530)                                                     |
| Kaplan-Meier estimates of Time to Event (months) Quartiles (95%6 C1) [3] |                                                                          |                                                                          |                                                                          |                                                                          |
| 10                                                                       | 7.8 (6.1, 10.0)                                                          | 7.8 (5.7,9.0)                                                            | 11.5 (5.5, 20.1)                                                         | 6.8 (3.7, 10.3)                                                          |
| Median                                                                   | 18.9 (13.3, 22.1)                                                        | 13.4 (10.4, 17.3)                                                        | 20.1 (10.6, NE)                                                          | 13.0 (9.6, NE)                                                           |
| Q3                                                                       | NE (25.1, NE)                                                            | 26.8 (21.0, NE)                                                          | NE (20.1, NE)                                                            | NE (30.0, NE)                                                            |
| Stratified analysis [4] Comparison vs BSC                                |                                                                          |                                                                          |                                                                          |                                                                          |
| Hazard Ratio [5]                                                         | 0.83                                                                     |                                                                          | 0.69                                                                     |                                                                          |
| 95% 01 [5]                                                               | 0.603, 1.131                                                             |                                                                          | 0.306, 1.550                                                             |                                                                          |

<div style=\"page-break-after: always\"></div>

Figure 22 Kaplan-Meier Plot of Overall Survival - Patients with PD-L1-Negative Tumours FAS (19 Jan. 2020)

<!-- image -->

Figure 23 Kaplan-Meier Plot of Overall Survival - Patients with PD-L1-Unknown Tumours (19 Jan. 2020)

<!-- image -->

## OS in subgroups

Subgroup analysis of OS for all patients and for patients with PD-L1-positive tumours display no detrimental effect in any subgroup of reasonable size.

<div style=\"page-break-after: always\"></div>

Subgroup analysis of OS for patients with PD-L1-negative tumours (data not shown) generally present with HR of ≤1, albeit with large confidence intervals due to small patient samples and more heterogeneity compared to the PFS subgroup results.

Figure 24. Forest Plot of Overall Survival by Subgroups - FAS (Study B9991001, 21 Oct. 2019)

|                                       | Numberof Events/ Numberof Subjects(N)   | Numberof Events/ Numberof Subjects(N)                                              | Numberof Events/ Numberof Subjects(N)                                              | Numberof Events/ Numberof Subjects(N)                                              |
|---------------------------------------|-----------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
| Subgroup                              | Avelumab+8SC                            | BSC                                                                                | Hazard Rato(95%C)[1]                                                               |                                                                                    |
| All subjects (stratified)[2]          | 145/350                                 | 179/350                                                                            | 0.69 (0.556,0.863)                                                                 |                                                                                    |
| All subjects (unstratifed)            | 145350                                  | 179.350                                                                            | 0.69(0.553,0.858)                                                                  |                                                                                    |
| Bestresponsetofirst-linechemotherapy: |                                         |                                                                                    |                                                                                    |                                                                                    |
| CRor PR(per IRT)                      | 104/253                                 | 127/252                                                                            | 0.69 (0.531,0.892)                                                                 |                                                                                    |
| SD (per IRT)                          | 41/97                                   | 52/98                                                                              | 0.70 (0.463,1.053)                                                                 |                                                                                    |
| Metastaticdisease site:               |                                         |                                                                                    |                                                                                    |                                                                                    |
| Visceral (per IRT)                    | 93/191                                  | 101/191                                                                            | 0.82 (0.620,1.091)                                                                 |                                                                                    |
| Non-Visceral (per IRT)                | 52/159                                  | 78/159                                                                             | 0.54 (0.377,0.763)                                                                 |                                                                                    |
| Age:                                  |                                         |                                                                                    |                                                                                    |                                                                                    |
| <65years                              | 61/129                                  | 53/107                                                                             | 0.79 (0.546,1.146)                                                                 |                                                                                    |
| 265years                              | 84/221                                  | 126/243                                                                            | 0.63 (0.475,0.825)                                                                 |                                                                                    |
| Gender.                               |                                         |                                                                                    |                                                                                    |                                                                                    |
| Male                                  | 105/266                                 | 145/275                                                                            | 0.64(0.499,0.826)                                                                  |                                                                                    |
| Female                                | 40/84                                   | 34/75                                                                              | 0.89 (0.561, 1.406)                                                                |                                                                                    |
| Race:                                 |                                         |                                                                                    |                                                                                    |                                                                                    |
| White                                 | 106/232                                 | 133/238                                                                            | 0.67(0.519,0.866)                                                                  |                                                                                    |
| Asian                                 | 26/75                                   | 36/81                                                                              | 0.70 (0.420,1.156)                                                                 |                                                                                    |
| Other                                 | 13/43                                   | 1031                                                                               | 0.91 (0.397,2.073)                                                                 |                                                                                    |
| Pooledgeographicregion:               |                                         |                                                                                    |                                                                                    |                                                                                    |
|                                       | 93/214                                  | 114/203                                                                            | 0.64 (0.488,0.846)                                                                 |                                                                                    |
| North America                         | 5/12                                    | 8/22                                                                               | 0.86 (0.280, 2.645)                                                                |                                                                                    |
| Asia                                  | 2573                                    | 3274                                                                               | 0.71 (0.423,1.207)                                                                 |                                                                                    |
| Australasia                           | 16/34                                   | 16/37                                                                              | 0.96(0.479,1.923)                                                                  |                                                                                    |
| Restof the Word                       | 6/17                                    | 914                                                                                | 0.38(0.126,1.137)                                                                  |                                                                                    |
| PD-L1 status at baseline:             |                                         |                                                                                    |                                                                                    |                                                                                    |
| Positive                              | 61/189                                  | 82/169                                                                             | 0.56(0.404,0.784)                                                                  |                                                                                    |
| Negative                              | 75/139                                  | 72/132                                                                             | 0.86(0.619,1.182)                                                                  |                                                                                    |
| Unknown                               | 8/22                                    | 25/49                                                                              | 0.69 (0.311,1.528)                                                                 |                                                                                    |
| First-line chemotherapyregimenc       |                                         |                                                                                    |                                                                                    |                                                                                    |
| Gemcitabine+cisplatin                 | 71/183                                  | 98/206                                                                             | 0.69(0.509,0.939)                                                                  |                                                                                    |
| Gemcitabine+carboplatin               | 68/147                                  | 73/122                                                                             | 0.66(0.471,0.913)                                                                  |                                                                                    |
| Gemcitabine+carbopiatin+cisplatin     | 6/20                                    | 7/20                                                                               | 0.75(0.251,2.255)                                                                  |                                                                                    |
| ECOGperfomancestatus:                 |                                         |                                                                                    |                                                                                    |                                                                                    |
| 0                                     | 77/213                                  | 101/211                                                                            | 0.64 (0.477,0.864)                                                                 |                                                                                    |
| 21                                    | 68/137                                  | 78/139                                                                             | 0.74(0.537,1.032)                                                                  |                                                                                    |
| Creatinine clearance at baseline:     |                                         |                                                                                    |                                                                                    |                                                                                    |
| ≥60mL/min                             | 74/181                                  | 97/196                                                                             | 0.68(0.501,0.919)                                                                  |                                                                                    |
| <60mL/min                             | 71/168                                  | 81/148                                                                             | 0.68(0.496,0.940)                                                                  |                                                                                    |
| Liverlesions at baseline:             |                                         |                                                                                    |                                                                                    |                                                                                    |
| Yes                                   | 27/43                                   | 28/44                                                                              | 0.92(0.538,1.557)                                                                  |                                                                                    |
| No                                    | 118/307                                 | 151/306                                                                            | 0.65(0.513,0.831)                                                                  |                                                                                    |
| Lung lesions at baseline:             |                                         |                                                                                    |                                                                                    |                                                                                    |
| Yes                                   | 44/83                                   | 44/83                                                                              | 0.85(0.564,1.303)                                                                  |                                                                                    |
| No                                    | 101/267                                 | 135/267                                                                            | 0.63(0.490,0.821)                                                                  |                                                                                    |
|                                       |                                         | 0.0 0.5 10 1.5 20 2.5 3.0 Hazard RatioforOSwith95% Ci FavorsAvelumab+BSC FavorsBSC | 0.0 0.5 10 1.5 20 2.5 3.0 Hazard RatioforOSwith95% Ci FavorsAvelumab+BSC FavorsBSC | 0.0 0.5 10 1.5 20 2.5 3.0 Hazard RatioforOSwith95% Ci FavorsAvelumab+BSC FavorsBSC |

Nis thenumberof subjectsinthefullanalysissetwithineachsubgroup and treatmentgroup.

[2]Stratified by bestresponse tofirst-line chemotherapy(CRorPRvs.SD).metastaticdisease site(visceral vs.non-visceral).IRT stratification values used.

[1]Hazardratiosand associatedClsarecalculated usingCoxproportional hazardmodel.

Otherthantheprimaryanalysispresentedwhich takesintoaccountstratificationfactors,allotheranalysesareunstratified.

PFIZERCONFIDENTIALSDTMCreaton:22NOV2019(07:14)OutputFile:/B9991001/B9991001\\_CSR/adtte\\_os\\_f003 DateofGeneration:14JAN2020(13:45)Cutoffdate:21OCT2019Snapshot Date:21NOV2019

Subgroupswith&lt;5%ofthepatientpopulation werepooled(Race:Black/AficanAmerican and Other)ornot presented(Ethnicity since only twosubgroupsandHispanic/Latinois&lt;5%of thepatient population).

<div style=\"page-break-after: always\"></div>

Figure 25. Forest Plot of Overall Survival by Subgroups - FAS (Study B9991001, non prespecified subgroups, 21 Oct. 2019)

<!-- image -->

Nisthenumberof subjects inthefullanalysisset ineachtreatment group.

[2] Stratified by bestresponse to first-line chemotherapy (CR or PRvs.SD),metastatic disease site(visceral vs.non-visceral).IRT stratificationvalues used.

[1]Hazardratios and associatedClsarecalculated usingCoxproportional hazardmodel.

Other than the primary analysis presented which takes into account stratificationfactors, all other analyses are unstratified.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (08:14) OutputFile: /B9991001/CHMP\\_IA/adlte\\_os\\_f003\\_OC\\_F12 Date of Generation: 21SEP2020(11:03) Cutoff date:21OCT2019 Snapshot Date:21NOV2019

<div style=\"page-break-after: always\"></div>

Figure 26. Forest Plot of Overall Survival by Subgroups - Subjects with PD-L1-Positive (Study B9991001, 21 Oct 2019)

Numberot Events/

|                                        | Numberof Subjects (N)   | Numberof Subjects (N)   | Numberof Subjects (N)                                                               | Numberof Subjects (N)                                                               |
|----------------------------------------|-------------------------|-------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Subgroup                               | Avelumab+BSC            | BSC                     |                                                                                     | Hazard Ratio(95%C0[1]                                                               |
| All sulbjects (stratified)[2]          | 61/189                  | 82/169                  |                                                                                     | 0.56(0.404,0.787)                                                                   |
| All subjects (unstratifed)             | 61/189                  | 82/169                  |                                                                                     | 0.56(0.404,0.784)                                                                   |
| Bestresponse tofirst-ine chemotherapy: |                         |                         |                                                                                     |                                                                                     |
| CRor PR(per IRT)                       | 46/139                  | 61/128                  |                                                                                     | 0.60(0.406,0.875)                                                                   |
| SD (perIRT)                            | 15/50                   | 21/41                   |                                                                                     | 0.49(0.251,0.948)                                                                   |
| Metastatic disease site                |                         |                         |                                                                                     |                                                                                     |
| Visceral(perIRT)                       | 32/88                   | 40/79                   |                                                                                     | 0.69 (0.430,1.091)                                                                  |
| Non-Visceral (perIRT)                  | 29/101                  | 42/90                   |                                                                                     | 0.46(0.288,0.747)                                                                   |
| Age:                                   |                         |                         |                                                                                     |                                                                                     |
| <65years                               | 23/62                   | 25/49                   |                                                                                     | 0.57(0.324,1.016)                                                                   |
| 265years                               | 38/127                  | 57/120                  |                                                                                     | 0.54(0.358,0.814)                                                                   |
| Gender.                                |                         |                         |                                                                                     |                                                                                     |
| Male                                   | 46/145                  | 63/129                  |                                                                                     | 0.56(0.384,0.823)                                                                   |
| Female                                 | 1544                    | 19/40                   |                                                                                     | 0.56(0.283,1.108)                                                                   |
|                                        |                         |                         | Race:                                                                               |                                                                                     |
| White                                  | 44/121                  | 65/119                  |                                                                                     | 0.49(0.336,0.724)                                                                   |
| Asian                                  | 12/42                   | 15/33                   |                                                                                     | 0.71(0.330,1.514)                                                                   |
|                                        | 5/26                    | 2/17                    | Other                                                                               | 2.02(0.391,10.461)                                                                  |
| Pooled geographicregion:               |                         |                         |                                                                                     |                                                                                     |
| Europe                                 | 38/110                  | 58/102                  |                                                                                     | 0.47(0.309,0.701)                                                                   |
| North America                          | 2/8                     | 2/8                     |                                                                                     | 0.80 (0.111,5.693)                                                                  |
| Asia                                   | 11/40                   | 14/31                   |                                                                                     | 0.66(0.300,1.465)                                                                   |
| Australasia                            | 6/20                    | 724                     |                                                                                     | 0.91(0.307,2.723)                                                                   |
| Restof the Word                        | 4/11                    | 14                      |                                                                                     | 1.49 (0.166,13.361)                                                                 |
| First-line chemotherapy regimen:       |                         |                         |                                                                                     |                                                                                     |
| Gemcitabine+csplatin                   | 31/101                  | 46/98                   |                                                                                     | 0.53(0.335,0.834)                                                                   |
| Gemcitabine+carboplatin                | 2774                    | 29/54                   |                                                                                     | 0.63 (0.375,1.069)                                                                  |
| Gemcitabine+carbopiadn+cisplatin       | 3/14                    | 6/15                    |                                                                                     | 0.47 (0.116,1.924)                                                                  |
| ECOGperfomancestatus:                  |                         |                         |                                                                                     |                                                                                     |
| 0                                      | 34/114                  | 51/107                  |                                                                                     | 0.52 (0.337,0.805)                                                                  |
| ≥1                                     | 27/75                   | 31/62                   |                                                                                     | 0.62 (0.368,1.037)                                                                  |
| Creatinine clearance at baseline:      |                         |                         |                                                                                     |                                                                                     |
| ≥60mL/min                              | 34/104                  | 51/97                   |                                                                                     | 0.49(0.319,0.762)                                                                   |
| <60mL/min                              | 27/84                   | 31/70                   |                                                                                     | 0.70(0.417,1.170)                                                                   |
| Liver leslons at baseline:             |                         |                         |                                                                                     |                                                                                     |
| Yes                                    | 9/13                    | 9/13                    |                                                                                     | 0.90 (0.354,2.297)                                                                  |
| No                                     | 52/176                  | 73/156                  |                                                                                     | 0.53(0.372,0.759)                                                                   |
| Lunglesions at baseliner               |                         |                         |                                                                                     |                                                                                     |
| Yes                                    | 14/36                   | 17/34                   |                                                                                     | 0.60 (0.297,1.225)                                                                  |
| No                                     | 47/153                  | 65/135                  |                                                                                     | 0.55 (0.375, 0.796)                                                                 |
|                                        |                         |                         | 00 0.5 1.0 15 2.0 25 3.0 Hazard Ratio for OSwith95% Ci FavorsAvelumab+BSC FavorsBSC | 00 0.5 1.0 15 2.0 25 3.0 Hazard Ratio for OSwith95% Ci FavorsAvelumab+BSC FavorsBSC |

Nisthenumberof subjectswithPD-L1-positive tumors inthefullanalysisset ineach teatment group.

[2] Stratified bybestresponse to first-line chemotherapy(CRorPRvs.SD).metastaticdisease site(Visceral vs.non-visceral).IRTstratification valuesused.

[1]HazardratiosandassociatedCisarecalculatedusingCoxproportionalhazardmodel.

Otherthantheprimaryanalysispresentedwhichtakesintoaccountstratificationfactors,all otheranalysesareunstratified.

population).

PFIZERCONFIDENTIALSDTMCreafon:22NOV2019（07:14)OutputFile:/B9991001/B9991001\\_CSR/adtte\\_os\\_f003\\_pdlpopDateofGeneration:14JAN2020(13:49)Cutoffdate:21OCT2019Snapshot Date:21NOV2019

<div style=\"page-break-after: always\"></div>

Figure 27. Forest Plot of Overall Survival by Subgroups - Subjects with PD-L1-Positive (Study B9991001, non prespecified subgroups, 21 Oct 2019)

<!-- image -->

Nis the number of subjects withPD-L1-positive tumors in the full analysis setineach treatment group.

- [2] Stratified bybestresponse to first-line chemotherapy(CRorPRvs.SD).metastaticdiseasesite(visceral vs.non-visceral).IRTstratificationvalues used.

[1]Hazardratios and associatedCls arecalculated usingCoxproportional hazard model.

Other thantheprimary analysispresentedwhich takes into account stratificationfactors,all other analyses areunstratified.

PFIZER CONFIDENTIAL SDTM Creation:22NOV2019(08:14)OutputFile:/B9991001/CHMP\\_IA/adtte\\_os\\_f003\\_OC\\_P12 Date ofGeneration: 21SEP2020(11:37)Cutoff date:21OCT2019Snapshot Date:21NOV2019

## Sensitivity analyses of OS

Only minor differences for the subgroup analyses per protocol and actual strata were detected for all subjects and each PD-L1-strata. Detected differences are of no clinical relevance.

## Ancillary analyses

## Secondary endpoints

## Progression Free Survival

The median PFS for avelumab plus BSC was 3.7 months (95% CI: 3.5, 5.5) and for BSC was 2.0 months (95% CI: 1.9, 2.7) for all patients. The median PFS for avelumab plus BSC was 5.7 months (95% CI: 3.7, 7.4) and for BSC was 2.1 months (95% CI: 1.9, 3.5) for patients with PD-L1-positive tumours and 3.0 months (95% CI 2.0, 3.7) for avelumab plus BSC and 1.9 months (95% CI 1.9, 2.1) for BSC for patients with PD-L1-negative tumours. Median PFS was 3.6 months (95% CI 1.9, 16.7) for avelumab plus BSC and 2.1 months (95% CI 1.9, 6.8) for BSC for patients with PD-L1-unknown tumours.

## Table 26. Summary of Progression Free Survival Based on BICR Assessment (RECIST v1.1, 21 Oct. 2019).

<div style=\"page-break-after: always\"></div>

|                                                  | All Subjects         | All Subjects         | Subjects with PD-Ll-Positive Tumors   | Subjects with PD-Ll-Positive Tumors   |
|--------------------------------------------------|----------------------|----------------------|---------------------------------------|---------------------------------------|
|                                                  | Avelumab+BSC (N=350) | BSC (N=350)          | Avelumab+BSC (N=189)                  | BSC (N=169)                           |
| Subjects with event, n (%)                       | 225 (64.3)           | 260 (74.3)           | 109 (57.7)                            | 130 (76.9)                            |
| Type of event, n (%)                             |                      |                      |                                       |                                       |
| Progressive disease                              | 216 (61.7)           | 251 (71.7)           | 105 (55.6)                            | 127 (75.1)                            |
| Death                                            | 9 (2.6)              | 9 (2.6)              | 4 (2.1)                               | 3 (1.8)                               |
| Subjects censored, n (%)                         | 125 (35.7)           | 90 (25.7)            | 80 (42.3)                             | 39 (23.1)                             |
| Reason for censoring, n (%)                      |                      |                      |                                       |                                       |
| No adequate baseline assessment                  | 11 (3.1)             | 1 (0.3)              | 5 (2.6)                               | 1 (0.6)                               |
| Start of new anti-cancer therapy                 | 17 (4.9)             | 44 (12.6)            | 11 (5.8)                              | 19 (11.2)                             |
| Event after ≥2 missing or inadequate             | 4 (1.1)              | 8 (2.3)              | 2 (1.1)                               | 1 (0.6)                               |
| post-baseline assessments                        |                      |                      |                                       |                                       |
| Withdrawal of consent                            | 8 (2.3)              | 9 (2.6)              | 5 (2.6)                               | 3 (1.8)                               |
| Lost to follow-up                                | 0                    | 1 (0.3)              | 0                                     | 0                                     |
| No adequate post-baseline tumor assessment       | 1 (0.3)              | 0                    | 0                                     | 0                                     |
| Ongoing without an event                         | 84 (24.0)            | 27 (7.7)             | 57 (30.2)                             | 15 (8.9)                              |
| Probability of being event-free (95% CI) [1]     |                      |                      |                                       |                                       |
| at 3 months                                      | 0.581 (0.525, 0.634) | 0.427 (0.371, 0.481) | 0.649 (0.572, 0.716)                  | 0.436 (0.357, 0.511)                  |
| at 6 months                                      | 0.407 (0.352,0.461)  | 0.218 (0.172, 0.267) | 0.481 (0.403, 0.555)                  | 0.229 (0.165, 0.300)                  |
| at 9 months                                      | 0.330 (0.278,0.384)  | 0.184 (0.140, 0.232) | 0.384 (0.308, 0.459)                  | 0.204 (0.142, 0.274)                  |
| at 12 months                                     | 0.296 (0.244, 0.350) | 0.131 (0.092, 0.178) | 0.356 (0.280, 0.433)                  | 0.148 (0.092, 0.218)                  |
| at 15 months                                     | 0.269 (0.218,0.323)  | 0.119 (0.081, 0.165) | 0.325 (0.249, 0.403)                  | 0.137 (0.082, 0.206)                  |
| Kaplan-Meier estimates of Time to Event (months) |                      |                      |                                       |                                       |
| Quartiles (95% CI) [2]                           |                      |                      |                                       |                                       |
| Q1                                               | 1.9 (1.8, 1.9)       | 1.8 (1.8, 1.8)       | 1.9 (1.9, 2.0)                        | 1.8 (1.8, 1.9)                        |
| Median                                           | 3.7 (3.5, 5.5)       | 2.0 (1.9, 2.7)       | 5.7 (3.7, 7.4)                        | 2.1 (1.9, 3.5)                        |
| Q3                                               | 17.9 (11.3, NE)      | 5.5 (4.1, 7.2)       | 25.0 (13.8, NE)                       | 5.6 (4.1, 11.1)                       |
| Stratified analysis [3] Comparison vs BSC        |                      |                      |                                       |                                       |
| Hazard Ratio [4]                                 | 0.62                 |                      | 0.56                                  |                                       |
| 95% CI [4]                                       | 0.519, 0.751         |                      | 0.431, 0.728                          |                                       |
| 1-sided p-value [5]                              | <.0001               |                      | <.0001                                |                                       |
| 2-sided p-value [5]                              | <.0001               |                      | <.0001                                |                                       |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

[1] CIs are derived using the log-log transformation with back transformation to untransformed scale.

[2] CIs are calculated using Brookmeyer and Crowley method.

[3] Stratified by best response to first-line chemotherapy (CR or PR vs. SD), metastatic disease site (visceral vs. nonvisceral). IRT stratification values used.

[4] Cox proportional hazard model used.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (07:14) Output File:

[5] Log-rank test is used.

/B9991001/B9991001\\_CSR/adtteb\\_pfs\\_s001\\_pdl1\\_cp Date of Generation: 14JAN2020 (16:10) Cutoff date:210CT2019 Snapshot Date:21NOV2019

Table 14.2.4.2 is for Pfizer intermal use.

<div style=\"page-break-after: always\"></div>

Table 27 Summary of Progression Free Survival Based on BICR Assessment (RECIST v1.1) - Subjects with PD-L1-negative (exploratory analysis) and PD-L1-unknown (not prespecified) tumours (21 Oct. 2019).

|                                                                         | Subjects with PD-L1- Negative Tumours   | Subjects with PD-L1- Negative Tumours   | Subjects with PD-L1-Unknown Tumours   | Subjects with PD-L1-Unknown Tumours   |
|-------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------|---------------------------------------|---------------------------------------|
|                                                                         | Avelumab+BSC (N=139)                    | BSC (N=131)                             | Avelumab+BSC (N=22)                   | BSC (N=50)                            |
| Subjects with event, n (%)                                              | 103 (74.1)                              | 99 (75.6)                               | 13 (59.1)                             | 31 (62.0)                             |
| Type of event, n (%)                                                    |                                         |                                         |                                       |                                       |
| Progressive disease                                                     | 98 (70.5)                               | 95 (72.5)                               | 13 (59.1)                             | 29 (58.0)                             |
| Death                                                                   | 5 (3.6)                                 | 4 (3.1)                                 | 0                                     | 2 (4.0)                               |
| Subjects censored, n (%)                                                | 36 (25.9)                               | 32 (24.4)                               | 9 (40.9)                              | 19 (38.0)                             |
| Reason for censoring, n (%)                                             |                                         |                                         |                                       |                                       |
| No adequate baseline assessment                                         | 6 (4.3)                                 | 0                                       | 0                                     | 0                                     |
| Start of new anti-cancer therapy                                        | 5 (3.6)                                 | 17 (13.0)                               | 1 (4.5)                               | 8 (16.0)                              |
| Event after ≥ 2 missing or post-baseline                                | 2 (1.4)                                 | 6 (4.6)                                 | 0                                     | 1 (2.0)                               |
| inadequate assessments                                                  |                                         |                                         |                                       |                                       |
| Withdrawal of consent                                                   | 1 (0.7)                                 | 1 (0.8)                                 | 2 (9.1)                               | 5 (10.0)                              |
| Lost to follow-up                                                       | 0                                       | 1 (0.8)                                 | 0                                     | 0                                     |
| No adequate post-baseline tumour assessment                             | 0                                       | 0                                       | 1 (4.5)                               | 0                                     |
| Ongoing without an event                                                | 22 (15.8)                               | 7 (5.3)                                 | 5 (22.7)                              | 5 (10.0)                              |
| Probability of being event-free (95% CI) [1]                            |                                         |                                         |                                       |                                       |
| at 3 months                                                             | 0.502 (0.413, 0.585)                    | 0.394 (0.304, 0.483)                    | 0.517 (0.275, 0.713)                  | 0.488 (0.328, 0.630)                  |
| at 6 months                                                             | 0.311 (0.233, 0.393)                    | 0.146 (0.085, 0.223)                    | 0.402 (0.184, 0.612)                  | 0.373 (0.224, 0.522)                  |
| at 9 months                                                             | 0.253 (0.180, 0.331)                    | 0.098 (0.048, 0.169)                    | 0.402 (0.184, 0.612)                  | 0.342 (0.197, 0.492)                  |
| at 12 months                                                            | 0.216 (0.148, 0.293)                    | 0.071 (0.029, 0.138)                    | 0.322 (0.119, 0.546)                  | 0.239 (0.113, 0.391)                  |
| at 15 months                                                            | 0.193 (0.127, 0.270)                    | 0.071 (0.029, 0.138)                    | 0.322 (0.119, 0.546)                  | 0.199 (0.083, 0.352)                  |
| Kaplan-Meier estimates of Time to Event (months) Quartiles (95% CI) [2] |                                         |                                         |                                       |                                       |
| Q1                                                                      | 1.8 (1.8, 1.9)                          | 1.8 (1.7, 1.8)                          | 1.9 (1.1, 2.4)                        | 1.8 (1.2, 1.9)                        |
| Median                                                                  | 3.0 (2.0, 3.7)                          | 1.9 (1.9, 2.1)                          | 3.6 (1.9, 16.7)                       | 2.1 (1.9, 6.8)                        |
| Q3                                                                      | 9.2 (5.7, 25.3)                         | 3.8 (3.6, 5.6)                          | 16.7 (3.6, NE)                        | 10.3 (3.8, NE)                        |
| Stratified analysis [3] Comparison vs BSC                               |                                         |                                         |                                       |                                       |
| Hazard Ratio [4]                                                        | 0.63                                    |                                         | 0.97                                  |                                       |
| 95% CI [4]                                                              | 0.474, 0.847                            |                                         | 0.488, 1.914                          |                                       |

<div style=\"page-break-after: always\"></div>

## Subjects with PD-L1Negative Tumours

## Subjects with PD-L1-Unknown Tumours

Avelumab+BSC

(N=139)

BSC (N=131)

Avelumab+BSC (N=22)

BSC (N=50)

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

[1] CIs are derived using the log-log transformation with back transformation to untransformed scale.

[2] CIs are calculated using Brookmeyer and Crowley method.

[3] Stratified by best response to first-line chemotherapy (CR or PR vs. SD), metastatic disease site (visceral vs. non-visceral).

IRT stratification values used.

[4] Cox proportional hazard model used.

Cutoff date: 21OCT2019

Table 28. Summary of Progression Free Survival Based on Investigator Assessment (RECIST v1.1).

|                                                                         | All Subjects         | All Subjects         | Subjects with PD-Ll-PositiveTumors   | Subjects with PD-Ll-PositiveTumors   |
|-------------------------------------------------------------------------|----------------------|----------------------|--------------------------------------|--------------------------------------|
|                                                                         | Avelumab+BSC (N=350) | BSC (N=350)          | Avelumab+BSC (N=189)                 | BSC (N=169)                          |
| Subjects with event, n (%)                                              | 235 ( 67.1)          | 277 ( 79.1)          | 111 ( 58.7)                          | 138 ( 81.7)                          |
| Type of event, n (%)                                                    |                      |                      |                                      |                                      |
| Progressive disease                                                     | 225 ( 64.3)          | 271 ( 77.4)          | 105 ( 55.6)                          | 135 ( 79.9)                          |
| Death                                                                   | 10 (2.9)             | 6 (1.7)              | 6 (3.2)                              | 3 ( 1.8)                             |
| Subjects censored, n (%)                                                | 115 ( 32.9)          | 73 ( 20.9)           | 78 ( 41.3)                           | 31 ( 18.3)                           |
| Reason for censoring. n (%)                                             |                      |                      |                                      |                                      |
| No adequate baseline assessment                                         | 9 ( 2.6)             | 10 (2.9)             | 4 ( 2.1)                             | 6 (3.6)                              |
| Start of new anti-cancer therapy                                        | 9 (2.6)              | 21(( 6.0)            | 6 (3.2)                              | 6 ( 3.6)                             |
| Event after ≥ 2 missing or inadequate post-baseline assessments         | 1( 0.3)              | 5(1 1.4)             | 0                                    | 1 ( 0.6)                             |
| Withdrawal of consent                                                   | 7( 2.0)              | 9( 2.6)              | 4 ( 2.1)                             | 4( 2.4)                              |
| Lost to follow-up                                                       | 1( 0.3)              | 1( 0.3)              | 1( 0.5)                              | 0                                    |
| No adequate post-baseline tumor assessment                              | 0                    | 0                    | 0                                    | 0                                    |
| Ongoing without an event                                                | 88 ( 25.1)           | 27 (7.7)             | 63 ( 33.3)                           | 14 (8.3)                             |
| Probability of being event-free (95% CI) [1]                            |                      |                      |                                      |                                      |
| at 3 months                                                             | 0.682 (0.629, 0.729) | 0.445 (0.390, 0.500) | 0.747 (0.677, 0.804)                 | 0.479 (0.398, 0.555)                 |
| at 6 months                                                             | 0.460 (0.406, 0.513) | 0.234 (0.188, 0.283) | 0.554 (0.478, 0.623)                 | 0.260 (0.193, 0.331)                 |
| at 9 months                                                             | 0.387 (0.334, 0.440) | 0.167 (0.127, 0.212) | 0.486 (0.410, 0.558)                 | 0.168 (0.113, 0.233)                 |
| at 12 months                                                            | 0.341 (0.288, 0.394) | 0.116 (0.081, 0.157) | 0.411 (0.335, 0.486)                 | 0.102 (0.058, 0.160)                 |
| at 15 months                                                            | 0.304 (0.252, 0.358) | 0.092 (0.061, 0.131) | 0.376 (0.299, 0.452)                 | 0.085 (0.045, 0.141)                 |
| Kaplan-Meier estimates of Time to Event (months) Quartiles (95% C1) [2] |                      |                      |                                      |                                      |
| Q1                                                                      | 1.9 (1.9, 2.2)       | 1.8 (1.8, 1.9)       | 2.8 (1.9, 3.7)                       | 1.9 (1.8, 1.9)                       |
| Median                                                                  | 5.5 (4.2, 7.2)       | 2.1 (1.9, 3.0)       | 7.5 (5.5, 11.2)                      | 2.8 (2.0, 3.7)                       |
| Q3                                                                      | 19.4 (15.1, NE)      | 5.7 (5.5, 7.2)       | NE (18.3, NE)                        | 6.0 (5.5, 8.3)                       |
| Stratified analysis [3] Comparison vs BSC                               |                      |                      |                                      |                                      |
| Hazard Ratio [4]                                                        | 0.52                 |                      | 0.43                                 |                                      |
| [] 10 %56                                                               | 0.437,0.625          |                      | 0.329, 0.552                         |                                      |
| 1-sided p-value [5]                                                     | <.0001               |                      | <.0001                               |                                      |
| 2-sided p-value [5]                                                     | <.0001               |                      | <.0001                               |                                      |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

[2] CIs are calculated using Brookmeyer and Crowley method.

[1]CIs arederived usingthelog-log transformationwithback transformation to untransformedscale.

[3] Stratified by best response to first-line chemotherapy (CR or PR vs. SD), metastatic disease site (visceral vs. non-visceral). IRT stratification values used.

[5] Log-rank test is used.

[4] Cox proportional hazard model used.

ate:21OCT2019SnapshotDate:21NOV2019

<div style=\"page-break-after: always\"></div>

Figure 28. Kaplan-Meier Plot of Progression-Free Survival Based on BICR Assessment (RECIST v1.1) - FAS (Study B9991001 21 Oct. 2019)

Figure 29   Kaplan-Meier Plot of Progression-Free Survival Based on BICR Assessment (RECIST v1.1) - Subjects with PD-L1-Positive Tumours (Study B9991001 21 Oct. 2019)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 30. Kaplan-Meier Plot of Progression-Free Survival Based on BICR Assessment (RECIST v1.1) - Subjects with PD-L1-Negative Tumours (Study B9991001, exploratory analysis, 21 Oct. 2019))

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 31. Kaplan-Meier Plot of Progression-Free Survival Based on BICR Assessment (RECIST v1.1) - Subjects with PD-L1-Unknown Tumours (Study B9991001, not prespecified endpoint)

<!-- image -->

Subgroup Analysis of PFS

<div style=\"page-break-after: always\"></div>

Figure 32. Forest Plot of Progression Free Survival by Subgroups Based on BICR Assessment - FAS (Study B9991001, 21 Oct. 2019)

NumberofEvents/

|                                          | Numberof Sublects (N)   | Numberof Sublects (N)   | Numberof Sublects (N)                                                                  | Numberof Sublects (N)                                                                  |
|------------------------------------------|-------------------------|-------------------------|----------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Subgroup                                 | Aveumab+BSC             | BSC                     |                                                                                        | Hazard Rato(95% C0[1]                                                                  |
| All subjects (stratifed)[2]              | 225/350                 | 260/350                 |                                                                                        | 0.62 (0.519,0.751)                                                                     |
| Allsubjects (unstratifed)                | 225/350                 | 260/350                 |                                                                                        | 0.62 (0.517,0.746)                                                                     |
| Best response to firstHine chemotherapy. |                         |                         |                                                                                        |                                                                                        |
| CRor PR(perIRT)                          | 167/253                 | 189/252                 |                                                                                        | 0.63 (0.506,0.776)                                                                     |
| SD (perIRT)                              | 58/97                   | 71/98                   |                                                                                        | 0.61(0.423,0.868)                                                                      |
| Metastaticdisease site:                  |                         |                         |                                                                                        |                                                                                        |
| Visceral(per IRT)                        | 138/191                 | 146/191                 |                                                                                        | 0.73 (0.576,0.929)                                                                     |
| Non-Viscera (perIRT)                     | 87/159                  | 114/159                 |                                                                                        | 0.50 (0.376,0.668)                                                                     |
| Age:                                     |                         |                         |                                                                                        |                                                                                        |
| <65years                                 | 94/129                  | 74/107                  |                                                                                        | 0.92(0.671,1.255)                                                                      |
| 265years                                 | 131/221                 | 186/243                 |                                                                                        | 0.50(0.393,0.623)                                                                      |
| Gender.                                  |                         |                         |                                                                                        |                                                                                        |
| Male                                     | 168/266                 | 204/275                 |                                                                                        | 0.60 (0.486,0.740)                                                                     |
| Female                                   | 57/84                   | 56/75                   |                                                                                        | 0.69 (0.473,1.014)                                                                     |
| Race:                                    |                         |                         |                                                                                        |                                                                                        |
| White                                    | 145/232                 | 173/238                 |                                                                                        | 0.65(0.516,0.813)                                                                      |
| Asian                                    | 5575                    | 60/81                   |                                                                                        | 0.55(0.372,0.801)                                                                      |
| Other                                    | 25/43                   | 27/31                   |                                                                                        | 0.64 (0.363,1.114)                                                                     |
| Pooledgeographicregion:                  |                         |                         |                                                                                        |                                                                                        |
| Europe                                   | 136/214                 | 153/203                 |                                                                                        | 0.66(0.524,0.842)                                                                      |
| North America                            | 4/12                    | 17/22                   |                                                                                        | 0.20(0.063,0.611)                                                                      |
| Asia                                     | 53/73                   | 53/74                   |                                                                                        | 0.57 (0.385,0.854)                                                                     |
| Australasia                              | 21/34                   | 26/37                   |                                                                                        | 0.83 (0.456,1.494)                                                                     |
| Restof the Word                          | 11/17                   | 11/14                   |                                                                                        | 0.32(0.128,0.811)                                                                      |
| PD-L1 status at baseline:                |                         |                         |                                                                                        |                                                                                        |
| Positive                                 | 109/189                 | 130/169                 |                                                                                        | 0.55 (0.424, 0.715)                                                                    |
| Negative                                 | 103/139                 | 100/132                 |                                                                                        | 0.63 (0.476, 0.845)                                                                    |
| Unknown                                  | 13/22                   | 3049                    |                                                                                        | 0.87 (0,444, 1.694)                                                                    |
| First-line chemotherapy regimen:         |                         |                         |                                                                                        |                                                                                        |
| Gemcitabine+cisplatin                    | 121/183                 | 153/206                 |                                                                                        | 0.63 (0.497,0.810)                                                                     |
| Gemcitabine+carboplatin                  | 93/147                  | 90/122                  |                                                                                        | 0.59 (0.437,0.800)                                                                     |
| Gemcitabine+carboplatin+cisplatin        | 11/20                   | 15/20                   |                                                                                        | 0.56 (0.255, 1.242)                                                                    |
| ECOG performance status:                 |                         |                         |                                                                                        |                                                                                        |
| 0                                        | 136213                  | 153/211                 |                                                                                        | 0.61 (0.484, 0.779)                                                                    |
| 21                                       | 89/137                  | 107/139                 |                                                                                        | 0.63 (0.475,0.846)                                                                     |
| Crestinine clearance at baseline!        |                         |                         |                                                                                        |                                                                                        |
| ≥60 mL/min                               | 116/181                 | 140/196                 |                                                                                        | 0.71 (0.551, 0.912)                                                                    |
| <60 mLimin                               | 108/168                 | 116/148                 |                                                                                        | 0.52 (0.395, 0.682)                                                                    |
| Liver lesions at baseline:               |                         |                         |                                                                                        |                                                                                        |
| Yes                                      | 38/43                   | 33/44                   |                                                                                        | 0.96 (0.593, 1.549)                                                                    |
| No                                       | 187307                  | 227/306                 |                                                                                        | 0.58 (0,476, 0.709)                                                                    |
| Lung lesions at baseline:                |                         |                         |                                                                                        |                                                                                        |
| Yes                                      | 63/83                   | 67/83                   |                                                                                        | 0.68 (0.476, 0.975)                                                                    |
| No                                       | 162/267                 | 193/267                 |                                                                                        | 0.60 (0.483, 0.742)                                                                    |
|                                          |                         |                         | 00 0.5 1.0 15 20 2.5 3.0 HazardRaloforPFSbyBICRwith95%CI Fevors Avelumsb+B5C FavorsBSC | 00 0.5 1.0 15 20 2.5 3.0 HazardRaloforPFSbyBICRwith95%CI Fevors Avelumsb+B5C FavorsBSC |

Nis the number of subjects in the full analysis set within each subgroup and treatment group.

[2] Stratified by bestresponse to first-line chemotherapy (CR or PR vs. SD), metastatic disease site (visceral vs. non-visceral). IRT straification values used.

[1]Hazardratios and associated Cls are calculated using Coxproportional hazardmodel.

Other than the analysisfor all subjects which takes into account stratificationfactors, allother analyses are unstratified.

Subgroups with &lt;5% of the patient population were pooled (Race: Black/AfficanAmerican and Other) ornot presented (Ethnicity since only two subgroups and Hispanic/Latinois &lt;5% of the patient population).

Date:21NOV2019

<div style=\"page-break-after: always\"></div>

Figure 33. Forest Plot of Progression Free Survival by Subgroups Based on BICR Assessment - FAS (Study B9991001, non prespecified subgroups, 21 Oct. 2019)

<!-- image -->

[1]Hazardratiosand associatedClsarecalculated usingCoxproportionalhazardmodel.

Other than the analysis for allsubjects which takes into account stratification factors, all other analyses are unstratified.

[2] Stratified by bestresponse to first-line chemotherapy(CR or PRvs.SD).metastatic disease site(visceral vs.non-visceral).IRT stratificationvalues used.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (08:14) OutputFile: /B9991001/CHMP\\_IA/adtteb\\_pfs\\_f003\\_OC\\_F12 Date of Generation: 21SEP2020 (12:15) Cutoff date:210CT2019 Snapshot Date:21NOV2019

<div style=\"page-break-after: always\"></div>

## Figure 34. Forest Plot of Progression Free Survival by Subgroups Based on BICR Assessment - Subjects with PD-L1-Positive Tumours (Study B9991001, 21 Oct 2019)

NumberofEvensl

|                                         | Numberof Subjects (N)   | Numberof Subjects (N)                                             | Numberof Subjects (N)                                             | Numberof Subjects (N)                                             |
|-----------------------------------------|-------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
| Subgroup                                | Avelumab+8Sc            | BSC                                                               | Hazard Rato(95% Cl）[1]                                            |                                                                   |
| Allsulbjects (stratifed)[2]             | 109/189                 | 130/169                                                           | 0.56(0.431,0.728)                                                 |                                                                   |
| All subjects （unstratifed)              | 109189                  | 130/169                                                           | 0.55(0.424,0.715)                                                 |                                                                   |
| Bestresponse tofirst-line chemotherapy. |                         |                                                                   |                                                                   |                                                                   |
| CRor PR(perIRT)                         | 85/139                  | 99/128                                                            | 0.60 (0.444,0.803)                                                |                                                                   |
| SD (perIRT)                             | 24/50                   | 31/41                                                             | 0.43 (0.247,0.755)                                                |                                                                   |
| Metastatic disease site:                |                         |                                                                   |                                                                   |                                                                   |
| Visceral(per IRT)                       | 57/88                   | 6479                                                              | 0.61(0.425,0.884)                                                 |                                                                   |
| Non-Visceral (per IRT)                  | 52/101                  | 66/90                                                             | 0.50(0.345,0.728)                                                 |                                                                   |
| Age:                                    |                         |                                                                   |                                                                   |                                                                   |
| <65years                                | 40/62                   | 3549                                                              | 0.81 (0.509,1.292)                                                |                                                                   |
| 65years                                 | 69/127                  | 95/120                                                            | 0.45(0.324,0.616)                                                 |                                                                   |
| Gender.                                 |                         |                                                                   |                                                                   |                                                                   |
| Male                                    | 86/145                  | 98/129                                                            | 0.58(0.431,0.779)                                                 |                                                                   |
| Female                                  | 23/44                   | 32/40                                                             | 0.48 (0.271,0.836)                                                |                                                                   |
| Race:                                   |                         |                                                                   |                                                                   |                                                                   |
| White                                   | 68/121                  | 90/119                                                            | 0.52 (0.376,0.721)                                                |                                                                   |
| Asian                                   | 29/42                   | 26/33                                                             | 0.61(0.354,1.052)                                                 |                                                                   |
| Other                                   | 12/26                   | 14/17                                                             | 0.62(0.284,1.365)                                                 |                                                                   |
| Pooled geographicregjon:                |                         |                                                                   |                                                                   |                                                                   |
| Europe                                  | 63/110                  | 79/102                                                            | 0.55(0.388,0.767)                                                 |                                                                   |
| NorthAmerica                            | 08                      | 68                                                                | <0.01(0.000,NE)                                                   |                                                                   |
| Asia                                    | 27140                   | 2431                                                              | 0.64(0.361,1.118)                                                 |                                                                   |
| Australasia                             | 11/20                   | 18/24                                                             | 0.69 (0.318,1.496)                                                |                                                                   |
| Restof the World                        | 8/11                    | 34                                                                | 0.16 (0.027,0.886)                                                |                                                                   |
| First-line chemotherapyregimen:         |                         |                                                                   |                                                                   |                                                                   |
| Gemcitabine+cisplatin                   | 60/101                  | 76/98                                                             | 0.52 (0.367,0.736)                                                |                                                                   |
| Gemcitabine+carboplatin                 | 43/74                   | 41/54                                                             | 0.61(0.389,0.946)                                                 |                                                                   |
| Gemcitabine+carboplatin+cisplatin       | 6/14                    | 11/15                                                             | 0.51 (0.184, 1.403)                                               |                                                                   |
| ECOGperfommance status:                 |                         |                                                                   |                                                                   |                                                                   |
| 0                                       | 66/114                  | 80/107                                                            | 0.54(0.386,0.755)                                                 |                                                                   |
| 1                                       | 43/75                   | 50/62                                                             | 0.57(0.376,0.865)                                                 |                                                                   |
| Creatinine clearance at baseline:       |                         |                                                                   |                                                                   |                                                                   |
| 260mL/min                               | 60/104                  | 73/97                                                             | 0.62(0.434,0.873)                                                 |                                                                   |
| <60mL/min                               | 48/84                   | 55/70                                                             | 0.47 (0.317,0.708)                                                |                                                                   |
| Liverlesions at baseline:               |                         |                                                                   |                                                                   |                                                                   |
| Yes                                     | 11/13                   | 10/13                                                             | 0.69 (0.268,1.767)                                                |                                                                   |
| No                                      | 98/176                  | 120/156                                                           | 0.54 (0.410, 0.709)                                               |                                                                   |
| Lung lesions at baseliner               |                         |                                                                   |                                                                   |                                                                   |
| Yes                                     |                         |                                                                   | 0.62 (0.360,1.070)                                                |                                                                   |
|                                         |                         |                                                                   | 0.54(0.397,0.722)                                                 |                                                                   |
|                                         | 27/36                   | 30/34                                                             |                                                                   |                                                                   |
| No                                      | 82/153                  | 100/135                                                           |                                                                   |                                                                   |
|                                         | 0.0 FavorsAvelumab+BSC  | 0.5 1.0 1.5 20 2.5 3.0 HazardRatioforPFSbyBiCRwith95%Ci FavorsBSC | 0.5 1.0 1.5 20 2.5 3.0 HazardRatioforPFSbyBiCRwith95%Ci FavorsBSC | 0.5 1.0 1.5 20 2.5 3.0 HazardRatioforPFSbyBiCRwith95%Ci FavorsBSC |

Nisthenumberof subjectswithPD-L1-positivetumors inthefull analysissetwithineach subgroupand treatment group.

[2] Stratified bybestresponse to first-line chemotherapy(CRorPRvs.SD).metastaticdisease site(visceral vs.non-visceral).IRT stratificationvaluesused.

[1]Hazardratiosand associatedCisarecalculatedusingCoxproportionalhazardmodel.

Otherthantheanalysisforallsubjectswhichtakesintoaccountstratificationfactors,allotheranalysesareunstratified.

Subgroupswith&lt;5%of thepatient populationwere pooled(Race:Black/AficanAmerican and Other)ornotpresented(Ethnicity since onlytwo subgroupsandHispanic/Latinois&lt;S%of thepatient \"(uogendod

Date:21NOV2019

<div style=\"page-break-after: always\"></div>

Figure 35 Forest Plot of Progression Free Survival by Subgroups Based on BICR Assessment - Subjects with PD-L1-Positive Tumours (Study B9991001, non prespecified subgroups, 21 Oct 2019)

<!-- image -->

[1]Hazardratios and associatedCls arecalculated usingCoxproportional hazardmodel.

Other than the analysis for all subjects which takes into account stratification factors, allother analyses are unstratified.

[2jStratified bybestresponse to first-line chemotherapy(CR or PRvs.SD).metastatic disease site(visceral vs.non-visceral).IRT stratification values used.

Date:21NOV2019

## Best Overall Response and Objective Response

<div style=\"page-break-after: always\"></div>

Table 29. Summary of Best Overall Response and Objective Response (Confirmed) based on BICR Assessment (RECIST v1.1, 21 Oct. 2019)).

|                                                                       | All Subjects         | All Subjects   | Subjects with PD-Ll-Positive Tumors   | Subjects with PD-Ll-Positive Tumors   |
|-----------------------------------------------------------------------|----------------------|----------------|---------------------------------------|---------------------------------------|
|                                                                       | Avelumab+BSC (N=350) | BSC (N=350)    | Avelumab+BSC (N=189)                  | BSC (N=169)                           |
| Confirmed Best Overall Response, n (%)                                |                      |                |                                       |                                       |
| Complete response (CR)                                                | 21 (6.0)             | 3 (0.9)        | 18 (9.5)                              | 1 (0.6)                               |
| Partial response (PR)                                                 | 13 (3.7)             | 2 (0.6)        | 8 (4.2)                               | 1 (0.6)                               |
| Stable disease (SD)                                                   | 44 (12.6)            | 46 (13.1)      | 19 (10.1)                             | 23 (13.6)                             |
| Non-CR/Non-PD                                                         | 66 (18.9)            | 45 (12.9)      | 38 (20.1)                             | 22 (13.0)                             |
| Progressive disease (PD)                                              | 130 (37.1)           | 169 (48.3)     | 59 (31.2)                             | 82 (48.5)                             |
| Not evaluable (NE)                                                    | 76 (21.7)            | 85 (24.3)      | 47 (24.9)                             | 40 (23.7)                             |
| Reason for NE, n (%)                                                  |                      |                |                                       |                                       |
| No evidence of disease at baseline                                    | 52 (14.9)            | 50 (14.3)      | 31 (16.4)                             | 28 (16.6)                             |
| No post-baseline assessments due to early death                       | 1 (0.3)              | 4 (1.1)        | 1 (0.5)                               | 1 (0.6)                               |
| No post-baseline assessments due to other reasons                     | 18 (5.1)             | 17 (4.9)       | 12 (6.3)                              | 5 (3.0)                               |
| All post-baseline assessments have overall response of NE             | 0                    | 1 (0.3)        | 0                                     | 0                                     |
| New anti-cancer therapy started before first post-baseline assessment | 1 (0.3)              | 3 (0.9)        | 1 (0.5)                               | 1 (0.6)                               |
| SD too early (<6 weeks after Randomization date)                      | 2 (0.6)              | 8 (2.3)        | 1 (0.5)                               | 3 (1.8)                               |
| PD too late (>12 weeks after Randomization date)                      | 2 (0.6)              | 2 (0.6)        | 1 (0.5)                               | 2 (1.2)                               |
| Objective Response (CR+PR), n (%)                                     | 34 (9.7)             | 5 (1.4)        | 26 (13.8)                             | 2 (1.2)                               |
| 95% CI [1]                                                            | 6.8, 13.3            | 0.5,3.3        | 9.2, 19.5                             | 0.1, 4.2                              |
| Disease Control (CR+PR+SD+Non-CR/Nonl- PD), n (%)                     | 144 (41.1)           | 96 (27.4)      | 83 (43.9)                             | 47 (27.8)                             |
| 95% CI [1]                                                            | 35.9. 46.5           | 22.8. 32.4     | 36.7. 51.3                            | 21.2.35.2                             |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

[1] Clopper-Pearson method used.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (07:14) Source Data: ADRSB Output File:

/B9991001/B9991001\\_CSR/adrsb\\_borc\\_s001b\\_pdl\\_cp Date of Generation: 04FEB2020 (11:42) Cutoff date:

210CT2019 Snapshot Date: 21NOV2019

Table 14.2.1.2.1.1 is for Pfizer internal use.

Table 30 Summary of Best Overall Response and Objective Response (Confirmed) based on BICR Assessment (RECIST v1.1) - Subjects with PD-L1-Negative (exploratory analysis) and PD-L1-Unknown tumours (not prespecified endpoint) (21 Oct. 2019)

<div style=\"page-break-after: always\"></div>

|                                                                       | SubjectswithPD-L1-NegativeTumor's   | SubjectswithPD-L1-NegativeTumor's   | Subjects with PD-L1-Unknown Tumor's   | Subjects with PD-L1-Unknown Tumor's   |
|-----------------------------------------------------------------------|-------------------------------------|-------------------------------------|---------------------------------------|---------------------------------------|
|                                                                       | Avelumab+BSC (N=139)                | BSC (N=131)                         | Avelumab+BSC (N=22)                   | BSC (N=50)                            |
| Confirmed Best Overall Response, n (%)                                |                                     |                                     |                                       |                                       |
| Complete response (CR)                                                | 3 (2.2)                             | 1( 0.8)                             | 0                                     | 1 ( 2.0)                              |
| Partial response (PR)                                                 | 5 (3.6)                             | 0                                   | 0                                     | 1 ( 2.0)                              |
| Stable disease (SD)                                                   | 24 ( 17.3)                          | 14 ( 10.7)                          | 1 ( 4.5)                              | 9 ( 18.0)                             |
| Non-CR/Non-PD                                                         | 24 ( 17.3)                          | 19 ( 14.5)                          | 4 ( 18.2)                             | 4 ( 8.0)                              |
| Progressive disease (PD)                                              | 62 ( 44.6)                          | 66 ( 50.4)                          | 9 ( 40.9)                             | 21 ( 42.0)                            |
| Not evaluable (NE)                                                    | 21 ( 15.1)                          | 31 ( 23.7)                          | 8 (36.4)                              | 14 ( 28.0)                            |
| Reason for NE, n (%)                                                  |                                     |                                     |                                       |                                       |
| No evidence of disease at baseline                                    | 15 ( 10.8)                          | 16 ( 12.2)                          | 6 (27.3)                              | 6 (12.0)                              |
| Nopost-baseline assessments due to early death                        | 0                                   | 3 (2.3)                             | 0                                     | 0                                     |
| No post-baseline assessments due to other reasons                     | 4 (2.9)                             | 5( 3.8)                             | 2( 9.1)                               | 7 (14.0)                              |
| Allpost-baseline assessmentshaveoverallresponseofNE                   | 0                                   | 1( 0.8)                             | 0                                     | 0                                     |
| New anti-cancer therapy started before first post-baseline assessment | 0                                   | 2( 1.5)                             | 0                                     | 0                                     |
| SDtooearly(<6weeksafterRandomizationdate)                             | 1 ( 0.7)                            | 4 ( 3.1)                            | 0                                     | 1 ( 2.0)                              |
| PD too late (>12 weeks after Randomization date)                      | 1(0.7)                              | 0                                   | 0                                     | 0                                     |
| Objective Response (CR+PR), n (%)                                     | 8 (5.8)                             | 1 ( 0.8)                            | 0                                     | 2 (4.0)                               |
| 95% CI [1]                                                            | 2.5, 11.0                           | 0.0, 4.2                            | 0.0, 15.4                             | 0.5,13.7                              |
| Disease Control (CR+PR+SD+Non-CR/Non-PD), n (%)                       | 56 ( 40.3)                          | 34 ( 26.0)                          | 5 (22.7)                              | 15 ( 30.0)                            |
| []10 %6                                                               | 32.1, 48.9                          | 18.7, 34.3                          | 7.8, 45.4                             | 17.9, 44.6                            |

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group. [1] Clopper-Pearson method used.

PFIZER CONFIDENTIAL SDTM Creation:22NOV2019(08:14)Source Data:ADRSBOutput File:./B9991001/CHMP\\_IA/adrsb\\_borc\\_s001b\\_pdl\\_moDate ofGen eration:28AUG2020(14:28)Cutoff date:210CT2019Snapshot Date:21NOV2019

All randomized patients (including patients with CR following first-line chemotherapy) were included in the analysis of objective response (refer to study B9991001 SAP Section 6.2.2.3). For patients with no evidence of disease, the BOR can only be NE or PD, which is different from patients without measurable disease as the latter can also have BOR of CR or non-CR/non-PD. Subgroup analyses including only patients with measurable tumours at baseline were performed.

Among the 78 patients with measurable disease by BICR at baseline with PD-L1-positive tumours treated with avelumab plus BSC, 7.7% achieved CR (BICR), 10.3% PR and 24.4% SD and 48.7% displayed PD. For the 78 patients treated with BSC, 1.3% achieved CR, 1.3% PR and 29.5% SD and 56.4% displayed PD. Among the 77 patients with measurable disease by BICR at baseline with PD-L1negative tumours treated with avelumab plus BSC, 1.3% achieved CR (BICR), 6.5% PR and 31.2% SD and 55.8% displayed PD. For the 62 patients treated with BSC, 0% achieved CR or PR and 22.6% SD and 64.5% displayed PD.

<div style=\"page-break-after: always\"></div>

Table 31. Summary of Time to Response Based on BICR Assessment (RECIST v1.1, 21 Oct. 2019))

<!-- image -->

Table 32.  Summary of Duration of Response Based on BICR Assessment (RECIST v1.1) Patients with confirmed CR or PR (21 Oct. 2019)

|                                                          | All Subjects        | All Subjects   | SubjectswithPD-Ll-PositiveTumors   | SubjectswithPD-Ll-PositiveTumors   |
|----------------------------------------------------------|---------------------|----------------|------------------------------------|------------------------------------|
|                                                          | Avelumab+BSC (N=34) | BSC (N=5)      | Avelumab+BSC (N=26)                | BSC (N=2)                          |
| Subjects with event, n (%)                               | 10 ( 29.4)          | 0              | 8 ( 30.8)                          | 0                                  |
| Type of event, n (%)                                     |                     |                |                                    |                                    |
| Progressive disease                                      | 9 ( 26.5)           | 0              | 7 ( 26.9)                          | 0                                  |
| Death                                                    | 1 ( 2.9)            | 0              | 1 (3.8)                            | 0                                  |
| Subjects censored,n (%)                                  | 24 ( 70.6)          | 5 (100.0)      | 18 ( 69.2)                         | 2 (100.0)                          |
| Reason for censoring, n (%)                              |                     |                |                                    |                                    |
| Start of new anti-cancer therapy                         | 2 (5.9)             | 1 ( 20.0)      | 2 (7.7)                            | 0                                  |
| Event after2missing orinadequatepost-baselineassessments | 0                   | 0              | 0                                  | 0                                  |
| Withdrawal of consent                                    | 0                   | 0              | 0                                  | 0                                  |
| Lost to follow-up                                        | 0                   | 0              | 0                                  | 0                                  |
| Noadequatepost-baselinetumorassessment                   | 0                   | 0              | 0                                  | 0                                  |
| Ongoingwithout anevent                                   | 22 ( 64.7)          | 4 ( 80.0)      | 16 ( 61.5)                         | 2 (100.0)                          |

Table 33 Summary of Duration of Response Based on BICR Assessment (RECIST v1.1) Patients with confirmed CR or PR, Subjects with PD-L1-negative (exploratory analysis) and PD-L1-Unknown tumours (not prespecified endpoint, 21 Oct. 2019)

|                                                                   | SubjectswithPD-Ll-NegativeTumors   | SubjectswithPD-Ll-NegativeTumors   | SubjectswithPD-L1-Unknown Tumors   | SubjectswithPD-L1-Unknown Tumors   |
|-------------------------------------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|
|                                                                   | Avelumab+BSC (N=8)                 | BSC (N=1)                          | Avelumab+BSC (N=0)                 | BSC (N=2)                          |
| Subjects with event, n (%)                                        | 2 ( 25.0)                          | 0                                  | 0                                  | 0                                  |
| Type of event, n (%)                                              |                                    |                                    |                                    |                                    |
| Progressive disease                                               | 2 ( 25.0)                          | 0                                  |                                    |                                    |
| Death                                                             | 0                                  | 0                                  |                                    |                                    |
| Subjects censored, n (%)                                          | 6 ( 75.0)                          | 1 (100.0)                          | 0                                  | 2 (100.0)                          |
| Reason for censoring, n (%)                                       |                                    |                                    |                                    |                                    |
| Start of newanti-cancer therapy                                   | 0                                  | 0                                  | 0                                  | 1 ( 50.0)                          |
| Event after2missingorinadequatepost-baselineassessments           | 0                                  | 0                                  | 0                                  | 0                                  |
| Withdrawalofconsent                                               | 0                                  | 0                                  | 0                                  | 0                                  |
| Lost to follow-up                                                 | 0                                  | 0                                  | 0                                  | 0                                  |
| Noadequatepost-baselinetumorassessment                            | 0                                  | 0                                  | 0                                  | 0                                  |
| Ongoingwithoutanevent                                             | 6 ( 75.0)                          | 1 (100.0)                          | 0                                  | 1 ( 50.0)                          |
| Kaplan-MeierestimatesofTimetoEvent(months) Quartiles (95% C1) [2] |                                    |                                    |                                    |                                    |
| Q1                                                                | 8.3 (3.7, NE)                      | NE (NE, NE)                        | NE (NE, NE)                        | NE (NE, NE)                        |
| Median                                                            | NE (3.7, NE)                       | NE (NE, NE)                        | NE (NE, NE)                        | NE (NE, NE)                        |
| Q3                                                                | NE (NE, NE)                        | NE (NE, NE)                        | NE (NE, NE)                        | NE (NE, NE)                        |

Overall Response and objective responses are higher in patients with PD-L1-expression. Very few patients in the Avelumab+BSC arm (5.8%) with PD-L1-negative tumours had an objective response and no patients with PD-L1-unknown tumours. Due to the low number of responses an assessment of duration of the responses cannot be made.

<div style=\"page-break-after: always\"></div>

## Time to end of next line treatment

PFS2 was not recorded during study B99910001. Time to end of next line treatment was not a prespecified endpoint. No detrimental effect on end of next line treatment is detected when avelumab plus BSC is compared to BSC.

Figure 36. Kaplan-Meier Plot of Time to End-of-next-line-treatment - Full Analysis Set (21 Oct. 2019)

<!-- image -->

Figure 37. Kaplan-Meier Plot of Time to End-of-next-line-treatment - Subjects with PD-L1Positive Tumours (21 Oct. 2019)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 38. Kaplan-Meier Plot of Time to End-of-next-line-treatment - Subjects with PD-L1Negative Tumours (21 Oct. 2019)

<!-- image -->

Figure 39. Kaplan-Meier Plot of Time to End-of-next-line-treatment - Subjects with PD-L1Unknown Tumours (21 Oct. 2019)

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Follow-up anti-cancer therapies

The majority of patients, regardless of PD-L1 tumour status, reported at least one type of follow-up anti-cancer therapy. However, follow-up anti-cancer drug therapies were more common among patients treated with BSC in patients with both PD-L1-positive and PD-L1-negative tumours. 6.3% of patients in the avelumab plus BSC arm were treated with a PD-1 or PD-L1 inhibitor whereas 43.7% of the patients in the BSC arm were treated with PD-1 or PD-L1 inhibitor.

Table 34. Summary of Follow-up Anti-Cancer Therapies - Full Analysis Set (Protocol B9991001).

|                                                                   | Avelumab+BSC (N=350)   | BSC (N=350)   |
|-------------------------------------------------------------------|------------------------|---------------|
| Subjects discontinued from study treatment^                       | 265 (75.7)             | 324 (92.6)    |
| Subjects ongoing with study treatment^                            | 85 (24.3)              | 26 (7.4)      |
| Subjects with at least one type of follow-up anti-cancer therapy  |                        |               |
| Yes                                                               | 167 (47.7)             | 228 (65.1)    |
| No                                                                | 47 (13.4)              | 37 (10.6)     |
| Not reported*                                                     | 136 (38.9)             | 85 (24.3)     |
| Subjects with at least one follow-up anti-cancer drug therapy     |                        |               |
| Yes                                                               | 148 (42.3)             | 216 (61.7)    |
| No                                                                | 73 (20.9)              | 50 (14.3)     |
| Not reported*                                                     | 129 (36.9)             | 84 (24.0)     |
| Subjects with at least one follow-up anti-cancer radiotherapy     |                        |               |
| Yes                                                               | 52 (14.9)              | 57 (16.3)     |
| No                                                                | 160 (45.7)             | 190 (54.3)    |
| Not reported*                                                     | 138 (39.4)             | 103 (29.4)    |
| Subjects with at least one follow-up anti-cancer radiotherapy [1] |                        |               |
| Curative                                                          | 2 (0.6)                | 3 (0.9)       |
| Palliative                                                        | 50 (14.3)              | 54 (15.4)     |
| Subjects with at least one follow-up anti-cancer surgery          |                        |               |
| Yes                                                               | 13 (3.7)               | 14 (4.0)      |
| No                                                                | 197 (56.3)             | 227 (64.9)    |
| Not reported*                                                     | 140 (40.0)             | 109 (31.1)    |
| Follow-up anti-cancer drug therapy regimens [2]                   |                        |               |
| 0 regimen                                                         | 73 (20.9)              | 50 (14.3)     |
| 1 regimen                                                         | 102 (29.1)             | 150 (42.9)    |
| 2 regimens                                                        | 33 (9.4)               | 52 (14.9)     |
| 3 regimens                                                        | 11 (3.1)               | 11 (3.1)      |
| ≥ 4 regimens                                                      | 2 (0.6)                | 3 (0.9)       |
| Not reported*                                                     | 129 (36.9)             | 84 (24.0)     |

Follow-up anti-cancer therapies as recorded in the Follow-up Cancer Therapy, Follow-up Radiation Therapy and Follow-up Surgery CRF pages.

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

^ Refer to Module 2.7.3 SCE In-text Table 2

* Includes subjects ongoing with study treatment

<div style=\"page-break-after: always\"></div>

[1] Subjects are counted once per category but may be counted in multiple categories.

[2] Includes the overall number of regimens in neoadjuvant, adjuvant, advanced/metastatic or locoregional disease/recurrence drug therapies

Table 35. Follow-up Anti-Cancer Drug Therapies by Category - All Subjects and Subjects with PD-L1-Positive Tumours in the Full Analysis Set (Protocol B9991001, 21 Oct. 2019)

|                                                        | All Subjects              | All Subjects     | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   |
|--------------------------------------------------------|---------------------------|------------------|---------------------------------------|---------------------------------------|
| Category                                               | Avelumab+BSC (N=350) n(%) | BSC (N=350) n(%) | Avelumab+BSC (N=189) n (%)            | BSC (N=169) n (%)                     |
| Subjects with any follow-up anti-cancer drug therapies | 148 (42.3)                | 216 (61.7)       | 68 (36.0)                             | 109 (64.5)                            |
| Any PD-1 or PD-L1 inhibitor                            | 22 (6.3)                  | 153 (43.7)       | 10 (5.3)                              | 81 (47.9)                             |
| FGFR inhibitor                                         | 9 (2.6)                   | 8 (2.3)          | 3 (1.6)                               | 4 (2.4)                               |
| Any other drug therapy                                 | 140 (40.0)                | 119 (34.0)       | 67 (35.4)                             | 57 (33.7)                             |

The denominator to caleulate percentages is N, the number of subjects in the full analysis set within each treatment group.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (07:14) Source Data: ADCM Output File:

/B9991001/B9991001\\_CSR/adcm\\_s009b\\_pdl1c Date of Generation: 14JAN2020 (21:38) Cutoff date: 21OCT2019 Snapshot Date: 21NOV2019

Table 14.4.2.7.1.4 is for Pfizer intermal use.

Table 36. Follow-up Anti-Cancer Drug Therapies by Category - Subjects with PD-L1-Negative Tumours and Subjects with PD-L1-Unknown Tumours in the Full Analysis Set (Protocol B9991001, 21 Oct. 2019)

|                                                         | Subjects with PD-L1- Negative Tumours   | Subjects with PD-L1- Negative Tumours   | Subjects with PD-L1- Unknown Tumours   | Subjects with PD-L1- Unknown Tumours   |
|---------------------------------------------------------|-----------------------------------------|-----------------------------------------|----------------------------------------|----------------------------------------|
| Category                                                | Avelumab+BSC (N=139) n (%)              | BSC (N=131) n (%)                       | Avelumab+BSC (N=22) n (%)              | BSC (N=50) n (%)                       |
| Subjects with any follow-up anti- cancer drug therapies | 69 (49.6)                               | 79 (60.3)                               | 11 (50.0)                              | 28 (56.0)                              |
| Any PD-1 or PD-L1 inhibitor                             | 8 (5.8)                                 | 51 (38.9)                               | 4 (18.2)                               | 21 (42.0)                              |
| FGFR inhibitor                                          | 6 (4.3)                                 | 3 (2.3)                                 | 0                                      | 1 (2.0)                                |
| Any other drug therapy                                  | 62 (44.6)                               | 48 (36.6)                               | 11 (50.0)                              | 14 (28.0)                              |

Subjects are counted only once within a given category but may be counted in more than one category.

The denominator to calculate percentages is N, the number of subjects in the full analysis set within each treatment group.

Cutoff date: 21OCT2019

<!-- image -->

<div style=\"page-break-after: always\"></div>

Over 90% of all randomized patients filled in the FB1SI-18 and this was similar in all groups. The proportion of patients completing the whole form was more variable and in general around 60% answered all questions during the treatment period and around 40% during the follow up phase in the FAS. It should be noted that not all items of FBlSI are required to be completed for scoring and one item was only applicable for male patients.

Time to deterioration (TTD) was defined as ≥3 -point decrease from baseline FB1SI-DRS-P for 2 consecutive assessments (death and progression were not considered as a deterioration event). The HR for TTD in all randomized patients was 1.26 (95% CI: 0.901, 1.768). Median TTD was not reached in the avelumab plus BSC arm (95% CI: 13.9 months, not reached) and 13.8 months in the BSC alone arm (95% CI: 12.9 months, not reached). The HR for TTD in all randomized patients with PD-L1positive tumours was 1.51 (95% CI: 0.946, 2.401). Median TTD was not reached in the avelumab plus BSC arm (95% CI: 9.3 months, not reached) and 28.5 months in the BSC alone arm (95% CI: 13.7 months, not reached).

The proportion of answered EQ-5D-5L forms were greater than 90% for the majority of the treatment periods and also the proportion of fully completed forms were high, generally greater than 90%. At the end of treatment, the proportion of completed forms where at least one question was answered was around 80% and the proportion of fully completed forms just under 80%. For the follow up period, the proportion of forms where at least one question was answered was between 50-70% and also the proportion of fully complete forms was between 50-70%.

The results of the FB1SI-18 and EQ-5D-5L forms were similar between avelumab + BSC and BSC alone for all randomized patients and for the patients with PD-L1 positive tumours.

Figure 40. Summary of FB1SI-18 Total Score Change from Baseline by Visit - FAS Study B9991001

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 41. Summary of FB1SI-18 Total Score Change from Baseline by Visit - Subjects with PD-L1-positive Tumours FAS Study B9991001

<!-- image -->

Figure 42. Summary of EQ-5D-5L Index Score Change from Baseline by Visit - FAS Study B9991001

<!-- image -->

21NOV/2019

<div style=\"page-break-after: always\"></div>

Figure 43. Summary of EQ-5D-5L Index Score Change from Baseline by Visit - Subjects with PD-L1-positive Tumours FAS Study B9991001

<!-- image -->

## Exploratory Endpoints

Data for exploratory endpoints were not available at the time of the interim analysis.

## Summary of main study(ies)

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 37. Summary of efficacy for Study B9991001

| Title: A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy   | Title: A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy   | Title: A phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                                                                                                             | Study B9991001, (JAVELIN Bladder 100)                                                                                                                                                                                                                                                                                                                                        | Study B9991001, (JAVELIN Bladder 100)                                                                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                                                                                                                                                       | A multicentre randomized, open label study for avelumab+BSC compared to BSC                                                                                                                                                                                                                                                                                                  | A multicentre randomized, open label study for avelumab+BSC compared to BSC                                                                                                                                                                                                                                                                                                  |
| Design                                                                                                                                                                                                                                                                                                                                                                       | Duration of main phase:                                                                                                                                                                                                                                                                                                                                                      | FPI: May 2016 LPI: June 2019                                                                                                                                                                                                                                                                                                                                                 |
| Hypothesis                                                                                                                                                                                                                                                                                                                                                                   | Superiority                                                                                                                                                                                                                                                                                                                                                                  | Superiority                                                                                                                                                                                                                                                                                                                                                                  |
| Treatments groups                                                                                                                                                                                                                                                                                                                                                            | Avelumab+BSC - All subjects                                                                                                                                                                                                                                                                                                                                                  | Maintenance avelumab 10 mg/kg Q2W, continued until confirmed disease progression as assessed by BICR or unacceptable toxicity, n=350                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                           | BSC - All subjects                                                            | BSC - All subjects                                                            | Per current treatment practices investigational site and per individual patient needs. BSC did not include any active anti- tumour therapy. Until disease progression or start of active anti-cancer treatment, n=350   |
|---------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                           | Avelumab+BSC - PD-L1- positive tumour                                         | Avelumab+BSC - PD-L1- positive tumour                                         | Maintenance avelumab 10 mg/kg Q2W, continued until confirmed disease progression as assessed by BICR or unacceptable toxicity, n=189                                                                                    |
|                           | BSC - PD-L1-positive tumour                                                   | BSC - PD-L1-positive tumour                                                   | Per current treatment practices investigational site and per individual patient needs. BSC did not include any active anti- tumour therapy. Until disease progression or start of active anti-cancer treatment, n=169   |
| Endpoints and definitions | Co-Primary endpoint                                                           | OS in: 1. patients with PD-L1- positive tumours 2. all randomized patients    | Time from the date of randomization to the date of death due to any cause.                                                                                                                                              |
| Endpoints and definitions | Secondary endpoint                                                            | Progression Free Survival Based on BICR Assessment per RECIST v1.1.           | Time from the date of randomization to the date of the first documentation of progressive disease (PD) or death due to any cause, whichever occurs first.                                                               |
| Endpoints and definitions | Secondary endpoint                                                            | Objective Response (OR), as assessed per RECIST v1.1 by BICR.                 | Complete response (CR), or partial response (PR), from the date of randomization, until the date of the first documentation of PD.                                                                                      |
| Database lock             | 21 Oct. 2019 (efficacy, interim analysis), 19 Jan. 2020 (updated OS analysis) | 21 Oct. 2019 (efficacy, interim analysis), 19 Jan. 2020 (updated OS analysis) | 21 Oct. 2019 (efficacy, interim analysis), 19 Jan. 2020 (updated OS analysis)                                                                                                                                           |

## Results and Analysis

Analysis description

Analysis population and time point

description

Descriptive statistics and estimate

variability

Updated OS (19 Jan 2020), PFS and OR Interim Analysis (21 Oct.

2020)

Intent to treat (FAS), Interim analysis

Treatment group

Number of subjects

OS (Median, months, 1-sided

p: 2-sided P)

95% CI

PFS (Median, months)

95% CI

OR (CR+PR, n

(%))

Avelumab+BSC

- All subjects

350

22.1

(19.0, 26.1)

3.7

(3.5, 5.5)

34 (9.7)

BSC

- All subjects

350

14.6

(12.8, 17.8)

2.0

(1.9, 2.7)

5 (1.4)

Hazard Ration/

p-value (1- sided)

700

0.70

p=0.0004

p=0.0008

(0.564, 0.862)

0.62

p= &lt;0.0001

(0.519, 0.751)

NA

<div style=\"page-break-after: always\"></div>

|                      | 95% CI                                    | (6.8, 13.3)                           | (0.5, 3.3)                   | NA                     |
|----------------------|-------------------------------------------|---------------------------------------|------------------------------|------------------------|
|                      | Treatment group                           | Avelumab+BSC -PD-L1- positive tumours | BSC -PD-L1- positive tumours | Hazard Ration/ p-value |
|                      | Number of subjects                        | 189                                   | 169                          | 358                    |
|                      | OS (Median, months, 1-sided p; 2-sided p) | NE                                    | 17.5                         | 0.60 p=0.0010 p=0.0019 |
|                      | 95% CI                                    | (20.6, NE)                            | (13.5, 31.6)                 | (0.439, 0.833)         |
|                      | PFS (Median, months)                      | 5.7                                   | 2.1                          | 0.56 p= <0.0001        |
|                      | 95% CI                                    | (3.7, 7.4)                            | (1.9, 3.5)                   | (0.431, 0.728)         |
|                      | OR (CR+PR, n (%))                         | 26 (13.8)                             | 2 (1.2)                      | NA                     |
|                      | 95% CI                                    | (9.2, 19.5)                           | (0.1, 4.2)                   | NA                     |
| Notes                |                                           |                                       |                              |                        |
| Analysis description |                                           |                                       |                              |                        |

## 2.4.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

The applicant provided data from a single phase 3 study, study B9991001 (JAVELIN Bladder 100), to support the proposed use of avelumab as maintenance treatment in patients with locally advanced or metastatic UC. The rationale for conducting an open trial is acknowledged. Eligibility criteria are considered acceptable. Measures taken to maintain objectivity by independent reviewers are noted. Data provided are from the interim analysis that was to be performed after 315 deaths, all patients had been randomized and at least 146 deaths among patients with PD-L1-positive tumours. The final analysis was planned to be performed after at least 425 of all randomized patients and at least 219 patients with PD-L1-positve tumours had died, and the last randomized patient has been followed for at least 12 months after randomization.

700 patients were randomized, and the randomization was stratified by best response to first-line chemotherapy (CR or PR vs SD), and metastatic disease site (visceral vs non-visceral) at the time of initiating first-line chemotherapy.

The primary objective of study B9991001 was to demonstrate the benefit of maintenance treatment with avelumab plus BSC versus BSC alone in prolonging OS in each coprimary aUC patient population: 1) all randomized patients and 2) patients determined to have PD-L1 positive tumours. To analyse the PD-L1 positive tumours separately is also appropriate. However, it is of importance that the efficacy in the entire population is evident also for patients without PD-L1 positive tumours in order to convincingly establish that the positive benefit-risk ratio is detected also in this patient population. Secondary and exploratory objectives are considered acceptable. In general, the assumptions in the sample size calculations seem overall reasonable.

<div style=\"page-break-after: always\"></div>

12.0% of the patients in the avelumab plus BSC and 20.0% in the BSC group did not meet the inclusion/exclusion criteria. This is of concern and introduces uncertainty towards the integrity of the study. However, a sensitivity analysis has been performed considering actual strata. This is almost completely overlapping with the primary OS analysis with a slight moderation of the stratified analysis with no clinical relevance. The results were also similar when patients with the clinically most important protocol deviations were removed as a sensitivity analysis.

The amendments introduced in the study protocol are overall acceptable, and they are not considered to have compromised the integrity of the study or been driven by knowledge of study results.

Potential important protocol deviations occurred in 38.9% of the patients in the study. The protocol deviations were generally quite evenly distributed between the treatment arms. The high number of randomization and inclusion/exclusion deviations are concerning. However, a sensitivity analysis has been performed considering actual strata. This is almost completely overlapping with the primary OS analysis with a slight moderation of the stratified analysis with no clinical relevance. The results were also similar when patients with the clinically most important protocol deviations were removed as a sensitivity analysis.

Baseline demographics and disease characteristics were generally balanced across the treatment arms in all the randomized patients. 77.3% of the patients were male in total and the mean and median age was 67.5 and 69.0 years respectively. 60.6% of the patients had ECOG performance status of 0 at baseline. There are however more patients under 65 years of age in the avelumab plus BSC group. For patients with PD-L1-positive tumours, the age is more homogenous between the two groups, albeit a slight tendency towards a larger proportion of patients under 65 years of age appears also here in the avelumab +BSC arm. PD-L1 status was unknown in 14..0% patients in the BSC arm which is more than double the proportion of unknowns in the avelumab plus BSC treatment group. In both coprimary populations, approximately three-quarters of patients in each arm entered the study with a best response to first-line chemotherapy of CR or PR, and approximately one-quarter of patients entered with a best response of SD. The patients with CR and PR are evenly distributed between the treatment groups for the different PD-L1-statuses. It is noted that the proportion of patients with CR is lower for patients with PD-L1-negative tumours ((18.5%) compared to patients with PD-L1-positive tumours (31.6%).

The choice of not randomizing for PD-L1-status introduced larger uncertainty in the interpretation of the results and a larger risk for non-comparable patient populations between treatment options.

## Efficacy data and additional analyses

For OS, results from two data cut-offs are available, including a requested later cut-off 90 days after the pre-planned interim analysis (19 January 2020), while the results from all other efficacy endpoints stem from the interim analysis (21 October 2019).

Efficacy data are provided from the interim analysis for PFS (both BICR and INV), overall response, objective response, disease control rate and subgroup analyses of PFS and OS. In addition, data from two PRO instrumentshave been presented.

The primary endpoint OS (21 Oct 2019) was improved in a statistically significant way in all patients (n=700) assigned to avelumab plus BSC compared with patients assigned to BSC (stratified HR 0.69; 95% CI 0.556, 0.863; 1-sided p-value 0.0005). The median OS was 21.4 months (95% CI: 18.9, 26.1) in the avelumab plus BSC arm, and 14.3 months (95% CI: 12.9, 17.9) in the BSC arm. In patients with PD-L1-positive tumours (n=358), a statistically significant improvement in OS was also demonstrated for patients assigned to avelumab plus BSC compared with patients assigned to BSC

<div style=\"page-break-after: always\"></div>

(stratified HR 0.56; 95% CI: 0.404, 0.787; 1-sided p -value 0.0003). The median OS was not reached (95% CI: 20.3 months, not reached) in the avelumab plus BSC arm, and was 17.1 months (95% CI: 13.5, 23.7) in the BSC arm.

The updated OS-data (19 Jan 2020) with an additional 90 days of follow-up rendered a median OS for all patients assigned to avelumab plus BSC of 22.1 months (95% CI 19.0, 26.1) and for patients treated with BSC of 14.6 months (95% CI 12.8, 17.8) and HR 0.70 (95% CI 0.564, 0.862). For patients with PD-L1-positive tumours the updated median OS was NE (95% CI 20.6, NE) for patients treated with avelumab plus BSC and 17.5 months (95% CI 13.5, 31.6) for the BSC patients, HR 0.60 (95% CI 0.439, 0.833). The OS results from the later data cut-off date are very similar to the results presented from the planned data cut-off date.

In all randomized patients, those assigned to avelumab plus BSC had a prolonged PFS (by BICR assessment per RECIST v1.1), compared with patients assigned to BSC with stratified HR 0.62 (95% CI: 0.519, 0.751; nominal 1-sided p value &lt;0.0001). The median PFS for avelumab plus BSC was 3.7 months (95% CI: 3.5, 5.5) and for BSC 2.0 months (95% CI: 1.9, 2.7) in all randomized patients. In patients with PD-L1-positive tumours, the median PFS for avelumab plus BSC was 5.7 months (95% CI: 3.7, 7.4) and for BSC 2.1 months (95% CI: 1.9, 3.5) with stratified HR 0.56 (95% CI 0.431, 0.728; 1-sided p-value &lt;0.0001).

OS and PFS for patients with PD-L1-negative tumours were exploratory analysis and part of the subgroup analysis. OS and PFS for patients with PD-L1-unknown tumours (n=72) were not prespecified endpoints. In patients with PD-L1-negative tumours (n=270), the median OS (19 Jan 2020) was 18.9 months (95% CI 13.3, 22.1) for patients treated with avelumab plus BSC and for BSC 13.4 months (95% CI 10.4, 17.3), with a HR 0.83 (95% CI 0.603, 1.131). There were no signs of a detrimental effect on OS in patients with PD-L1-negative tumours treated with avelumab plus BSC compared to BSC. PFS by BICR assessment for patients with PD-L1-negative tumours was prolonged for patients treated with avelumab in combination with BSC (3.6 months (95% CI 1.9, 16.7)) compared to BSC (2.1 months (95% CI 1.9, 6.8), HR 0.63 (95% CI 0.474, 0.847)). Subgroup analysis of PFS for patients with PD-L1-negative tumours should be interpreted with caution weighing in the small sample size and the risk of chance findings. Generally, the different subgroups present with HR of ≤1 with wide confidence intervals suggesting no identified subgroup with a seemingly detrimental PFS.

ORR was higher in patients treated with avelumab plus BSC compared to patients assigned to BSC, for all randomized patients and for patients with PD-L1-positive tumours. The proportion of patients with PD-L1-negative tumours that achieved objective response was higher for the patients treated with avelumab in combination with BSC, but the absolute numbers are low with 8 patients (5.8%, 95% CI 2.5, 11.0) achieving objective response.

PD-1 or PD-L1 inhibitors were administered as subsequent anti-cancer drug treatments in a higher proportion of patients in the BSC alone arm compared with the avelumab plus BSC arm in all patients and in each PD-L1-strata. Few patients (6.3%) treated with avelumab plus BSC received PD-1 or PDL1 inhibitor as subsequent anti-cancer therapy while a considerable proportion (43.7%) of patients from the BSC arm were treated with a PD-1 or PD-L1 inhibitor as subsequent anti-cancer therapy. The analysis of time to end-of-next-line treatment (as an approximation for PFS2) for all patients and in each PD-L1-strata do not imply a detrimental effect on time to end-of-next-line treatment. This supports the apparent lack of a detrimental effect of avelumab on OS for the patients with PD-L1negative tumours.

Subgroup analysis of OS for all patients and for patients with PD-L1-positive tumours display no detrimental effect in any subgroup of reasonable size. Subgroup analysis of OS for patients with PD-

<div style=\"page-break-after: always\"></div>

L1negative tumours (data not shown) generally present with HR of ≤1, albeit with large confidence intervals due to small patient numbers and more heterogeneity compared to the PFS subgroup results. It is also notable that for the subgroups of PD-L1 negative patients where the HR for OS is ≥1, the HR for PFS is &lt;1.

The efficacy data from patients with PD-L1-unknown tumours are challenging to interpret due to very low patient numbers. However, no evident detrimental effect on PFS or OS is seemingly detected in patients with PD-L1-unknown tumours.

A majority of the patients continued with anti-PD-L1 treatment after progression. The median number of infusions received after progression was 3.0 across all PD-L1-strata, the mean was 5.4 (SD 7.09) for patients with PD-L1-positive tumours and 6.4 (SD 10.41) for patients with PD-L1-negative tumours. The posology proposed state that treatment should continue until progression or unacceptable toxicity. We currently have no indication that the OS efficacy is driven by the post-progression treatment.

## PRO

The results for the PRO NCCN/FACT Bladder Symptom Index (NFB1SI-18) and EQ-5D-5L) do not imply that addition of avelumab to BSC conferred a detrimental effect on the quality of life of patients. These results should however be interpreted with caution due to the open label study design and imputation of answers in the analyses for NFB1SI-18. The results from the EQ-5D-5L form do not suggest that the avelumab addition to BSC conferred a detrimental effect of the quality of life for the patients. However, due to the open-label study design the results are open to patient bias, conferring a degree of uncertainty.

## 2.4.3. Conclusions on the clinical efficacy

Based on the currently provided data, a benefit for the addition of avelumab as a maintenance treatment has been demonstrated in the overall population. Although this OS benefit is not solely driven by the PD-L1-positive tumour population, the benefit of the addition of avelumab to BSC for patients with PD-L1-negative tumours is less pronounced. Patients with PD-L1-negative tumours on a group level display a modest prolongation of PFS in combination with no display of detrimental effect on OS.

## 2.5. Clinical safety

## Introduction

Safety data are presented for the use of avelumab plus BSC vs. BSC as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy (study B9991001). Safety data from study EMR100070-001 included two cohorts (secondary expansion n=44; efficacy expansion n=205) where patients with aUC had progressive disease and the majority having received 2 or more lines of prior therapy are also presented. Study B9991001 and study EMR100070-001 are not pooled as the MAH considers the populations to be different. Study EMR100070-001 enrolled heavily pre-treated patients whereas study B9991001 enrolled patients with aUC who had received only 1 line of chemotherapy without PD.

Safety database cut-off date was January 19, 2020 (12 weeks after primary efficacy cut-off date).

<div style=\"page-break-after: always\"></div>

The safety database includes data from 689 patients, who received any amount of study treatment in study B9991001 (344 patients treated with avelumab plus BSC; 345 in the BSC arm). The Pooled Safety Data that consists of data from 1738 patients treated with avelumab 10 mg/kg Q2W as a single agent (1650 patients with various solid tumours from study EMR100070-001, including the 249 patients from the aUC cohorts, and 88 patients with mMCC from Part A of Study EMR100070-003 with a data cut-off of 09 June 2016) are presented for reference. Study EMR100070-003, the pivotal study for the mMCC indication, is an open-label, multicentre, single arm study in patients with mMCC.

The safety profile of avelumab has been described previously when used as monotherapy for mMCC. The general class safety profile for PD-L1-inhibitors is considered well known.

Table 38 . Summary of studies with Single-Agent Avelumab contributing to the safety evaluation

| Protocol Number/ Study Design/ Sponsor                                                                                                                                                                                                                                                                                                                                                 | Primary Objective(s)/ Key Secondary Objectives (if applicable)/ Primary Endpoint(s)                                                                                                                                                                                                                                                                    | Single or Multicente r/ Location Planned Countries                                           | Status a / Dates                                                                                                | No. of Patients Treated/ Doses Evaluated                                                                                                                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B9991001 Phase 3, multicenter, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) plus best supportive care versus best supportive care alone as a maintenance treatment in patients with locally advanced or metastatic urothelial cancer whose disease did not progress after completion of first-line platinum-containing chemotherapy Pfizer Inc. | Primary Objective: To demonstrate the benefit of maintenance treatment with avelumab plus BSC versus BSC in prolonging OS in 2 co- primary aUC patient populations: 1) patients determined to have PD-L1- positive tumours (including infiltrating immune cells) by a verified GMP PD-L1 IHC test, and 2) all randomized patients Primary Endpoint: OS | 187 centers North America, Central/Sou th America, Asia- Pacific including Japan, and Europe | Completed FPFD: May 2016 Data cut-off date efficacy: 21 Oct 2019 Data cut-off date safety: 19 Jan 2020          | 1:1 randomization of 700 patients to 2 treatment arms including 689 patients in the safety data set Avelumab plus BSC arm (344 patients) BSC alone arm (345 patients) Avelumab dose: 10 mg/kg IV Q2W |
| Study EMR100070-003 Phase 2, single arm, open- label, multicenter study to investigate the clinical activity and safety of avelumab in subjects with Merkel cell carcinoma Merck KGaA/EMD Serono                                                                                                                                                                                       | Part A - Primary Objective: To assess the clinical activity of avelumab in patients with mMCC whose disease progressed during or after receiving chemotherapy (Part A) or in systemic chemotherapy naïve patients with mMCC (Part B) Primary Endpoint: ORR for Part A; Durable response rate for Part B                                                | Part A: 38 centers Part B: 46 centers US, Australia, Europe, and Asia                        | Completed Part A First patient informed consent: 03 Jul 2014 Part B First patient informed consent: 31 Mar 2016 | As of 02 May 2019: Part A: 88 patients Part B: 116 patients (not included in the safety evaluations) Avelumab dose: 10 mg/kg IV Q2W                                                                  |

<div style=\"page-break-after: always\"></div>

| EMR100070-001 Phase 1, open-label, multiple- ascending dose trial to investigate the safety, tolerability, pk, biological and clinical activity of avelumab and expansion to selected indications in subjects with metastatic or locally advanced solid tumours Merck KGaA/EMD Serono   | Primary Objective: To assess the safety and tolerability of avelumab and to determine theMTD of avelumab; To assess the best overall response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in the efficacy expansion cohorts Primary Endpoints: Dose-escalation part: Occurrence of DLTs during the first 3 weeks of treatment Efficacy expansion cohorts: Confirmed best overall response, per RECIST v1.1, as adjudicated by an Independent Endpoint Review Committee   | Patients with aUC were enrolled at 1 center for dose- escalation and 89 centers for treatment expansion) US, Europe, and Asian Countries   | Completed Dose-escalation: First patient informed consent date: 31 Jan 2013 First aUC cohort patient informed consent date: 03 Sep 2014 Data cut-off date for aUC cohorts: 31 March 2017   | As of 27 Apr 2018: 1758 patients (1650 included in the safety evaluations) Dose Escalation Phase: 61 patients • 1 mg/kg Q2W - 4 • 3 mg/kg Q2W - 13 • 10 mg/kg Q2W - 15 • 10 mg/kg weekly - 8 • 20 mg/kg Q2W - 21 Expansion Phase: 1697 patients • aUC secondary expansion cohort - 44 (2 active as of 27 Aug 2019) • aUC efficacy expansion cohort - 205 (2 active as of 27 Aug 2019) Dose selected for Expansion Phase: 10 mg/kg Q2W   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

a. 'Completed' refers to a study for which the primary analysis has been conducted and a CSR finalized; patients enrolled in these studies may still be receiving treatment or continue to be followed for safety and survival data per protocol.  'Ongoing' refers to a study for which the primary analysis has not been conducted.

## Patient exposure

The median treatment duration in study B9991001 was 25.3 weeks (range: 2.0, 173.9) in the avelumab plus BSC arm and considerably shorter, 13.1 weeks (range: 0.1, 168.4) in the BSC alone arm (19 Jan 2020). The following results are presented with data from 21 October 2019 cut-off. Mean number of infusions with avelumab in study B9991001 was 18.4 (SD 16.26) with a wide interval for standard deviation. The median number of avelumab infusions was 11.0 (range 1.0, 80.0). 45.9% of the patients treated with avelumab experienced dose delays. Few patients had dose reductions which is to be expected with the study design not permitting dose modifications. 9.3% of the avelumab patients in study B9991001 had at least one infusion rate reduction of 50% or more. 6.4% had 4 or more infusion rate reductions. 4.7% had infusion interruptions.

Patients with PD-L1-positive tumours were exposed to avelumab for longer time compared to patients with PD-L1-negative tumours.

The duration of treatment is longer and cumulative dose is higher in study B99910001 compared to the reported safety set.

Table 39. Duration and extent of exposure to study drug

<div style=\"page-break-after: always\"></div>

|                                  | B9991001 Avelumab+ BSC (N=344)   | B9991001 BSC (N=345)   | Pooled Safety Population (N=1738)   | Overall (N=2082)   |
|----------------------------------|----------------------------------|------------------------|-------------------------------------|--------------------|
| Duration of treatment (weeks)[1] |                                  |                        |                                     |                    |
| N                                | 344                              | 345                    | 1738                                | 2082               |
| Mean (SD)                        | 38.7 (33.74)                     | 23.2 (24.59)           | 19.9 (20.69)                        | 23.0 (24.37)       |
| Q1                               | 13.2                             | 8.4                    | 6.0                                 | 6.1                |
| Median                           | 24.9                             | 13.1                   | 12.0                                | 12.6               |
| Q3                               | 57.9                             | 26.7                   | 24.1                                | 30.0               |
| Range (min, max)                 | (2.0, 159.9)                     | (0.1, 155.6)           | (2.0; 137.9)                        | (2.0; 159.9)       |
| Person exposure-100 years [2]    | 2.55                             | 1.53                   | 6.63                                | 9.18               |
| Cumulative dose (mg/kg) [3]      |                                  |                        |                                     |                    |
| N                                | 344                              | NA                     | 1738                                | 2082               |
| Mean (SD)                        | 182.6 (161.6)                    | NA                     | 95.8 (99.37)                        | 110.1 (116.56)     |
| Q1                               | 60.0                             | NA                     | 30.0                                | 30.1               |
| Median                           | 112.6                            | NA                     | 60.0                                | 60.1               |
| Q3                               | 266.7                            | NA                     | 120.1                               | 140.3              |
| Range (min, max)                 | (1.6, 787.7)                     | NA                     | (3.0; 630.1)                        | (1.6; 787.7)       |
| Dose intensity (mg/kg/cycle) [4] |                                  |                        |                                     |                    |
| N                                | 344                              | NA                     | 1738                                | NA                 |
| Mean (SD)                        | 16.9 (2.56)                      | NA                     | 9.7 (0.84)                          | NA                 |
| Q1                               | 16.0                             | NA                     | 9.7                                 | NA                 |
| Median                           | 17.6                             | NA                     | 10.0                                | NA                 |
| Q3                               | 18.7                             | NA                     | 10.0                                | NA                 |
| Range (min, max)                 | (1.6, 20.4)                      | NA                     | (3.0; 11.2)                         | NA                 |
| Relative dose intensity (%) [5]  |                                  |                        |                                     |                    |
| N                                | 344                              | NA                     | 1738                                | 2082               |
| Mean (SD)                        | 84.6 (12.82)                     | NA                     | 96.7 (8.44)                         | 94.7 (10.33)       |
| Q1                               | 80.0                             | NA                     | 96.6                                | 92.3               |
| Median                           | 88.2                             | NA                     | 100                                 | 99.9               |
| Q3                               | 93.5                             | NA                     | 100.2                               | 100.0              |
| Range (min, max)                 | (8.0, 102.1)                     | NA                     | (30.0; 112.0)                       | (8.0; 112.0)       |

N is the number of subjects in the safety analysis set within each treatment group.

[1] Duration of avelumab treatment is defined as Duration (weeks) = (last dose date of avelumab - first dose date of avelumab + 14)/7.

Duration of BSC treatment is defined as Duration (weeks) = (end date of BSC - start date of BSC + 1)/7

[2] Person exposure-100 years = Sum of duration of exposure (in days) to study drug for all patients / (100*365.25).

[3] Cumulative dose (mg/kg) = sum of all doses (mg/kg) of avelumab.

[4] Dose Intensity (mg/kg/cycle) = [Overall cumulative dose (mg/kg)] / [(intended duration of avelumab treatment

(weeks)/cycle length]. Dose Intensity is calculated as mg/kg/4-week cycle for Study B9991001 and as mg/kg/2-week cycle for the Pooled Safety Population, therefore Dose Intensity for the Overall is not available.

[5] Relative Dose Intensity (%) = 100 × [Dose Intensity (mg/kg/cycle)] / [intended dose (mg/kg/cycle)]

The descriptive summary statistics are calculated based on n, the number of subjects who have received at least one dose of study drug.

Cut-off dates: 09Jun2016 on pooled safety population (EMR100070-001 and EMR100070-003 Part A), 21OCT2019 on study B9991001

<div style=\"page-break-after: always\"></div>

Table 40. Exposure to avelumab - SAS Study B9991001

|                                   | Avelumab+BSC (N=344)   |
|-----------------------------------|------------------------|
| Duration of treatment (weeks)[1]  |                        |
| n1                                | 344                    |
| Mean (SD)                         | 38.7 (33.74)           |
| Q1                                | 13.2                   |
| Median                            | 24.9                   |
| Q3                                | 57.9                   |
| Range (min, max)                  | (2.0, 159.9)           |
| Total number ofinfusions received |                        |
| n                                 | 344                    |
| Mean (SD)                         | 18.4 (16.26)           |
| Q1                                | 6.0                    |
| Median                            | 11.0                   |
| Q3                                | 27.0                   |
| Range (min, max)                  | (1.0, 80.0)            |
| Number of cycles [2]              |                        |
| n                                 | 344                    |
| Mean (SD)                         | 9.8 (8.39)             |
| Q1                                | 3.0                    |
| Median                            | 6.0                    |
| Q3                                | 14.0                   |
| Range (min, max)                  | (1.0, 40.0)            |
| Subjects starting [2]. n (%)      |                        |
| 1 cycle                           | 344 (100.0)            |
| 2 cycles                          | 325 ( 94.5)            |
| 3 cycles                          | 296 ( 86.0)            |
| 4 cycles                          | 256 ( 74.4)            |
| 5 cycles                          | 218 ( 63.4)            |
| 6 cycles                          | 193 ( 56.1)            |
| 7 cycles                          | 171 ( 49.7)            |
| 8 cycles                          | 158 ( 45.9)            |
| ≥9 cycles                         | 148 ( 43.0)            |

[1]Duration of avelumab treatment is defined as Duration(weeks)=(last dose date of avelumab-first dose date of avelumab +14)/7

[3]Includes only cycleswith at least one dose of avelumab&gt; 0

Includes cycles withmissed doses of avelumab

The descriptive summary statistics are calculated based on n, the number of subjects who have received at least one dose of avelumab. The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group.

PFIZER CONFIDENTIAL SDTM Creation:22NOV2019(07:14)Source Data:ADEX Output File:.B9991001/B9991001\\_CSR/adex\\_s001a Date ofGeneration:14J AN2020(09:05)Cutoff date:210CT2019Snapshot Date:21NOV2019

Table 41. Dose modifications - SAS Study B9991001.

|                             | Avelumab+BSC (N=344) n (%)   |
|-----------------------------|------------------------------|
| Duration of dose delays [1] |                              |
| No Delay                    | 186 (54.1)                   |
| 0 days                      | 81 (23.5)                    |
| 1 - 3 days                  | 105 (30.5)                   |
| Dose delays                 | 158 (45.9)                   |
| 4 - 6 days                  | 28 (8.1)                     |
| ≥7 days                     | 130 (37.8)                   |

<div style=\"page-break-after: always\"></div>

Table 41. Dose modifications - SAS Study B9991001.

|                                                                       | Avelumab+BSC (N=344) n (%)   |
|-----------------------------------------------------------------------|------------------------------|
| Subjects with at least one dose reduction [2]                         | 11 (3.2)                     |
| 1 reduction                                                           | 10 (2.9)                     |
| 2 reductions                                                          | 1 (0.3)                      |
| 3 reductions                                                          | 0                            |
| ≥4 reductions                                                         | 0                            |
| Subjects with at least one infusion rate reduction of 50% or more [3] | 32 (9.3)                     |
| 1 infusion rate reduction                                             | 7 (2.0)                      |
| 2 infusion rate reductions                                            | 1 (0.3)                      |
| 3 infusion rate reductions                                            | 2 (0.6)                      |
| ≥4 infusion rate reductions                                           | 22 (6.4)                     |
| Subjects with at least one infusion interruption [4]                  | 16 (4.7)                     |
| 1 infusion interruption                                               | 14 (4.1)                     |
| 2 infusion interruptions                                              | 2 (0.6)                      |
| 3 infusion interruptions                                              | 0                            |
| ≥4 infusion interruptions                                             | 0                            |

[1] Dose delay is the difference between the actual time between two consecutive non-zero doses and the planned time between the same two consecutive non-zero doses. A delay of 1-3 days is not counted as a delay.

[2] Dose reduction is defined as actual non-zero dose &lt; 90% of the planned dose.

[3] Infusion rate reduction is defined as decrease in the infusion rate by 50% or more compared to the first infusion rate.

[4] An infusion interruption is defined as an infusion that is stopped and re-started on the same day.

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group.

Cut-off date: 21OCT2019

Table 42. Exposure to Study Drugs - All Subjects and Subjects with PD-L1-Positive Tumours in the Safety Analysis Set (Protocol B9991001)

|                                  | All Subjects         | All Subjects   | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   |
|----------------------------------|----------------------|----------------|----------------------------------------|----------------------------------------|
|                                  | Avelumab+BSC (N=344) | BSC (N=345)    | Avelumab+BSC (N=187)                   | BSC (N=167)                            |
| Duration of treatment (weeks)[1] |                      |                |                                        |                                        |
| N                                | 344                  | 345            | 187                                    | 167                                    |
| Mean (SD)                        | 41.5 (37.13)         | 24.1 (26.89)   | 45.2 (38.04)                           | 26.0 (28.28)                           |
| Q1                               | 13.2                 | 8.4            | 14.0                                   | 8.9                                    |
| Median                           | 25.3                 | 13.1           | 35.1                                   | 16.0                                   |
| Q3                               | 62.0                 | 26.7           | 64.0                                   | 29.1                                   |
| Range (min, max)                 | (2.0, 173.9)         | (0.1, 168.4)   | (2.0, 144.0)                           | (0.3, 168.4)                           |

[1] Duration of avelumab treatment is defined as Duration (weeks) = (last dose date of avelumab - first dose date of avelumab + 14)/7

Duration of BSC treatment is defined as Duration (weeks) = (end date of BSC - start date of BSC + 1)/7.

The descriptive summary statistics are calculated based on n, the number of subjects who have received at least one dose of the study drug.

Cutoff date: 19JAN2020

<div style=\"page-break-after: always\"></div>

Table 43. Exposure to Study Drugs - Subjects with PD-L1-Negative Tumours and Subjects with PD-L1-Unknown Tumours in the Safety Analysis Set (Protocol B9991001)

|                                  | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Negative Tumours   | Subjects with PD-L1-Unknown Tumours   | Subjects with PD-L1-Unknown Tumours   |
|----------------------------------|----------------------------------------|----------------------------------------|---------------------------------------|---------------------------------------|
|                                  | Avelumab+BSC (N=137)                   | BSC (N=131)                            | Avelumab+BSC (N=20)                   | BSC (N=47)                            |
| Duration of treatment (weeks)[1] |                                        |                                        |                                       |                                       |
| N                                | 137                                    | 131                                    | 20                                    | 47                                    |
| Mean (SD)                        | 35.1 (32.99)                           | 19.9 (19.79)                           | 34.4 (31.11)                          | 25.6 (30.13)                          |
| Q1                               | 12.4                                   | 8.3                                    | 9.5                                   | 8.1                                   |
| Median                           | 21.1                                   | 13.1                                   | 24.1                                  | 9.4                                   |
| Q3                               | 50.3                                   | 24.0                                   | 45.2                                  | 37.1                                  |
| Range (min, max)                 | (2.0, 159.9)                           | (0.1, 118.7)                           | (4.0, 105.9)                          | (0.1, 121.1)                          |

[1] Duration of avelumab treatment is defined as Duration (weeks) = (last dose date of avelumab - first dose date of avelumab + 14)/7

Duration of BSC treatment is defined as Duration (weeks) = (end date of BSC - start date of BSC + 1)/7.

The descriptive summary statistics are calculated based on n, the number of subjects who have received at least one dose of the study drug.

Cutoff date: 21OCT2019

## Adverse events

## Summary of Adverse events

Nearly all patients reported AEs, as expected, with avelumab treatment. The proportion of patients that reported AE of grade 3 or higher was lower in study B9991001 compared to the pooled safety set, 47.4% compared to 58.0% respectively.

The frequency of each AE of grade ≥ 3 is mostly relatively low in study B9991001 and the pooled safety set. The most common AEs of grade ≥ 3 for patients in study B9991001 are urinary tract infection and anaemia. Generally, the frequency is lower with the exception of urinary tract infection and haematuria when comparing study B9991001 to the pooled safety set. The general frequency of AEs of any grade differs slightly from the pooled safety set in study B9991001 but does not raise serious concerns and the deviations go both ways.

Exposure adjusted data does not indicate that treatment of the new suggested indication would confer a more serious AE profile. The incident rate per 100 patient months (IR) are similar or appear lower for study B9991001 compared to the pooled safety population for the overview of safety parameters (Table 46), most common AE (Table 51) with a few exceptions where the IR frequency is higher.

<div style=\"page-break-after: always\"></div>

Table 44. Summary of adverse events - SAS Study B9991001.

|                                                                                | All Subjects         | All Subjects   | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   |
|--------------------------------------------------------------------------------|----------------------|----------------|---------------------------------------|---------------------------------------|
|                                                                                | Avelumab+BSC (N=344) | BSC (N=345)    | Avelumab+BSC (N=187)                  | BSC (N=167)                           |
| Number(%6)of Subjects                                                          | n (%)                | n (%)          | n (%)                                 | n (%)                                 |
| Subjects with TEAEs                                                            | 337 (98.0)           | 268 (77.7)     | 186 (99.5)                            | 133 (79.6)                            |
| Subjects with grade > 3 TEAEs                                                  | 163 (47.4)           | 87 (25.2)      | 94 (50.3)                             | 40 (24.0)                             |
| Subjects with treatment-related TEAEs                                          | 266 (77.3)           | 4 (1.2)        | 150 (80.2)                            | 2 (1.2)                               |
| Subjects with grade > 3 treatment-related TEAEs                                | 57 (16.6)            | 0              | 36 (19.3)                             | 0                                     |
| Subjects with serious TEAEs                                                    | 96 (27.9)            | 69 (20.0)      | 51 (27.3)                             | 34 (20.4)                             |
| Subjects with serious treatment-related TEAEs                                  | 31 (9.0)             | 0              | 20 (10.7)                             | 0                                     |
| Subjects with TEAEs leading to dose reduction of Avelumab                      | 1 (0.3)              |                |                                       |                                       |
| Subjectswith TEAEsleading to intemuption of Avelumab                           | 140 (40.7)           | 0              | 81 (43.3)                             | 0                                     |
| Subjects with TEAEs leading to discontinuation of study drug                   | 41 (11.9)            |                | 28 (15.0)                             |                                       |
| Subjects with treatment-related TEAEs leading to discontinuation of study dnug | 33 (9.6)             |                | 25 (13.4)                             | 0                                     |
| Subjects with TEAEs leading to death                                           | 4 (1.2)              | 24 (7.0)       | 2 (1.1)                               | 13 (7.8)                              |
| Subjects with treatment-related TEAEs leading to death                         | 1 (0.3)              | 0              | 1 (0.5)                               | 0                                     |
| Subjects with immune-related adverse events (irAEs)                            | 101 (29.4)           | 5 (1.4)        | 63 (33.7)                             | 2 (1.2)                               |
| Subjects with infusion-related reactions (IRRs)                                | 74 (21.5)            | 0              | 40 (21.4)                             |                                       |

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group.

MedDRA v22.1 coding dictionary and CTCAE version 4.03 applied.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (07:14) Source Data: ADAE Output File:

/B9991001/B9991001 SCS/adae s012 pdl1c Date of Generation: 16JAN2020 (14:51) Cutoff date: 21OCT2019 Snapshot Date: 21NOV2019

Table 14.3.1.1.1.1 is for Pfizer intermal use.

<div style=\"page-break-after: always\"></div>

Table 45. Summary of AE - Pooled safety set and avelumab treated in Study B9991001.

Table12.13.9:overviewofTreatmentEmergentAdverseEvents

|                                                                          | Pooled Safety Population (N=1738) n (%)   | B9991001Avelumab + BSC (N=344) n (%)   | overall (N=2082) n(%)   |
|--------------------------------------------------------------------------|-------------------------------------------|----------------------------------------|-------------------------|
| Subjects with TEAES                                                      | 1697 97.6)                                | 337 98.0)                              | 2034 97.7)              |
| Subjects with grade >=3 TEAEs                                            | 1008 58.0)                                | 163 47.4)                              | 1171 56.2)              |
| Subjects withtreatment-relatedTEAEs                                      | 1164 67.0)                                | 266 77.3)                              | 1430 68.7)              |
| Subjects with grade >= 3 treatment-related TEAES                         | 177 10.2)                                 | 57 16.6)                               | 234 (11.2)              |
| Subjects withserious TeAEs                                               | 777 44.7)                                 | 96 27.9)                               | 873 41.9)               |
| Subjects withserious treatment-relatedTEAEs                              | 108 6.2)                                  | 31 9.0)                                | 139 6.7)                |
| Subjects with TEAEs leading to dose reductionof Avelumab                 | NA                                        | 1 0.3)                                 | 1 0.0)                  |
| Subjects with TEAEs leading to interruption ofAvelumab                   | 363 (20.9)                                | 140 (40.7)                             | 503(24.2)               |
| Subjects with TEAEs leading to discontinuation of study drug             | 244 (14.0)                                | 41 (11.9)                              | 285 (13.7)              |
| Subjectswithtreatment-relatedTEAEs leading todiscontinuation ofstudydrug | 107 6.2)                                  | 33 9.6)                                | 140 （ 6.7)              |
| Subjects with TEAEs leading todeath                                      | 228 13.1)                                 | 4 1.2)                                 | 232 11.1)               |
| Subjects with treatment-relatedTEAEs leadingtodeath                      | 4 0.2)                                    | 0.3)                                   | 5 0.2)                  |
| Subjectswithimmune-relatedadverseevents (irAES)                          | 247 (14.2)                                | 101 (29.4)                             | 348 (16.7)              |
| Subjects with infusion-relatedreactions (IRRS)                           | 439(25.3)                                 | 74 ( 21.5)                             | 513 ( 24.6)             |

NA= Informationnot available in Safety set.

N:thenumber of subjectswhohave receivedat leastonedoseofavelumab. Thedenominator tocalculatepercentages isN. EventsarecodedinthelatestMedDRAversionavailableatthetimeofcut-off. Gradingcategories determinedusingNcI-cTcAEversion 4.0inpooledsafetypopulationandversion4.03inB9991o01. Cut-off dates:09Jun2016 on pooled safety population (EMR100070-001 and EMRi00070-003 Part A)，210ct2019 on study B9991001.

Table 46 Exposure-Adjusted Analysis of Summary of Adverse Event - Pooled Safety Population and Avelumab-Treated Patients in Study B9991001

|                                                                                | Pooled Safety Population (N=1738) PM(IR)   | B9991001 Avelumab + BSC (N=344) PM(IR)   | Overall (N=2082) PM(IR)   |
|--------------------------------------------------------------------------------|--------------------------------------------|------------------------------------------|---------------------------|
| Subjects with TEAEs                                                            | 844.6 (200.9)                              | 350.8 (96.1)                             | 1195.4 (170.2)            |
| Subjects with grade ≥3 TEAEs                                                   | 5973.6 (16.9)                              | 2224.5 (7.3)                             | 8198.0 (14.3)             |
| Subjects with treatment-related TEAEs                                          | 3042.9 (38.3)                              | 1030.6 (25.8)                            | 4073.5 (35.1)             |
| Subjects with grade ≥3 treatment -related TEAEs                                | 8190.8 (2.2)                               | 2912.4 (2.0)                             | 11103.2 (2.1)             |
| Subjects with serious TEAEs                                                    | 7007.3 (11.1)                              | 2685.4 (3.6)                             | 9692.7 (9.0)              |
| Subjects with serious treatment-related TEAEs                                  | 8340.3 (1.3)                               | 3055.2 (1.0)                             | 11395.5 (1.2)             |
| Subjects with TEAEs leading to interruption of Avelumab                        | 7261.7 (5.0)                               | 2304.1 (6.1)                             | 9565.8 (5.3)              |
| Subjects with TEAEs leading to discontinuation of study drug                   | 8363.7 (2.9)                               | 3140.6 (1.3)                             | 11504.3 (2.5)             |
| Subjects with treatment-related TEAEs leading to discontinuation of study drug | 8437.4 (1.3)                               | 3144.5 (1.0)                             | 11581.9 (1.2)             |
| Subjects with TEAEs leading to death                                           | 8469.7 (2.7)                               | 3174.2 (0.1)                             | 11644.0 (2.0)             |
| Subjects with treatment-related TEAEs leading to death                         | 8514.5 (0.0)                               | 3174.2 (0.0)                             | 11688.7 (0.0)             |
| Subjects with immune-related adverse events (irAEs)                            | 7436.6 (3.3)                               | 2435.7 (4.1)                             | 9872.3 (3.5)              |
| Subjects with infusion-related reactions (IRRs)                                | 6446.4 (6.8)                               | 2600.1 (2.8)                             | 9046.5 (5.7)              |

irAEs = Immune-related adverse events.

IR: Incident Rate per 100 patient months, PM: Patient Months of Exposure

The exposure-adjusted incidence rate is defined as the number of patients with a particular AE divided by the total exposure time among patients in the respective treatment group at risk of an initial occurrence of AE.

Cut-off dates: 09Jun2016 on pooled safety population (EMR100070-001 and EMR100070-003 Part A), 21Oct2019 on study B9991001.

<div style=\"page-break-after: always\"></div>

Table 47 Exposure-adjusted analysis of Summary of Adverse Events -All Subjects and Subjects with PD-L1-Positive Tumours in the Safety Analysis Set (Protocol B9991001)

|                                                                                | All Subjects         | All Subjects   | Subjects with PD-L1- Positive Tumours   | Subjects with PD-L1- Positive Tumours   |
|--------------------------------------------------------------------------------|----------------------|----------------|-----------------------------------------|-----------------------------------------|
|                                                                                | Avelumab+BSC (N=344) | BSC (N=345)    | Avelumab+BSC (N=187)                    | BSC (N=167)                             |
| Number (IR) of Subjects                                                        | PM                   |                |                                         | PM                                      |
|                                                                                | (IR)                 | PM (IR)        | PM (IR)                                 | (IR)                                    |
| Subjects with TEAEs                                                            | 350.8 (96.1)         | 737.0 (36.4)   | 166.2 (111.9)                           | 373.4 (35.6)                            |
| Subjects with grade ≥ 3 TEAEs                                                  | 2224.5 (7.3)         | 1827.6 (4.8)   | 1201.6 (7.8)                            | 953.7 (4.2)                             |
| Subjects with treatment-related TEAEs                                          | 1030.6 (25.8)        | 2014.0 (0.2)   | 549.1 (27.3)                            | 1048.1 (0.2)                            |
| Subjects with grade ≥ 3 treatment - related TEAEs                              | 2912.4 (2.0)         | 2033.1 (0.0)   | 1660.4 (2.2)                            | 1056.3 (0.0)                            |
| Subjects with serious TEAEs                                                    | 2685.4 (3.6)         | 1853.2 (3.7)   | 1535.8 (3.3)                            | 960.4 (3.5)                             |
| Subjects with serious treatment-related TEAEs                                  | 3055.2 (1.0)         | 2033.1 (0.0)   | 1761.1 (1.1)                            | 1056.3 (0.0)                            |
| Subjects with TEAEs leading to dose reduction of Avelumab                      | 3171.2 (<0.1)        | 2033.1 (0.0)   | 1851.1 (0.0)                            | 1056.3 (0.0)                            |
| Subjects with TEAEs leading to interruption of Avelumab                        | 2304.1 (6.1)         | 2033.1 (0.0)   | 1223.5 (6.6)                            | 1056.3 (0.0)                            |
| Subjects with TEAEs leading to discontinuation of study drug                   | 3140.6 (1.3)         | 2033.1 (0.0)   | 1825.2 (1.5)                            | 1056.3 (0.0)                            |
| Subjects with treatment-related TEAEs leading to discontinuation of study drug | 3144.5 (1.0)         | 2033.1 (0.0)   | 1826.4 (1.4)                            | 1056.3 (0.0)                            |
| Subjects with TEAEs leading to death                                           | 3174.2 (0.1)         | 2033.1 (1.2)   | 1851.1 (0.1)                            | 1056.3 (1.2)                            |
| Subjects with treatment-related TEAEs leading to death                         | 3174.2 (<0.1)        | 2033.1 (0.0)   | 1851.1 (<0.1)                           | 1056.3 (0.0)                            |
| Subjects with immune-related adverse events (irAEs)                            | 2435.7 (4.1)         | 2011.7 (0.2)   | 1349.9 (4.7)                            | 1047.6 (0.2)                            |
| Subjects with infusion-related reactions (IRRs)                                | 2600.1 (2.8)         | 2033.1 (0.0)   | 1542.5 (2.6)                            | 1056.3 (0.0)                            |

IR: Incident Rate per 100 patient months, PM: Patient Months of Exposure

The exposure-adjusted incidence rate is defined as the number of patients with a particular AE divided by the total exposure time among patients in the respective treatment group at risk of an initial occurrence of AE.

MedDRA v22.1 coding dictionary and CTCAE version 4.03 applied.

Cutoff date: 21OCT2019

There were no major differences with regard to safety based on PD-L1-status.

<div style=\"page-break-after: always\"></div>

## Summary of most common adverse events

Table 48. Summary of Most Common TEAEs (Any Grade in ≥ 10% Subjects or Grade ≥ 3 in ≥ 5% Subjects in Any Treatment Group), by PT and Maximum CTCAE Grade During the On-Treatment Period - SAS Study B9991001

|                           | All Subjects           | All Subjects           | All Subjects     | All Subjects    | Subjects with PD-L1-Positive   | Subjects with PD-L1-Positive   | Subjects with PD-L1-Positive   | Subjects with PD-L1-Positive   |
|---------------------------|------------------------|------------------------|------------------|-----------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|
| Preferred Term            | Avelumab + BSC (N=344) | Avelumab + BSC (N=344) | BSC (N=345)      | BSC (N=345)     | Tumours Avelumab + BSC (N=187) | Tumours Avelumab + BSC (N=187) | BSC (N=167)                    | BSC (N=167)                    |
| Preferred Term            | All Grades n (%)       | Grade ≥ 3 n (%)        | All Grades n (%) | Grade ≥ 3 n (%) | All Grades n (%)               | Grade ≥ 3 n (%)                | All Grades n (%)               | Grade ≥ 3 n (%)                |
| Subjects with events      | 337 (98.0)             | 163 (47.4)             | 268 (77.7)       | 87 (25.2)       | 186 (99.5)                     | 94 (50.3)                      | 133 (79.6)                     | 40 (24.0)                      |
| Fatigue                   | 61 (17.7)              | 6 (1.7)                | 24 (7.0)         | 2 (0.6)         | 36 (19.3)                      | 2 (1.1)                        | 14 (8.4)                       | 1 (0.6)                        |
| Pruritus                  | 59 (17.2)              | 1 (0.3)                | 6 (1.7)          | 0               | 37 (19.8)                      | 1 (0.5)                        | 2 (1.2)                        | 0                              |
| Urinary tract infection   | 59 (17.2)              | 15 (4.4)               | 36 (10.4)        | 9 (2.6)         | 38 (20.3)                      | 11 (5.9)                       | 16 (9.6)                       | 3 (1.8)                        |
| Diarrhoea                 | 57 (16.6)              | 2 (0.6)                | 17 (4.9)         | 1 (0.3)         | 32 (17.1)                      | 2 (1.1)                        | 8 (4.8)                        | 0                              |
| Arthralgia                | 56 (16.3)              | 2 (0.6)                | 19 (5.5)         | 0               | 32 (17.1)                      | 1 (0.5)                        | 5 (3.0)                        | 0                              |
| Asthenia                  | 56 (16.3)              | 0                      | 19 (5.5)         | 4 (1.2)         | 30 (16.0)                      | 0                              | 11 (6.6)                       | 3 (1.8)                        |
| Constipation              | 56 (16.3)              | 2 (0.6)                | 31 (9.0)         | 0               | 35 (18.7)                      | 1 (0.5)                        | 17 (10.2)                      | 0                              |
| Back pain                 | 55 (16.0)              | 4 (1.2)                | 34 (9.9)         | 8 (2.3)         | 33 (17.6)                      | 1 (0.5)                        | 14 (8.4)                       | 3 (1.8)                        |
| Nausea                    | 54 (15.7)              | 1 (0.3)                | 22 (6.4)         | 2 (0.6)         | 31 (16.6)                      | 0                              | 7 (4.2)                        | 0                              |
| Pyrexia                   | 51 (14.8)              | 1 (0.3)                | 12 (3.5)         | 0               | 23 (12.3)                      | 0                              | 6 (3.6)                        | 0                              |
| Decreased appetite        | 47 (13.7)              | 1 (0.3)                | 23 (6.7)         | 2 (0.6)         | 23 (12.3)                      | 1 (0.5)                        | 10 (6.0)                       | 0                              |
| Cough                     | 44 (12.8)              | 1 (0.3)                | 16 (4.6)         | 0               | 28 (15.0)                      | 0                              | 7 (4.2)                        | 0                              |
| Vomiting                  | 43 (12.5)              | 4 (1.2)                | 12 (3.5)         | 2 (0.6)         | 22 (11.8)                      | 2 (1.1)                        | 3 (1.8)                        | 0                              |
| Hypothyroidism            | 40 (11.6)              | 1 (0.3)                | 2 (0.6)          | 0               | 21 (11.2)                      | 0                              | 1 (0.6)                        | 0                              |
| Rash                      | 40 (11.6)              | 1 (0.3)                | 4 (1.2)          | 0               | 22 (11.8)                      | 0                              | 2 (1.2)                        | 0                              |
| Anaemia                   | 39                     | 13                     | 23 (6.7)         | 10 (2.9)        | 17 (9.1)                       | 8 (4.3)                        | 10 (6.0)                       | 5 (3.0)                        |
| Haematuria                | (11.3) 36              | (3.8) 6 (1.7)          | 37 (10.7)        | 5 (1.4)         | 17 (9.1)                       | 2 (1.1)                        | 16 (9.6)                       | 2 (1.2)                        |
| Infusion related reaction | (10.5) 35 (10.2)       | 3 (0.9)                | 0                | 0               | 16 (8.6)                       | 2 (1.1)                        | 0                              | 0                              |
| Abdominal pain            | 31 (9.0)               | 2 (0.6)                | 25 (7.2)         | 7 (2.0)         | 14 (7.5)                       | 1 (0.5)                        | 17 (10.2)                      | 7 (4.2)                        |
| Myalgia                   | 29 (8.4)               | 0                      | 10 (2.9)         | 0               | 20 (10.7)                      | 0                              | 5 (3.0)                        | 0                              |
| Lipase increased          | 17 (4.9)               | 14 (4.1)               | 1 (0.3)          | 1 (0.3)         | 12 (6.4)                       | 10 (5.3)                       | 0                              | 0                              |

<div style=\"page-break-after: always\"></div>

Table 48. Summary of Most Common TEAEs (Any Grade in ≥ 10% Subjects or Grade ≥ 3 in ≥ 5% Subjects in Any Treatment Group), by PT and Maximum CTCAE Grade During the On-Treatment Period - SAS Study B9991001

|                     | All Subjects           | All Subjects           | All Subjects     | All Subjects    | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   |
|---------------------|------------------------|------------------------|------------------|-----------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|                     | Avelumab + BSC (N=344) | Avelumab + BSC (N=344) | BSC (N=345)      | BSC (N=345)     | Avelumab + BSC (N=187)                 | Avelumab + BSC (N=187)                 | BSC (N=167)                            | BSC (N=167)                            |
| Preferred Term      | All Grades n (%)       | Grade ≥ 3 n (%)        | All Grades n (%) | Grade ≥ 3 n (%) | All Grades n (%)                       | Grade ≥ 3 n (%)                        | All Grades n (%)                       | Grade ≥ 3 n (%)                        |
| Disease progression | 3 (0.9)                | 3 (0.9)                | 16 (4.6)         | 16 (4.6)        | 1 (0.5)                                | 1 (0.5)                                | 12 (7.2)                               | 12 (7.2)                               |

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group. Subjects reporting more than one adverse event (AE) within a preferred term are counted only once in that preferred term.

For subjects reporting more than one AE within a preferred term, the AE with maximum grade is included in the table.

Sorted in descending order of the frequency of PTs by All Grades in Avelumab+BSC arm.

MedDRA (v22.1) coding dictionary and CTCAE version 4.03 applied.

Cut-off date: 21OCT2019 Snapshot Date: 21NOV2019.

Table 49 Exposureadjusted analysis of Most Common TEAEs (Any Grade in ≥ 10% Subjects or Grade ≥ 3 in ≥ 5% Subjects in Any Treatment Group), by PT and Maximum CTCAE Grade During the On-Treatment Period - All Subjects and Subjects with PD-L1-Positive Tumours in the Safety Analysis Set (Protocol B9991001)

|                         | All Subjects           | All Subjects           | All Subjects       | All Subjects      | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   |
|-------------------------|------------------------|------------------------|--------------------|-------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                         | Avelumab + BSC (N=344) | Avelumab + BSC (N=344) | BSC (N=345)        | BSC (N=345)       | Avelumab + BSC (N=187)                | Avelumab + BSC (N=187)                | BSC (N=167)                           | BSC (N=167)                           |
| Preferred Term          | All Grades PM (IR)     | Grade ≥ 3 PM (IR)      | All Grades PM (IR) | Grade ≥ 3 PM (IR) | All Grades PM (IR)                    | Grade ≥ 3 PM (IR)                     | All Grades PM (IR)                    | Grade ≥ 3 PM (IR)                     |
|                         | 1.                     | 1.                     | 1.                 | 1.                | 1.                                    | 1.                                    | 1.                                    | 1.                                    |
| Subjects with events    | 350.8 (96.1)           | 2224.5 (7.3)           | 737.0 (36.4)       | 1827.6 (4.8)      | 166.2 (111.9)                         | 1201.6 (7.8)                          | 373.4 (35.6)                          | 953.7 (4.2)                           |
| Fatigue                 | 2747.6 (2.2)           | 3165.9 (0.2)           | 1966.2 (1.2)       | 2031.6 (<0.1)     | 1559.0 (2.3)                          | 1849.3 (0.1)                          | 1011.6 (1.4)                          | 1055.4 (<0.1)                         |
| Pruritus                | 2673.8 (2.2)           | 3172.6 (<0.1)          | 2005.9 (0.3)       | 2033.1 (0.0)      | 1541.0 (2.4)                          | 1849.5 (<0.1)                         | 1040.4 (0.2)                          | 1056.3 (0.0)                          |
| Urinary tract infection | 2731.1 (2.2)           | 3062.9 (0.5)           | 1867.4 (1.9)       | 2010.0 (0.4)      | 1572.2 (2.4)                          | 1769.0 (0.6)                          | 978.3 (1.6)                           | 1044.9 (0.3)                          |
| Diarrhoea               | 2753.6 (2.1)           | 3163.1 (<0.1)          | 1955.6 (0.9)       | 2028.2 (<0.1)     | 1579.1 (2.0)                          | 1840.0 (0.1)                          | 1018.6 (0.8)                          | 1056.3 (0.0)                          |
| Arthralgia              | 2785.0 (2.0)           | 3168.8 (<0.1)          | 1922.9 (1.0)       | 2033.1 (0.0)      | 1583.4 (2.0)                          | 1850.4 (<0.1)                         | 1024.7 (0.5)                          | 1056.3 (0.0)                          |
| Asthenia                | 2780.9 (2.0)           | 3174.2 (0.0)           | 1966.9 (1.0)       | 2031.4 (0.2)      | 1625.7 (1.8)                          | 1851.1 (0.0)                          | 1012.2 (1.1)                          | 1054.9 (0.3)                          |
| Constipation            | 2848.3 (2.0)           | 3171.1 (<0.1)          | 1928.2 (1.6)       | 2033.1 (0.0)      | 1585.7 (2.2)                          | 1850.2 (<0.1)                         | 997.6 (1.7)                           | 1056.3 (0.0)                          |
| Back pain               | 2886.5 (1.9)           | 3162.8 (0.1)           | 1895.5 (1.8)       | 2011.8 (0.4)      | 1655.8 (2.0)                          | 1842.2 (<0.1)                         | 1015.0 (1.4)                          | 1038.9 (0.3)                          |

<div style=\"page-break-after: always\"></div>

|                           | All Subjects           | All Subjects           | All Subjects       | All Subjects      | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   | Subjects with PD-L1-Positive Tumors   |
|---------------------------|------------------------|------------------------|--------------------|-------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
|                           | Avelumab + BSC (N=344) | Avelumab + BSC (N=344) | BSC (N=345)        | BSC (N=345)       | Avelumab + BSC (N=187)                | Avelumab + BSC (N=187)                | BSC (N=167)                           | BSC (N=167)                           |
| Preferred Term            | All Grades PM (IR)     | Grade ≥ 3 PM (IR)      | All Grades PM (IR) | Grade ≥ 3 PM (IR) | All Grades PM (IR)                    | Grade ≥ 3 PM (IR)                     | All Grades PM (IR)                    | Grade ≥ 3 PM (IR)                     |
|                           | 1.                     | 1.                     | 1.                 | 1.                | 1.                                    | 1.                                    | 1.                                    | 1.                                    |
| Nausea                    | 2841.9 (1.9)           | 3171.9 (<0.1)          | 1943.9 (1.1)       | 2032.0 (<0.1)     | 1614.4 (1.9)                          | 1851.1 (0.0)                          | 1031.8 (0.7)                          | 1056.3 (0.0)                          |
| Pyrexia                   | 2838.4 (1.8)           | 3173.4 (<0.1)          | 2001.2 (0.6)       | 2033.1 (0.0)      | 1717.2 (1.3)                          | 1851.1 (0.0)                          | 1046.3 (0.6)                          | 1056.3 (0.0)                          |
| Decreased appetite        | 2932.7 (1.6)           | 3173.3 (<0.1)          | 1980.2 (1.2)       | 2032.0 (<0.1)     | 1690.4 (1.4)                          | 1850.2 (<0.1)                         | 1046.3 (1.0)                          | 1056.3 (0.0)                          |
| Cough                     | 2828.4 (1.6)           | 3173.7 (<0.1)          | 1972.8 (0.8)       | 2033.1 (0.0)      | 1601.3 (1.7)                          | 1851.1 (0.0)                          | 1033.3 (0.7)                          | 1056.3 (0.0)                          |
| Vomiting                  | 2954.3 (1.5)           | 3148.2 (0.1)           | 1982.1 (0.6)       | 2032.0 (<0.1)     | 1716.8 (1.3)                          | 1828.0 (0.1)                          | 1041.5 (0.3)                          | 1056.3 (0.0)                          |
| Hypothyroidism            | 2855.3 (1.4)           | 3173.6 (<0.1)          | 2012.5 (<0.1)      | 2033.1 (0.0)      | 1618.8 (1.3)                          | 1851.1 (0.0)                          | 1048.8 (<0.1)                         | 1056.3 (0.0)                          |
| Rash                      | 2819.2 (1.4)           | 3168.7 (<0.1)          | 2005.5 (0.2)       | 2033.1 (0.0)      | 1625.8 (1.4)                          | 1851.1 (0.0)                          | 1045.3 (0.2)                          | 1056.3 (0.0)                          |
| Anaemia                   | 3044.1 (1.3)           | 3154.4 (0.4)           | 1967.7 (1.2)       | 2023.8 (0.5)      | 1779.2 (1.0)                          | 1838.2 (0.4)                          | 1034.9 (1.0)                          | 1053.4 (0.5)                          |
| Haematuria                | 3016.3 (1.2)           | 3152.7 (0.2)           | 1892.6 (2.0)       | 2026.3 (0.2)      | 1757.9 (1.0)                          | 1844.0 (0.1)                          | 985.2 (1.6)                           | 1053.8 (0.2)                          |
| Infusion related reaction | 2951.0 (1.2)           | 3171.3 (<0.1)          | 2033.1 (0.0)       | 2033.1 (0.0)      | 1712.0 (0.9)                          | 1849.2 (0.1)                          | 1056.3 (0.0)                          | 1056.3 (0.0)                          |
| Abdominal pain            | 3087.7 (1.0)           | 3172.9 (<0.1)          | 1987.4 (1.3)       | 2026.3 (0.3)      | 1801.4 (0.8)                          | 1850.2 (<0.1)                         | 1028.8 (1.7)                          | 1049.5 (0.7)                          |
| Myalgia                   | 2880.8 (1.0)           | 3174.2 (0.0)           | 1995.0 (0.5)       | 2033.1 (0.0)      | 1627.3 (1.2)                          | 1851.1 (0.0)                          | 1047.4 (0.5)                          | 1056.3 (0.0)                          |
| Lipase increased          | 3069.1 (0.6)           | 3102.6 (0.5)           | 2029.7 (<0.1)      | 2029.7 (<0.1)     | 1776.1 (0.7)                          | 1803.7 (0.6)                          | 1056.3 (0.0)                          | 1056.3 (0.0)                          |
| Disease progression       | 3174.2 (<0.1)          | 3174.2 (<0.1)          | 2033.1 (0.8)       | 2033.1 (0.8)      | 1851.1 (<0.1)                         | 1851.1 (<0.1)                         | 1056.3 (1.1)                          | 1056.3 (1.1)                          |

## 2. IR: Incident Rate per 100 patient months, PM: Patient Months of Exposure

The exposure-adjusted incidence rate is defined as the number of patients with a particular AE divided by the total exposure time among patients in the respective treatment group at risk of an initial occurrence of AE.

Subjects reporting more than one adverse event (AE) within a preferred term are counted only once in that preferred term. Sorted in descending order of the frequency of PTs by All Grades in Avelumab+BSC arm.

MedDRA (v22.1) coding dictionary and CTCAE version 4.03 applied.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (08:14) Source Data: ADAE Output

File: ./B9991001/CHMP\\_IA/adae\\_s999b\\_expadj Date of Generation: 21SEP2020 (11:13) Cutoff date: 21OCT2019 Snapshot Date: 21NOV2019

Table 23-3 is for Pfizer internal use.

<div style=\"page-break-after: always\"></div>

Table 50. Summary of most common TEAE (Any grade in ≥ 10% Subjects or grade ≥3 in ≥5% subjects in any treatment group - Pooled safety population and avelumab treated patients in Study B9991001

|                                           | Pooled Safety Population (N=1738)   | Pooled Safety Population (N=1738)   | Pooled Safety Population (N=1738)   | Pooled Safety Population (N=1738)   | B9991001Avelumab+BsC (N=344)   | B9991001Avelumab+BsC (N=344)   | B9991001Avelumab+BsC (N=344)   | B9991001Avelumab+BsC (N=344)   | overall (N=2082)               | overall (N=2082)               | overall (N=2082)   |
|-------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------|
| Preferred Term                            | All grades n(%)                     | All grades n(%)                     | Grade >=3 n(%)                      | Grade >=3 n(%)                      | All grades n (%)               | Grade >=3 n (%)                | Grade >=3 n (%)                | Grade >=3 n (%)                | All grades Grade >=3 n(%) n(%) | All grades Grade >=3 n(%) n(%) |                    |
| Number of subjects withat least one event | 1697                                | 97.6)                               | 1008                                | 58.0)                               | 337 98.0)                      |                                | 163                            | 47.4)                          | 2034                           | 97.7)                          | 1171 56.2)         |
| Fatigue                                   | 563                                 | 32.4)                               | 51                                  | 2.9)                                | 61                             | 17.7)                          | 6                              | 1.7)                           | 624                            | 30.0)                          | 57 2.7)            |
| pruritus                                  | 128                                 | 7.4)                                | 2                                   | 0.1)                                | 59 17.2)                       | 1                              |                                | 0.3)                           | 187 9.0)                       |                                | 3 0.1)             |
| Urinary tract infection                   | 167                                 | 9.6)                                | 19                                  | 1.1)                                | 59 17.2)                       |                                | 15                             | 4.4)                           | 226                            | 10.9) 18.5)                    | 34 1.6)            |
| Diarrhoea                                 | 329                                 | 18.9)                               | 22                                  | 1.3)                                | 57 16.6)                       | 2                              |                                | 0.6)                           | 386                            |                                | 24 1.2)            |
| Arthralgia                                | 180                                 | 10.4)                               | 18                                  | 1.0)                                | 56 16.3)                       |                                | 2                              | 0.6) 236                       | 11.3)                          |                                | 20 1.0)            |
| Asthenia                                  | 151                                 | 8.7)                                | 29                                  | 1.7)                                | 56 16.3)                       |                                | 0                              |                                | 207                            | 9.9)                           | 29 1.4)            |
| Constipation                              | 320                                 | 18.4)                               | 17                                  | 1.0)                                | 56 16.3)                       |                                | 2                              | 0.6) 1.2)                      | 376 18.1)                      |                                | 19 0.9)            |
| Back pain                                 | 205                                 | 11.8)                               | 24                                  | 1.4)                                | 55                             | 16.0)                          | 4                              | 260                            | 12.5)                          | 28                             | 1.3)               |
| Nausea                                    | 437                                 | 25.1)                               | 27                                  | 1.6)                                | 54                             | 15.7)                          | 1                              | 491                            | 23.6)                          |                                | 28 1.3)            |
| Pyrexia                                   | 237                                 | 13.6)                               | 5                                   | 0.3)                                | 51 14.8)                       | 1                              | 0.3)                           | 0.3) 0.3)                      | 288                            | 6                              | 0.3)               |
| Decreased appetite                        | 320                                 | 18.4)                               | 19                                  | 1.1)                                | 47                             | 13.7)                          | 1                              | 367                            | 13.8) 17.6)                    |                                | 20 1.0)            |
| Cough                                     | 240                                 | 13.8)                               | 2                                   | 0.1)                                | 44                             | 12.8)                          | 1                              | 0.3)                           | 284 13.6)                      |                                | 3 0.1)             |
| vomiting                                  | 281                                 | 16.2)                               | 31                                  | 1.8)                                | 43 12.5)                       | 4                              |                                | 1.2)                           | 324                            |                                | 35 1.7)            |
| Hypothyroidism                            | 111                                 | 6.4)                                | 4                                   | 0.2)                                | 40                             | 11.6)                          | 1                              | 0.3)                           | 15.6) 7.3) 7.9)                |                                | 5 0.2)             |
| Rash                                      | 124                                 | 7.1)                                | 3                                   | 0.2)                                | 40                             | 11.6)                          | 1                              | 0.3)                           | 151 164                        |                                | 4 0.2)             |
| Anaemia                                   | 259                                 | 14.9)                               | 104                                 | 6.0)                                | 39 11.3)                       | 13                             |                                | 3.8)                           | 298 14.3)                      | 117                            | 5.6)               |
| Haematuria                                | 41                                  | 2.4)                                | 8                                   | 0.5)                                | 36 10.5)                       |                                | 6                              | 1.7)                           | 77 3.7)                        |                                | 14 0.7)            |
| Infusionrelatedreaction                   | 297                                 | 17.1)                               | 10                                  | 0.6)                                | 35                             | 10.2)                          | 3                              | 0.9)                           | 332 15.9)                      | 13                             | 0.6)               |
| Abdominal pain                            | 250                                 | 14.4)                               | 52                                  | 3.0)                                | 31                             | 9.0)                           | 2                              | 0.6)                           | 281 13.5)                      |                                | 54 2.6)            |
| Dyspnoea                                  | 229                                 | 13.2)                               | 68                                  | 3.9)                                | 23                             | 6.7)                           | 5                              | 1.5)                           | 252 12.1)                      | 73                             | 3.5)               |
| Oedema peripheral                         | 206                                 | 11.9)                               | 8                                   | 0.5)                                | 22                             | 6.4)                           | 1                              | 0.3)                           | 228 11.0)                      | 9                              | 0.4)               |
| Weight decreased                          | 288                                 | 16.6)                               | 12                                  | 0.7)                                | 13                             | 3.8)                           | 1                              | 0.3)                           | 301 14.5)                      |                                | 13 0.6)            |
| Diseaseproaression                        | 179                                 | 10.3)                               | 172                                 | 9.9)                                | 3                              | 0.9)                           | 3                              | 0.9)                           | 182 8.7)                       |                                | 175 8.4)           |

Most common: Any Grade in &gt;=lo% subjects or Grade&gt;=3 in &gt;=5% subjects in any treatment group

Thedenominator tocalculatepercentages is N.

N:thenumberofsubjectswhohavereceivedatleastonedoseofavelumab.

Apatientwithmultiple occurrencesof anAEis countedonlyonce.

Grading categories determined using NCI-cTcAE version 4.0 in pooled safety population and version 4.03 in B9991o01.

EventsarecodedinthelatestMedDRAversionavailableat thetimeof cut-off.

Sorted in descending order of thefrequency of pTs byAllGradesin B999ioo1Avelumab+BsC arm. Cut-off dates:09Jun2016 on pooled safety population (EMR100070-001 and EMR100070-003 Part A)，210ct2019 on study B9991001.

Table 51. Exposure-Adjusted Analysis of Most Common TEAE by PT

|                                  | Pooled Safety Population (N=1738)   | Pooled Safety Population (N=1738)   | B9991001 Avelumab+BSC (N=344)   | B9991001 Avelumab+BSC (N=344)   |                   |                 |
|----------------------------------|-------------------------------------|-------------------------------------|---------------------------------|---------------------------------|-------------------|-----------------|
| Preferred Term                   | All Grades PM(IR)                   | Grade ≥3 PM(IR)                     | All Grades PM(IR)               | Grade ≥3 PM(IR)                 | All Grades PM(IR) | Grade ≥3 PM(IR) |
| Subjects with at least one event | 844.6 (200.9)                       | 5973.6 (16.9)                       | 350.8 (96.1)                    | 2224.5 (7.3)                    | 1195.4 (170.2)    | 8198.0 (14.3)   |
| Fatigue                          | 6270.9 (9.0)                        | 8431.5 (0.6)                        | 2747.6 (2.2)                    | 3165.9 (0.2)                    | 9018.5 (6.9)      | 11597.4 (0.5)   |
| Pruritus                         | 7897.6 (1.6)                        | 8509.2 (0.0)                        | 2673.8 (2.2)                    | 3172.6 (0.0)                    | 10571.3 (1.8)     | 11681.8 (0.0)   |
| Urinary tract infection          | 7849.6 (2.1)                        | 8464.2 (0.2)                        | 2731.1 (2.2)                    | 3062.9 (0.5)                    | 10580.7 (2.1)     | 11527.1 (0.3)   |
| Diarrhoea                        | 6988.1 (4.7)                        | 8456.2 (0.3)                        | 2753.6 (2.1)                    | 3163.1 (0.1)                    | 9741.7 (4.0)      | 11619.3 (0.2)   |
| Arthralgia                       | 7682.2 (2.3)                        | 8487.8 (0.2)                        | 2785.0 (2.0)                    | 3168.8 (0.1)                    | 10467.2 (2.3)     | 11656.5 (0.2)   |
| Asthenia                         | 8097.6 (1.9)                        | 8492.6 (0.3)                        | 2780.9 (2.0)                    | 3174.2 (0.0)                    | 10878.5 (1.9)     | 11666.9 (0.2)   |
| Constipation                     | 7555.6 (4.2)                        | 8490.5 (0.2)                        | 2848.3 (2.0)                    | 3171.1 (0.1)                    | 10403.9 (3.6)     | 11661.5 (0.2)   |
| Back pain                        | 7799.0 (2.6)                        | 8482.0 (0.3)                        | 2886.5 (1.9)                    | 3162.8 (0.1)                    | 10685.5 (2.4)     | 11644.8 (0.2)   |
| Nausea                           | 6930.0 (6.3)                        | 8484.5 (0.3)                        | 2841.9 (1.9)                    | 3171.9 (0.0)                    | 9771.9 (5.0)      | 11656.4 (0.2)   |
| Pyrexia                          | 7586.8 (3.1)                        | 8511.2 (0.1)                        | 2838.4 (1.8)                    | 3173.4 (0.0)                    | 10425.2 (2.8)     | 11684.7 (0.1)   |
| Decreased appetite               | 7500.1 (4.3)                        | 8499.9 (0.2)                        | 2932.7 (1.6)                    | 3173.3 (0.0)                    | 10432.8 (3.5)     | 11673.2 (0.2)   |
| Cough                            | 7529.5 (3.2)                        | 8503.4 (0.0)                        | 2828.4 (1.6)                    | 3173.7 (0.0)                    | 10357.8 (2.7)     | 11677.0 (0.0)   |
| Vomiting                         | 7669.7 (3.7)                        | 8469.0 (0.4)                        | 2954.3 (1.5)                    | 3148.2 (0.1)                    | 10623.9 (3.0)     | 11617.2 (0.3)   |
| Hypothyroidism                   | 7992.9 (1.4)                        | 8510.1 (0.0)                        | 2855.3 (1.4)                    | 3173.6 (0.0)                    | 10848.3 (1.4)     | 11683.6 (0.0)   |
| Rash                             | 7918.9 (1.6)                        | 8505.6 (0.0)                        | 2819.2 (1.4)                    | 3168.7 (0.0)                    | 10738.1 (1.5)     | 11674.2 (0.0)   |
| Anaemia                          | 7831.9 (3.3)                        | 8334.7 (1.2)                        | 3044.1 (1.3)                    | 3154.4 (0.4)                    | 10876.0 (2.7)     | 11489.0 (1.0)   |
| Haematuria                       | 8338.6 (0.5)                        | 8502.9 (0.1)                        | 3016.3 (1.2)                    | 3152.7 (0.2)                    | 11354.8 (0.7)     | 11655.6 (0.1)   |
| Infusion related reaction        | 7184.0 (4.1)                        | 8503.9 (0.1)                        | 2951.0 (1.2)                    | 3171.3 (0.1)                    | 10135.0 (3.3)     | 11675.2 (0.1)   |
| Abdominal pain                   | 7844.9 (3.2)                        | 8456.2 (0.6)                        | 3087.7 (1.0)                    | 3172.9 (0.1)                    | 10932.6 (2.6)     | 11629.2 (0.5)   |
| Dyspnoea                         | 7869.0 (2.9)                        | 8402.8 (0.8)                        | 3071.0 (0.7)                    | 3169.0 (0.2)                    | 10940.0 (2.3)     | 11571.7 (0.6)   |
| Oedema peripheral                | 7795.5 (2.6)                        | 8507.5 (0.1)                        | 3021.1 (0.7)                    | 3173.7 (0.0)                    | 10816.6 (2.1)     | 11681.1 (0.1)   |
| Weight decreased                 | 7679.5 (3.8)                        | 8501.1 (0.1)                        | 3065.2 (0.4)                    | 3168.2 (0.0)                    | 10744.8 (2.8)     | 11669.3 (0.1)   |
| Disease progression              | 8447.2 (2.1)                        | 8456.5 (2.0)                        | 3174.2 (0.1)                    | 3174.2 (0.1)                    | 11621.5 (1.6)     | 11630.8 (1.5)   |

<div style=\"page-break-after: always\"></div>

## Table 51. Exposure-Adjusted Analysis of Most Common TEAE by PT

|                | B9991001                          | B9991001                          | B9991001             | B9991001             | B9991001          | B9991001         |
|----------------|-----------------------------------|-----------------------------------|----------------------|----------------------|-------------------|------------------|
|                | Pooled Safety Population (N=1738) | Pooled Safety Population (N=1738) | Avelumab+BSC (N=344) | Avelumab+BSC (N=344) | Overall (N=2082)  | Overall (N=2082) |
| Preferred Term | All Grades PM(IR)                 | Grade ≥3 PM(IR)                   | All Grades PM(IR)    | Grade ≥3 PM(IR)      | All Grades PM(IR) | Grade ≥3 PM(IR)  |

Most common: Any Grade in ≥10% subjects or Grade ≥3 in ≥5% subjects in any treatment group

IR: Incident Rate per 100 patient months, PM: Patient Months of Exposure

The exposure-adjusted incidence rate is defined as the number of patients with a particular AE divided by the total exposure time among patients in the respective treatment group at risk of an initial occurrence of AE.

Cut-off dates: 09Jun2016 on pooled safety population (EMR100070-001 and EMR100070-003 Part A), 21Oct2019 on study B9991001

## Serious adverse event/deaths/other significant events

## Summary of deaths

Table 52. Summary of deaths - SAS Study B9991001.

|                                                          | All Subjects               | All Subjects      | Subjectswith PD-Ll-Positive Tumors   | Subjectswith PD-Ll-Positive Tumors   |
|----------------------------------------------------------|----------------------------|-------------------|--------------------------------------|--------------------------------------|
|                                                          | Avelumab+BSC (N=344) n (%) | BSC (N=345) n (%) | Avelumab+BSC (N=187) n (%)           | BSC (N=167) n (%)                    |
| Deaths                                                   | 144 (41.9)                 | 176 (51.0)        | 61 (32.6)                            | 81 (48.5)                            |
| Cause of death                                           |                            |                   |                                      |                                      |
| Disease progression                                      | 133 (38.7)                 | 157 (45.5)        | 57 (30.5)                            | 77 (46.1)                            |
| Study treatment toxicity                                 | 2 (0.6)                    | 0                 | 1(0.5)                               | 0                                    |
| Adverse event not related to study treatment             | 2 (0.6)                    | 10 (2.9)          | 1 (0.5)                              | 3 (1.8)                              |
| Other                                                    | 2 (0.6)                    | 3 (0.9)           | 1 (0.5)                              | 1 (0.6)                              |
| Unlmow                                                   | 6 (1.7)                    | 6 (1.7)           | 1 (0.5)                              | 0                                    |
| Deaths within 30 days after last dose of study treatment | 5 (1.5)                    | 33 (9.6)          | 3 (1.6)                              | 18 (10.8)                            |
| Cause of death                                           |                            |                   |                                      |                                      |
| Disease progression                                      | 4 (1.2)                    | 27 (7.8)          | 2 (1.1)                              | 17 (10.2)                            |
| Study treatment toxicity                                 | 1 (0.3)                    | 0                 | 1 (0.5)                              | 0                                    |
| Adverse event not related to study                       | 0                          | 6 (1.7)           | 0                                    | 1 (0.6)                              |
| treatment                                                |                            |                   |                                      |                                      |
| Other                                                    | 0                          | 0                 | 0                                    | 0                                    |
| Unlnowm                                                  | 0                          | 0                 | 0                                    | 0                                    |

A subject can have more than one cause of death

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group.

Last dose of study treatment in BSC amm refers to the date of completion or discontinuation as collected on the End of treatment disposition CRF

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (07:14) Source Data: ADSL Output File:

/B9991001/B9991001 SCS/adae s500a pdl1c Date of Generation: 17JAN2020 (14:32) Cutoff date: 21OCT2019

Snapshot Date:21NOV2019

Table 14.3.2.1.1.1 is for Pfizer intemal use.

<div style=\"page-break-after: always\"></div>

Table 53 Exposure-adjusted analysis of Deaths - All Subjects and Subjects with PD-L1Positive Tumours in the Safety Analysis Set (Protocol B9991001)

|                                                          | All Subjects                 | All Subjects        | Subjects with PD-L1-Positive Tumours   | Subjects with PD-L1-Positive Tumours   |
|----------------------------------------------------------|------------------------------|---------------------|----------------------------------------|----------------------------------------|
|                                                          | Avelumab+BSC (N=344) PM (IR) | BSC (N=345) PM (IR) | Avelumab+BSC (N=187) PM (IR)           | BSC (N=167) PM (IR)                    |
| Deaths                                                   | 5051.7 (2.9)                 | 4378.9 (4.0)        | 2860.4 (2.1)                           | 2224.6 (3.6)                           |
| Cause of death                                           |                              |                     |                                        |                                        |
| Disease progression                                      | 5051.7 (2.6)                 | 4378.9 (3.6)        | 2860.4 (2.0)                           | 2224.6 (3.5)                           |
| Study treatment toxicity                                 | 5051.7 (<0.1)                | 4378.9 (0.0)        | 2860.4 (<0.1)                          | 2224.6 (0.0)                           |
| Adverse event not related to study treatment             | 5051.7 (<0.1)                | 4378.9 (0.2)        | 2860.4 (<0.1)                          | 2224.6 (0.1)                           |
| Other                                                    | 5051.7 (<0.1)                | 4378.9 (<0.1)       | 2860.4 (<0.1)                          | 2224.6 (<0.1)                          |
| Unknown                                                  | 5051.7 (0.1)                 | 4378.9 (0.1)        | 2860.4 (<0.1)                          | 2224.6 (0.0)                           |
| Deaths within 30 days after last dose of study treatment | 3189.3 (0.2)                 | 2132.2 (1.5)        | 1855.5 (0.2)                           | 1105.2 (1.6)                           |
| Cause of death                                           |                              |                     |                                        |                                        |
| Disease progression                                      | 3189.3 (0.1)                 | 2132.2 (1.3)        | 1855.5 (0.1)                           | 1105.2 (1.5)                           |
| Study treatment toxicity                                 | 3189.3 (<0.1)                | 2132.2 (0.0)        | 1855.5 (<0.1)                          | 1105.2 (0.0)                           |
| Adverse event not related to study treatment             | 3189.3 (0.0)                 | 2132.2 (0.3)        | 1855.5 (0.0)                           | 1105.2 (<0.1)                          |
| Other                                                    | 3189.3 (0.0)                 | 2132.2 (0.0)        | 1855.5 (0.0)                           | 1105.2 (0.0)                           |
| Unknown                                                  | 3189.3 (0.0)                 | 2132.2 (0.0)        | 1855.5 (0.0)                           | 1105.2 (0.0)                           |

IR: Incident Rate per 100 patient months, PM: Patient Months of Exposure

The exposure-adjusted incidence rate is defined as the number of patients with a particular cause of death divided by the total exposure time among patients in the

respective treatment group at risk of death.

A subject can have more than one cause of death.

Last dose of study treatment in BSC arm refers to the date of completion or discontinuation as collected on the End of treatment disposition CRF.

Cutoff date: 21OCT2019

<div style=\"page-break-after: always\"></div>

Table 54 Summary of Deaths - Study B9991001 and Pooled safety population

|                                                          | Avelumab+BSC (N=344) n (%)   | BSC (N=345) n (%)   | Pooled Safety Population (N=1738) n (%)   | Overall (N=2082) n (%)   |
|----------------------------------------------------------|------------------------------|---------------------|-------------------------------------------|--------------------------|
| Deaths                                                   | 144 ( 41.9)                  | 176 ( 51.0)         | 911 ( 52.4)                               | 1055 ( 50.7)             |
| Cause of death                                           |                              |                     |                                           |                          |
| Disease progression                                      | 133 ( 38.7)                  | 157 ( 45.5)         | 744 ( 42.8)                               | 877 ( 42.1)              |
| Study treatment toxicity                                 | 2 ( 0.6)                     | 0                   | 4 ( 0.2)                                  | 6 ( 0.3)                 |
| AE not related to study treatment                        | 2 ( 0.6)                     | 10 ( 2.9)           | 59 ( 3.4)                                 | 61 ( 2.9)                |
| Other                                                    | 2 ( 0.6)                     | 3 ( 0.9)            | 17 ( 1.0)                                 | 19 ( 0.9)                |
| Unknown                                                  | 6 ( 1.7)                     | 6 ( 1.7)            | 83 ( 4.8)                                 | 89 ( 4.3)                |
| Missing                                                  | 0                            | 0                   | 4 ( 0.2)                                  | 4 ( 0.2)                 |
| Deaths within 30 days after last dose of study treatment | 5 ( 1.5)                     | 33 ( 9.6)           | 228 ( 13.1)                               | 233 ( 11.2)              |
| Cause of death                                           |                              |                     |                                           |                          |
| Disease progression                                      | 4 ( 1.2)                     | 27 ( 7.8)           | 174 ( 10.0)                               | 178 ( 8.5)               |
| Study treatment toxicity                                 | 1 ( 0.3)                     | 0                   | 4 ( 0.2)                                  | 5 ( 0.2)                 |
| AE not related to study treatment                        | 0                            | 6 ( 1.7)            | 41 ( 2.4)                                 | 41 ( 2.0)                |
| Other                                                    | 0                            | 0                   | 4 ( 0.2)                                  | 4 ( 0.2)                 |
| Unknown                                                  | 0                            | 0                   | 5 ( 0.3)                                  | 5 ( 0.2)                 |
| Missing                                                  | 0                            | 0                   | 0                                         | 0                        |

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group. A subject can have more than one cause of death.

Last dose of study treatment in BSC arm refers to the date of completion or discontinuation as collected on the End of treatment disposition CRF

Table 55 Exposure-Adjusted Analysis of Deaths

|                                                          | Pooled Safety Population (N=1738) PM(IR)   | B9991001 Avelumab + BSC (N=344) PM(IR)   | Overall (N=2082) PM(IR)   |
|----------------------------------------------------------|--------------------------------------------|------------------------------------------|---------------------------|
| Deaths                                                   | 15394.8 (5.9)                              | 5051.7 (2.9)                             | 20446.5 (5.2)             |
| Cause of death                                           |                                            |                                          |                           |
| Disease Progression                                      | 15394.8 (4.8)                              | 5051.7 (2.6)                             | 20446.5 (4.3)             |
| Study Treatment Toxicity                                 | 15394.8 (0.0)                              | 5051.7 (0.0)                             | 20446.5 (0.0)             |
| AE Not Related to Study Treatment                        | 15394.8 (0.4)                              | 5051.7 (0.0)                             | 20446.5 (0.3)             |
| Other                                                    | 15394.8 (0.1)                              | 5051.7 (0.0)                             | 20446.5 (0.1)             |
| Unknown                                                  | 15394.8 (0.5)                              | 5051.7 (0.1)                             | 20446.5 (0.4)             |
| Missing                                                  | 15394.8 (0.0)                              | 5051.7 (0.0)                             | 20446.5 (0.0)             |
| Deaths within 30 days after last dose of study treatment | 8598.7 (2.7)                               | 3189.3 (0.2)                             | 11788.0 (2.0)             |
| Cause of death                                           |                                            |                                          |                           |
| Disease Progression                                      | 8598.7 (2.0)                               | 3189.3 (0.1)                             | 11788.0 (1.5)             |
| Study Treatment Toxicity                                 | 8598.7 (0.0)                               | 3189.3 (0.0)                             | 11788.0 (0.0)             |
| AE Not Related to Study Treatment                        | 8598.7 (0.5)                               | 3189.3 (0.0)                             | 11788.0 (0.3)             |
| Other                                                    | 8598.7 (0.0)                               | 3189.3 (0.0)                             | 11788.0 (0.0)             |
| Unknown                                                  | 8598.7 (0.1)                               | 3189.3 (0.0)                             | 11788.0 (0.0)             |
| Missing                                                  | 8598.7 (0.0)                               | 3189.3 (0.0)                             | 11788.0 (0.0)             |

IR: Incident Rate per 100 patient months, PM: Patient Months of Exposure

The exposure-adjusted incidence rate is defined as the number of patients with a particular AE divided by the total exposure time among patients in the respective treatment group at risk of an initial occurrence of AE.

Cut-off dates: 09Jun2016 on pooled safety population (EMR100070-001 and EMR100070-003 Part A), 21Oct2019 on study B9991001

<div style=\"page-break-after: always\"></div>

Table 56. Summary of TEAEs During the On-Treatment Period Leading to Death by SOC and PT - SAS Study B9991001

|                                                                     | All Subjects         | All Subjects   | Subjects with PD-L1- Positive Tumours   | Subjects with PD-L1- Positive Tumours   |
|---------------------------------------------------------------------|----------------------|----------------|-----------------------------------------|-----------------------------------------|
|                                                                     | Avelumab+BSC (N=344) | BSC (N=345 )   | Avelumab+BSC (N=187)                    | BSC (N=167 )                            |
| System Organ Class and Preferred Term                               | n (%)                | n (%)          | n (%)                                   | n (%)                                   |
| Subjects with events                                                | 4 (1.2)              | 24 (7.0)       | 2 (1.1)                                 | 13 (7.8)                                |
| General disorders and administration site conditions                | 3 (0.9)              | 16 (4.6)       | 1 (0.5)                                 | 12 (7.2)                                |
| Disease progression                                                 | 3 (0.9)              | 16 (4.6)       | 1 (0.5)                                 | 12 (7.2)                                |
| Infections and infestations                                         | 1 (0.3)              | 2 (0.6)        | 1 (0.5)                                 | 0                                       |
| Sepsis                                                              | 1 (0.3)              | 0              | 1 (0.5)                                 | 0                                       |
| Biliary sepsis                                                      | 0                    | 1 (0.3)        | 0                                       | 0                                       |
| Urosepsis                                                           | 0                    | 1 (0.3)        | 0                                       | 0                                       |
| Cardiac disorders                                                   | 0                    | 1 (0.3)        | 0                                       | 1 (0.6)                                 |
| Cardiogenic shock                                                   | 0                    | 1 (0.3)        | 0                                       | 1 (0.6)                                 |
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 0                    | 4 (1.2)        | 0                                       | 0                                       |
| Bladder cancer                                                      | 0                    | 1 (0.3)        | 0                                       | 0                                       |
| Malignant neoplasm progression                                      | 0                    | 1 (0.3)        | 0                                       | 0                                       |
| Metastatic carcinoma of the bladder                                 | 0                    | 1 (0.3)        | 0                                       | 0                                       |
| Neoplasm progression                                                | 0                    | 1 (0.3)        | 0                                       | 0                                       |
| Respiratory, thoracic and mediastinal disorders                     | 0                    | 1 (0.3)        | 0                                       | 0                                       |
| Chronic obstructive pulmonary disease                               | 0                    | 1 (0.3)        | 0                                       | 0                                       |

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group. Subjects reporting more than one adverse event within a preferred term are counted only once in that preferred term. Subjects reporting multiple preferred terms within the same system organ class (SOC) are counted only once within each SOC. Sorted in descending order of the frequency of SOC and PTs in Avelumab + BSC arm in all subjects. MedDRA v22.1 coding dictionary applied.

Cut-off date: 21OCT2019 Snapshot Date: 21NOV2019

<div style=\"page-break-after: always\"></div>

## Summary of serious adverse events

Table 57. Summary of most common serious AE ( ≥ 2 subjects in any treatment group) by PT during the on-treatment period - SAS Study B9991001.

|                                        | Avelumab +BSC (N=344)   | BSC (N=345)   |
|----------------------------------------|-------------------------|---------------|
| Preferred Term                         | (n %)                   | (n %)         |
| Subjects with events                   | 96 (27.9)               | 69 (20.0)     |
| Urinary tract imfection                | 16 (4.7)                | 7 (2.0)       |
| Acute kidney injury                    | 6 (1.7)                 | 6 (1.7)       |
| Haematuria                             | 5 (1.5)                 | 2 (0.6)       |
| Infiusion related reaction             | 4 (1.2)                 | 0             |
| Pain                                   | 4 (1.2)                 | 1 (0.3)       |
| Sepsis                                 | 4 (1.2)                 | 1 (0.3)       |
| Atrial fibrillation                    | 3 (0.9)                 | 1 (0.3)       |
| Back pain                              | 3 (0.9)                 | 1 (0.3)       |
| Disease progression                    | 3 (0.9)                 | 16 (4.6)      |
| Hydronephrosis                         | 3 (0.9)                 | 1 (0.3)       |
| Ileus                                  | 3 (0.9)                 | 1 (0.3)       |
| Pyelonephritis                         | 3 (0.9)                 | 3 (0.9)       |
| Vomiting                               | 3 (0.9)                 | 0             |
| Blood creatine phosphokinase increased | 2 (0.6)                 | 0             |
| Colitis                                | 2 (0.6)                 | 0             |
| Constipation                           | 2 (0.6)                 | 0             |
| Dyspnoea                               | 2 (0.6)                 | 1 (0.3)       |
| Kidney infection                       | 2 (0.6)                 | 0             |
| Myocardial infarction                  | 2 (0.6)                 | 0             |
| Pvrexia                                | 2 (0.6)                 | 1 (0.3)       |
| Vascular device infection              | 2 (0.6)                 | 0             |
| Abdominal pain                         | 1 (0.3)                 | 3 (0.9)       |
| Anaemia                                | 1 (0.3)                 | 2 (0.6)       |
| Basal cell carcinoma                   | 1(0.3)                  | 2 (0.6)       |
| Urosepsis                              | 1 (0.3)                 | 2 (0.6)       |
| Syncope                                | 0                       | 2 (0.6)       |
| Tumour pain                            | 0                       | 2 (0.6)       |
| Urinary tract obstruction              | 0                       | 2 (0.6)       |

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group.

Subjects reporting more than one adverse event (AE) within a preferred tenm are coumted only once in that preferred termm.

Sorted in descending order of the frequency of PTs in the Avelumab+BSC amm.

MedDRA (v22.1) coding dictionary amd CTCAE version 4.03 applied.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (07:14) Source Data: ADAE Output File:

/B9991001/B9991001 CSR/adae s999 ser Date of Generation: 14JAN2020 (04:41) Cutoff date: 21OCT2019 Snapshot Date: 21NOV2019

Table 14.3.1.2.2.15 is for Pfizer intemal use.

<div style=\"page-break-after: always\"></div>

## Table 58. Serious AE reported per organ class - Pooled safety population and avelumab treated patients in Study B9991001.

| System Organ Class Preferred Term                                  | Pooled safety Population (N=1738) n (%)   | B9991001 Avelumab +BSC (N=344) n (8)   | overall (N=2082) n (%)   |
|--------------------------------------------------------------------|-------------------------------------------|----------------------------------------|--------------------------|
| Numberofsubjectswithatleastoneevent                                | 777 (44.7)                                | 96 (27.9)                              | 873 (41.9)               |
| Infections and infestations                                        | 162 （ 9.3)                                | 28 8.1)                                | 190 9.1)                 |
| Renalandurinarydisorders                                           | 44 2.5)                                   | 18 5.2)                                | 62 3.0)                  |
| Gastrointestinal disorders                                         | 178 (10.2)                                | 15 4.4)                                | 193 9.3)                 |
| Generaldisordersandadministrationsite conditions                   | 248 14.3)                                 | 12 3.5)                                | 260 12.5)                |
| Injury,poisoning and procedural complications                      | 51 2.9)                                   | 11 3.2)                                | 62 3.0)                  |
| Cardiac disorders                                                  | 43 2.5)                                   | 8 2.3)                                 | 51 2.4)                  |
| Musculoskeletalandconnective tissue disorders                      | 47 2.7)                                   | 7 2.0)                                 | 54 2.6)                  |
| Respiratory, thoracic and mediastinal disorders                    | 184 (10.6)                                | 7 2.0)                                 | 191 （ 9.2)               |
| Neoplasms benign,malignant and unspecified (incl cysts and polyps) | 53 3.0)                                   | 4 1.2)                                 | 57 2.7)                  |
| Hepatobiliarydisorders                                             | 22 1.3)                                   | 3 0.9)                                 | 25 1.2)                  |
| Investiqations                                                     | 26 1.5)                                   | 3 0.9)                                 | 29 1.4)                  |
| Nervous system disorders                                           | 55 3.2)                                   | 3 0.9)                                 | 58 2.8)                  |
| Vascular disorders                                                 | 42 ( 2.4)                                 | 3 0.9)                                 | 45 2.2)                  |
| Endocrine disorders                                                | 17 1.0)                                   | 2 ( 0.6)                               | 19 0.9)                  |
| Bloodand lymphaticsystem disorders                                 | 35 2.0)                                   | 1 0.3)                                 | 36 1.7)                  |
| Metabolism and nutrition disorders                                 | 63 3.6)                                   | 2 0.6)                                 | 65 3.1)                  |
| Ear and labyrinth disorders                                        | 1 0.1)                                    | 1 0.3)                                 | 2 0.1)                   |
| Product issues                                                     | 2 0.1)                                    | 1 0.3)                                 | 3 0.1)                   |
| Psychiatric disorders                                              | 17 1.0)                                   | 1 0.3)                                 | 18 0.9)                  |
| Reproductive system and breast disorders                           | 4 0.2)                                    | 1 0.3)                                 | 5 0.2)                   |
| Eye disorders                                                      | 7 0.4)                                    | 0                                      | 7 0.3)                   |
| Immune system disorders                                            | 4 0.2)                                    | 0                                      | 4 0.2)                   |
| Skinand subcutaneous tissue disorders                              | 4 0.2)                                    | 0                                      | 4 0.2)                   |

N:thenumberofsubjectswhohavereceivedatleastonedoseofavelumab.

ApatientwithmultipleoccurrencesofanAEunder onetreatmentiscountedonlyonce.

ThedenominatortocalculatepercentagesisN.

Events arecodedin thelatestMedDRA version\\_availableat the time of cut-off.

Sortedindescending order of thefrequencyof socandPTsinB9991oo1Avelumab+BsC arm.

B9991001.

<div style=\"page-break-after: always\"></div>

## Adverse events leading to discontinuation of study drug or dose interruptions

Table 59. Adverse events leading to discontinuation of study drug - Pooled safety population and avelumab treated patients in Study B9991001

| System Organ Class Preferred Term                                       | Pooled Safety Population (N=1738)   | B9991001Avelumab +BSC (N=344) n (%)   | overall (N=2082) n (%)   |
|-------------------------------------------------------------------------|-------------------------------------|---------------------------------------|--------------------------|
|                                                                         | n (%)                               |                                       |                          |
| Numberofsubjectswithatleastoneevent                                     | 244 (14.0)                          | 41 (11.9)                             | 285 (13.7)               |
| Investigations                                                          | 36 2.1)                             | 10 2.9)                               | 46 2.2)                  |
| Lipase increased                                                        | 3 0.2)                              | 3 0.9)                                | 6 0.3)                   |
| Troponin T increased                                                    | 0                                   | 3 0.9)                                | 3 0.1)                   |
| Alanineaminotransferase increased                                       | 5 0.3)                              | 2 0.6)                                | 7 0.3)                   |
| Amylase increased                                                       | 1 0.1)                              | 2 0.6)                                | 3 0.1)                   |
| Aspartate aminotransferase increased                                    | 7 0.4)                              | 1 0.3)                                | 8 0.4)                   |
| Bloodalkalinephosphataseincreased                                       | 3 0.2)                              | 1 0.3)                                | 4 0.2)                   |
| Gamma-glutamyltransferaseincreased                                      | 9 0.5)                              | 1 0.3)                                | 10 0.5)                  |
| Neutrophil count decreased                                              | 1 0.1)                              | 1 0.3)                                | 2 0.1)                   |
| Platelet count decreased                                                |                                     | 0.3)                                  | 1 0.0)                   |
|                                                                         | 0                                   | 1                                     |                          |
| Bloodbilirubin increased                                                | 2 0.1)                              | 0                                     | 2 0.1)                   |
| Blood creatine phosphokinase increased                                  | 4 0.2)                              | 0                                     | 4 0.2)                   |
| Generalphysicalcondition abnormal                                       | 1 0.1)                              | 0                                     | 1 0.0)                   |
| Haemoglobin decreased                                                   | 1 0.1)                              | 0                                     | 1 0.0)                   |
| Hepatic enzyme increased                                                | 1 0.1)                              | 0                                     | 1 0.0)                   |
| Transaminases increased                                                 | 3 0.2)                              | 0                                     | 3 0.1)                   |
| Weight decreased                                                        |                                     |                                       | 1 0.0)                   |
|                                                                         | 1                                   | 0                                     |                          |
| Gastrointestinal disorders                                              | 0.1)                                |                                       |                          |
| Colitis                                                                 | 31 1.8) 3 0.2)                      | 6 1.7) 2 0.6)                         | 37 1.8) 5 0.2) 1 0.0)    |
| Autoimmune pancreatitis Gastric ulcer                                   | 0                                   | 1 0.3) 1 0.3)                         | 1 0.0)                   |
| Pancreatitis                                                            | 0 0                                 | 1 0.3)                                | 1 0.0)                   |
| vomiting                                                                | 1 0.1)                              | 1 0.3) 0                              | 2 0.1) 2                 |
| Abdominal pain                                                          | 2 0.1)                              |                                       | 1                        |
| Ascites                                                                 |                                     | 0                                     | 0.1) 0.0)                |
| Diarrhoea                                                               | 1 0.1)                              | 0                                     | 5 0.2)                   |
| Dysphagia                                                               | 5 0.3) 3 0.2)                       | 0                                     | 3 0.1)                   |
| Enterocolitis                                                           | 1 0.1)                              | 0                                     | 1                        |
| Gastrointestinal haemorrhage                                            | 1 0.1)                              | 0                                     | 0.0) 1 0.0)              |
| Ileus                                                                   | 2 0.1) 3                            | 0 0                                   | 2 0.1) 3 0.1)            |
| Intestinal obstruction                                                  | 0.2)                                |                                       |                          |
| Intestinal perforation Nausea                                           | 1 0.1)                              | 0 0                                   | 1 0.0)                   |
| obstruction gastric                                                     | 1 0.1)                              | 0                                     | 1 2                      |
|                                                                         | 2 0.1)                              |                                       | 0.0) 0.1)                |
| Rectalhaemorrhage                                                       | 1 0.1) 2 0.1)                       | 0 0                                   | 1 0.0) 2 0.1)            |
| Small intestinal obstruction                                            |                                     |                                       |                          |
| Small intestinal perforation stomatitis                                 | 1 0.1)                              | 0 0                                   | 1 0.0) 1                 |
|                                                                         | 1 0.1)                              |                                       | 0.0)                     |
| Subileus                                                                | 1                                   | 0                                     | 1 0.0)                   |
|                                                                         | 0.1)                                |                                       |                          |
| Generaldisordersandadministrationsite                                   | 56 3.2)                             | 4 1.2)                                | 60 （                     |
|                                                                         |                                     |                                       | 2.9)                     |
| conditions Disease progression                                          | 38                                  | 2 0.6)                                | 40 1.9) 10 0.5) 1 0.0)   |
| Fatigue Malaise                                                         | 2.2) 9 0.5) 0                       | 1 0.3) 1 0.3) 0                       | 6                        |
| Asthenia                                                                | 1 0.1) 6 0.3)                       | 0                                     |                          |
| Generalphysicalhealth deterioration Influenza iike illness              |                                     |                                       | 1 0.0) 0.3) 1            |
| Localisedoedema                                                         | 1                                   | 0                                     | 0.0)                     |
|                                                                         | 0.1)                                |                                       | 1 0.0)                   |
| Oedema peripheral                                                       | 1 0.1)                              | 0                                     |                          |
|                                                                         | 1                                   | 0                                     | 1                        |
|                                                                         | 0.1)                                |                                       | 0.0)                     |
| Injury,poisoning and procedural complications Infusion related reaction | 33 1. 9)                            | 1.2) 1.2)                             | 37 1.8) 36               |
|                                                                         | 32 1.8)                             |                                       | 1.7)                     |
| Radiation pneumonitis                                                   | 1 0.1)                              | 0                                     | 1 0.0)                   |

<div style=\"page-break-after: always\"></div>

| Musculoskeletaland connective tissue disorders                                                      | 10                                   | 0.6) 6                 | 13        | 0.6)                |
|-----------------------------------------------------------------------------------------------------|--------------------------------------|------------------------|-----------|---------------------|
| Muscular weakness                                                                                   | 1 0.1) 3 0.2)                        | 1 0.3)                 | 2         | 0.1)                |
| Myositis Rheumatoid arthritis                                                                       | 1 0.1)                               | 1 0.3) 1 0.3)          | 4 2       | 0.2) 0.1)           |
| Arthralgia Arthritis                                                                                | 3 0.2) 1 0.1)                        | 0 0                    | 3 1       | 0.1) 0.0)           |
| Musculoskeletalchestpain Pathologicalfracture                                                       | 1 0.1)                               | 0                      | 1         | 0.0)                |
|                                                                                                     | 1 0.1)                               | 0                      | 1         | 0.0)                |
| Renalandurinarydisorders                                                                            | （ 0.4)                               | 3 ( 0.9)               | 10        | 0.5)                |
| Nephritis                                                                                           | 0                                    | 1 0.3) 1 0.3)          | 1 1       | 0.0) 0.0)           |
| Tubulointerstitialnephritis Ureteric obstruction                                                    | 0 0                                  | 1 ( 0.3) 0             | 1         | 0.0)                |
| Acute kidney injury                                                                                 | 5 （ 0.3) 0.1)                        | 0                      | 5         | 0.2)                |
| Nephroticsyndrome Renal failure                                                                     | 1 1 0.1)                             | 0                      | 1 1       | 0.0) 0.0)           |
| Respiratory,thoracic and mediastinal                                                                | 22 1.3)                              | 3 0.9)                 | 25        | 1.2)                |
| disorders Interstitial lung disease                                                                 | 0 3 0.2)                             | 2 0.6) 0.3)            | 2 4       | 0.1) 0.2)           |
| Pneumonitis Acuterespiratoryfailure                                                                 | 3                                    | 0                      | 3         | 0.1)                |
| Chronicobstructivepulmonarydisease                                                                  | 0.2) 1 0.1)                          | 0                      | 1         | 0.0)                |
| Dyspnoea Dyspnoea exertional                                                                        | 5 0.3) 1 0.1)                        | 0 0                    | 5 1       | 0.2) 0.0)           |
| Epistaxis                                                                                           | 1 0.1)                               | 0                      | 1         | 0.0)                |
| Hypoxia                                                                                             | 2 0.1)                               | 0                      | 2         | 0.1)                |
| pleural effusion Respiratory distress                                                               | 3 0.2) 0.1)                          | 0 0                    | 3 2       | 0.1) 0.1)           |
| Respiratory failure                                                                                 | 2 3 0.2)                             | 0                      | 3         |                     |
|                                                                                                     |                                      |                        |           | 0.1)                |
| Cardiac disorders                                                                                   | 6                                    |                        |           | 0.4)                |
| Acute myocardialinfarction                                                                          | 0.3) 0 0.1)                          | 2 0.6) 1 0.3) 1 0.3)   | 8 1       | 0.0) 0.1)           |
| Myocardial infarction                                                                               | 1                                    |                        | 2         |                     |
| Atrial fibrillation Cardiactamponade                                                                | 1 0.1) 2                             | 0 0                    | 1 2       | 0.0) 0.1)           |
| Cardio-respiratoryarrest                                                                            | 0.1) 1 0.1)                          | 0                      | 1 1       | 0.0) 0.0)           |
| Pericardial effusion Endocrine disorders                                                            | 1 0.1) 4 0.2)                        | 0                      | 6         | 0.3) 0.0)           |
| Autoimmune thyroiditis Hyperthyroidism                                                              | 0 1 0.1) 2                           | 2 0.6) 1 0.3) 1 ( 0.3) | 1 2       | 0.1)                |
| Adrenal insufficiency                                                                               |                                      | 0                      |           |                     |
| Hypothyroidism                                                                                      | 0.1) 1 0.1)                          | 0                      | 2 1       | 0.1) 0.0)           |
| Hepatobiliarydisorders Autoimmunehepatitis                                                          | 6 0.3) 2 0 1                         | 2 0.6) 1 0.3) 1 0.3)   | 8 3 1     | 0.4) 0.1)           |
| Hepatotoxicity                                                                                      | 0.1) 0.1)                            | 0                      | 1         | 0.0) 0.0)           |
| Cholestasis Hepatitis                                                                               | 1 0.1)                               | 0                      | 1 1       | 0.0)                |
|                                                                                                     | 1                                    | 0 0                    | 1         | 0.0)                |
| Hepatocellular injury Hyperbilirubinaemia                                                           | 0.1) 1                               |                        |           | 0.0)                |
|                                                                                                     | 0.1) 15 0.9)                         | 2 0.6)                 | 17        | 0.8) 0.2)           |
| Infections andinfestations Sepsis Aspergillus infection                                             | 2 0.1) 1 0.1) 0.1)                   | 2 0.6) 0 0             | 4 1 1     | 0.0) 0.0)           |
| Cellulitis Gastroenteritis viral                                                                    | 1 1 0.1)                             | 0 0                    | 1         | 0.0)                |
| Lung infection Pelvic abscess                                                                       | 2 0.1) 1 0.1)                        | 0                      | 2 1       | 0.1) 0.0)           |
| Pneumonia                                                                                           | 0.2)                                 | 0                      | 3 1       |                     |
| pulmonarysepsis                                                                                     | 3 0.1)                               | 0                      |           | 0.1) 0.0)           |
| Pyelonephritis                                                                                      |                                      | 0                      | 1         |                     |
|                                                                                                     |                                      | 0                      |           | 0.0)                |
| streptococcalbacteraemia Urosepsis                                                                  | 1 1 0.1) 1 0.1) 1 0.1)               | 0                      | 1 1       | 0.0) 0.0) 0.3)      |
| Bloodandlymphaticsystemdisorders Anaemia Autoimmuneneutropenia                                      | 5 0.3) 2 0.1) 1                      | 0.3) 1 0.3) 0          | 6 3 1 1   | 0.1)                |
| Neutropenia                                                                                         |                                      | 0                      |           |                     |
| Thrombocytopenia                                                                                    | 0.1)                                 | 0                      | 1         | 0.0) 0.0) 0.0)      |
| Metabolism andnutrition disorders                                                                   | 1 0.1) 1 0.1) 7 0.4)                 | 1 0.3) 1 0.3)          | 8 1 1     | 0.4) 0.0) 0.0) 0.0) |
| Hypokalaemia Decreased appetite Dehydration                                                         | 0 1 0.1) 0.1) 0.1)                   | 0 0                    | 1 1       |                     |
| Diabetes mellitus                                                                                   | 1 1                                  | 0                      | 1         | 0.0) 0.0)           |
| Failure to thrive Hyperglycaemia                                                                    |                                      | 0 0                    | 1         | 0.0)                |
| Hyperkalaemia                                                                                       | 0.1) C                               | 0                      |           |                     |
| Hyponatraemia                                                                                       | 0.1) 1 1 10                          | 0                      | 1 1       |                     |
|                                                                                                     | 0.1)                                 |                        |           |                     |
|                                                                                                     | 0.1)                                 |                        |           |                     |
|                                                                                                     | 0.6)                                 | 0.3)                   | 11        | 0.0) 0.0) 0.5)      |
| Neoplasms benign，malignant and unspecified (incl cysts and polyps) Oesophagealsquamouscellcarcinoma | 0 0.1)                               | 0.3) 0 0               | 1 1 1 1   | 0.0) 0.0) 0.0) 0.0) |
| Hepatic cancer Leukaemia Malignant pleuraleffusion Metastases tomeninges Myelodysplastic syndrome   | 1 1 0.1) 1 0.1) 1 0.1) 2 0.1) 1 0.1) | 0 0 0 0 0              | 1 2 1 1 1 |                     |
| Tumour compression Tumour pain                                                                      |                                      |                        | 1         | 0.0) 0.1) 0.0)      |
| Prostate cancer                                                                                     |                                      | 0 0                    |           |                     |
| Toxic neuropathy                                                                                    | 1 1 1                                |                        |           |                     |
| Neoplasmprogression                                                                                 | 0.1) 0.1)                            |                        |           | 0.0) 0.0) 0.0) 0.5) |
|                                                                                                     | 0.1)                                 |                        | 11 1      |                     |
| Nervoussystemdisorders                                                                              | 10 0.6) 0 1 0.1)                     | 0.3) 0.3)              | 1         | 0.0)                |
| Ataxia                                                                                              | 1 0.1) 1                             | 0 0                    | 1         |                     |
| Brain injury                                                                                        |                                      | 0 0                    | 1 1       | 0.0) 0.0) 0.0) 0.0) |
| Brainoedema Cerebral infarction                                                                     | 0.1) 1 1                             |                        |           |                     |
| Cerebrovascular accident Guillain-Barre syndrome                                                    | 0.1) 0.1) 1                          |                        | 1 1       | 0.0)                |
| Peripheralmotor neuropathy                                                                          | 0.1)                                 | 0                      | 1 1       | 0.0)                |
| Posteriorreversibleencephalopathy                                                                   | 0.1)                                 | 0 0 0                  |           | 0.0) 0.0)           |
| syndrome Seizure                                                                                    | 1 1 0.1)                             |                        | 1         | 0.0)                |
|                                                                                                     | 0.1) 1 0.1)                          | 0 0                    |           | 0.0)                |
| Symcope                                                                                             | 1                                    |                        |           |                     |

<div style=\"page-break-after: always\"></div>

| skinandsubcutaneous tissuedisorders Pruritus   | 4 ( 0.2)   | 1 0.3)   | 5 0.2)   |
|------------------------------------------------|------------|----------|----------|
|                                                | 0          | 1 ( 0.3) | 0.0)     |
| Rashmaculo-papular                             | 1 0.1)     | 1 0.3)   | 0.1)     |
| Erythema                                       | 1 0.1)     | 0        | 121 0.0) |
| Pemphigoid                                     | 1 0.1)     | 0        | 1 0.0)   |
| Rash                                           | 1 0.1)     | 0        | 1 0.0)   |
| Immunesystemdisorders                          | 3 0.2)     |          | 3 （ 0.1) |
| Anaphylacticreaction                           | 1 0.1)     |          | 1 0.0)   |
| Sarcoidosis                                    | 1 0.1)     |          | 1 0.0)   |
| TypeIhypersensitivity                          | 1 0.1)     | 0        | 1 0.0)   |
| Psychiatric disorders                          | 2 ( 0.1)   | 0        | 2 0.1)   |
| Confusionalstate                               | 1 0.1)     | 0        | 11 0.0)  |
| Mentalstatuschanges                            | 1 0.1)     | 0        | 0.0)     |
| Vasculardisorders                              | 2 0.1)     | 0        | 2 0.1)   |
| Embolism                                       | 2 0.1)     | 0        | 2 0.1)   |

N:thenumberofsubjectswhohavereceivedatleastonedoseofavelumab.

ThedenominatortocalculatepercentagesisN. ApatientwithmultipleoccurrencesofanAEunderonetreatmentiscountedonlyonce. EventsarecodedinthelatestMedDRAversionavailableatthetimeofcut-off. SortedindescendingorderofthefrequencyofSocandpTsinB9991oo1Avelumab+Bscarm.

Cut-off dates:09Jun2016 on pooled safety population (EMR100070-001 and EMR100070-003 Part A)，210ct2019 on study B9991001.

## Immune related adverse events

Table 60. Summary of irAEs: Overall - SAS Study B9991001

|                                                | Avelumab+BSC (N=344)   | BSC (N=345)   |
|------------------------------------------------|------------------------|---------------|
|                                                | n (%)                  | n (%)         |
| Subjects with irAEs (maximum severity)         |                        |               |
| Any Grade                                      | 101 (29.4)             | 5 (1.4)       |
| Grade ≥ 3                                      | 24 (7.0)               | 1 (0.3)       |
| Subjects with irAEs leading to discontinuation | 19 (5.5)               | 0             |
| Subjects with serious irAEs                    | 16 (4.7)               | 1 (0.3)       |

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group. MedDRA v22.1 coding dictionary applied.

Cut-off date: 21OCT2019

Table 61. Overview of irAEs - Pooled safety set and avelumab treated patients in Study B9991001.

|                                                | PooledSafety Population (N=1738) n(%)   | B9991001Avelumab + BSC (N=344) n(%)   | overall (N=2082) n(%)   |
|------------------------------------------------|-----------------------------------------|---------------------------------------|-------------------------|
| Subjects withirAEs(maximum Severity) Any Grade | 247(14.2)                               | 101(29.4)                             | 348(16.7)               |
| Grade>=3                                       | 39 2.2)                                 | 24 7.0)                               | 63 3.0)                 |
| SubjectswithirAEsleadingto                     | 34 2.0)                                 | 19 5.5)                               | 53 2.5)                 |
| discontinuation Subjects with serious irAEs    | 43（ 2.5)                                | 16( 4.7)                              | 59 2.8)                 |

Eventsarecodedinthe latestMedDRAversionavailableatthetimeofcut-off. irAEs with anonset after the on-treatmentperiod are alsoconsidered intheavelumab+Bsc arm of studyB999ioo1, whereastreatment-emergentirAEsareshownforthePooledSafetypopulation. Cut-off dates:09Jun2016onpooledsafetypopulation（EMR100070-001andEMR100070-003 Part A)，210ct2019onstudy B9991001.

<div style=\"page-break-after: always\"></div>

Table 62. Summary of irAEs by Cluster, PT and Maximum CTCAE Grade - SAS Study B9991001

|                                                                          | Avelumab+BSC         | Avelumab+BSC     | BSC              | BSC                    |
|--------------------------------------------------------------------------|----------------------|------------------|------------------|------------------------|
| Cluster and Preferred Term                                               | All Grades           | (N=344) Grade ≥3 | All Grades n (%) | (N=345) Grade ≥3 n (%) |
|                                                                          | n (%)                | n (%)            |                  |                        |
| Subjects with events IMMUNE- RELATED ENDOCRINOPATHIES: THYROID DISORDERS | 101 (29.4) 42 (12.2) | 24 (7.0) 1 (0.3) | 5 (1.4) 2 (0.6)  | 1 (0.3) 0              |
| Hypothyroidism                                                           | 35 (10.2)            | 1 (0.3)          | 1 (0.3)          | 0                      |
| Hyperthyroidism                                                          | 16 (4.7)             | 0                | 1 (0.3)          | 0                      |
| Autoimmune thyroiditis                                                   | 2 (0.6)              | 0                | 0                |                        |
| Autoimmune hypothyroidism                                                | 1 (0.3)              | 0                | 0                | 0 0                    |
| Blood thyroid stimulating hormone increased                              | 1 (0.3)              | 0                | 0                | 0                      |
| Thyroiditis                                                              | 1 (0.3)              | 0                | 0                | 0                      |
| Thyroxine free decreased                                                 | 1 (0.3)              | 0                | 0                | 0                      |
| IMMUNE-RELATED RASH                                                      | 35 (10.2)            | 5 (1.5)          | 1 (0.3)          | 0                      |
| Rash                                                                     | 17 (4.9)             | 1 (0.3)          | 0                | 0                      |
| Rash maculo-papular                                                      | 8 (2.3)              | 1 (0.3)          | 0                | 0                      |
| Pruritus                                                                 | 7 (2.0)              | 0                | 1 (0.3)          | 0                      |
| Erythema                                                                 | 2 (0.6)              | 1 (0.3)          | 0                | 0                      |
| Purpura                                                                  | 2 (0.6)              | 0                | 0                | 0                      |
| Rash erythematous                                                        | 2 (0.6)              | 0                | 0                | 0                      |
| Drug eruption                                                            | 1 (0.3)              | 1 (0.3)          | 0                | 0                      |
| Erythema multiforme                                                      | 1 (0.3)              | 1 (0.3) 0        | 0 0              | 0 0                    |
| Lichen planus                                                            | 1 (0.3) 1 (0.3)      | 0                | 0                | 0                      |
| Rash popular Rash pruritic                                               | 1 (0.3)              | 0                | 0                | 0                      |
|                                                                          | 9 (2.6)              | 2 (0.6)          | 0                | 0                      |
| OTHER IMMUNE-RELATED ADVERSE EVENTS: OTHER Psoriasis                     | 3 (0.9)              | 0                | 0                | 0                      |
| Vitiligo                                                                 | 2 (0.6)              | 0                | 0                | 0                      |
| Arthritis                                                                | 1 (0.3)              | 0                | 0                | 0                      |
| Dermatitis psoriasiform                                                  | 1 (0.3)              | 0                | 0                | 0                      |
| Oligoarthritis                                                           | 1 (0.3)              | 1 (0.3)          | 0                | 0                      |
| Polyarthritis                                                            | 1 (0.3)              | 0                | 0                | 0                      |
| Rheumatoid arthritis                                                     | 1 (0.3)              | 1 (0.3)          | 0                | 0                      |
| IMMUNE-RELATED PNEUMONITIS                                               | 7 (2.0)              | 1 (0.3)          | 0                | 0                      |
| Pneumonitis                                                              | 5 (1.5)              | 1 (0.3)          | 0                | 0                      |
| IMMUNE-RELATED NEPHRITIS AND                                             | 2 (0.6)              | 0                |                  | 0                      |
| Interstitial lung disease                                                |                      |                  | 0                |                        |
| RENAL                                                                    | 6 (1.7)              | 1 (0.3)          | 0                | 0                      |
| DYSFUNCTION                                                              |                      |                  |                  |                        |
| Nephritis                                                                | 3 (0.9)              | 0                | 0                | 0                      |
| Renal failure                                                            | 3 (0.9)              | 1 (0.3)          | 0                | 0                      |
| Tubulointerstitial nephritis                                             | 1 (0.3)              | 0                | 0                | 0                      |
| IMMUNE-RELATED COLITIS                                                   | 5 (1.5)              | 3 (0.9)          | 0                | 0                      |
| Colitis                                                                  | 3 (0.9)              | 2 (0.6)          | 0                | 0                      |
| Diarrhoea                                                                | 2 (0.6)              | 0                | 0                | 0                      |
| Enteritis                                                                | 1 (0.3)              | 1 (0.3)          | 0                | 0                      |
| Proctitis                                                                | 1 (0.3)              | 0                | 0                | 0                      |
| IMMUNE-RELATED HEPATITIS                                                 | 5 (1.5)              | 5 (1.5)          | 0                | 0                      |
| Alanine aminotransferase increased                                       | 3 (0.9)              | 3 (0.9)          | 0                | 0                      |
| Aspartate aminotransferase increased                                     | 2 (0.6)              | 2 (0.6)          | 0                | 0                      |
| Autoimmune hepatitis                                                     | 1 (0.3)              | 1 (0.3)          | 0                | 0                      |
| Hepatotoxicity                                                           | 1 (0.3)              | 1 (0.3)          | 0                | 0                      |
| IMMUNE-RELATED ENDOCRINOPATHIES: ADRENAL INSUFFICIENCY                   | 3 (0.9)              | 0                | 0                | 0                      |
| Adrenal insufficiency                                                    | 3 (0.9)              | 0                | 0                | 0                      |

<div style=\"page-break-after: always\"></div>

Table 62. Summary of irAEs by Cluster, PT and Maximum CTCAE Grade - SAS Study B9991001

|                                                               | Avelumab+BSC (N=344)   | Avelumab+BSC (N=344)   | BSC (N=345)   | BSC (N=345)   |
|---------------------------------------------------------------|------------------------|------------------------|---------------|---------------|
|                                                               | All Grades             | Grade ≥3               | All Grades    | Grade ≥3      |
| Cluster and Preferred Term                                    | n (%)                  | n (%)                  | n (%)         | n (%)         |
| IMMUNE- RELATED ENDOCRINOPATHIES: TYPE 1 DIABETES MELLITUS    | 3 (0.9)                | 3 (0.9)                | 1 (0.3)       | 1 (0.3)       |
| Hyperglycaemia                                                | 3 (0.9)                | 3 (0.9)                | 0             | 0             |
| Diabetes mellitus                                             | 0                      | 0                      | 1 (0.3)       | 1 (0.3)       |
| IMMUNE-RELATED PANCREATITIS                                   | 2 (0.6)                | 1 (0.3)                | 0             | 0             |
| Autoimmune pancreatitis                                       | 1 (0.3)                | 1 (0.3)                | 0             | 0             |
| Pancreatitis                                                  | 1 (0.3)                | 0                      | 0             | 0             |
| OTHER IMMUNE-RELATED ADVERSE EVENTS: MYOSITIS                 | 2 (0.6)                | 2 (0.6)                | 0             | 0             |
| Myositis                                                      | 2 (0.6)                | 2 (0.6)                | 0             | 0             |
| OTHER IMMUNE-RELATED ADVERSE EVENTS: GUILLAIN- BARRE SYNDROME | 1 (0.3)                | 1 (0.3)                | 0             | 0             |
| Miller Fisher syndrome                                        | 1 (0.3)                | 1 (0.3)                | 0             | 0             |
| OTHER IMMUNE-RELATED ADVERSE EVENTS: UVEITIS                  | 1 (0.3)                | 0                      | 1 (0.3)       | 0             |
| Uveitis                                                       | 1 (0.3)                | 0                      | 1 (0.3)       | 0             |

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group. Subjects reporting more than one adverse event (AE) within a preferred term are counted only once in that preferred term. Subjects reporting multiple preferred terms within the same cluster are counted only once within each cluster.

For subjects reporting more than one AE within a cluster or preferred term, the AE with maximum grade are included in the table.

Sorted in descending order of the frequency of clusters and PTs within cluster for all grades in the Avelumab+BSC arm. MedDRA v22.1 coding dictionary and CTCAE version 4.03 applied.

Cut-off date: 21OCT2019

<div style=\"page-break-after: always\"></div>

Table 63. Summary of irAE by irAE category - Pooled safety set and avelumab treated patients in Study B9991001.

L

|                                              | Pooled Safety Population (N=1738)   | Pooled Safety Population (N=1738)   | Pooled Safety Population (N=1738)   | B9991001Avelumab+BSC (N=344)   | B9991001Avelumab+BSC (N=344)   | overall (N=2082)   | overall (N=2082)   |
|----------------------------------------------|-------------------------------------|-------------------------------------|-------------------------------------|--------------------------------|--------------------------------|--------------------|--------------------|
| irAE category Preferred Term                 | All grades n(%)                     | Grade >= 3 n (8)                    | All grades n (%)                    | Grade >=3 n (%)                | n(%)                           | All grades         | Grade >=3 n (%)    |
| Any irAEs                                    | 247 14.2)                           | 39 2.2)                             |                                     | 101 (29.4)                     | 24 （ 7.0)                      | 348 16.7)          | 63 3.0)            |
| Immune relatedendocrinopathies:              | 98                                  | 5.6)                                | 3 0.2)                              | 42 12.2)                       | 1 0.3)                         | 140 6.7)           | 4 0.2)             |
| Thyroid disorders                            |                                     |                                     |                                     |                                |                                |                    |                    |
| Hypothyroidism                               | 88                                  | 3 ( 0.2)                            | 35 10.2)                            | 1                              | 0.3) 123                       | 5.9)               | 4 0.2)             |
| Hyperthyroidism                              | 7                                   | 5.1) 0.4)                           | 0 16                                | 4.7)                           |                                | 23 1.1)            | 0                  |
| Autoimmune thyroiditis                       | 2                                   | 0.1)                                | 0 2                                 | 0.6)                           | 0 0                            | 0.2)               | 0                  |
| Autoimmunehypothyroidism                     | 2                                   | 0.1)                                | 0 1                                 | 0.3)                           | 4 3                            | 0.1)               | 0                  |
| Blood thyroid stimulating                    |                                     |                                     | 0                                   | 0                              |                                | 0.0)               |                    |
|                                              | 0                                   |                                     | 1                                   | 0                              | 1                              |                    | 0                  |
| hormone increased                            |                                     | 0.1)                                |                                     | 0.3)                           |                                |                    |                    |
| Thyroiditis                                  | 2                                   | 0                                   |                                     | 3 0                            |                                | 0.1)               | 0                  |
| Thyroxine free decreased                     | 0                                   |                                     | 0                                   | 0                              |                                | 0.0)               | 0                  |
| Immune related rash                          | 90                                  | 5.2) 1                              | 0.1) 35 10.2)                       | 5 1.5)                         | 125 57                         | 6.0)               | 6                  |
| Rash                                         | 40                                  | 2.3)                                | 17                                  | 1                              | 0.3)                           | 2.7)               | 0.3) 2 0.1)        |
| Rashmaculo-papular                           | 20                                  | 1.2)                                | 0.1) 0 8                            | 4.9) 2.3) 1                    | 0.3)                           | 28 1.3)            | 1 0.0)             |
| Pruritus                                     | 26                                  | 1.5)                                | 0 7                                 | 2.0) 0.6)                      | 0                              | 33 1.6)            | 0                  |
| Erythema                                     | 5                                   | 0.3) 0                              | 2                                   | 0                              | 0.3)                           | 7 0.3)             | 0.0)               |
| Purpura                                      | 0                                   |                                     | 0 2                                 | 0.6)                           |                                | 2 0.1)             | 0                  |
| Rash erythematous                            | 4                                   | 0.2)                                | 0 2                                 | 0.6)                           | 0                              | 6 0.3)             | 0                  |
| Drug eruption                                | 0                                   |                                     | 0 1                                 | 0.3)                           | 0.3)                           | 1 0.0)             | 0.0)               |
| Erythema multiforme                          | 1 (                                 | 0.1)                                | 0 1                                 | 0.3)                           | 0.3)                           | 2 0.1)             | 0.0)               |
| Lichen planus                                | 0                                   | 0                                   | 1                                   | 0.3)                           | 0                              | 1 0.0)             | 0 0                |
| Rash papular                                 | 2                                   | 0.1) 0                              | 1 1                                 | 0.3) 0.3)                      | 0                              | 3 0.1) 0.4)        | 0                  |
| Rash pruritic                                | 7                                   | 0.4)                                | 0                                   |                                | 0                              | 8                  |                    |
| Dermatitis exfoliative                       | 1                                   | 0.1)                                | 0 0                                 |                                | 0                              | 1 0.0)             | 0                  |
| Pemphigoid                                   | 1                                   | 0.1)                                | 0 0                                 |                                | 0                              | 1 0.0)             | 0                  |
| Pruritus generalised                         | 1                                   |                                     | 0 0                                 |                                | 0                              | 1 0.0)             | 0                  |
| Rash generalised                             | 5                                   | 0.1) 0.3)                           | 0 0                                 |                                | 0                              | 5 0.2)             | 0                  |
| Rash macular                                 | 3                                   | 0.2)                                | 0 0                                 |                                | 0                              | 3 0.1)             | 0                  |
| Other immune related adverse                 | 8                                   | 0.5)                                | 0.1) 6                              | 2.6)                           | 0.6)                           | 17 0.8)            | 4 0.2)             |
| events:other                                 |                                     | 2                                   |                                     | 2                              |                                |                    |                    |
| Psoriasis                                    | 5                                   | 0.3)                                | 0.1) 3                              |                                | 0                              | 8 0.4)             | 1 0.0)             |
| vitiligo                                     | 0                                   |                                     | 1 2                                 | 0.9) 0.6)                      | 0                              | 2 0.1)             | 0                  |
| Arthritis                                    |                                     |                                     | 0 0 1                               | 0.3)                           | 0                              | 0.0)               | 0                  |
|                                              |                                     | 0                                   |                                     | 0.3)                           | 1 1                            |                    |                    |
| Dermatitis psoriasiform                      | 0                                   |                                     | 0 1                                 |                                | 0                              | 0.0)               | 0                  |
| oligoarthritis                               | 0                                   |                                     | 0 1                                 | 0.3)                           | 0.3)                           | 1 0.0)             | 0.0)               |
| Polyarthritis Rheumatoid arthritis           | 0                                   | 0.1)                                | 0 1 0 1                             | 0.3) 0.3)                      | 0 0.3)                         | 1 0.0) 3 0.1)      | 0 0.0)             |
| Systemic inflammatory response               |                                     | 0.1)                                | 1 0.1)                              | 0                              | 0                              | 1 0.0)             | 0.0)               |
| syndrome                                     |                                     |                                     |                                     |                                |                                |                    |                    |
| Immune relatedpneumonitis                    | 21                                  | 2                                   | 0.4)                                | 7 2.0)                         | 0.3)                           | 28 . 3)            | 8 0.4)             |
| Pneumonitis                                  | 21                                  | 1.2) 7                              | 0.4) 5                              | 1.5)                           | 0.3)                           | 26 1.2)            | 8 0.4)             |
| Interstitial lung disease                    | 0                                   |                                     | 0 2                                 | 0.6)                           | 0                              | 2 0.1)             | 0                  |
| Immune relatednephritisand renal dysfunction | (                                   | 0.1)                                | 0 6                                 | 1. 7)                          | 0.3)                           | 7 0.3)             | 0.0)               |
| Nephritis                                    | 0 0                                 |                                     | 0 3                                 | 0.9) 0                         | 3                              | 0.1)               | 0                  |
| Renal failure Tubulointerstitial nephritis   | 1                                   | 0 0.1)                              | 3 0 1                               | 0.9) 0.3)                      | 0.3) 0                         | 3 0.1) 2 0.1)      | 0.0) 0             |

<div style=\"page-break-after: always\"></div>

| Immune related colitis                                                          | 26     | 1.5)      | 7      | 0.4)      | 5     | 1.5)      | 3 0.9)        | 31    | 1.5)      | 10   | 0.5)        |
|---------------------------------------------------------------------------------|--------|-----------|--------|-----------|-------|-----------|---------------|-------|-----------|------|-------------|
| Colitis                                                                         | 5      | 0.3)      | 4      | 0.2)      | 3     | 0.9)      | 2 0.6)        | 8     | 0.4)      | 6    | ( 0.3)      |
| Diarrhoea                                                                       | 21 (   | 1.2)      | 4      | 0.2)      | 2     | 0.6)      | 0             | 23    | 1.1)      | 4    | 0.2)        |
| Enteritis                                                                       | 0      |           | 0      |           | 1     | 0.3)      | 0.3)          | 1     | 0.0)      | 1    | 0.0)        |
| Proctitis                                                                       | 0      |           | 0      |           | 1     | 0.3)      | 0             | 1     | 0.0)      |      | 0           |
| Autoimmune colitis                                                              | 1      | 0.1)      | 0      |           | 0     |           | 0             | 1     | 0.0)      |      | 0           |
| Enterocolitis                                                                   | 1      | 0.1)      | 0      |           | 0     |           | 0             | 1     | 0.0)      |      | 0           |
| Immune related hepatitis Alanine aminotransferase                               | 16 9 ( | 0.9) 0.5) | 13 4 ( | 0.7) 0.2) | 5 3   | 1.5) 0.9) | 5 1.5) 3 0.9) | 21 12 | 1.0) 0.6) | 18 7 | 0.9) 0.3)   |
| increased Aspartate aminotransferase                                            | 10     | 0.6)      | 3      | 0.2)      | 2     | 0.6)      | 2 0.6)        | 12    | 0.6)      | 5    | 0.2)        |
| increased                                                                       | 5 （    | 0.3)      | 4      | 0.2)      | 1     | 0.3)      | 0.3)          | 6     | 0.3)      | 5    | 0.2)        |
| Autoimmune hepatitis Hepatotoxicity                                             | 0      |           | 0      |           | 1     | 0.3)      | 0.3)          | 1     | 0.0)      | 1    | 0.0)        |
| Acutehepatic failure                                                            | 1      | 0.1)      | 1      | 0.1)      | 0     |           | 0             | 1     | 0.0)      | 1    | 0.0)        |
| Hepatic failure                                                                 | 1      | 0.1)      | 1      | 0.1)      | 0     |           | 0             | 1     | 0.0)      | 1    | 0.0)        |
| Hepatitis                                                                       | 1      | 0.1)      | 1      | 0.1)      | 0     |           | 0             | 1     | 0.0)      | 1    | 0.0)        |
| Transaminases increased                                                         | 2      | 0.1)      | 2      | 0.1)      | 0     |           | 0             | 2     | 0.1)      | 2    | 0.1)        |
| Immunerelatedendocrinopathies:                                                  | 8      | 0.5)      | 1      | 0.1)      | 3     | 0.9)      | 0             | 11    | 0.5)      | 1    | 0.0)        |
| Adrenal insufficiency Adrenal insufficiency                                     | 8      | 0.5)      | 1      | 0.1)      | 3 (   | 0.9)      | 0             | 11    |           |      | 0.0)        |
| Adrenocortical insufficiency                                                    | 1      | 0.1)      | 0      |           | 0     |           | 0             | 1     | 0.5) 0.0) | 1    | 0           |
| acute Immune relatedendocrinopathies:                                           | 2      | 0.1)      | 2      | 0.1)      | 3     | 0.9)      | 3 0.9)        | 5     | 0.2)      |      | 0.2)        |
| Type 1 Diabetes Mellitus Hyperglycaemia Diabetes mellitus                       |        | 0.1) 0.1) |        | 0.1)      |       | 0.9)      | 0.9) 0        |       | 0.2) 0.0) |      | 0.2) 0.0)   |
| Immune related pancreatitis                                                     | 0      |           | 0      | 0.1)      | 0     | 0.6)      | 0.3)          | 2     | 0.1)      |      | 0.0)        |
| Autoimmune pancreatitis                                                         | 0 0    |           |        |           | 2 ? 1 |           | 0.3)          |       |           |      |             |
|                                                                                 |        |           | 0 0    |           | 1     | 0.3) 0.3) | 0             | 1 1   | 0.0) 0.0) |      | 0.0) 0      |
| Pancreatitis otherimmunerelatedadverse                                          | 6      | 0.5)      | 5      | 0.3)      | 2     | 0.6)      | 2 0.6)        | 11    | 0.5)      | 7 (  | 0.3)        |
| events:Myositis Myositis                                                        | 5      | 0.3)      | 2      | 0.1)      | 2     | 0.6)      | 2 0.6)        | 7     | 0.3)      | 4 3  | 0.2)        |
| Bloodcreatine phosphokinase increased                                           | 5      | 0.3)      | 3      | 0.2)      | 0     |           | 0             | 5     | 0.2)      |      | 0.1)        |
| otherimmunerelatedadverse events:Guillain-Barre Syndrome Miller Fisher syndrome | 1 0    | 0.1)      | 1      | 0.1)      | 1 (   | 0.3) 0.3) | 1 0.3) 1 0.3) | 2 1   | 0.1)      | 2    | 0.1)        |
| Guillain-Barre syndrome                                                         | 1      | 0.1)      | 0 1    | 0.1)      | 0     |           | 0             |       | 0.0)      | 1    | 0.0) ( 0.0) |
|                                                                                 | 1      | 0.1)      |        | 0         | 1 (   | 0.3)      | 0             | 1 2   | 0.0) 0.1) |      | 0           |
| other immunerelatedadverse events:Uveitis uveitis                               | 1 （    | 0.1)      |        | 0         | 1 (   | 0.3)      | 0             | 2     | 0.1)      |      | 0           |
| Immune related endocrinopathies: Hypogonadism                                   | 0      |           |        | 0         | 0     |           | 0             | 0     |           |      | 0           |
| Immune related endocrinopathies: pituitary dysfunction                          | 1      | 0.1)      |        | 0         | 0     |           | 0             | 1     | 0.0)      |      | 0           |
|                                                                                 | 1      | 0.1)      |        |           |       |           |               | 1     | 0.0)      |      |             |
| Hypopituitarism                                                                 |        |           | 0      |           | 0     |           | 0             |       |           |      | 0           |
| Immune related myocarditis other immune relatedadverse                          | 0 0    |           | 0      |           | 0 0   |           | 0 0           | 0 0   |           |      | 0 0         |
| events:Encephalitis                                                             | D      |           | 0      | 0         | 0     |           | 0             | 0     |           |      | 0           |
| otherimmunerelatedadverse eventS:GVHD                                           |        |           |        |           |       |           |               |       |           |      | 0           |
| otherimmunerelatedadverse events:Myasthenic syndrome                            | 0      |           |        | 0         | 0     |           |               | 0     |           |      |             |

irAEs=Immune-relatedadverseevents.N:thenumberof subjectswhohavereceivedatleastonedoseof avelumab. ThedenominatortocalculatepercentagesisN.EventsarecodedinthelatestMedDRAversionavailableatthetime ofcut-off.irAEswithanonsetafter theon-treatmentperiodarealsoconsideredintheavelumab+Bscarmof study B999iool，whereastreatment-emergent irAEsare showm for the Pooled Safetypopulation.

Grading categories determined using NCI-CTcAE version 4.0in pooled safetypopuiation andversion 4.03 inB9991o01. Sortedindescending order of thefrequencyof irAEcategoryandpTs within irAE categoryfor allgradesinthe B9991001Avelumab+BSC arm.

ApatientwithmultipleoccurrencesofanAEunderonetreatmentiscountedonlyonce.

Cut-off dates: 09Jun2016 on pooled safety population (EMR100070-001 and EMR100070-003 Part A)， 210ct2019 on study B9991001.

<div style=\"page-break-after: always\"></div>

Table 64. Serious irAE by irAE category - Pooled safety set and avelumab treated patients in Study B9991001

| irAE category Preferred Term                                                                                           | pooled safety Population (N=1738) n (%)   | B9991001Avelumab +BSC (N=344) n (3)   | overall (N=2082) n(%)            | overall (N=2082) n(%)            | overall (N=2082) n(%)            | overall (N=2082) n(%)            | overall (N=2082) n(%)            |
|------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|---------------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|----------------------------------|
| Any irAEs                                                                                                              | 43 2.5)                                   | 16 4.7)                               | 59 2.8)                          | 59 2.8)                          | 59 2.8)                          | 59 2.8)                          | 59 2.8)                          |
| Immune related colitis Colitis Enteritis Diarrhoea                                                                     | 8 0.5) 4 0.2) 0 4 0.2)                    | 3 0.9) 2 0.6) 1 0.3) 0 E              | 11 0.5) 6 0.3) 1 0.0) 4 0.2)     | 11 0.5) 6 0.3) 1 0.0) 4 0.2)     | 11 0.5) 6 0.3) 1 0.0) 4 0.2)     | 11 0.5) 6 0.3) 1 0.0) 4 0.2)     | 11 0.5) 6 0.3) 1 0.0) 4 0.2)     |
| Immunerelatednephritisand                                                                                              |                                           | 0.9)                                  | 4 0.2)                           | 4 0.2)                           | 4 0.2)                           | 4 0.2)                           | 4 0.2)                           |
| renal dysfunction Nephritis Renal failure                                                                              | 1 0.1)                                    | 0.3)                                  | 1 0.0) 0.0) 2 0.1)               | 1 0.0) 0.0) 2 0.1)               | 1 0.0) 0.0) 2 0.1)               | 1 0.0) 0.0) 2 0.1)               | 1 0.0) 0.0) 2 0.1)               |
| Tubulointerstitial nephritis                                                                                           | 0 0 0.1)                                  | 0.3) 1 0.3)                           |                                  |                                  |                                  |                                  |                                  |
| Immunerelatedendocrinopathies: Thyroiddisorders                                                                        | 6 0.3)                                    | 2 0.6) 0.3)                           | 8 0.4)                           | 8 0.4)                           | 8 0.4)                           | 8 0.4)                           | 8 0.4)                           |
| Hyperthyroidism Hypothyroidism                                                                                         | 4 0.2) 1)                                 | 0.3) 0                                | 5 2 0.2) 0.1) 1 0.0)             | 5 2 0.2) 0.1) 1 0.0)             | 5 2 0.2) 0.1) 1 0.0)             | 5 2 0.2) 0.1) 1 0.0)             | 5 2 0.2) 0.1) 1 0.0)             |
| Thyroiditis                                                                                                            | 1 0.1)                                    |                                       | 6                                | 6                                | 6                                | 6                                | 6                                |
| Immunerelatedhepatitis Autoimmunehepatitis Hepatotoxicity Acutehepaticfailure                                          | 7 0.4) 3 0.2) 0                           | 2 0.6) 0.3) 0.3) 0 0                  | 0.4) 4 0.2) 1 0.0) 1 0.0) 1 0.0) | 0.4) 4 0.2) 1 0.0) 1 0.0) 1 0.0) | 0.4) 4 0.2) 1 0.0) 1 0.0) 1 0.0) | 0.4) 4 0.2) 1 0.0) 1 0.0) 1 0.0) | 0.4) 4 0.2) 1 0.0) 1 0.0) 1 0.0) |
| Aspartateaminotransferase increased Hepatic failure Hepatitis Transaminases increased                                  | 1 0.1) 1 0.1) 1 0.1) 1 0.1) 2 0.1)        | 0 0 0 2 0.6) 1 0.3) 1 0.3) 3)         | 1 0.0) 1 0.0) 2 0.1)             | 1 0.0) 1 0.0) 2 0.1)             | 1 0.0) 1 0.0) 2 0.1)             | 1 0.0) 1 0.0) 2 0.1)             | 1 0.0) 1 0.0) 2 0.1)             |
| Immunerelated pneumonitis Interstitial lung disease                                                                    | 10 0.6) 0                                 |                                       | 12 0.6)                          | 12 0.6)                          | 12 0.6)                          | 12 0.6)                          | 12 0.6)                          |
|                                                                                                                        |                                           |                                       | 1 0.0)                           | 1 0.0)                           | 1 0.0)                           | 1 0.0)                           | 1 0.0)                           |
| Pneumonitis                                                                                                            | 10                                        |                                       | 11 0.5)                          | 11 0.5)                          | 11 0.5)                          | 11 0.5)                          | 11 0.5)                          |
|                                                                                                                        | 0.6)                                      |                                       |                                  |                                  |                                  |                                  |                                  |
|                                                                                                                        | 0                                         |                                       | 0.0) 0.0)                        | 0.0) 0.0)                        | 0.0) 0.0)                        | 0.0) 0.0)                        | 0.0) 0.0)                        |
| Immunerelatedpancreatitis Autoimmunepancreatitis Immune relatedrash Drug eruption                                      | 1 0.1) 0 1 0.1)                           | 0 0.3) 1 0.3) 1 0.3) 0                | 2 0.1) 0.0) 1 0.0) 2 0.1)        | 2 0.1) 0.0) 1 0.0) 2 0.1)        | 2 0.1) 0.0) 1 0.0) 2 0.1)        | 2 0.1) 0.0) 1 0.0) 2 0.1)        | 2 0.1) 0.0) 1 0.0) 2 0.1)        |
| Rash generalised otherimmunerelatedadverse events:Guillain-BarreSyndrome MillerFisher syndrome Guillain-Barre syndrome | 0.1) 0 0.1)                               | 0.3) 1 0.3)                           | 0.0) 1 0.0)                      | 0.0) 1 0.0)                      | 0.0) 1 0.0)                      | 0.0) 1 0.0)                      | 0.0) 1 0.0)                      |
|                                                                                                                        | 4                                         | 0                                     | 5 0.2)                           | 5 0.2)                           | 5 0.2)                           | 5 0.2)                           | 5 0.2)                           |
| Myositis                                                                                                               | 0.2) 2                                    | 0.3)                                  | 0.1)                             | 0.1)                             | 0.1)                             | 0.1)                             | 0.1)                             |
| otherimmunerelatedadverse events:Myositis Blood creatine phosphokinase                                                 | 0.1)                                      | 1 0.3) 0                              | 2 0.1)                           | 2 0.1)                           | 2 0.1)                           | 2 0.1)                           | 2 0.1)                           |
| increased                                                                                                              | 2 0.1)                                    |                                       |                                  |                                  |                                  |                                  |                                  |
| Immunerelatedendocrinopathies: Adrenal insufficiency Adrenocortical insufficiency                                      | 0.2) 0.1)                                 | 0 0 0                                 | 0.1) 2 0.1) 1 0.0)               | 0.1) 2 0.1) 1 0.0)               | 0.1) 2 0.1) 1 0.0)               | 0.1) 2 0.1) 1 0.0)               | 0.1) 2 0.1) 1 0.0)               |
| Adrenal insufficiency acute                                                                                            | 1 0.1)                                    |                                       |                                  |                                  |                                  |                                  |                                  |
| Immune related endocrinopathies:                                                                                       |                                           | 0 0                                   |                                  |                                  |                                  |                                  |                                  |
| Hypogonadism pituitary dysfunction                                                                                     | 0                                         | 0                                     |                                  |                                  |                                  |                                  |                                  |
| Immunerelatedendocrinopathies: Immunerelated endocrinopathies:                                                         | 2 0.1)                                    | 0                                     | 2 0.1)                           | 2 0.1)                           | 2 0.1)                           | 2 0.1)                           | 2 0.1)                           |
| Type 1Diabetes Mellitus Diabetes mellitus Hyperglycaemia                                                               | 1 0.1) 1 0.1)                             | 0 0                                   | 0.0) 1 0.0)                      | 0.0) 1 0.0)                      | 0.0) 1 0.0)                      | 0.0) 1 0.0)                      | 0.0) 1 0.0)                      |
|                                                                                                                        |                                           |                                       | 0                                | 0                                | 0                                | 0                                | 0                                |
| Immunerelatedmyocarditis                                                                                               | 0                                         | 0                                     |                                  |                                  |                                  |                                  |                                  |
| otherimmunerelatedadverse events:Encephalitis                                                                          | 0                                         | 0                                     | 0                                | 0                                | 0                                | 0                                | 0                                |
| otherimmunerelatedadverse eventS:GVHD                                                                                  | 0                                         | 0                                     | 0                                | 0                                | 0                                | 0                                | 0                                |
| events:Myasthenic symdrome                                                                                             | 0                                         | 0                                     | 0                                | 0                                | 0                                | 0                                | 0                                |
| otherimmunerelatedadverse                                                                                              |                                           | 0                                     |                                  |                                  |                                  |                                  |                                  |
| Psoriasis syndrome                                                                                                     | 0.1) 0.1)                                 | 0 0                                   | 0.0) 0.0)                        | 0.0) 0.0)                        | 0.0) 0.0)                        | 0.0) 0.0)                        | 0.0) 0.0)                        |
| Systemicinflammatoryresponse                                                                                           |                                           |                                       |                                  |                                  |                                  |                                  |                                  |
| otherimmunerelatedadverse                                                                                              |                                           | 0                                     |                                  |                                  |                                  |                                  |                                  |
|                                                                                                                        | 0                                         |                                       | 0                                | 0                                | 0                                | 0                                | 0                                |
| events:uveitis                                                                                                         |                                           |                                       |                                  |                                  |                                  |                                  |                                  |
| events: other                                                                                                          |                                           |                                       |                                  |                                  |                                  |                                  |                                  |
|                                                                                                                        | 2                                         |                                       |                                  |                                  |                                  |                                  |                                  |
|                                                                                                                        | 0.1)                                      |                                       |                                  |                                  |                                  |                                  |                                  |
|                                                                                                                        |                                           |                                       | 2                                | 2                                | 2                                | 2                                | 2                                |
|                                                                                                                        |                                           |                                       | 0.1)                             | 0.1)                             | 0.1)                             | 0.1)                             | 0.1)                             |
|                                                                                                                        | otherimmunerelatedadverse                 |                                       |                                  |                                  |                                  |                                  |                                  |

irAEs=Immune-relatedadverseevents.

ThedenominatortocalculatepercentagesisN.

N:thenumberofsubjectswhohavereceivedatleastonedoseofavelumab.

irAEswithanonsetaftertheon-treatmentperiodarealsoconsideredintheavelumab+BscarmofstudyB999ioo1, whereastreatment-emergentirAEsareshownforthePooledSafetypopulation.

EventsarecodedinthelatestMedDRAversionavailableatthetimeofcut-off.Sortedindescendingorderofthe frequency of irAEcategoryandpTswithinirAEcategoryintheB9991oo1Avelumab+Bscarm.

ApatientwithmultipleoccurrencesofanAEunderonetreatmentiscountedonlyonce.

cut-off dates:09Jun2016 onpooled safety population (EMR100070-001 and EMR100070-003 Part A)，210ct2019 on study B9991001.

<div style=\"page-break-after: always\"></div>

In the BSC arm of Study B9991001 only one subject presented with a serious irAE event, diabetes mellitus.

Table 65. irAE leading to permanent treatment discontinuation by irAE category - Pooled safety set and avelumab treated patients in Study B9991001

| irAE category                                         | Pooled safety Population (N=1738)   | B9991001Avelumab + BSC (N=344)   | overall (N=2082)   |
|-------------------------------------------------------|-------------------------------------|----------------------------------|--------------------|
| Preferred Term                                        | n (8)                               | n (%)                            | n(%)               |
| Any irAEs                                             | 34 2.0)                             | 19 5.5)                          | 53 2.5)            |
| Immune related hepatitis                              | 9 0.5)                              | 4 1.2)                           | 13 0.6)            |
| Alanine aminotransferase                              | 3 0.2)                              | 2 0.6)                           | 5 0.2)             |
| increased Aspartate aminotransferase                  | 1 （ 0.1)                            | 1 0.3)                           | 2 0.1)             |
| increased Autoimmunehepatitis                         | 2 0.1)                              | 0.3) 0.3)                        | 3 0.1)             |
| Hepatotoxicity Hepatitis                              | 0                                   |                                  | 1 0.0)             |
|                                                       | 0.1)                                | 0                                | 1 0.0)             |
| Transaminases increased                               | 2 0.1)                              | 0                                | 2 0.1)             |
| Immunerelatednephritisand                             | 0                                   | 0.9)                             | E 0.1)             |
| renal dysfunction                                     | 0                                   | D 3                              | 1 0.0)             |
| Nephritis Renal failure                               |                                     | 0. 3)                            | 1 0.0)             |
| Immunerelatedpneumonitis Pneumonitis                  | 0 0                                 | 0.3)                             |                    |
| Tubulointerstitial nephritis                          | 0.2)                                | 3 0.9)                           | 1 0.0) 6 0.3)      |
| Interstitial lung disease                             | 3                                   |                                  | 2 0.1)             |
|                                                       | 0 0.2)                              | 2 0.6) 1 0.3)                    | 4 0.2)             |
| Immune related colitis                                | 8 0.5)                              | 2 0.6)                           | 10 0.5)            |
| Colitis                                               | 3 0.2) 5                            | 2 0.6)                           | 5 0.2) 5 0.2)      |
| Diarrhoea                                             | 0.3)                                | 0                                | 1                  |
| Enterocolitis                                         | 1 0.1)                              | 0                                | 0.0)               |
| Immune related endocrinopathies:                      | 0.1)                                | 2 （ 0.6)                         | 3 0.1)             |
| Thyroid disorders Autoimmune thyroiditis              | 0 0                                 | 0.3) 0.3) 0                      | 1 0.0) 1 0.0) 1    |
| Hyperthyroidism Hypothyroidism                        | 0                                   | 0.6)                             | 0.0)               |
|                                                       | 0.1)                                |                                  | 2 0.1)             |
| Pancreatitis                                          | 0                                   | 0.3)                             | 1 0.0)             |
| Immune relatedpancreatitis Autoimmunepancreatitis     | 0                                   | 0.3)                             | 1 0.0)             |
|                                                       | 0                                   | 0.                               | 1 0.0)             |
| Immune related rash Pruritus                          | 3 0.2)                              | D . 3) 3)                        | 4 0.2)             |
| Rash maculo-papular                                   | 1 0.1) 1 0.1)                       | 0.3)                             | 2 0.1)             |
| Pemphigoid                                            |                                     | 0                                | 1 0.0)             |
|                                                       |                                     | 0                                | 1 0.0)             |
| Rash                                                  | 5 0.3)                              |                                  |                    |
|                                                       | 1 0.1)                              |                                  |                    |
| other immunerelatedadverse events:Myositis Myositis   |                                     | 1 0.3)                           | 6 0.3) 0.2)        |
| Blood creatine phosphokinase increased                | 3 0.2) 2 0.1)                       | 0.3) 0                           | 4 2 0.1)           |
| otherimmunerelatedadverse                             | 0.1)                                |                                  | 2 0.1)             |
| events:other                                          | 0.1)                                | 1 0.3)                           | 2 0.1)             |
| Rheumatoidarthritis                                   |                                     | 0.3)                             |                    |
| Immune relatedendocrinopathies: Adrenal insufficiency | 1 0.1)                              | 0                                | 1 0.0)             |

<div style=\"page-break-after: always\"></div>

| Adrenal insufficiency                                      |    |      |     |           |
|------------------------------------------------------------|----|------|-----|-----------|
| Immunerelatedendocrinopathies: Hypogonadism                | 0  |      | 0   | 0         |
| Immunerelatedendocrinopathies: pituitary dysfunction       |    |      | 0   | 0         |
| Immune related endocrinopathies: Type1 Diabetes Mellitus   | 2  | 0.1) | 0   | 2 0.1)    |
| Diabetes mellitus Hyperglycaemia                           |    | 0.1) | 0 0 | 0.0) 0.0) |
| Immune related myocarditis                                 | 0  |      | 0   | 0         |
| otherimmunerelatedadverse events:Encephalitis              | 0  |      | 0   | 0         |
| otherimmunerelatedadverse eventS:GVHD                      | 0  |      | 0   | 0         |
| other immunerelatedadverse events: Guillain-Barre Symdrome |    |      | 0   | 0.0)      |
| Guillain-Barre syndrome                                    |    | 0.1) | 0   | 0.0)      |
| other immune relatedadverse events:Myasthenic syndrome     | 0  |      | 0   | 0         |
| Other immunerelatedadverse events:Uveitis                  | 0  |      | 0   |           |

irAEs=Immune-relatedadverseevents. N:thenumberofsubjectswhohavereceivedatleastonedoseofavelumab. Thedenominator to calculatepercentages isN. irAEs with an onset after the on-treatment period are also considered in the avelumab + Bsc arm of study B999iool, whereastreatment-emergentirAEsareshownforthePooledSafetypopulation. ApatientwithmultipleoccurrencesofanAEunderonetreatmentiscountedonlyonce. EventsarecodedinthelatestMedDRAversionavailableatthetimeofcut-off.Sortedindescendingorderof the frequencyofirAEcategoryandpTswithinirAEcategoryintheB9991oo1Avelumab+Bscarm.

B9991001.

Table 66. Summary of irAEs Leading to Interruption of Avelumab by Cluster and PT SAS Study B9991001

| Cluster and Preferred Term                                 | Avelumab+BSC (N=344)   |
|------------------------------------------------------------|------------------------|
|                                                            | n (%)                  |
| Subjects with events                                       | 28 (8.1)               |
| IMMUNE- RELATED ENDOCRINOPATHIES: THYROID DISORDERS        | 8 (2.3)                |
| Hyperthyroidism                                            | 5 (1.5)                |
| Hypothyroidism                                             | 3 (0.9)                |
| IMMUNE-RELATED RASH                                        | 6 (1.7)                |
| Rash                                                       | 2 (0.6)                |
| Erythema                                                   | 1 (0.3)                |
| Erythema multiforme                                        | 1 (0.3)                |
| Purpura                                                    | 1 (0.3)                |
| Rash erythematous                                          | 1 (0.3)                |
| Rash maculo-papular                                        | 1 (0.3)                |
| IMMUNE-RELATED COLITIS                                     | 3 (0.9)                |
| Colitis                                                    | 2 (0.6)                |
| Enteritis                                                  | 1 (0.3)                |
| Proctitis                                                  | 1 (0.3)                |
| IMMUNE-RELATED NEPHRITIS AND RENAL DYSFUNCTION             | 3 (0.9)                |
| Renal failure                                              | 2 (0.6)                |
| Nephritis                                                  | 1 (0.3)                |
| IMMUNE-RELATED PNEUMONITIS                                 | 3 (0.9)                |
| Pneumonitis                                                | 2 (0.6)                |
| Interstitial lung disease                                  | 1 (0.3)                |
| IMMUNE- RELATED ENDOCRINOPATHIES: ADRENAL INSUFFICIENCY    | 2 (0.6)                |
| Adrenal insufficiency                                      | 2 (0.6)                |
| IMMUNE-RELATED HEPATITIS                                   | 2 (0.6)                |
| Alanine aminotransferase increased                         | 2 (0.6)                |
| Aspartate aminotransferase increased                       | 2 (0.6)                |
| IMMUNE- RELATED ENDOCRINOPATHIES: TYPE 1 DIABETES MELLITUS | 1 (0.3)                |
| Hyperglycaemia                                             | 1 (0.3)                |

<div style=\"page-break-after: always\"></div>

Table 66. Summary of irAEs Leading to Interruption of Avelumab by Cluster and PT SAS Study B9991001

| Cluster and Preferred Term                     | Avelumab+BSC (N=344)   |
|------------------------------------------------|------------------------|
|                                                | n (%)                  |
| OTHER IMMUNE- RELATED ADVERSE EVENTS: MYOSITIS | 1 (0.3)                |
| Myositis                                       | 1 (0.3)                |
| OTHER IMMUNE-RELATED ADVERSE EVENTS: OTHER     | 1 (0.3)                |
| Arthritis                                      | 1 (0.3)                |

The denominator to calculate percentages is N, the number of subjects in the safety analysis set within each treatment group. Subjects reporting more than one adverse event within a preferred term are counted only once in that preferred term. Subjects reporting multiple preferred terms within the same cluster are counted only once within each cluster. Sorted in descending order of the frequency of Cluster and PTs in Avelumab + BSC arm. MedDRA v22.1 coding dictionary applied.

Cut-off date: 21OCT2019 Snapshot Date: 21NOV2019

## Immune-Related Adverse Events by Cluster

## Immune-related pneumonitis

Immune-related pneumonitis occurred in 7 (2.0%) of patients receiving avelumab including 1 (0.3%) patient with grade 3 immune-related pneumonitis. Immune-related pneumonitis led to permanent discontinuation of avelumab in 0.9% of patients. Among the 7 patients with immune-related pneumonitis, the median time to onset was 3.6 months (range: 1.5 months to 13.8 months) and the median duration was 2.3 months (range: 1 month to 4.9 months). All 7 patients were treated with systemic corticosteroids; 4 (57.1%) of the 7 patients received high-dose corticosteroids for a median of 2.8 weeks (range: 1 week to 1.6 months).  No patients received additional immunosuppressants. Resolution of immune-related pneumonitis occurred in 6 (85.7%) of the 7 patients at the time of data cut-off.

## Prior experience:

- Current avelumab product information (pooled safety dataset): immune-related pneumonitis occurred in 1.2% of patients receiving avelumab including 1 patient with grade 5 (0.1%), 1 with grade 4 (0.1%), and 5 with grade 3 (0.3%) pneumonitis.

## Immune-related hepatitis

Immune-related hepatitis occurred in 1.5% of patients receiving avelumab including 5 (1.5%) patients with grade 3 immune-related hepatitis. Immune-related hepatitis led to permanent discontinuation of avelumab in 1.2% of patients. Among the 5 patients with immunerelated hepatitis, the median time to onset was 4.2 months (range: 2.8 months to 8.9 months), and the median duration was 2.2 months (range: 1.3 weeks to 3.0 months). All 5 patients were treated with high dose systemic corticosteroids for a median of 3.3 weeks (range: 1.9 weeks to 4.1 months). Resolution of immunerelated hepatitis occurred in 3 (60%) of the 5 patients at the time of data cut-off.

## Prior experience:

- Current avelumab product information (Pooled Safety Dataset): Immune-related hepatitis occurred in 0.9% of patients receiving avelumab including 2 patients (0.1%) with Grade 5 and 11 patients (0.6 %) with Grade 3 immune-mediated hepatitis.

## Immune-related colitis

Immune-related colitis occurred in 1.5% of patients receiving avelumab including 3 (0.9%) patients with grade 3 immune-related colitis. Immune-related colitis led to permanent discontinuation of

<div style=\"page-break-after: always\"></div>

avelumab in 0.6% of patients. Among the 5 patients with immune-related-colitis, the median time to onset was 4.0 months (range: 2.1 weeks to 5.8 months) and the median duration was 3.7 weeks (range: 2 weeks to 5.4+ months). All 5 patients were treated with systemic corticosteroids; 4 (80%) of the 5 patients received high-dose corticosteroids for a median of 2 weeks (range: 1.0 day to 1.1 months). One patient was treated with a non-steroidal immunosuppressant. Resolution of immune-related colitis occurred in 4 (80%) of the 5 patients at the time of data cut-off.

Prior experience:

- Current avelumab product information (Pooled Safety Dataset): Immune-related colitis occurred in 1.5% of patients receiving avelumab including 7 patients (0.4%) with Grade 3 colitis.

## Immune-related adrenal insufficiency

Immune-related adrenal insufficiency occurred in 0.9% of patients receiving avelumab. Immune-related adrenal insufficiency led to permanent discontinuation of avelumab in 0 patients. Among the 3 patients with immune-related adrenal insufficiency, the median time to onset was 3.7 months (range: 2 weeks to 6.5 months), and the median duration was 2.1 weeks (range: 2 weeks to 2.2 months). All 3 patients were treated with systemic corticosteroids; 1 (33.3%) of the 3 patients received high-dose corticosteroids for 2.3 weeks. Resolution of immune-related adrenal insufficiency occurred in 3 (100.0%) of the 3 patients at the time of data cut-off.

Prior experience:

- Current avelumab product information (pooled safety dataset): immune-related adrenal insufficiency occurred in 0.5% of patients receiving avelumab including 1 patient (0.1%) with grade 3 adrenal insufficiency.

## Immune-related: thyroid disorders

Immune-related thyroid disorders occurred in 12.2% of patients receiving avelumab including 1 (0.3%) patient with grade 3 immune-related thyroid disorders. Immune-related thyroid disorders led to permanent discontinuation of avelumab in 0.6% of patients. Hypothyroidism occurred in 37 (10.8%) patients; hyperthyroidism in 16 (4.7%) patients; and thyroiditis in 3 (0.9%) patients treated with avelumab.  Among the 42 patients with immune-related thyroid disorders, the median time to onset was 1.9 months (range: 2.1 weeks to 9.4 months), and the median duration was not estimable (range: 3.0 days to 27.6+ months).

A total of 38 (90.5%) patients with immune-related thyroid disorders required thyroid hormonal replacement therapy, with 37 (88.1%) maintaining thyroid hormonal replacement therapy as of the data cut-off date. Five (11.9%) patients with immune-related thyroid disorders required antithyroid preparations.

Seven (16.7%) patients were treated with systemic corticosteroids; 6 (14.3%) of 42 patients received high-dose corticosteroids for a median of 1.9 weeks (range: 1.0 days to 2.2 months). Resolution off immune-related thyroid disorders occurred in 7 (16.7%) of the 42 patients at the time of data cut-off.

Prior experience:

- Current avelumab product information (Pooled Safety Dataset): Immune-related thyroid disorders occurred in 6% of patients receiving avelumab including 3 patients (0.2%) with Grade 3 immune-mediated thyroid disorders.

## Immune-related type 1 diabetes mellitus

<div style=\"page-break-after: always\"></div>

Immune-related type 1 diabetes mellitus occurred in 0.9% of patients receiving avelumab including 3 (0.9%) patients with grade 3 immune-related type 1 diabetes mellitus. Immune-related type 1 diabetes mellitus led to permanent discontinuation of avelumab in 0 patients. Among the 3 patients with immune-related type 1 diabetes mellitus, the median time to onset was 2.0 months (range: 0.7 days to 9.2 months) and the median duration was 4.1 weeks (range: 2 weeks to 4.8+ months).

Three (100.0%) patients with immune-related type 1 diabetes mellitus were treated with insulin. Resolution of immune-related type 1 diabetes mellitus occurred in 2 (66.7%) of the 3 patients at the time of data cut-off.

Prior experience:

- Current avelumab product information (pooled safety dataset): immune-related type 1 diabetes mellitus without an alternative etiology occurred in 0.1% of patients including 2 cases (0.1%) of grade 3 hyperglycaemia that led to permanent discontinuation of avelumab.

## Immune-related nephritis and renal dysfunction

Immune-related nephritis and renal dysfunction occurred in 1.7% of patients receiving avelumab including 1 (0.3%) patient with grade 3 immune-related nephritis and renal dysfunction. Immune-related nephritis and renal dysfunction led to permanent discontinuation of avelumab in 0.9% of patients. Among the 6 patients with immune-related nephritis and renal dysfunction, the median time to onset was 3.0 months (range: 1.6 months to 21.9 months), and the median duration was 3.1 weeks (range: 1.3 weeks to 6.1 months).  All 6 patients were treated with systemic corticosteroids; 5 (83.3%) of the 6 patients received high-dose corticosteroids for a median of 2.4 weeks (range: 6.0 days to 2.8 months). Resolution of immune-related nephritis and renal dysfunction occurred in 4 (66.7%) of the 6 patients at the time of data cut-off.

Prior experience:

- Current avelumab product information (pooled safety dataset): immune-related nephritis and renal dysfunction occurred in 0.1% of patients receiving avelumab.

## Immune-related rash

Immune-related rash occurred in 10.2% of patients receiving avelumab including 5 (1.5%) patients with grade 3 immune-related rash. The grade 3 events were rash, erythema, drug eruption, rash maculo-papular, and erythema multiforme (1 patient each). None of these grade 3 events led to treatment discontinuation. The event of drug eruption was serious, occurred after the end of the ontreatment period, and at the start of another anticancer treatment. However, the event was adjudicated as an irAE based on clinical presentation and a conservative assessment. Immune-related rash led to permanent discontinuation of avelumab in 0.3% of patients. Among the 35 patients with immune-related rash, the median time to onset was 2.6 months (range: 0.7 days to 18.3 months), and the median duration was 2.5 months (range: 3.0 days to 21.5+ months).

Twenty two (62.9%) patients were treated with topical corticosteroids, for a median of 3.8 months (range: 1.0 day to 19.9 months). One (2.9%) patient received topical immunosuppressive drugs only (pimecrolimus).  Eight (22.9%) patients were treated with systemic corticosteroids. Four (11.4%) of the 8 patients treated with systemic corticosteroids, received high-dose corticosteroids for a median of 1.9 weeks (range: 1.1 weeks to 3.8 months). Resolution of immune-related rash occurred in 22 (62.9%) of the 35 patients at the time of data cut-off.

Prior experience:

<div style=\"page-break-after: always\"></div>

- Current avelumab product information (pooled safety dataset): there is no specific section for immune-mediated rash in the current product information. However, the frequencies of immune-related rash events are presented in the table of adverse reactions:

Common (≥1/100 to &lt; 1/10 patients): rash, pruritus, and rash maculo-papular

Uncommon (≥1/1,000 to &lt; 1/100 patients):  rash pruritic, erythema, rash generalised, psoriasis, rash erythematous, rash macular, rash papular, dermatitis exfoliative, erythema multiforme, pemphigoid, pruritus generalised.

## Immune-related myositis

Immune-related myositis occurred in 0.6% of patients receiving avelumab including 2 (0.6%) patients with grade 3 immune-related myositis. Immune-related myositis led to permanent discontinuation of avelumab in 0.3% of patients. Among the 2 patients with immune-related myositis, the median time to onset was 2.3 months (range: 2.1 weeks to 4.2 months), and the median duration was 2.0 months (range: 2.3 weeks to 3.4 months). Both patients were treated with high dose systemic corticosteroids for a median of 2 weeks (range: 6.0 days to 3.1 weeks). Resolution of immune-related myositis occurred in 2 (100.0%) of the 2 patients at the time of data cut-off.

Prior experience:

- Current avelumab product information (pooled safety dataset): there is no section specific to immune-related myositis in the current product information. However, immune-related myositis was reported in less than 1% of patients in studies of avelumab as a single agent in patients with solid tumours.

## Immune-related pancreatitis

Immune-related pancreatitis occurred in 0.6% of patients receiving avelumab including 1 (0.3%) patient with grade 3 immune-related pancreatitis. Immune-related pancreatitis led to permanent discontinuation of avelumab in 0.6% of patients. Among the 2 patients with immune-related pancreatitis, the median time to onset was 1.5 months (range: 1.4 months to 1.6 months), and the median duration was not estimable (range: 1 week to 2.6+ months). Both patients were treated with systemic corticosteroids; 1 (50%) of the 2 patients received high-dose corticosteroids for 2 days. Resolution of immune-related pancreatitis occurred in 1 (50.0%) of the 2 patients at the time of data cut-off.

Prior experience:

- Current avelumab product information (pooled safety dataset): immune-related pancreatitis occurred in less than 1% of patients receiving avelumab as a single agent.

## Immune-related other: uveitis

Immune-related uveitis occurred in 1 (0.3%) patient receiving avelumab, with an onset at 9.1 months and a duration of 2.0 months. Immune related uveitis resolved by the time of data cut-off.

Prior experience:

- Current avelumab product information (pooled safety dataset): there is no section specific to immune-mediated uveitis in the current product information. However, immune-related uveitis was reported in less than 1% of patients in studies of avelumab as a single agent in patients with solid tumours.

## Immune-related other: Guillain-Barre syndrome

<div style=\"page-break-after: always\"></div>

Grade 3 immune-related Guillain-Barre syndrome (PT = Miller-Fisher Syndrome) occurred in 1 (0.3%) patient receiving avelumab with an onset at 2.6 months. Immune related Guillain-Barre syndrome did not resolve by the time of data cut-off. The patient was treated with high-dose systemic corticosteroids for 15.8 months.

Prior experience:

- Current avelumab product information (pooled safety dataset): there is no section specific to immune-related Guillain-Barre syndrome. However, immune-related Guillain-Barre syndrome was reported in less than 1% of patients in studies of avelumab as a single agent in patients with solid tumours.

## Immune-related other: other

Immune-related other adverse events occurred in 2.6% of patients receiving avelumab, including 1 (0.3%) patient with grade 3 rheumatoid arthritis, and 1 (0.3) patient with grade 3 oligoarthritis. Grade 3 rheumatoid arthritis led to permanent discontinuation of avelumab.

The patient with grade 3 rheumatoid arthritis had been diagnosed with this disease before study entry and experienced a disease flare during the study. Avelumab was withdrawn and the patient was treated with dexamethasone, hydroxychloroquine, prednisone, methotrexate and sulfasalazine. The patient was recovering at the time of data cut-off.

The patient with grade 3 oligoarthritis was also suffering with psoriasis and received several short cycles of systemic corticosteroids over a period of approximately 2 months to manage the event. Avelumab was continued. The events resolved.

Prior experience:

- Current avelumab product information (pooled safety dataset): there is no section in the current product information for events categorized here as 'other'. The exception is psoriasis which is listed as an uncommon ( ≥ 1/1,000 to &lt; 1/100 patients) immune-related AE.

## Safety in special populations

Table 67 Selected Safety Data by Age Group in the Avelumab + BSC Arm of Study B9991001

| MedDRA Terms                                       | <65 years (N=129) n (%)   | 65-<75 years (N=130) n (%)   | 75-<85 years (N=80) n (%)   | ≥ 85 years (N=5) n (%)   |
|----------------------------------------------------|---------------------------|------------------------------|-----------------------------|--------------------------|
| Total AEs                                          | 127 (98.4)                | 128 (98.5)                   | 77 (96.3)                   | 5 (100.0)                |
| Patients with SAEs - Total                         | 29 (22.5)                 | 38 (29.2)                    | 25 (31.3)                   | 4 (80.0)                 |
| Serious AEs - Total                                | 44                        | 61                           | 40                          | 8                        |
| - Fatal                                            | 3 (6.8)                   | 1 (1.6)                      | 2 (5.0)                     | 0                        |
| - Hospitalization/prolong existing hospitalization | 43 (97.7)                 | 54 (88.5)                    | 37 (92.5)                   | 8 (100.0)                |
| - Life-threatening                                 | 1 (2.3)                   | 1 (1.6)                      | 0                           | 0                        |
| - Disability/incapacity                            | 1 (2.3)                   | 0                            | 0                           | 0                        |
| - Other (medically significant)                    | 3 (6.8)                   | 5 (8.2)                      | 3 (7.5)                     | 0                        |
| AE leading to drop-out 1                           | 13 (10.1)                 | 15 (11.5)                    | 11 (13.8)                   | 2 (40.0)                 |
| Psychiatric disorders                              | 18 (14.0)                 | 10 (7.7)                     | 8 (10.0)                    | 2 (40.0)                 |
| Nervous system disorders                           | 35 (27.1)                 | 26 (20.0)                    | 21 (26.3)                   | 3 (60.0)                 |
| Accidents and injuries                             | 11 (8.5)                  | 15 (11.5)                    | 13 (16.3)                   | 1 (20.0)                 |

<div style=\"page-break-after: always\"></div>

| MedDRA Terms                                                                            | <65 years (N=129) n (%)   | 65-<75 years (N=130) n (%)   | 75-<85 years (N=80) n (%)   | ≥ 85 years (N=5) n (%)   |
|-----------------------------------------------------------------------------------------|---------------------------|------------------------------|-----------------------------|--------------------------|
| Cardiac disorders                                                                       | 6 (4.7) 000               | 12 (9.2)                     | 03 (3.8) 0                  | 1 (20.0)                 |
| Vascular disorders                                                                      | 9 (7.0)                   | 13 (10.0)                    | 13 (16.3)                   | 1 (20.0)                 |
| Cerebrovascular disorders                                                               | 1 (0.8)                   | 2 (1.5)                      | 1 (1.3)                     | 0                        |
| Infections and infestations                                                             | 68 (52.7)                 | 61 (46.9)                    | 43 (53.8)                   | 5 (100.0)                |
| Anticholinergic syndrome                                                                | 35 (27.1)                 | 31 (23.8)                    | 25 (31.3)                   | 2 (40.0)                 |
| Quality of life decreased 2                                                             | NA                        | NA                           | NA                          | NA                       |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures 3 | 12 (9.3)                  | 13 (10.0)                    | 13 (16.3)                   | 1 (20.0)                 |
| irAEs                                                                                   | 33 (25.6)                 | 35 (26.9)                    | 31 (38.8)                   | 2 (40.0)                 |
| IRRs                                                                                    | 23 (17.8)                 | 24 (18.5)                    | 27 (33.8)                   | 0                        |

1. AEs leading to drop-out are TEAEs leading to permanent treatment discontinuation, 2. No analysis of QoL by age was done for Study B9991001 3. The 'Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures' includes the PTs of Orthostatic hypotension, Fall, Loss of consciousness, Syncope, Dizziness, Ataxia, and the HLGT of Fractures. The following AE categories have been analyzed by MedDRA SMQs (broad and narrow): Accidents and Injuries (SMQ: Accidents and Injuries), Cerebrovascular disorders (SMQ: Central nervous system vascular disorders), and Anticholinergic syndrome (SMQ: Anticholinergic syndrome). The 'Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia, fractures' includes the PTs of Orthostatic hypotension, Fall, Loss of consciousness, Syncope, Dizziness, Ataxia, and the HLGT of Fractures

## Immunogenicity

Blood samples for evaluation of avelumab immunogenicity were collected from patients on Arm A within 2 hours before the start of the avelumab infusion on Day 1 and Day 15 of Cycles 1 through 3 and then on Day 1 of Cycle 5, 7, 9, 11, and 13.

Treatment-induced ADA incidence was 62 of 325 patients (19.1%) treated with avelumab with 43 (13.2%) having persistent ADA response and 19 (5.8%) having transient response in study B9991001. Of the patients who were ADA positive at baseline (n=4, 1.2% patients), none had treatment-boosted ADA (Table 68).

<div style=\"page-break-after: always\"></div>

Table 68. Summary of Subject ADA Categories - Immunogenicity Analysis Set Study B9991001

|                                                                                                         | Avelumab+BSC (N=344) (%) u   |
|---------------------------------------------------------------------------------------------------------|------------------------------|
| Subjects with at least one valid ADA result at any time point (No)                                      | 344 (100.0)                  |
| Subjects with valid baseline ADA result (N1)                                                            | 329 (95.6)                   |
| Subjectswithvalid baselineADAresults and at leastonevalid post-baseline ADAresult (N2)                  | 329 (95.6)                   |
| Subjects with at least one valid post-baseline ADA result and without positive baseline ADA result (N3) | 325 (94.5)                   |
| ADA never-positive (n/N0)                                                                               | 278 (80.8)                   |
| ADA ever-positive (n/NO)                                                                                | 66 (19.2)                    |
| Baseline ADA positive (n/N1)                                                                            | 4 (1.2)                      |
| Treatment-boosted ADA (n/N2)                                                                            | 0                            |
| Treatment-induced ADA (n/N3)                                                                            | 62 (19.1)                    |
| Transient ADA response (n/N3)                                                                           | 19 (5.8)                     |
| Persistent ADA response (n/N3)                                                                          | 43 (13.2)                    |

Baseline is defined as the last assessment on or prior to the date/time of thefirst dose of avelumab.

The denominator to calculate percentages for N0, N1, N2, N3 is N, the number of subjects in the immunogenicity analysis set. PFIZERCONFIDENTIAL SDTM Creation:29DEC2019 (22:00)SourceData:ADIS OutputFile:

./B9991001\\_restricted/B9991001/adis\\_s001 Date of Generation:14JAN2020 (09:20) Cutoff Date: 30JUN2019 Snapshot Date: 24DEC2019

Of the 62 patients with treatment-induced ADA, the median time to ADA positive value was 10.2 weeks (range: 2.1, 35.7). The median duration seropositivity was 2.4 weeks (95% CI 0.1, 7.7).

No effect of ADA status on avelumab PK was detected (see Pharmacokinetics section above).

Adverse events by treatment-induced ADA vs ADA never-positive or baseline ADA positive status are summarized in Table 69. The percentage of patients reporting TEAEs was similar for treatment-induced ADA-positive patients (98.4%) and ADA never-positive or baseline ADA-positive patients (97.9%). The proportions of patient with reported Grade ≥ 3 TEAEs (51.6% versus 46.5%), serious TEAEs (35.5% versus 26.2%), TEAEs leading to discontinuation of avelumab (17.7% versus 10.6%), and IRRs (27.4% versus 20.2%) were numerically higher in the treatment-induced ADA positive patients than in the ADA never-positive or baseline ADA positive patients, respectively; however, the comparison was limited by the overall low incidence of immunogenicity.

<div style=\"page-break-after: always\"></div>

Table 69. Summary of Adverse Events, by Treatment-Induced ADA versus ADA NeverPositive or Baseline ADA Positive - Immunogenicity Analysis Set Study B9991001

|                                                            | Avelumab+BSC                 | Avelumab+BSC                                      | Avelumab+BSC   |
|------------------------------------------------------------|------------------------------|---------------------------------------------------|----------------|
|                                                            | Treatment-induced ADA (N=62) | ADA never-positive orbaselineADA positive (N=282) | Total (N=344)  |
| Number (%) of Subjects                                     | (%) u                        | n (%)                                             | n (%)          |
| Subjects with TEAEs                                        | 61 (98.4)                    | 276 (97.9)                                        | 337 (98.0)     |
| SubjectswithGrade≥3TEAEs                                   | 32 (51.6)                    | 131 (46.5)                                        | 163 (47.4)     |
| Subjects with SeriousTEAEs                                 | 22 (35.5)                    | 74 (26.2)                                         | 96 (27.9)      |
| Subjects with TEAEs Leading to Dose Reduction of Avelumab  | 0                            | 1 (0.4)                                           | 1 (0.3)        |
| Subjects with TEAEs Leading to Discontinuation of Avelumab | 11 (17.7)                    | 30 (10.6)                                         | 41 (11.9)      |
| Subjects with Infusion-Related Reactions (IRRs)            | 17 (27.4)                    | 57 (20.2)                                         | 74 (21.5)      |

The denominator to calculate percentages is N, the number of subjects in the immunogenicity analysis set within each ADA category.

MedDRA v22.1 coding dictionary and CTCAE version 4.03 applied.

PFIZER CONFIDENTIAL SDTM Creation: 22NOV2019 (07:14) Source Data: ADAE Output File:

./B9991001\\_restricted/B9991001/adae\\_ada\\_s020\\_1 Date of Generation:14JAN2020 (10:00) Cutoff Date:30JUN2019 SnapshotDate:24DEC2019

A previously assessed ADA assay (aRCC indication) was used in the current analysis. The incidence of treatment induced ADAs in the UC population was 19.1%, which is slightly higher than in the aRCC population (14.6%) where the same ADA assay was used. It is, however, agreed that ADA formation does not seem to be influential for avelumab PK or safety in the UC population.

## 2.5.1. Discussion on clinical safety

The safety data to support the claimed extension of indication for bavencio as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy, are based on data from the interim analysis of the phase 3 study B9991001. The safety database for study B9991001 consisted of 689 patients receiving any study treatment with avelumab plus BSC (n=344) or BSC (n=345). Safety database cut-off date was January 19, 2020 (12 weeks after CSR data cut-off date).

The pooled safety data set for avelumab monotherapy consisted of patients from EMR100070-001 and study EMR100070-003, in total 1738 patients.

The median treatment duration in study B9991001 was 25.3 weeks (range: 2.0, 173.9) in the avelumab plus BSC arm and considerably shorter, 13.1 weeks (range: 0.1, 168.4) in the BSC alone arm (19 Jan 2020). Patients with PD-L1-positive tumours are exposed to avelumab for longer time compared to patients with PD-L1-negative tumours. Mean and median exposure to avelumab is about double in study B9991001 compared to the pooled safety set.

Adverse events were observed in nearly all patients treated with avelumab. Compared with only BSC, the incidence for AEs was higher in patients treated with avelumab. The difference is more pronounced for ARs of grade 3 or higher. AEs reported from study B9991001, which were considerably more common in the avelumab plus BSC arm, were irAEs and IRRs, which could be expected. In relation to

<div style=\"page-break-after: always\"></div>

the pooled safety set, IRRs were similar as observed in study B9991001, but irAEs were more common in Study B9991001.

The most commonly reported AE for patients in study B9991001 treated with avelumab plus BSC was fatigue, 17.7%. This was more common in the pooled safety set with 32.4%. The most frequent AEs were generally more common in study B9991001 for patients treated with avelumab plus BSC compared to only BSC.  There are no major differences between patients with PD-L1-positive tumours and the entire population in study B9991001.

Overall, the majority of deaths was caused by disease progression in both the pooled safety set and study B9991001. The proportion was lower in patients with PD-L1-positive tumours compared to all other groups. Deaths caused by study treatment toxicity was higher in patients in study B9991001 treated with avelumab plus BSC (0.6%) compared to the pooled safety population (0.2%). However, the absolute number of deaths assessed by the investigator to be due to study treatment is low and the reported cases display several confounding factors that do not support a clear relationship to study treatment.

The frequency of deaths attributed to AEs not related to study treatment is lower (0.6%) in the avelumab plus BSC care arm compared to the pooled safety set (3.4%). The frequency of death related to unknown causes was the same in both treatment arms (1.7%) of study B9991001 and lower compared to the pooled safety population (4.8%). In the avelumab + BSC arm of study B9991001, all patients in the 'Unknown' subgroup were diagnosed with disease progression, 3 out of 6 patients received some new anticancer therapy after avelumab, and in all patients the death occurred ≥3 months after the last dose of avelumab.

In conclusion, the frequency of deaths not attributed to disease progression in study B9991001 do not raise any serious new safety concerns for avelumab monotherapy treatment for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.

Serious AEs were less frequent or similar in study B9991001 compared to the pooled safety set overall and for all organ system except for 'renal and urinary disorders' where the proportion of affected was doubled. For intra study comparison of serious AEs in study B9991001, serious adverse events are more common among patients treated with avelumab plus BSC, 27.9% compared to the BSC arm, 20.0%. The similar incidence of serious acute kidney injury in both arms (1.7%) in study B9991001 suggest that this, in part, can be attributed to the patient population. However, the incidence of serious acute kidney injury is similar also in the pooled safety set (1.6%). Overall, the profile of serious AEs in study B9991001 does not raise any concern.

The proportion of patients that interrupted the treatment with avelumab was almost double for patients in study B9991001 compared to the pooled safety set, 40.7% compared to 20.9 %. The exposure adjusted analysis shows a slight increase for patients with AEs leading to interruption of avelumab treatment. Incidence rate per 100 patient months for study B9991001 was 6.1 compared to the pooled safety population 5.0. This is not as pronounced as the non-adjusted analysis. The proportion of patients that discontinued treatment was quite similar between the groups, 11.9% for the study B9991001 and 14.0% for the pooled safety set. Exposure adjusted analysis show a lower treatment (about half) discontinuation of avelumab in study B9991001 compared to the Pooled Safety Set (1.3 vs. 2.9). In conclusion, the dose interruptions and proportion of patients discontinuing avelumab treatment raises no new safety concerns.

The most common irAEs categories in study B9991001 of any grade and with an incidence over 1% for patients treated with avelumab plus BSC were: immune-related endocrinopathies: thyroid disorders (12.2%), immune-related rash (10.2%), other immune-related adverse events: other (2.6%),

<div style=\"page-break-after: always\"></div>

immune-related pneumonitis (2.0%), immune-related nephritis and renal dysfunction (1.7%), immune-related colitis (1.5%) and immune-related hepatitis (1.5%). The most common irAE categories of grade 3 and above and with an incidence over 1% in study B9991001 for patients treated with avelumab plus BSC was: immune-related rash (1.5%) and immune-related hepatis (1.5%). For the pooled safety population, the most common irAE categories of any grade and with an incidence over 1% were: immune-related endocrinopathies: thyroid disorders (5.6%), immune-related rash (5.2%), immune-related pneumonitis (1.2%) and immune-related colitis (1.5%). There was no irAE category of grade 3 and above with an incidence over 1% in the pooled safety set.

IrAEs weremore common in study B9991001 for patients treated with avelumab plus BSC, 29.4% compared to 14.2% in the pooled safety set. There was also a higher frequency of irAEs of grade 3 and above (7.0% vs. 2.2%), irAEs leading to discontinuation (5.5% vs. 2.0%) and serious irAEs (4.7 % vs. 2.5%). Generally, the irAE categories of all grades and 3 and higher were more common in study B9991001 compared to the pooled safety population or of similar frequency.1.4% of the patients in the BSC arm in study B9991001 reported irAEs, and 0.3% were of grade 3 and higher. The median time to onset of irAEs is highly variable. The resolution of irAEs differed between irAEs from 16.7% for immune related thyroid disorders to 100% for immune related adrenal insufficiency at the time of data cut-off. The exposure adjusted IR per 100 patient months of irAEs is higher in study B9991001 compared to the pooled population, 4.1 compared to 3.3However, this increase raises no major concern in relation to the benefit risk assessment.

Overall, presented data do not imply that the safety profile would be markedly different in patients with PD-L1-positive and PD-L1-negative tumours.

The incidence of treatment induced ADAs in the UC population was 19.1%, which is slightly higher than in the aRCC population (14.6%) where the same ADA assay was used. The graphical analysis based on the population PK analysis does not indicate that ADA formation is influential for PK. Furthermore, the exposure-safety analysis did not indicate that ADA formation is a factor for the probability of adverse events. Thus, it is agreed that ADA formation does not seem to be influential for avelumab PK or safety in the UC population.

## 2.5.2. Conclusions on clinical safety

Overall, the safety profile of avelumab in the pivotal study B9991001 is similar, regardless of PD-L1status, to the previously reported safety profile of avelumab monotherapy. No new safety concerns were raised, and the safety profile is considered manageable.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 5.0 is acceptable.

<div style=\"page-break-after: always\"></div>

The CHMP endorsed the Risk Management Plan version 5.0 with the following content: The safety profile of Bavencio monotherapy in the new indication is comparable to the already established safety profile of avelumab monotherapy in other solid tumours.

Therefore, no changes to the safety concerns, Pharmacovigilance plan or Risk minimisations measures are needed.

Existing pharmacovigilance plan and risk minimisations measures remain sufficient to address the risk of the product in all approved indications.

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-related pneumonitis Immune-related hepatitis Immune-related colitis Immune-related pancreatitis Immune-related myocarditis Immune-related endocrinopathies (thyroid disorders, adrenal insufficiency, type 1 diabetes mellitus, pituitary disorders) Other immune-related events (myositis, Guillain-Barré syndrome, uveitis, myasthenia gravis/myasthenic syndrome) Immune-related nephritis and renal dysfunction Severe infusion- related reactions (grade ≥ 3) |
| Important potential risks    | Other immune-related events (encephalitis) Severe cutaneous reactions Immunogenicity Embryofetal toxicity                                                                                                                                                                                                                                                                                                                                                                 |
| Missing information          | Safety in patients with autoimmune disease Safety in patients with HIV, Hepatitis B or C infections Safety in patients with organ transplants Long-term treatment Safety and efficacy in immune compromised patients                                                                                                                                                                                                                                                      |

## Pharmacovigilance plan

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                      | Safety concerns addressed                                                                                                                                                                                                  | Milestone s                                                                                                                                                                                                                | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| None                                                                                                                                                                                                                       |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| None                                                                                                                                                                                                                       |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Safety concerns addressed                                                                                                                                                                                                  | Milestone s                                                                                                                                                                                                                | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| None                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                                                                                                                                                                                                                                                                                                                                                                           | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| None                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Non- interventional cohort registry study to assess characteristics and management of patients with Merkel cell carcinoma in Germany (Study MS100070-0031) Planned                                                         | 5-year open cohort study (based on primary data collection) of patients with MCC in Germany to 1) describe patient characteristics (including co- morbidities and concomitant medications), 2) estimate background rates of relevant comorbidities, 3) describe treatment patterns, 4) characterize disease outcomes (overall, per treatment and in immune compromised patients treated with avelumab), 5) describe safety events of interest (e.g., immune- related adverse drug reactions) overall and in immune compromised patients treated with avelumab Exploratory objectives: Compare safety and effectiveness profile of avelumab in immune | Safety in immune compromised patients in addition to gathering of other real- world data                                                                                                                                   | Interim reports Final report                                                                                                                                                                                               | Interim reports (first interim annual progress update report on 03/2020 and following reports yearly) 31/12/2024                                                                                                           |

## Risk minimisation measures

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                                                                                       |
|----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related pneumonitis | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab based on the severity of pneumonitis in SmPC section 4.2 Warning to monitor for immune- related pneumonitis and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related pneumonitis in patients exposed to avelumab in the ongoing clinical trials |

<div style=\"page-break-after: always\"></div>

| Safety concern           | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Pharmacovigilance activities                                                                                                                                                                                                                                                   |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                          | Description of immune-related pneumonitis observed in clinical trials in SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have problems due to inflammation of their lungs in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures: Patient Educational Material                                                                                                                                                                                                                                             | Additional pharmacovigilance activities: None                                                                                                                                                                                                                                  |
| Immune-related hepatitis | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab based on the severity of hepatitis in SmPC section 4.2 Warning to monitor for immune- related hepatitis and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Description of immune-related hepatitis observed in clinical trials in SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have problems due to inflammation of their liver in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related hepatitis in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None |
| Immune-related colitis   | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab based on the severity of colitis in SmPC section 4.2 Warning to monitor for immune- related colitis and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Description of Immune-related colitis observed in clinical trials in SmPC section 4.8                                                                                                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related colitis in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None   |

<div style=\"page-break-after: always\"></div>

| Safety concern              | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Pharmacovigilance activities                                                                                                                                                                                                                                                      |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                             | Warning for the patient to talk to their doctor before receiving avelumab if they have problems due to inflammation of their intestines in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures: Patient Educational Material                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                   |
| Immune-related pancreatitis | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab due to immune-related pancreatitis in SmPC section 4.2 Warning to monitor for immune- related pancreatitis and treatment advice in SmPC section 4.4 SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have problems due to inflammation of their pancreas in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related pancreatitis in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None |
| Immune-related myocarditis  | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab due to immune-related myocarditis in SmPC section 4.2 Warning to monitor for immune- related myocarditis and treatment advice in SmPC section 4.4 SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have problems due to inflammation of their heart in PL section 2 PL section 4 Legal status (prescription only medicine)                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related myocarditis in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None  |

<div style=\"page-break-after: always\"></div>

| Safety concern                                          | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Pharmacovigilance activities                                                                                                                                                                                                                                     |
|---------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                         | Additional risk minimization measures: Patient Educational Material                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                  |
| Immune-related endocrinopathies (thyroid disorders)     | Routine risk minimization measures: Guidance for withholding avelumab based on the severity of endocrinopathies in SmPC section 4.2 Warning to monitor for changes in thyroid function and signs and symptoms of thyroid disorders and treatment advice in SmPC section 4.4 SmPC section 4.8 Description of immune-related endocrinopathies including thyroid disorders observed in clinical trials in SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have problems with their hormone producing glands in PL section 2 PL section 4 Legal status (prescription only medicine) | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related endocrinopathies (thyroid disorders) in patients exposed to avelumab in the ongoing clinical trials None |
| Immune-related endocrinopathies (thyroid disorders)     | risk minimization measures:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Additional pharmacovigilance activities:                                                                                                                                                                                                                         |
| Immune-related endocrinopathies (adrenal insufficiency) | Guidance for withholding avelumab based on the severity of endocrinopathies in SmPC section 4.2 Warning to monitor for signs and symptoms of adrenal insufficiency and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Description of Immune-related endocrinopathies including adrenal insufficiency observed in clinical trials in SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have problems with their hormone producing glands in PL section 2 PL section 4 Legal status (prescription only                                                     | activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related endocrinopathies (adrenal insufficiency) in patients exposed avelumab in the ongoing clinical trials                               |
|                                                         | medicine)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | to                                                                                                                                                                                                                                                               |
|                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Additional pharmacovigilance activities:                                                                                                                                                                                                                         |
|                                                         | Additional                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                  |
|                                                         | Patient Educational Material                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                  |
|                                                         | Routine risk minimization measures:                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Routine pharmacovigilance                                                                                                                                                                                                                                        |
|                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | None                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Safety concern                                             | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                                                                                                                                                                                                     |
|------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Immune-related endocrinopathies (type 1 diabetes mellitus) | Patient Educational Material Routine risk minimization measures: Guidance for withholding avelumab based on the severity of endocrinopathies in SmPC section 4.2 Warning to monitor for hyperglycaemia or other signs and symptoms of diabetes and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Description of immune-related endocrinopathies including type 1 diabetes mellitus observed in clinical trials in SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have type 1 diabetes mellitus including acid in the blood produced from diabetes in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures: | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related endocrinopathies (type 1 diabetes mellitus) in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None |
| Immune-related endocrinopathies (pituitary disorders)      | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab based on the severity of other immune-related adverse reactions in SmPC section 4.2 Warning to monitor for other immune- related adverse reactions (hypopituitarism) and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have problems with their hormone producing glands in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures:                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related endocrinopathies (pituitary disorders) in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None      |

<div style=\"page-break-after: always\"></div>

| Safety concern                                         | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Pharmacovigilance activities                                                                                                                                                                                                                                                                                 |
|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Other immune- related events (myositis)                | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab based on the severity of other immune-related adverse reactions in SmPC section 4.2 Warning to monitor for other immune- related adverse reactions (myositis) and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have inflammation of their muscles in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures: Patient Educational Material | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related myositis in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None                                |
| Other immune- related events (Guillain-Barré syndrome) | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab based on the severity of other immune-related adverse reactions in SmPC section 4.2 Warning to monitor for other immune- related adverse reactions (Guillain- Barré syndrome) and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have an autoimmune disease in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures:                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of other immune- related events (Guillain-Barré syndrome) in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None |
| Other immune- related events (uveitis)                 | Patient Educational Material Routine risk minimization measures: Guidance for withholding or discontinuing avelumab based on the severity of other immune-related adverse reactions in SmPC section 4.2 Warning to monitor for other immune- related adverse reactions (uveitis) and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8                                                                                                                                                                                                                                     | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of other immune- related events (uveitis) in patients exposed to avelumab in the ongoing clinical trials                                                               |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                       | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | Pharmacovigilance activities                                                                                                                                                                                                                                                                                       |
|----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                      | Warning for the patient to talk to their doctor before receiving avelumab if they have an autoimmune disease in PL section 2 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures: Patient Educational Material                                                                                                                                                                                                                                                                                                                                                               | Additional pharmacovigilance activities: None                                                                                                                                                                                                                                                                      |
| Other immune- related events (myasthenia gravis/myasthenic syndrome) | Routine risk minimisation measures: Guidance for withholding or discontinuing avelumab based on the severity of other immune-related adverse reactions in SmPC section 4.2 Warning to adequately evaluate other immune-related adverse reactions ( myasthenia gravis/myasthenic syndrome) and treatment advice based on severity in SmPC section 4.4. SmPC section 4.8 Myasthenia gravis/myasthenic syndrome listed as an adverse reaction in SmPC section 4.8 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures:                                                          | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of other immune- related myasthenia gravis/ myasthenic syndrome in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None |
| Immune-related nephritis and renal dysfunction                       | Routine risk minimization measures: Guidance for withholding or discontinuing avelumab based on the severity of nephritis and renal dysfunction in SmPC section 4.2 Warning to monitor for immune- related nephritis and renal dysfunction and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Description of the case of immune- related nephritis observed in clinical trials in SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have problems with their kidneys in PL section 2 PL section 4 Legal status (prescription only medicine) | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of immune-related nephritis and renal dysfunction in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None               |

<div style=\"page-break-after: always\"></div>

| Safety concern                                 | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Pharmacovigilance activities                                                                                                                                                                                                                                                              |
|------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                | Additional risk minimization measures: Patient Educational Material                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                           |
| Severe infusion- related reactions (grade ≥ 3) | Routine risk minimization measures: Guidance to pre-medicate with an antihistamine and paracetamol prior to the first 4 infusions of avelumab in SmPC section 4.2 Guidance for withholding or discontinuing avelumab based on the severity of infusion-related reactions in SmPC section 4.2 Description of infusion-related reactions observed in clinical trials in SmPC section 4.4 Warning to monitor for infusion- related reactions and treatment advice based on severity in SmPC section 4.4 SmPC section 4.8 Information that anti-drug antibodies (ADA) positive patients may be at increased risk of infusion-related reactions in SmPC section 4.8 Warning for the patient to talk to their doctor before receiving avelumab if they have infusion-related reactions in PL section 2 Information for the patient that they will receive paracetamol and an antihistamine before at least the first 4 treatments of avelumab in PL section 3 PL section 4 Legal status (prescription only medicine) | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of severe infusion- related reactions in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None  |
| Other immune- related events (encephalitis)    | Routine risk minimization measures: Warning to monitor for immune- related adverse reactions and treatment advice based on etiology in SmPC section 4.4 Information that avelumab works on the immune system and may cause inflammation which may be serious and life-threatening requiring avelumab withdrawal or treatment in PL section 4                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of other immune- related event encephalitis in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: |

<div style=\"page-break-after: always\"></div>

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                                                                                                                                                                     |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | Legal status (prescription only medicine) Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                                                         | None                                                                                                                                                                                                                                                                             |
| Severe cutaneous reactions | Routine risk minimization measures: Warning to monitor for immune- related adverse reactions and treatment advice based on etiology in SmPC section 4.4 SmPC section 4.8 Information that avelumab works on the immune system and may cause inflammation which may be serious and life-threatening requiring avelumab withdrawal or treatment in PL section 4 PL section 4 Legal status (prescription only medicine) Additional risk minimization measures:   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of severe cutaneous reactions in patients exposed to avelumab in the ongoing clinical trials Additional pharmacovigilance activities: None |
| Immunogenicity             | Routine risk minimization measures: Information that treatment-emergent ADA were observed in clinical trials and that there may be an increased risk for infusion-related reactions in ADA positive patients but the impact of ADA on pharmacokinetics, efficacy and safety is uncertain and the impact of neutralizing antibodies (nAb) is unknown in SmPC section 4.8 Legal status (prescription only medicine) Additional risk minimization measures: None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of subjects developing ADAs in the ongoing clinical trials Additional pharmacovigilance activities: None                                   |
| Embryofetal toxicity       | Routine risk minimization measures: Guidance for women of childbearing to avoid becoming pregnant and to use effective contraception during treatment and for at least 1 month after the last dose in SmPC section 4.6 Guidance that avelumab is not recommended for use during pregnancy unless the woman requires treatment in SmPC section 4.6                                                                                                             | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Safety concern                                           | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Pharmacovigilance activities                                                                                                                     |
|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                          | Information that there are no or limited data in pregnant women in SmPC section 4.6 Information that blockade of PD-L1 signalling has been shown to disrupt tolerance to the fetus and result in increased fetal loss in murine models of pregnancy in SmPC section 5.3 Guidance for the patient to seek advice before taking avelumab if they are pregnant, think they may be pregnant or are planning to have a baby in PL section 2 Warning for the patient not to use avelumab if they are pregnant unless their doctor specifically recommends it in PL section 2 Guidance for a woman to use effective contraceptives while they are being treated and for at least 1 month after their last dose in PL section 2 Legal status (prescription only medicine) Additional risk minimization measures: None |                                                                                                                                                  |
| Safety in patients with autoimmune disease               | Routine risk minimization measures: Information that patients with active or a history of autoimmune disease were excluded from clinical trials in SmPC section 4.4 Information that patients with active or a history of autoimmune disease were excluded from Study EMR100070- 003 in SmPC section 5.1 Guidance for the patient to check with their doctor or nurse before receiving avelumab if they have an autoimmune disease in PL section 2 Legal status (prescription only medicine) Additional risk minimization measures: None                                                                                                                                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None |
| Safety in patients with HIV, Hepatitis B or C infections | Routine risk minimization measures: Information that patients with conditions requiring therapeutic immune suppression or active infection with HIV, or hepatitis B or C were excluded from clinical trials in SmPC section 4.4 and section 5.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities:      |

<div style=\"page-break-after: always\"></div>

| Safety concern                                     | Risk minimization measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Pharmacovigilance activities                                                                                                                                                                                                                       |
|----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                    | Guidance for the patient to check with their doctor or nurse before receiving avelumab if they have human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS) in PL section 2 Guidance for the patient to check with their doctor or nurse before receiving avelumab if they have ever had chronic viral infection of the liver, including hepatitis B (HBV) or hepatitis C (HCV) in PL section 2 Legal status (prescription only medicine) Additional risk minimization measures: None | None                                                                                                                                                                                                                                               |
| Safety in patients with organ transplants          | Routine risk minimization measures: Information that patients with an organ transplant were excluded from clinical trials in SmPC section 4.4 Information that patients with an organ transplant were excluded from Study EMR100070- 003 in SmPC section 5.1 Guidance for the patient to check with their doctor or nurse before receiving avelumab if they have had an organ transplant in PL section 2 Legal status (prescription only medicine) Additional risk minimization measures:                                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                   |
| Long-term treatment                                | Routine risk minimization measures: Legal status (prescription only medicine) Additional risk minimization measures: None                                                                                                                                                                                                                                                                                                                                                                                                | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Further monitoring and characterization of long-term avelumab treatment in the ongoing clinical trials Additional pharmacovigilance activities: None |
| Safety and efficacy in immune compromised patients | Routine risk minimization measures: Information that patients with active or a history of autoimmune disease, organ transplant, conditions requiring therapeutic immune suppression or active infection with HIV, or hepatitis B or C were excluded from clinical                                                                                                                                                                                                                                                        | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Review of data from an Early Access Program with mMCC patients                                                                                       |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Risk minimization measures                                                                                                                                                                                                                                                 | Pharmacovigilance activities                                                                                                                                                              |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | trials in SmPC section 4.4 and section 5.1 Guidance for the patient to check with their doctor or nurse before receiving avelumab if they have an autoimmune disease in PL section 2 Legal status (prescription only medicine) Additional risk minimization measures: None | Additional pharmacovigilance activities: Non-interventional cohort study to assess characteristics and management of patients with Merkel cell carcinoma in Germany (Study MS100070_0031) |

## 2.7. Update of the Product information

As a consequence of this new indication, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.7.1. User consultation

No justification for not performing a full user consultation with target patient groups on the Package Leaflet has been submitted by the MAH. However, the changes to the Package Leaflet are minimal and do not require user consultation with target patient groups.

## 2.7.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Bavencio (avelumab) is included in the additional monitoring list as it is a new active substance and it is biological product that is authorised after 1 January 2011.

Therefore, the Summary of Product Characteristics and the Package Leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Final Indication:

Bavencio is indicated as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinumbased chemotherapy.

The aim of the maintenance therapy with avelumab is to extend the durability of the initial benefit of platinum-based chemotherapy.

<div style=\"page-break-after: always\"></div>

## 3.1.2. Available therapies and unmet medical need

Platinum-based regimens are the standard-of-care first-line treatment for patients with aUC and result in median OS ranging from 9-14 months (De Santis et al, 2012; Calabro et al, 2009). Despite initial high response rates, durations of progression free survival (PFS) and overall survival (OS) are limited because of emergent chemotherapy resistance. Further, severe side effects limit long-term use of current chemotherapy agents. Following successful first-line treatment, patients are typically managed with best supportive care (BSC) until disease progression. Most patients will experience disease progression within 9 months after the initiation of treatment (von der Maase et al, 2005).

Recently approved PD-L1 inhibitors are new systemic therapies for metastatic UC, both for first-line treatment in cisplatinineligible patients for patients with tumours expressing ≥ 5% PD -L1 and for patients experiencing disease progression after platinum-based chemotherapy regardless of PD-L1status.

Galsky et al evaluated PD-1 inhibitor pembrolizumab as a maintenance treatment versus placebo in a Phase 2 study in patients with metastatic UC following first-line treatment. PFS according to irRECIST was significantly longer in patients randomized to pembrolizumab versus placebo (log-rank p=0.038; Galsky et al, 2019).

## 3.1.3. Main clinical studies

The pivotal trial for this application is study B9991001 ('JAVELIN Bladder 100'), a Phase 3, multicentre, multinational, randomized, open-label, parallel-arm study of avelumab (MSB0010718C) plus BSC versus BSC alone as a maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma whose disease did not progress after completion of first-line platinum-containing chemotherapy.

Primary objective was to demonstrate the benefit of avelumab plus BSC versus BSC alone in prolonging OS for patients with PD-L1 positive tumours and in all randomized patients.

## 3.2. Favourable effects

The primary objective of OS is appropriate as it also would weigh in the answer to the question of whether it is preferable to use the treatment option PD-L1 following response to first-line chemotherapy treatment or save the option for use in later treatment lines. The proportion of patients receiving second line treatment with a PD-L1-inhibitor was considerably higher for patients receiving BSC as maintenance treatment, 43.7%, than for patients receiving avelumab plus BSC, 6.3%.

For OS, results from two data cut-offs are available, including a requested later cut-off 90 days after the pre-planned interim analysis (19 January 2020), while the results from all other efficacy endpoints stem from the interim analysis (21 October 2019).

The primary endpoint OS (21 October 2019) was statistically significant in all patients (n=700) assigned to avelumab plus BSC compared with patients assigned to BSC (stratified hazard ratio (HR) 0.69; 95% confidence interval (CI) 0.556, 0.863; 1-sided p-value 0.0005). The median OS was 21.4 months (95% CI: 18.9, 26.1) in the avelumab plus BSC arm, and 14.3 months (95% CI: 12.9, 17.9) in the BSC arm. In patients with PD-L1-positive tumours (n=358) a statistically significant OS was also demonstrated for patients assigned to avelumab plus BSC compared with patients assigned to BSC (stratified HR 0.56; 95% CI: 0.404, 0.787; 1-sided p -value 0.0003). The median OS was not reached (95% CI: 20.3 months, not reached) in the avelumab plus BSC arm, and was 17.1 months (95% CI: 13.5, 23.7) in the BSC arm.

<div style=\"page-break-after: always\"></div>

The updated OS-data (19 January 2020) with an additional 90 days of follow-up rendered a median OS for all patients assigned to avelumab plus BSC of 22.1 months (95% CI 19.0, 26.1) and for patients treated with BSC of 14.6 months (95% CI 12.8, 17.8) and HR 0.70 (95% CI 0.564, 0.862; 2 sided pvalue 0.0008). For patients with PD-L1-positive tumours the updated median OS was not evaluable (NE) (95% CI 20.6, NE) for patients treated with avelumab plus BSC and 17.5 months (95% CI 13.5, 31.6) for the BSC patients, HR 0.60 (95% CI 0.439, 0.833; 2-sided p-value 0.0019). The OS results from the later data cut-off date are very similar to the results presented from the planned data cut-off date.

In all randomized patients, patients assigned to avelumab plus BSC had a statistically significant PFS (by BICR assessment per RECIST v1.1), compared with patients assigned to BSC with stratified HR 0.62 (95% CI: 0.519, 0.751; nominal 2-sided p value &lt;0.0001). The median PFS for avelumab plus BSC was 3.7 months (95% CI: 3.5, 5.5) and for BSC 2.0 months (95% CI: 1.9, 2.7) in all randomized patients. In patients with PD-L1-positive tumours, the median PFS for avelumab plus BSC was 5.7 months (95% CI: 3.7, 7.4) and for BSC 2.1 months (95% CI: 1.9, 3.5) with stratified HR 0.56 (95% CI 0.431, 0.728; 2-sided p-value &lt;0.0001).

OS and PFS for patients with PD-L1-negative tumours was an exploratory analysis and part of the subgroup analysis. OS and PFS for patients with PD-L1-unknown tumours (n=72) was not a prespecified endpoint. In patients with PD-L1-negative tumours (n=270), the median OS (19 Jan 2020) was 18.9 months (95% CI 13.3, 22.1) for patients treated with avelumab plus BSC and for BSC 13.4 months (95% CI 10.4, 17.3), with a HR 0.83 (95% CI 0.603, 1.131). There were no signs of a detrimental effect on OS in patients with PD-L1-negative tumours treated with avelumab plus BSC compared to BSC. PFS by BICR assessment for patients with PD-L1-negative tumours was prolonged for patients treated with avelumab in combination with BSC (3.0 months (95% CI 2.0, 3.7)) compared to BSC (1.9 months (95% CI 1.9, 2.1), HR 0.63 (95% CI 0.474, 0.847).

## 3.3. Uncertainties and limitations about favourable effects

The efficacy data from patients with PD-L1-unknown tumours are challenging to interpret due to very low patient numbers. However, no evident detrimental effect on PFS or OS is seemingly detected in patients with PD-L1-unknown tumours.

Patients with PD-L1-negative tumours, on a group level, display a modest prolongation of PFS with avelumab plus BSC compared with BSC alone and no signs of a detrimental effect on OS. The OS subgroup analyses in patients with PD-L1negative tumours generally present with HR of ≤1, albeit with large confidence intervals due to small patient samples and more heterogeneity compared to the PFS subgroup results. No conclusion can be drawn that any patient population display a detrimental effect on OS that would motivate an exclusion of this patient population from the indication. It is noted that for the subgroups where HR for OS is ≥1, the HR for PFS is &lt;1.

Due to the low number of patients with PD-L1-negative tumours achieving objective response rate (ORR) and also the lack of information regarding follow-up time for these responses, firm conclusions cannot be drawn. Hence, the duration of the response in PD-L1-negative tumours is uncertain.

## 3.4. Unfavourable effects

Nearly all patients treated with avelumab reported adverse event (AE), in line with the known safety profile. The proportion of patients that reported AE of grade 3 or higher was lower in study B9991001 compared to the safety set, 47.4% compared to 58.9% respectively.

<div style=\"page-break-after: always\"></div>

The proportion of patients that interrupted the treatment with avelumab was almost double for patients in study B9991001 compared to the pooled safety set, 40.7% compared to 20.9 %. The exposure-adjusted incident rate per 100 patient months AE analysis shows a slightly higher incident rate for patients with AE leading to interruption of avelumab treatment in study B9991001. Incidence rate per 100 patient months was 6.1 compared to the pooled safety population 5.0. This is not as pronounced as the non-adjusted analysis.

The proportion of patients that discontinued treatment due to an AE was quite similar between the groups, 11.9% for study B9991001 and 14.0% for the pooled safety set. Exposure adjusted analysis incident rate per 100 patient months show a lower treatment (about half) discontinuation rate of avelumab in study B9991001 compared to the Pooled Safety Set (1.3 vs. 2.9). Immune-related adverse events (irAE) were more common in study B9991001 for patients treated with avelumab plus BSC, 29.4% compared to the pooled safety set where 14.2% presented with irAEs. The exposure adjusted incident rate per 100 patient months of irAEs is higher in study B9991001 compared to the pooled population, 4.1 compared to 3.3. However, the increase when analysed adjusted for exposure raises no major concern in relation to the benefit risk assessment.

Most common cause of death, both in study B9991001 and the pooled safety set was disease progression. Deaths related to study treatment toxicity was 0.6% in study B9991001 compared to 0.2% in the pooled safety set. Considering that avelumab in study B9991001 is used in a maintenance setting this increased rate of deaths related to study treatment toxicity could be of concern. However, the absolute number of deaths assessed by the investigator to be related to study treatment is low and the reported cases display several confounding factors that do not support a clear relationship to study treatment. The frequency of deaths not attributed to disease progression in study B9991001 does not raise new safety concerns for avelumab treatment in patients treated with avelumab plus BSC with advanced urothelial carcinoma that did not progress on first-line platinum-based chemotherapy.

## 3.5. Uncertainties and limitations about unfavourable effects

Compared to the pooled safety set an increased frequency of deaths was reported in study B9991001 although the absolute numbers were low.

In relation to the BSC patients, a considerably higher incidence of AE of grade 3 and above was reported along with the irAE increase and increase in serious AE compared to patients treated with avelumab plus BSC.

## 3.6. Effects Table

Table 70. Effects Table for Bavencio as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) whose disease has not progressed with first-line platinum-based induction chemotherapy (Study B9991001, data cut-off: 21 October 2019 (efficacy), 19 January 2020 (updated OS and safety)).

| Effect             | Short description   | Unit               | Avelumab +BSC       | BSC                | Uncertainties / Strength of evidence             | Ref                |
|--------------------|---------------------|--------------------|---------------------|--------------------|--------------------------------------------------|--------------------|
| Favourable Effects | Favourable Effects  | Favourable Effects | Favourable Effects  | Favourable Effects | Favourable Effects                               | Favourable Effects |
| OS                 |                     | Months             | 22.1                | 14.6               | The OS-results for patients with PD-L1-          |                    |
|                    |                     | HR (95% CI)        | 0,70 (0.564, 0.862) |                    | negative tumours display no signs of detrimental |                    |
| PFS                | BIRC, RECIST v1.1   | Months             | 3.7                 | 2.0                | OS effect (HR 0.83 (95% CI 0.603, 1.131)).       |                    |
|                    |                     | HR (95% CI)        | 0.62 (0.519, 0.751) |                    |                                                  |                    |

<div style=\"page-break-after: always\"></div>

| Effect                                         | Short description                              | Unit                 | Avelumab +BSC        | BSC                  | Uncertainties / Strength of evidence                                                                         | Ref                  |
|------------------------------------------------|------------------------------------------------|----------------------|----------------------|----------------------|--------------------------------------------------------------------------------------------------------------|----------------------|
| OR                                             | BIRC, RECIST v1.1                              | n (%)                | 34 (9.7)             | 5 (1.4)              |                                                                                                              |                      |
| Unfavourable Effects                           | Unfavourable Effects                           | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                                                         | Unfavourable Effects |
| Any AE                                         | Any AE                                         | %                    | 98.0                 | 77.7                 | Median treatment duration*: Avelumab+BSC: 25.3 weeks (range: 2.0, 173.9) BSC: 13.1 weeks (range: 0.1, 168.4) |                      |
| grade≥3 AE                                     | grade≥3 AE                                     | %                    | 47.4                 | 25.2                 | Median treatment duration*: Avelumab+BSC: 25.3 weeks (range: 2.0, 173.9) BSC: 13.1 weeks (range: 0.1, 168.4) |                      |
| SAE                                            | SAE                                            | %                    | 27.9                 | 20.0                 | Median treatment duration*: Avelumab+BSC: 25.3 weeks (range: 2.0, 173.9) BSC: 13.1 weeks (range: 0.1, 168.4) |                      |
| Any irAE                                       | Any irAE                                       | %                    | 29.4                 | 1.4                  |                                                                                                              |                      |
| grade≥3 irAE                                   | grade≥3 irAE                                   | %                    | 7.0                  | 0.3                  |                                                                                                              |                      |
| AEs leading to treatment dis- continuation     | AEs leading to treatment dis- continuation     | %                    | 11.9                 | 0                    |                                                                                                              |                      |
| Death: Cause of death study treatment toxicity | Death: Cause of death study treatment toxicity | %                    | 0.6                  | 0                    |                                                                                                              |                      |

*DCO: 19 Jan. 2020

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The interim OS-analysis from study B9991001 demonstrated a statistically significant and clinically relevant prolonged OS of 7.1 months for all included patients and also for patients with PD-L1-positive tumours. The updated OS-analysis demonstrated a prolonged OS of 7.5 months for all included patients. The benefit of the addition of avelumab to BSC for patients with PD-L1-negative tumours is less pronounced, nevertheless, patients with PD-L1-negative tumours, on a group level, display a modest increase of PFS and no signs of a detrimental effect on OS that would otherwise motivate exclusion of this patient population from the indication.

Overall, the safety profile of avelumab in the pivotal study B9991001 is similar, regardless of PD-L1status, to the previously reported safety profile of avelumab monotherapy. No new safety concerns were raised, and the safety profile is considered manageable.

## 3.7.2. Balance of benefits and risks

Efficacy has been demonstrated in all patients independent of PD-L1-status and the safety profile is manageable. Hence, the benefit-risk balance is positive.

## 3.7.3. Additional considerations on the benefit-risk balance

Exposure comparisons between the 10 mg/kg dosing and a flat 800 mg dose based on simulations from population PK models are the justification for the change of the posology to flat-dosing for the treatment of aUC patients. The benefit-risk balance for the 800 mg Q2W flat-dose posology is considered unchanged compared to the 10 mg/kg Q2W posology since the flat-dose exposure range is comparable to the weight-based dosing exposure range.

## 3.8. Conclusions

The overall B/R of avelumab is positive in the new sought indication.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of indication to include a new indication for Bavencio in the treatment as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum based chemotherapy; as a consequence, sections 4.1 , 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.0 of the RMP has also been submitted. The MAH took also the occasion to include some editorial changes in the PI.

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annexes I, II and IIIB and to the Risk Management Plan are recommended.

## Additional market protection

Furthermore, the CHMP reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion Bavencio-H-C-4338-II-0018.